Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics

ABSTRACT

The invention provides isolated polypeptide and nucleic acid sequences derived from  Streptococcus pneumoniae  that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No. 11/028,458, now U.S. Pat. No. 7,378,258, filed Dec. 30, 2004, which is a continuation of U.S. application Ser. No. 10/640,833, now abandoned, filed Aug. 14, 2003, which is a continuation of U.S. application Ser. No. 09/583,110 (now U.S. Pat. No. 6,699,703) filed May 26, 2000, which is a continuation-in-part of U.S. application Ser. No. 09/107,433 (now U.S. Pat. No. 6,800,744), filed Jun. 30, 1998, which claims the benefit of U.S. Application No. 60/085,131, filed May 12, 1998 and of U.S. Application No. 60/051,553, filed Jul. 2, 1997. The entire teachings of the above applications are incorporated herein by reference.

INCORPORATION BY REFERENCE OF MATERIAL ON COMPACT DISK

This application incorporates by reference the Sequence Listing contained on the two compact disks (Copy 1 and Copy 2), filed concurrently herewith, containing the following file:

File name: 3687.1000-052SequenceList.txt; created Dec. 19, 2006, 8,135 KB in size.

This application also incorporates by reference Table 2 contained on the two compact disks (Copy 1 and Copy 2), filed concurrently herewith, containing the following file:

File name: Table2_(—)2.txt; created Nov. 30, 2006, 351 KB in size.

TABLES The patent contains table(s) that have been included at the end of the specification.

FIELD OF THE INVENTION

The invention relates to isolated nucleic acids and polypeptides derived from Streptococcus pneumoniae that are useful as molecular targets for diagnostics, prophylaxis and treatment of pathological conditions, as well as materials and methods for the diagnosis, prevention, and amelioration of pathological conditions resulting from bacterial infection.

BACKGROUND OF THE INVENTION

Streptococcus pneumoniae (S. pneumoniae) is a common, spherical, gram-positive bacterium. Worldwide it is a leading cause of illness among children, the elderly, and individuals with debilitating medical conditions (Breiman, R. F. et al., 1994, JAMA 271: 1831). S. pneumoniae is estimated to be the causal agent in 3,000 cases of meningitis, 50,000 cases of bacteremia, 500,000 cases of pneumonia, and 7,000,000 cases of otitis media annually in the United States alone (Reichler, M. R. et al., 1992, J. Infect. Dis. 166: 1346; Stool, S. E. and Field, M. J., 1989 Pediatr. Infect. Dis J. 8: S11). In the United States alone, 40,000 deaths result annually from S. pneumoniae infections (Williams, W. W. et al., 1988 Ann. Intern. Med. 108: 616) with a death rate approaching 30% from bacteremia (Butler, J. C. et al., 1993, JAMA 270: 1826). Pneumococcal pneumonia is a serious problem among the elderly of industrialized nations (Käyhty, H. and Eskola, J., 1996 Emerg. Infect. Dis. 2: 289) and is a leading cause of death among children in developing nations (Käyhty, H. and Eskola, J., 1996 Emerg. Infect. Dis. 2: 289; Stansfield, S. K., 1987 Pediatr. Infect. Dis. 6: 622).

Vaccines against S. pneumoniae have been available for a number of years. There are a large number of serotypes based on the polysaccharide capsule (van Dam, J. E., Fleer, A., and Snippe, H., 1990 Antonie van Leeuwenhoek 58: 1) although only a fraction of the serotypes seem to be associated with infections (Martin, D. R. and Brett, M. S., 1996 N. Z. Med. J. 109: 288). A multivalent vaccine against capsular polysaccharides of 23 serotypes (Smart, L. E., Dougall, A. J. and Gridwood, R. W., 1987 J. Infect. 14: 209) has provided protection for some groups but not for several groups at risk for pneumococcal infections, such as infants and the elderly (Mäkel, P. H. et al., 1980 Lancet 2: 547; Sankilampi, U., 1996 J. Infect. Dis. 173: 387). Conjugated pneumococcal capsular polysaccharide vaccines have somewhat improved efficacy, but are costly and, therefore, are not likely to be in widespread use (Käyhty, H. and Eskola, J., 1996 Emerg. Infect. Dis. 2: 289).

At one time, S. pneumoniae strains were uniformly susceptible to penicillin. The report of a penicillin-resistant strain of (Hansman, D. and Bullen, M. M., 1967 Lancet 1: 264) was followed rapidly by many reports indicating the worldwide emergence of penicillin-resistant and penicillin non-susceptible strains (Klugman, K. P., 1990 Clin. Microbiol. Rev. 3: 171). S. pneumoniae strains which are resistant to multiple antibiotics (including penicillin) have also been observed recently within the United States (Welby, P. L., 1994 Pediatr. Infect. Dis. J. 13: 281; Ducin, J. S. et al., 1995 Pediatr. Infect. Dis. J. 14: 745; Butler, J. C., 1996 J. Infect. Dis. 174: 986) as well as internationally (Boswell, T. C. et al., 1996; J. Infect. 33: 17; Catchpole, C., Fraise, A., and Wise, R., 1996 Microb. Drug Resist. 2: 431; Tarasi, A. et al., 1997 Microb. Drug Resist. 3: 105).

A high incidence of morbidity is associated with invasive S. pneumoniae infections (Williams, W. W. et al., 1988 Ann. Intern. Med. 108: 616). Because of the incomplete effectiveness of currently available vaccines and antibiotics, the identification of new targets for antimicrobial therapies, including, but not limited to, the design of vaccines and antibiotics, which may help prevent infection or that may be useful in fighting existing infections, is highly desirable.

SUMMARY OF THE INVENTION

The present invention fulfills the need for diagnostic tools and therapeutics by providing bacterial-specific compositions and methods for detecting, treating, and preventing bacterial infection, in particular S. pneumoniae infection.

The present invention encompasses isolated polypeptides and nucleic acids derived from S. pneumoniae that are useful as reagents for diagnosis of bacterial infection, components of effective antibacterial vaccines, and/or as targets for antibacterial drugs, including anti-S. pneumoniae drugs. The nucleic acids and peptides of the present invention also have utility for diagnostics and therapeutics for S. pneumoniae and other Streptococcus species. They can also be used to detect the presence of S. pneumoniae and other Streptococcus species in a sample; and in screening compounds for the ability to interfere with the S. pneumoniae life cycle or to inhibit S. pneumoniae infection. More specifically, this invention features compositions of nucleic acids corresponding to entire coding sequences of S. pneumoniae proteins, including surface or secreted proteins or parts thereof, nucleic acids capable of binding mRNA from S. pneumoniae proteins to block protein translation, and methods for producing S. pneumoniae proteins or parts thereof using peptide synthesis and recombinant DNA techniques. This invention also features antibodies and nucleic acids useful as probes to detect S. pneumoniae infection. In addition, vaccine compositions and methods for the protection or treatment of infection by S. pneumoniae are within the scope of this invention.

The nucleotide sequences provided in SEQ ID NO: 1-SEQ ID NO: 2661, a fragment thereof, or a nucleotide sequence at least 99.5% identical to a sequence contained within SEQ ID NO: 1-SEQ ID NO: 2661 may be “provided” in a variety of medias to facilitate use thereof. As used herein, “provided” refers to a manufacture, other than an isolated nucleic acid molecule, which contains a nucleotide sequence of the present invention, i.e., the nucleotide sequence provided in SEQ ID NO: 1-SEQ ID NO: 2661, a fragment thereof, or a nucleotide sequence at least 99.5% identical to a sequence contained within SEQ ID NO: 1-SEQ ID NO: 2661. Uses for and methods for providing nucleotide sequences in a variety of media is well known in the art (see e.g., EPO Publication No. EP 0 756 006)

In one application of this embodiment, a nucleotide sequence of the present invention can be recorded on computer readable media. As used herein, “computer readable media” refers to any media which can be read and accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage media, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. A person skilled in the art can readily appreciate how any of the presently known computer readable media can be used to create a manufacture comprising computer readable media having recorded thereon a nucleotide sequence of the present invention.

As used herein, “recorded” refers to a process for storing information on computer readable media. A person skilled in the art can readily adopt any of the presently known methods for recording information on computer readable media to generate manufactures comprising the nucleotide sequence information of the present invention.

A variety of data storage structures are available to a person skilled in the art for creating a computer readable media having recorded thereon a nucleotide sequence of the present invention. The choice of the data storage structure will generally be based on the means chosen to access the stored information. In addition, a variety of data processor programs and formats can be used to store the nucleotide sequence information of the present invention on computer readable media. The sequence information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and Microsoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like. A person skilled in the art can readily adapt any number of data processor structuring formats (e.g. text file or database) in order to obtain computer readable media having recorded thereon the nucleotide sequence information of the present invention.

By providing the nucleotide sequence of SEQ ID NO: 1-SEQ ID NO: 2661, a fragment thereof, or a nucleotide sequence at least 99.5% identical to a sequence contained within SEQ ID NO: 1-SEQ ID NO: 2661 in computer readable form, a person skilled in the art can routinely access the sequence information for a variety of purposes. Computer software is publicly available which allows a person skilled in the art to access sequence information provided in a computer readable media. Examples of such computer software include programs of the “Staden Package”, “DNA Star”, “MacVector”, GCG “Wisconsin Package” (Genetics Computer Group, Madison, Wis.) and “NCBI toolbox” (National Center for Biotechnology Information).

Computer algorithms enable the identification of S. pneumoniae open reading frames (ORFs) within SEQ ID NO: 1-SEQ ID NO: 2661 which contain homology to ORFs or proteins from other organisms. Examples of such similarity-search algorithms include the BLAST [Altschul et al., J. Mol. Biol. 215:403-410 (1990)] and Smith-Waterman [Smith and Waterman (1981) Advances in Applied Mathematics, 2:482-489] search algorithms. These algorithms are utilized on computer systems as exemplified below. The ORFs so identified represent protein encoding fragments within the S. pneumoniae genome and are useful in producing commercially important proteins such as enzymes used in fermentation reactions and in the production of commercially useful metabolites.

The present invention further provides systems, particularly computer-based systems, which contain the sequence information described herein. Such systems are designed to identify commercially important fragments of the S. pneumoniae genome. As used herein, “a computer-based system” refers to the hardware means, software means, and data storage means used to analyze the nucleotide sequence information of the present invention. The minimum hardware means of the computer-based systems of the present invention comprises a central processing unit (CPU), input means, output means, and data storage means. A person skilled in the art can readily appreciate that any one of the currently available computer-based systems is suitable for use in the present invention. The computer-based systems of the present invention comprise a data storage means having stored therein a nucleotide sequence of the present invention and the necessary hardware means and software means for supporting and implementing a search means. As used herein, “data storage means” refers to memory which can store nucleotide sequence information of the present invention, or a memory access means which can access manufactures having recorded thereon the nucleotide sequence information of the present invention.

As used herein, “search means” refers to one or more programs which are implemented on the computer-based system to compare a target sequence or target structural motif with the sequence information stored within the data storage means. Search means are used to identify fragments or regions of the S. pneumoniae genome which are similar to, or “match”, a particular target sequence or target motif. A variety of known algorithms are known in the art and have been disclosed publicly, and a variety of commercially available software for conducting homology-based similarity searches are available and can be used in the computer-based systems of the present invention. Examples of such software include, but is not limited to, FASTA (GCG Wisconsin Package), Bic_SW (Compugen Bioccelerator, BLASTN2, BLASTP2 and BLASTX2 (NCBI) and Motifs (GCG). BLASTN2, A person skilled in the art can readily recognize that any one of the available algorithms or implementing software packages for conducting homology searches can be adapted for use in the present computer-based systems.

As used herein, a “target sequence” can be any DNA or amino acid sequence of six or more nucleotides or two or more amino acids. A person skilled in the art can readily recognize that the longer a target sequence is, the less likely a target sequence will be present as a random occurrence in the database. The most preferred sequence length of a target sequence is from about 10 to 100 amino acids or from about 30 to 300 nucleotide residues. However, it is well recognized that many genes are longer than 500 amino acids, or 1.5 kb in length, and that commercially important fragments of the S. pneumoniae genome, such as sequence fragments involved in gene expression and protein processing, will often be shorter than 30 nucleotides.

As used herein, “a target structural motif,” or “target motif,” refers to any rationally selected sequence or combination of sequences in which the sequence(s) are chosen based on a specific functional domain or three-dimensional configuration which is formed upon the folding of the target polypeptide. There are a variety of target motifs known in the art. Protein target motifs include, but are not limited to, enzymatic active sites, membrane spanning regions, and signal sequences. Nucleic acid target motifs include, but are not limited to, promoter sequences, hairpin structures and inducible expression elements (protein binding sequences).

A variety of structural formats for the input and output means can be used to input and output the information in the computer-based systems of the present invention. A preferred format for an output means ranks fragments of the S. pneumoniae genome possessing varying degrees of homology to the target sequence or target motif. Such presentation provides a person skilled in the art with a ranking of sequences which contain various amounts of the target sequence or target motif and identifies the degree of homology contained in the identified fragment.

A variety of comparing means can be used to compare a target sequence or target motif with the data storage means to identify sequence fragments of the S. pneumoniae genome. In the present examples, implementing software which implement the BLASTP2 and bic_SW algorithms (Altschul et al., J. Mol. Biol. 215:403-410 (1990); Compugen Biocellerator) was used to identify open reading frames within the S. pneumoniae genome. A person skilled in the art can readily recognize that any one of the publicly available homology search programs can be used as the search means for the computer-based systems of the present invention.

The invention features S. pneumoniae polypeptides, preferably a substantially pure preparation of an S. pneumoniae polypeptide, or a recombinant S. pneumoniae polypeptide. In preferred embodiments: the polypeptide has biological activity; the polypeptide has an amino acid sequence at least 60%, 70%, 80%, 90%, 95%, 98%, or 99% identical to an amino acid sequence of the invention contained in the Sequence Listing, preferably it has about 65% sequence identity with an amino acid sequence of the invention contained in the Sequence Listing, and most preferably it has about 92% to about 99% sequence identity with an amino acid sequence of the invention contained in the Sequence Listing; the polypeptide has an amino acid sequence essentially the same as an amino acid sequence of the invention contained in the Sequence Listing; the polypeptide is at least 5, 10, 20, 50, 100, or 150 amino acid residues in length; the polypeptide includes at least 5, preferably at least 10, more preferably at least 20, more preferably at least 50, 100, or 150 contiguous amino acid residues of the invention contained in the Sequence Listing. In yet another preferred embodiment, the amino acid sequence which differs in sequence identity by about 7% to about 8% from the S. pneumoniae amino acid sequences of the invention contained in the Sequence Listing is also encompassed by the invention.

In preferred embodiments: the S. pneumoniae polypeptide is encoded by a nucleic acid of the invention contained in the Sequence Listing, or by a nucleic acid having at least 60%, 70%, 80%, 90%, 95%, 98%, or 99% homology with a nucleic acid of the invention contained in the Sequence Listing.

In a preferred embodiment, the subject S. pneumoniae polypeptide differs in amino acid sequence at 1, 2, 3, 5, 10 or more residues from a sequence of the invention contained in the Sequence Listing. The differences, however, are such that the S. pneumoniae polypeptide exhibits an S. pneumoniae biological activity, e.g., the S. pneumoniae polypeptide retains a biological activity of a naturally occurring S. pneumoniae enzyme.

In preferred embodiments, the polypeptide includes all or a fragment of an amino acid sequence of the invention contained in the Sequence Listing; fused, in reading frame, to additional amino acid residues, preferably to residues encoded by genomic DNA 5′ or 3′ to the genomic DNA which encodes a sequence of the invention contained in the Sequence Listing.

In yet other preferred embodiments, the S. pneumoniae polypeptide is a recombinant fusion protein having a first S. pneumoniae polypeptide portion and a second polypeptide portion, e.g., a second polypeptide portion having an amino acid sequence unrelated to S. pneumoniae. The second polypeptide portion can be, e.g., any of glutathione-5-transferase, a DNA binding domain, or a polymerase activating domain. In preferred embodiment the fusion protein can be used in a two-hybrid assay.

Polypeptides of the invention include those which arise as a result of alternative transcription events, alternative RNA splicing events, and alternative translational and postranslational events.

In a preferred embodiment, the encoded S. pneumoniae polypeptide differs (e.g., by amino acid substitution, addition or deletion of at least one amino acid residue) in amino acid sequence at 1, 2, 3, 5, 10 or more residues, from a sequence of the invention contained in the Sequence Listing. The differences, however, are such that: the S. pneumoniae encoded polypeptide exhibits a S. pneumoniae biological activity, e.g., the encoded S. pneumoniae enzyme retains a biological activity of a naturally occurring S. pneumoniae.

In preferred embodiments, the encoded polypeptide includes all or a fragment of an amino acid sequence of the invention contained in the Sequence Listing; fused, in reading frame, to additional amino acid residues, preferably to residues encoded by genomic DNA 5′ or 3′ to the genomic DNA which encodes a sequence of the invention contained in the Sequence Listing.

The S. pneumoniae strain, 14453, from which genomic sequences have been sequenced, has been deposited on Jun. 26, 1997 in the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, and assigned the ATCC designation # 55987.

Included in the invention are: allelic variations; natural mutants; induced mutants; proteins encoded by DNA that hybridize under high or low stringency conditions to a nucleic acid which encodes a polypeptide of the invention contained in the Sequence Listing (for definitions of high and low stringency see Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989, 6.3.1-6.3.6, hereby incorporated by reference); and, polypeptides specifically bound by antisera to S. pneumoniae polypeptides, especially by antisera to an active site or binding domain of S. pneumoniae polypeptide. The invention also includes fragments, preferably biologically active fragments. These and other polypeptides are also referred to herein as S. pneumoniae polypeptide analogs or variants.

The invention further provides nucleic acids, e.g., RNA or DNA, encoding a polypeptide of the invention. This includes double stranded nucleic acids as well as coding and antisense single strands.

In preferred embodiments, the subject S. pneumoniae nucleic acid will include a transcriptional regulatory sequence, e.g. at least one of a transcriptional promoter or transcriptional enhancer sequence, operably linked to the S. pneumoniae gene sequence, e.g., to render the S. pneumoniae gene sequence suitable for expression in a recombinant host cell.

In yet a further preferred embodiment, the nucleic acid which encodes an S. pneumoniae polypeptide of the invention, hybridizes under stringent conditions to a nucleic acid probe corresponding to at least 8 consecutive nucleotides of the invention contained in the Sequence Listing; more preferably to at least 12 consecutive nucleotides of the invention contained in the Sequence Listing; more preferably to at least 20 consecutive nucleotides of the invention contained in the Sequence Listing; more preferably to at least 40 consecutive nucleotides of the invention contained in the Sequence Listing.

In another aspect, the invention provides a substantially pure nucleic acid having a nucleotide sequence which encodes an S. pneumoniae polypeptide. In preferred embodiments: the encoded polypeptide has biological activity; the encoded polypeptide has an amino acid sequence at least 60%, 70%, 80%, 90%, 95%, 98%, or 99% homologous to an amino acid sequence of the invention contained in the Sequence Listing; the encoded polypeptide has an amino acid sequence essentially the same as an amino acid sequence of the invention contained in the Sequence Listing; the encoded polypeptide is at least 5, 10, 20, 50, 100, or 150 amino acids in length; the encoded polypeptide comprises at least 5, preferably at least 10, more preferably at least 20, more preferably at least 50, 100, or 150 contiguous amino acids of the invention contained in the Sequence Listing.

In another aspect, the invention encompasses: a vector including a nucleic acid which encodes an S. pneumoniae polypeptide or an S. pneumoniae polypeptide variant as described herein; a host cell transfected with the vector; and a method of producing a recombinant S. pneumoniae polypeptide or S. pneumoniae polypeptide variant; including culturing the cell, e.g., in a cell culture medium, and isolating an S. pneumoniae polypeptide or an S. pneumoniae polypeptide variant, e.g., from the cell or from the cell culture medium.

In another series of embodiments, the invention provides isolated nucleic acids comprising sequences at least about 8 nucleotides in length, more preferably at least about 12 nucleotides in length, and most preferably at least about 15-20 nucleotides in length, that correspond to a subsequence of any one of SEQ ID NO: 1-SEQ ID NO: 2661 or complements thereof. Alternatively, the nucleic acids comprise sequences contained within any ORF (open reading frame), including a complete protein-coding sequence, of which any of SEQ ID NO: 1-SEQ ID NO: 2661 forms a part. The invention encompasses sequence-conservative variants and function-conservative variants of these sequences. The nucleic acids may be DNA, RNA, DNA/RNA duplexes, protein-nucleic acid (PNA), or derivatives thereof.

In another aspect, the invention features, a purified recombinant nucleic acid having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% homology with a sequence of the invention contained in the Sequence Listing.

In another aspect, the invention features nucleic acids capable of binding mRNA of S. pneumoniae. Such nucleic acid is capable of acting as antisense nucleic acid to control the translation of mRNA of S. pneumoniae. A further aspect features a nucleic acid which is capable of binding specifically to an S. pneumoniae nucleic acid. These nucleic acids are also referred to herein as complements and have utility as probes and as capture reagents.

In another aspect, the invention features an expression system comprising an open reading frame corresponding to S. pneumoniae nucleic acid. The nucleic acid further comprises a control sequence compatible with an intended host. The expression system is useful for making polypeptides corresponding to S. pneumoniae nucleic acid.

In another aspect, the invention features a cell transformed with the expression system to produce S. pneumoniae polypeptides.

In yet another embodiment, the invention encompasses reagents for detecting bacterial infection, including S. pneumoniae infection, which comprise at least one S. pneumoniae-derived nucleic acid defined by any one of SEQ ID NO: 1-SEQ ID NO: 2661, or sequence-conservative or function-conservative variants thereof. Alternatively, the diagnostic reagents comprise polypeptide sequences that are contained within any open reading frames (ORFs), including complete protein-coding sequences, contained within any of SEQ ID NO: 1-SEQ ID NO: 2661, or polypeptide sequences contained within any of SEQ ID NO: 2662-SEQ ID NO: 5322, or polypeptides of which any of the above sequences forms a part, or antibodies directed against any of the above peptide sequences or function-conservative variants and/or fragments thereof.

The invention further provides antibodies, preferably monoclonal antibodies, which specifically bind to the polypeptides of the invention. Methods are also provided for producing antibodies in a host animal. The methods of the invention comprise immunizing an animal with at least one S. pneumoniae-derived immunogenic component, wherein the immunogenic component comprises one or more of the polypeptides encoded by any one of SEQ ID NO: 1-SEQ ID NO: 2661 or sequence-conservative or function-conservative variants thereof; or polypeptides that are contained within any ORFs, including complete protein-coding sequences, of which any of SEQ ID NO: 1-SEQ ID NO: 2661 forms a part; or polypeptide sequences contained within any of SEQ ID NO: 2662-SEQ ID NO: 5322; or polypeptides of which any of SEQ ID NO: 2662-SEQ ID NO: 5322 forms a part. Host animals include any warm blooded animal, including without limitation mammals and birds. Such antibodies have utility as reagents for immunoassays to evaluate the abundance and distribution of S. pneumoniae-specific antigens.

In yet another aspect, the invention provides a method for detecting bacterial antigenic components in a sample, which comprises the steps of: (i) contacting a sample suspected to contain a bacterial antigenic component with a bacterial-specific antibody, under conditions in which a stable antigen-antibody complex can form between the antibody and bacterial antigenic components in the sample; and (ii) detecting any antigen-antibody complex formed in step (i), wherein detection of an antigen-antibody complex indicates the presence of at least one bacterial antigenic component in the sample. In different embodiments of this method, the antibodies used are directed against a sequence encoded by any of SEQ ID NO: 1-SEQ ID NO: 2661 or sequence-conservative or function-conservative variants thereof, or against a polypeptide sequence contained in any of SEQ ID NO: 2662-SEQ ID NO: 5322 or function-conservative variants thereof.

In yet another aspect, the invention provides a method for detecting antibacterial-specific antibodies in a sample, which comprises: (i) contacting a sample suspected to contain antibacterial-specific antibodies with a S. pneumoniae antigenic component, under conditions in which a stable antigen-antibody complex can form between the S. pneumoniae antigenic component and antibacterial antibodies in the sample; and (ii) detecting any antigen-antibody complex formed in step (i), wherein detection of an antigen-antibody complex indicates the presence of antibacterial antibodies in the sample. In different embodiments of this method, the antigenic component is encoded by a sequence contained in any of SEQ ID NO: 1-SEQ ID NO: 2661 or sequence-conservative and function-conservative variants thereof, or is a polypeptide sequence contained in any of SEQ ID NO: 2662-SEQ ID NO: 5322 or function-conservative variants thereof.

In another aspect, the invention features a method of generating vaccines for immunizing an individual against S. pneumoniae. The method includes: immunizing a subject with an S. pneumoniae polypeptide, e.g., a surface or secreted polypeptide, or active portion thereof, and a pharmaceutically acceptable carrier. Such vaccines have therapeutic and prophylactic utilities.

In another aspect, the invention features a method of evaluating a compound, e.g. a polypeptide, e.g., a fragment of a host cell polypeptide, for the ability to bind an S. pneumoniae polypeptide. The method includes: contacting the candidate compound with an S. pneumoniae polypeptide and determining if the compound binds or otherwise interacts with an S. pneumoniae polypeptide. Compounds which bind S. pneumoniae are candidates as activators or inhibitors of the bacterial life cycle. These assays can be performed in vitro or in vivo.

In another aspect, the invention features a method of evaluating a compound, e.g. a polypeptide, e.g., a fragment of a host cell polypeptide, for the ability to bind an S. pneumoniae nucleic acid, e.g., DNA or RNA. The method includes: contacting the candidate compound with an S. pneumoniae nucleic acid and determining if the compound binds or otherwise interacts with an S. pneumoniae polypeptide. Compounds which bind S. pneumoniae are candidates as activators or inhibitors of the bacterial life cycle. These assays can be performed in vitro or in vivo.

DETAILED DESCRIPTION OF THE INVENTION

The sequences of the present invention include the specific nucleic acid and amino acid sequences set forth in the Sequence Listing that forms a part of the present specification, and which are designated SEQ ID NO: 1-SEQ ID NO: 5322. Use of the terms “SEQ ID NO: 1-SEQ ID NO: 2661”, “SEQ ID NO: 2662-SEQ ID NO: 5322”, “the sequences depicted in Table 2”, etc., is intended, for convenience, to refer to each individual SEQ ID NO individually, and is not intended to refer to the genus of these sequences. In other words, it is a shorthand for listing all of these sequences individually. The invention encompasses each sequence individually, as well as any combination thereof.

Definitions

“Nucleic acid” or “polynucleotide” as used herein refers to purine- and pyrimidine-containing polymers of any length, either polyribonucleotides or polydeoxyribonucleotides or mixed polyribo-polydeoxyribo nucleotides. This includes single- and double-stranded molecules, i.e., DNA-DNA, DNA-RNA and RNA-RNA hybrids, as well as “protein nucleic acids” (PNA) formed by conjugating bases to an amino acid backbone. This also includes nucleic acids containing modified bases.

A nucleic acid or polypeptide sequence that is “derived from” a designated sequence refers to a sequence that corresponds to a region of the designated sequence. For nucleic acid sequences, this encompasses sequences that are homologous or complementary to the sequence, as well as “sequence-conservative variants” and “function-conservative variants.” For polypeptide sequences, this encompasses “function-conservative variants.” Sequence-conservative variants are those in which a change of one or more nucleotides in a given codon position results in no alteration in the amino acid encoded at that position. Function-conservative variants are those in which a given amino acid residue in a polypeptide has been changed without altering the overall conformation and function of the native polypeptide, including, but not limited to, replacement of an amino acid with one having similar physico-chemical properties (such as, for example, acidic, basic, hydrophobic, and the like). “Function-conservative” variants also include any polypeptides that have the ability to elicit antibodies specific to a designated polypeptide.

An “S. pneumoniae-derived” nucleic acid or polypeptide sequence may or may not be present in other bacterial species, and may or may not be present in all S. pneumoniae strains. This term is intended to refer to the source from which the sequence was originally isolated. Thus, a S. pneumoniae-derived polypeptide, as used herein, may be used, e.g., as a target to screen for a broad spectrum antibacterial agent, to search for homologous proteins in other species of bacteria or in eukaryotic organisms such as fungi and humans, etc.

A purified or isolated polypeptide or a substantially pure preparation of a polypeptide are used interchangeably herein and, as used herein, mean a polypeptide that has been separated from other proteins, lipids, and nucleic acids with which it naturally occurs. Preferably, the polypeptide is also separated from substances, e.g., antibodies or gel matrix, e.g., polyacrylamide, which are used to purify it. Preferably, the polypeptide constitutes at least 10, 20, 50 70, 80 or 95% dry weight of the purified preparation. Preferably, the preparation contains: sufficient polypeptide to allow protein sequencing; at least 1, 10, or 100 mg of the polypeptide.

A purified preparation of cells refers to, in the case of plant or animal cells, an in vitro preparation of cells and not an entire intact plant or animal. In the case of cultured cells or microbial cells, it consists of a preparation of at least 10% and more preferably 50% of the subject cells.

A purified or isolated or a substantially pure nucleic acid, e.g., a substantially pure DNA, (are terms used interchangeably herein) is a nucleic acid which is one or both of the following: not immediately contiguous with both of the coding sequences with which it is immediately contiguous (i.e., one at the 5′ end and one at the 3′ end) in the naturally-occurring genome of the organism from which the nucleic acid is derived; or which is substantially free of a nucleic acid with which it occurs in the organism from which the nucleic acid is derived. The term includes, for example, a recombinant DNA which is incorporated into a vector, e.g., into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other DNA sequences. Substantially pure DNA also includes a recombinant DNA which is part of a hybrid gene encoding additional S. pneumoniae DNA sequence.

A “contig” as used herein is a nucleic acid representing a continuous stretch of genomic sequence of an organism.

An “open reading frame”, also referred to herein as ORF, is a region of nucleic acid which encodes a polypeptide. This region usually represents the total coding region for the polypeptide and can be determined from a stop to stop codon or from a start to stop codon.

As used herein, a “coding sequence” is a nucleic acid which is transcribed into messenger RNA and/or translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the five prime terminus and a translation stop codon at the three prime terminus. A coding sequence can include but is not limited to messenger RNA, synthetic DNA, and recombinant nucleic acid sequences.

A “complement” of a nucleic acid as used herein refers to an anti-parallel or antisense sequence that participates in Watson-Crick base-pairing with the original sequence.

A “gene product” is a protein or structural RNA which is specifically encoded by a gene.

As used herein, the term “probe” refers to a nucleic acid, peptide or other chemical entity which specifically binds to a molecule of interest. Probes are often associated with or capable of associating with a label. A label is a chemical moiety capable of detection. Typical labels comprise dyes, radioisotopes, luminescent and chemiluminescent moieties, fluorophores, enzymes, precipitating agents, amplification sequences, and the like. Similarly, a nucleic acid, peptide or other chemical entity which specifically binds to a molecule of interest and immobilizes such molecule is referred herein as a “capture ligand”. Capture ligands are typically associated with or capable of associating with a support such as nitro-cellulose, glass, nylon membranes, beads, particles and the like. The specificity of hybridization is dependent on conditions such as the base pair composition of the nucleotides, and the temperature and salt concentration of the reaction. These conditions are readily discernable to one of ordinary skill in the art using routine experimentation.

“Homologous” refers to the sequence similarity or sequence identity between two polypeptides or between two nucleic acid molecules. When a position in both of the two compared sequences is occupied by the same base or amino acid monomer subunit, e.g., if a position in each of two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percent of homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared×100. For example, if 6 of 10 of the positions in two sequences are matched or homologous then the two sequences are 60% homologous. By way of example, the DNA sequences ATTGCC and TATGGC share 50% homology. Generally, a comparison is made when two sequences are aligned to give maximum homology.

Nucleic acids are hybridizable to each other when at least one strand of a nucleic acid can anneal to the other nucleic acid under defined stringency conditions. Stringency of hybridization is determined by: (a) the temperature at which hybridization and/or washing is performed; and (b) the ionic strength and polarity of the hybridization and washing solutions. Hybridization requires that the two nucleic acids contain complementary sequences; depending on the stringency of hybridization, however, mismatches may be tolerated. Typically, hybridization of two sequences at high stringency (such as, for example, in a solution of 0.5×SSC, at 65° C.) requires that the sequences be essentially completely homologous. Conditions of intermediate stringency (such as, for example, 2×SSC at 65° C.) and low stringency (such as, for example 2×SSC at 55° C.), require correspondingly less overall complementarity between the hybridizing sequences. (1×SSC is 0.15 M NaCl, 0.015 M Na citrate).

The terms peptides, proteins, and polypeptides are used interchangeably herein.

As used herein, the term “surface protein” refers to all surface accessible proteins, e.g. inner and outer membrane proteins, proteins adhering to the cell wall, and secreted proteins.

A polypeptide has S. pneumoniae biological activity if it has one, two and preferably more of the following properties: (1) if when expressed in the course of an S. pneumoniae infection, it can promote, or mediate the attachment of S. pneumoniae to a cell; (2) it has an enzymatic activity, structural or regulatory function characteristic of an S. pneumoniae protein; (3) or the gene which encodes it can rescue a lethal mutation in an S. pneumoniae gene. A polypeptide has biological activity if it is an antagonist, agonist, or super-agonist of a polypeptide having one of the above-listed properties.

A biologically active fragment or analog is one having an in vivo or in vitro activity which is characteristic of the S. pneumoniae polypeptides of the invention contained in the Sequence Listing, or of other naturally occurring S. pneumoniae polypeptides, e.g., one or more of the biological activities described herein. Especially preferred are fragments which exist in vivo, e.g., fragments which arise from post transcriptional processing or which arise from translation of alternatively spliced RNA's. Fragments include those expressed in native or endogenous cells as well as those made in expression systems, e.g., in CHO cells. Because peptides such as S. pneumoniae polypeptides often exhibit a range of physiological properties and because such properties may be attributable to different portions of the molecule, a useful S. pneumoniae fragment or S. pneumoniae analog is one which exhibits a biological activity in any biological assay for S. pneumoniae activity. Most preferably the fragment or analog possesses 10%, preferably 40%, more preferably 60%, 70%, 80% or 90% or greater of the activity of S. pneumoniae, in any in vivo or in vitro assay.

Analogs can differ from naturally occurring S. pneumoniae polypeptides in amino acid sequence or in ways that do not involve sequence, or both. Non-sequence modifications include changes in acetylation, methylation, phosphorylation, carboxylation, or glycosylation. Preferred analogs include S. pneumoniae polypeptides (or biologically active fragments thereof) whose sequences differ from the wild-type sequence by one or more conservative amino acid substitutions or by one or more non-conservative amino acid substitutions, deletions, or insertions which do not substantially diminish the biological activity of the S. pneumoniae polypeptide. Conservative substitutions typically include the substitution of one amino acid for another with similar characteristics, e.g., substitutions within the following groups: valine, glycine; glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. Other conservative substitutions can be made in view of the table below.

TABLE 1 CONSERVATIVE AMINO ACID REPLACEMENTS For Amino Acid Code Replace with any of Alanine A D-Ala, Gly, beta-Ala, L-Cys, D-Cys Arginine R D-Arg, Lys, D-Lys, homo-Arg, D-homo- Arg, Met, Ile, D-Met, D-Ile, Orn, D-Orn Asparagine N D-Asn, Asp, D-Asp, Glu, D-Glu, Gln, D-Gln Aspartic D D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln Acid Cysteine C D-Cys, S-Me-Cys, Met, D-Met, Thr, D-Thr Glutamine Q D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp Glutamic E D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, D-Gln Acid Glycine G Ala, D-Ala, Pro, D-Pro, β-Ala, Acp Isoleucine I D-Ile, Val, D-Val, Leu, D-Leu, Met, D-Met Leucine L D-Leu, Val, D-Val, Leu, D-Leu, Met, D-Met Lysine K D-Lys, Arg, D-Arg, homo-Arg, D-homo-Arg, Met, D-Met, Ile, D-Ile, Orn, D-Orn Methionine M D-Met, S-Me-Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val Phenylalanine F D-Phe, Tyr, D-Thr, L-Dopa, His, D-His, Trp, D-Trp, Trans-3,4, or 5-phenylproline, cis-3,4, or 5-phenylproline Proline P D-Pro, L-I-thioazolidine-4-carboxylic acid, D-or L-1-oxazolidine-4-carboxylic acid Serine S D-Ser, Thr, D-Thr, allo-Thr, Met, D-Met, Met(O), D-Met(O), L-Cys, D-Cys Threonine T D-Thr, Ser, D-Ser, allo-Thr, Met, D-Met, Met(O), D-Met(O), Val, D-Val Tyrosine Y D-Tyr, Phe, D-Phe, L-Dopa, His, D-His Valine V D-Val, Leu, D-Leu, Ile, D-Ile, Met, D-Met

Other analogs within the invention are those with modifications which increase peptide stability; such analogs may contain, for example, one or more non-peptide bonds (which replace the peptide bonds) in the peptide sequence. Also included are: analogs that include residues other than naturally occurring L-amino acids, e.g., D-amino acids or non-naturally occurring or synthetic amino acids, e.g., β or γ amino acids; and cyclic analogs.

As used herein, the term “fragment”, as applied to an S. pneumoniae analog, will ordinarily be at least about 20 residues, more typically at least about 40 residues, preferably at least about 60 residues in length. Fragments of S. pneumoniae polypeptides can be generated by methods known to those skilled in the art. The ability of a candidate fragment to exhibit a biological activity of S. pneumoniae polypeptide can be assessed by methods known to those skilled in the art as described herein. Also included are S. pneumoniae polypeptides containing residues that are not required for biological activity of the peptide or that result from alternative mRNA splicing or alternative protein processing events.

An “immunogenic component” as used herein is a moiety, such as an S. pneumoniae polypeptide, analog or fragment thereof, that is capable of eliciting a humoral and/or cellular immune response in a host animal.

An “antigenic component” as used herein is a moiety, such as an S. pneumoniae polypeptide, analog or fragment thereof, that is capable of binding to a specific antibody with sufficiently high affinity to form a detectable antigen-antibody complex.

The term “antibody” as used herein is intended to include fragments thereof which are specifically reactive with S. pneumoniae polypeptides.

As used herein, the term “cell-specific promoter” means a DNA sequence that serves as a promoter, i.e., regulates expression of a selected DNA sequence operably linked to the promoter, and which effects expression of the selected DNA sequence in specific cells of a tissue. The term also covers so-called “leaky” promoters, which regulate expression of a selected DNA primarily in one tissue, but cause expression in other tissues as well.

Misexpression, as used herein, refers to a non-wild type pattern of gene expression. It includes: expression at non-wild type levels, i.e., over or under expression; a pattern of expression that differs from wild type in terms of the time or stage at which the gene is expressed, e.g., increased or decreased expression (as compared with wild type) at a predetermined developmental period or stage; a pattern of expression that differs from wild type in terms of decreased expression (as compared with wild type) in a predetermined cell type or tissue type; a pattern of expression that differs from wild type in terms of the splicing size, amino acid sequence, post-translational modification, or biological activity of the expressed polypeptide; a pattern of expression that differs from wild type in terms of the effect of an environmental stimulus or extracellular stimulus on expression of the gene, e.g., a pattern of increased or decreased expression (as compared with wild type) in the presence of an increase or decrease in the strength of the stimulus.

As used herein, “host cells” and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities refers to cells which can become or have been used as recipients for a recombinant vector or other transfer DNA, and include the progeny of the original cell which has been transfected. It is understood by individuals skilled in the art that the progeny of a single parental cell may not necessarily be completely identical in genomic or total DNA compliment to the original parent, due to accident or deliberate mutation.

As used herein, the term “control sequence” refers to a nucleic acid having a base sequence which is recognized by the host organism to effect the expression of encoded sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include a promoter, ribosomal binding site, terminators, and in some cases operators; in eukaryotes, generally such control sequences include promoters, terminators and in some instances, enhancers. The term control sequence is intended to include at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences.

As used herein, the term “operably linked” refers to sequences joined or ligated to function in their intended manner. For example, a control sequence is operably linked to coding sequence by ligation in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequence and host cell.

The “metabolism” of a substance, as used herein, means any aspect of the expression, function, action, or regulation of the substance. The metabolism of a substance includes modifications, e.g., covalent or non-covalent modifications of the substance. The metabolism of a substance includes modifications, e.g., covalent or non-covalent modification, the substance induces in other substances. The metabolism of a substance also includes changes in the distribution of the substance. The metabolism of a substance includes changes the substance induces in the distribution of other substances.

A “sample” as used herein refers to a biological sample, such as, for example, tissue or fluid isolated from an individual (including without limitation plasma, serum, cerebrospinal fluid, lymph, tears, saliva and tissue sections) or from in vitro cell culture constituents, as well as samples from the environment.

Technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which the present invention pertains, unless otherwise defined. Reference is made herein to various methodologies known to those of skill in the art. Publications and other materials setting forth such known methodologies to which reference is made are incorporated herein by reference in their entireties as though set forth in full. The practice of the invention will employ, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See e.g., Sambrook, Fritsch, and Maniatis, Molecular Cloning; Laboratory Manual 2nd ed. (1989); DNA Cloning, Volumes I and II (D. N Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed, 1984); Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); the series, Methods in Enzymology (Academic Press, Inc.), particularly Vol. 154 and Vol. 155 (Wu and Grossman, eds.); PCR-A Practical Approach (McPherson, Quirke, and Taylor, eds., 1991); Immunology, 2d Edition, 1989, Roitt et al., C. V. Mosby Company, and New York; Advanced Immunology, 2d Edition, 1991, Male et al., Grower Medical Publishing, New York; DNA Cloning: A Practical Approach, Volumes I and II, 1985 (D. N. Glover ed.); Oligonucleotide Synthesis, 1984, (M. L. Gait ed); Transcription and Translation, 1984 (Hames and Higgins eds.); Animal Cell Culture, 1986 (R. I. Freshney ed.); Immobilized Cells and Enzymes, 1986 (IRL Press); Perbal, 1984, A Practical Guide to Molecular Cloning; and Gene Transfer Vectors for Mammalian Cells, 1987 (J. H. Miller and M. P. Calos eds., Cold Spring Harbor Laboratory).

Any suitable materials and/or methods known to those of skill can be utilized in carrying out the present invention: however preferred materials and/or methods are described. Materials, reagents and the like to which reference is made in the following description and examples are obtainable from commercial sources, unless otherwise noted.

S. pneumoniae Genomic Sequence

This invention provides nucleotide sequences of the genome of S. pneumoniae which thus comprises a DNA sequence library of S. pneumoniae genomic DNA. The detailed description that follows provides nucleotide sequences of S. pneumoniae, and also describes how the sequences were obtained and how ORFs and protein-coding sequences were identified. Also described are methods of using the disclosed S. pneumoniae sequences in methods including diagnostic and therapeutic applications. Furthermore, the library can be used as a database for identification and comparison of medically important sequences in this and other strains of S. pneumoniae.

To determine the genomic sequence of S. pneumoniae, DNA was isolated from strain 14453 of S. pneumoniae and mechanically sheared by nebulization to a median size of 2 kb. Following size fractionation by gel electrophoresis, the fragments were blunt-ended, ligated to adapter oligonucleotides, and cloned into each of 20 different pMPX vectors (Rice et al., abstracts of Meeting of Genome Mapping and Sequencing, Cold Spring Harbor, N.Y., 5/11-5/15, 1994, p. 225) and the PUC19 vector to construct a series of “shotgun” subclone libraries.

DNA sequencing was achieved using two sequencing methods. The first method used multiplex sequencing procedures essentially as disclosed in Church et al., 1988, Science 240:185; U.S. Pat. Nos. 4,942,124 and 5,149,625). DNA was extracted from pooled cultures and subjected to chemical or enzymatic sequencing. Sequencing reactions were resolved by electrophoresis, and the products were transferred and covalently bound to nylon membranes. Finally, the membranes were sequentially hybridized with a series of labelled oligonucleotides complimentary to “tag” sequences present in the different shotgun cloning vectors. In this manner, a large number of sequences could be obtained from a single set of sequencing reactions. The remainder of the sequencing was performed on ABI377 automated DNA sequencers. The cloning and sequencing procedures are described in more detail in the Exemplification.

Individual sequence reads were assembled using PHRAP (P. Green, Abstracts of DOE Human Genome Program Contractor-Grantee Workshop V, January 1996, p. 157). The average contig length was about 3-4 kb.

A variety of approaches are used to order the contigs so as to obtain a continuous sequence representing the entire S. pneumoniae genome. Synthetic oligonucleotides are designed that are complementary to sequences at the end of each contig. These oligonucleotides may be hybridized to libaries of S. pneumoniae genomic DNA in, for example, lambda phage vectors or plasmid vectors to identify clones that contain sequences corresponding to the junctional regions between individual contigs. Such clones are then used to isolate template DNA and the same oligonucleotides are used as primers in polymerase chain reaction (PCR) to amplify junctional fragments, the nucleotide sequence of which is then determined.

The S. pneumoniae sequences were analyzed for the presence of open reading frames (ORFs) comprising at least 180 nucleotides. As a result of the initial analysis of ORFs based on stop-to-stop codon reads, it should be understood that these ORFs may not correspond to the ORF of a naturally-occurring S. pneumoniae polypeptide. These ORFs may contain start codons which indicate the initiation of protein synthesis of a naturally-occurring S. pneumoniae polypeptide. Such start codons within the ORFs provided herein can be identified by those of ordinary skill in the relevant art, and the resulting ORF and the encoded S. pneumoniae polypeptide is within the scope of this invention. For example, within the ORFs a codon such as AUG or GUG (encoding methionine or valine) which is part of the initiation signal for protein synthesis can be identified and the portion of an ORF to corresponding to a naturally-occurring S. pneumoniae polypeptide can be recognized.

The second analysis of the ORFs included identifying the start codons and the predicted coding regions. These ORFs provided in this invention were defined by one or more of the following methods: evaluating the coding potential of such sequences with the program GENEMARK™ (Borodovsky and McIninch, 1993, Comp. 17:123), distinguishing the coding from noncoding regions using the program Glimmer (Fraser et al, Nature, 1997), determining codon usage (Staden et al., Nucleic Acid Research 10: 141), and each predicted ORF amino acid sequence was compared with all protein sequences found in current GENBANK, SWISS-PROT, and PIR databases using the BLAST algorithm. BLAST identifies local alignments occurring by chance between the ORF sequence and the sequence in the databank (Altschal et al., 1990, L Mol. Biol. 215:403-410). Homologous ORFs (probabilities less than 10⁻⁵ by chance) and ORF's that are probably non-homologous (probabilities greater than 10⁻⁵ by chance) but have good codon usage were identified. Both homologous, sequences and non-homologous sequences with good codon usage are likely to encode proteins and are encompassed by the invention.

S. pneumoniae Nucleic Acids

The nucleic acids of this invention may be obtained directly from the DNA of the above referenced S. pneumoniae strain by using the polymerase chain reaction (PCR). See “PCR, A Practical Approach” (McPherson, Quirke, and Taylor, eds., IRL Press, Oxford, UK, 1991) for details about the PCR. High fidelity PCR can be used to ensure a faithful DNA copy prior to expression. In addition, the authenticity of amplified products can be verified by conventional sequencing methods. Clones carrying the desired sequences described in this invention may also be obtained by screening the libraries by means of the PCR or by hybridization of synthetic oligonucleotide probes to filter lifts of the library colonies or plaques as known in the art (see, e.g., Sambrook et al., Molecular Cloning, A Laboratory Manual 2nd edition, 1989, Cold Spring Harbor Press, NY).

It is also possible to obtain nucleic acids encoding S. pneumoniae polypeptides from a cDNA library in accordance with protocols herein described. A cDNA encoding an S. pneumoniae polypeptide can be obtained by isolating total mRNA from an appropriate strain. Double stranded cDNAs can then be prepared from the total mRNA. Subsequently, the cDNAs can be inserted into a suitable plasmid or viral (e.g., bacteriophage) vector using any one of a number of known techniques. Genes encoding S. pneumoniae polypeptides can also be cloned using established polymerase chain reaction techniques in accordance with the nucleotide sequence information provided by the invention. The nucleic acids of the invention can be DNA or RNA. Preferred nucleic acids of the invention are contained in the Sequence Listing.

The nucleic acids of the invention can also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (See e.g., Itakura et al. U.S. Pat. No. 4,598,049; Caruthers et al. U.S. Pat. No. 4,458,066; and Itakura U.S. Pat. Nos. 4,401,796 and 4,373,071, incorporated by reference herein).

Nucleic acids isolated or synthesized in accordance with features of the present invention are useful, by way of example, without limitation, as probes, primers, capture ligands, antisense genes and for developing expression systems for the synthesis of proteins and peptides corresponding to such sequences. As probes, primers, capture ligands and antisense agents, the nucleic acid normally consists of all or part (approximately twenty or more nucleotides for specificity as well as the ability to form stable hybridization products) of the nucleic acids of the invention contained in the Sequence Listing. These uses are described in further detail below.

Probes

A nucleic acid isolated or synthesized in accordance with the sequence of the invention contained in the Sequence Listing can be used as a probe to specifically detect S. pneumoniae. With the sequence information set forth in the present application, sequences of twenty or more nucleotides are identified which provide the desired inclusivity and exclusivity with respect to S. pneumoniae, and extraneous nucleic acids likely to be encountered during hybridization conditions. More preferably, the sequence will comprise at least twenty to thirty nucleotides to convey stability to the hybridization product formed between the probe and the intended target molecules.

Sequences larger than 1000 nucleotides in length are difficult to synthesize but can be generated by recombinant DNA techniques. Individuals skilled in the art will readily recognize that the nucleic acids, for use as probes, can be provided with a label to facilitate detection of a hybridization product.

Nucleic acid isolated and synthesized in accordance with the sequence of the invention contained in the Sequence Listing can also be useful as probes to detect homologous regions (especially homologous genes) of other Streptococcus species using appropriate stringency hybridization conditions as described herein.

Capture Ligand

For use as a capture ligand, the nucleic acid selected in the manner described above with respect to probes, can be readily associated with a support. The manner in which nucleic acid is associated with supports is well known. Nucleic acid having twenty or more nucleotides in a sequence of the invention contained in the Sequence Listing have utility to separate S. pneumoniae nucleic acid from the nucleic acid of each other and other organisms. Nucleic acid having twenty or more nucleotides in a sequence of the invention contained in the Sequence Listing can also have utility to separate other Streptococcus species from each other and from other organisms. Preferably, the sequence will comprise at least twenty nucleotides to convey stability to the hybridization product formed between the probe and the intended target molecules. Sequences larger than 1000 nucleotides in length are difficult to synthesize but can be generated by recombinant DNA techniques.

Primers

Nucleic acid isolated or synthesized in accordance with the sequences described herein have utility as primers for the amplification of S. pneumoniae nucleic acid. These nucleic acids may also have utility as primers for the amplification of nucleic acids in other Streptococcus species. With respect to polymerase chain reaction (PCR) techniques, nucleic acid sequences of ≧10-15 nucleotides of the invention contained in the Sequence Listing have utility in conjunction with suitable enzymes and reagents to create copies of S. pneumoniae nucleic acid. More preferably, the sequence will comprise twenty or more nucleotides to convey stability to the hybridization product formed between the primer and the intended target molecules. Binding conditions of primers greater than 100 nucleotides are more difficult to control to obtain specificity. High fidelity PCR can be used to ensure a faithful DNA copy prior to expression. In addition, amplified products can be checked by conventional sequencing methods.

The copies can be used in diagnostic assays to detect specific sequences, including genes from S. pneumoniae and/or other Streptococcus species. The copies can also be incorporated into cloning and expression vectors to generate polypeptides corresponding to the nucleic acid synthesized by PCR, as is described in greater detail herein.

Antisense

Nucleic acid or nucleic acid-hybridizing derivatives isolated or synthesized in accordance with the sequences described herein have utility as antisense agents to prevent the expression of S. pneumoniae genes. These sequences also have utility as antisense agents to prevent expression of genes of other Streptococcus species.

In one embodiment, nucleic acid or derivatives corresponding to S. pneumoniae nucleic acids is loaded into a suitable carrier such as a liposome or bacteriophage for introduction into bacterial cells. For example, a nucleic acid having twenty or more nucleotides is capable of binding to bacteria nucleic acid or bacteria messenger RNA. Preferably, the antisense nucleic acid is comprised of 20 or more nucleotides to provide necessary stability of a hybridization product of non-naturally occurring nucleic acid and bacterial nucleic acid and/or bacterial messenger RNA. Nucleic acid having a sequence greater than 1000 nucleotides in length is difficult to synthesize but can be generated by recombinant DNA techniques. Methods for loading antisense nucleic acid in liposomes is known in the art as exemplified by U.S. Pat. No. 4,241,046 issued Dec. 23, 1980 to Papahadjopoulos et al.

The present invention encompasses isolated polypeptides and nucleic acids derived from S. pneumoniae that are useful as reagents for diagnosis of bacterial infection, components of effective antibacterial vaccines, and/or as targets for antibacterial drugs, including anti-S. pneumoniae drugs.

Expression of S. pneumoniae Nucleic Acids

Table 2 provides a list of open reading frames (ORFs) in both strands. An ORF is a region of nucleic acid which encodes a polypeptide. This region normally represents a complete coding sequence or a total sequence and was determined from an initial analysis of stop to stop codons followed by the prediction of start codons. The first column lists the ORF designation. The second and third columns list the SEQ ID numbers for the nucleic acid and amino acid sequences corresponding to each ORF, respectively. The fourth and fifth columns list the length of the nucleic acid ORF and the length of the amino acid ORF, respectively. Most of the nucleotide sequences corresponding to each ORF begin at the first nucleotide of the start codon and end at the nucleotide immediately preceding the next downstream stop codon in the same reading frame. It will be recognized by one skilled in the art that the natural translation initiation sites will correspond to ATG, GTG, or TTG codons located within the ORFs. The natural initiation sites depend not only on the sequence of a start codon but also on the context of the DNA sequence adjacent to the start codon. Usually, a recognizable ribosome binding site is found within 20 nucleotides upstream from the initiation codon. In some cases where genes are translationally coupled and coordinately expressed together in “operons”, ribosome binding sites are not present, but the initiation codon of a downstream gene may occur very close to, or overlap, the stop codon of the an upstream gene in the same operon. The correct start codons can be generally identified rapidly and efficiently because only a few codons need be tested. It is recognized that the translational machinery in bacteria initiates most polypeptide chains with the amino acid methionine. In some cases, polypeptides are post-translationally modified, resulting in an N-terminal amino acid other than methionine in vivo. The sixth and seventh columns provide metrics for assessing the likelihood of the homology match (determined by the BLASTP2 algorithm), as is known in the art, to the genes indicated in the description field. Specifically, the sixth column represents the “Score” for the match (a higher score is a better match), and the seventh column represents the “P-value” for the match (the probability that such a match could have occurred by chance; the lower the value, the more likely the match is valid). If a BLASTP2 score of less than 46 was obtained, no value is reported in the table the “P-value”. The description field provides, where available, the accession number (AC) or the Swissprot accession number (SP), the locus name (LN), Superfamily Classification (CL), the Organism (OR), Source of variant (SR), E.C. number (EC), the gene name (GN), the product name (PN), the Function Description (FN), the Map Position (MP), Left End (LE), Right End (RE), Coding Direction (DI), the Database from which the sequence originates (DB), and the description (DE) or notes (NT) for each ORF. This information allows one of ordinary skill in the art to determine a potential use and function for each identified coding sequence and, as a result, allows the use of the polypeptides of the present invention for commercial and industrial purposes.

Using the information provided in SEQ ID NO: 1-SEQ ID NO: 2661 and in Table 2 together with routine cloning and sequencing methods, one of ordinary skill in the art will be able to clone and sequence all the nucleic acid fragments of interest including open reading frames (ORFs) encoding a large variety proteins of S. pneumoniae.

Nucleic acid isolated or synthesized in accordance with the sequences described herein have utility to generate polypeptides. The nucleic acid of the invention exemplified in SEQ ID NO: 1-SEQ ID NO: 2661 and in Table 2 or fragments of said nucleic acid encoding active portions of S. pneumoniae polypeptides can be cloned into suitable vectors or used to isolate nucleic acid. The isolated nucleic acid is combined with suitable DNA linkers and cloned into a suitable vector.

The function of a specific gene or operon can be ascertained by expression in a bacterial strain under conditions where the activity of the gene product(s) specified by the gene or operon in question can be specifically measured. Alternatively, a gene product may be produced in large quantities in an expressing strain for use as an antigen, an industrial reagent, for structural studies, etc. This expression can be accomplished in a mutant strain which lacks the activity of the gene to be tested, or in a strain that does not produce the same gene product(s). This includes, but is not limited to, Eucaryotic species such as the yeast Saccharomyces cerevisiae, Methanobacterium strains or other Archaea, and Eubacteria such as E. coli, B. subtilis, S. aureus, S. pneumonia or Pseudomonas putida. In some cases the expression host will utilize the natural S. pneumoniae promoter whereas in others, it will be necessary to drive the gene with a promoter sequence derived from the expressing organism (e.g., an E. coli beta-galactosidase promoter for expression in E. coli).

To express a gene product using the natural S. pneumoniae promoter, a procedure such as the following can be used. A restriction fragment containing the gene of interest, together with its associated natural promoter element and regulatory sequences (identified using the DNA sequence data) is cloned into an appropriate recombinant plasmid containing an origin of replication that functions in the host organism and an appropriate selectable marker. This can be accomplished by a number of procedures known to those skilled in the art. It is most preferably done by cutting the plasmid and the fragment to be cloned with the same restriction enzyme to produce compatible ends that can be ligated to join the two pieces together. The recombinant plasmid is introduced into the host organism by, for example, electroporation and cells containing the recombinant plasmid are identified by selection for the marker on the plasmid. Expression of the desired gene product is detected using an assay specific for that gene product.

In the case of a gene that requires a different promoter, the body of the gene (coding sequence) is specifically excised and cloned into an appropriate expression plasmid. This subcloning can be done by several methods, but is most easily accomplished by PCR amplification of a specific fragment and ligation into an expression plasmid after treating the PCR product with a restriction enzyme or exonuclease to create suitable ends for cloning.

A suitable host cell for expression of a gene can be any procaryotic or eucaryotic cell. For example, an S. pneumoniae polypeptide can be expressed in bacterial cells such as E. coli or B. subtilis, insect cells (baculovirus), yeast, or mammalian cells such as Chinese hamster ovary cell (CHO). Other suitable host cells are known to those skilled in the art.

Expression in eucaryotic cells such as mammalian, yeast, or insect cells can lead to partial or complete glycosylation and/or formation of relevant inter- or intra-chain disulfide bonds of a recombinant peptide product. Examples of vectors for expression in yeast S. cerivisae include pYepSec1 (Baldari. et al., (1987) Embo J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al., (1987) Gene 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, Calif.). Baculovirus vectors available for expression of proteins in cultured insect cells (SF 9 cells) include the pAc series (Smith et al., (1983) Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow, V. A., and Summers, M. D., (1989) Virology 170:31-39). Generally, COS cells (Gluzman, Y., (1981) Cell 23:175-182) are used in conjunction with such vectors as pCDM 8 (Aruffo, A. and Seed, B., (1987) Proc. Natl. Acad. Sci. USA 84:8573-8577) for transient amplification/expression in mammalian cells, while CHO (dhfr⁻ Chinese Hamster Ovary) cells are used with vectors such as pMT2PC (Kaufman et al. (1987), EMBO J. 6:187-195) for stable amplification/expression in mammalian cells. Vector DNA can be introduced into mammalian cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, or electroporation. Suitable methods for transforming host cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks.

Expression in procaryotes is most often carried out in E. coli with either fusion or non-fusion inducible expression vectors. Fusion vectors usually add a number of NH₂ terminal amino acids to the expressed target gene. These NH₂ terminal amino acids often are referred to as a reporter group or an affinity purification group. Such reporter groups usually serve two purposes: 1) to increase the solubility of the target recombinant protein; and 2) to aid in the purification of the target recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the reporter group and the target recombinant protein to enable separation of the target recombinant protein from the reporter group subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase, maltose E binding protein, or protein A, respectively, to the target recombinant protein. A preferred reporter group is poly(His), which may be fused to the amino or carboxy terminus of the protein and which renders the recombinant fusion protein easily purifiable by metal chelate chromatography.

Inducible non-fusion expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and pET11d (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 60-89). While target gene expression relies on host RNA polymerase transcription from the hybrid trp-lac fusion promoter in pTrc, expression of target genes inserted into pET11d relies on transcription from the T7 gn10-lac 0 fusion promoter mediated by coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7 gnl under the transcriptional control of the lacUV 5 promoter.

For example, a host cell transfected with a nucleic acid vector directing expression of a nucleotide sequence encoding an S. pneumoniae polypeptide can be cultured under appropriate conditions to allow expression of the polypeptide to occur. The polypeptide may be secreted and isolated from a mixture of cells and medium containing the peptide. Alternatively, the polypeptide may be retained cytoplasmically and the cells harvested, lysed and the protein isolated. A cell culture includes host cells, media and other byproducts. Suitable media for cell culture are well known in the art. Polypeptides of the invention can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for such polypeptides. Additionally, in many situations, polypeptides can be produced by chemical cleavage of a native protein (e.g., tryptic digestion) and the cleavage products can then be purified by standard techniques.

In the case of membrane bound proteins, these can be isolated from a host cell by contacting a membrane-associated protein fraction with a detergent forming a solubilized complex, where the membrane-associated protein is no longer entirely embedded in the membrane fraction and is solubilized at least to an extent which allows it to be chromatographically isolated from the membrane fraction. Several different criteria are used for choosing a detergent suitable for solubilizing these complexes. For example, one property considered is the ability of the detergent to solubilize the S. pneumoniae protein within the membrane fraction at minimal denaturation of the membrane-associated protein allowing for the activity or functionality of the membrane-associated protein to return upon reconstitution of the protein. Another property considered when selecting the detergent is the critical micelle concentration (CMC) of the detergent in that the detergent of choice preferably has a high CMC value allowing for ease of removal after reconstitution. A third property considered when selecting a detergent is the hydrophobicity of the detergent. Typically, membrane-associated proteins are very hydrophobic and therefore detergents which are also hydrophobic, e.g., the triton series, would be useful for solubilizing the hydrophobic proteins. Another property important to a detergent can be the capability of the detergent to remove the S. pneumoniae protein with minimal protein-protein interaction facilitating further purification. A fifth property of the detergent which should be considered is the charge of the detergent. For example, if it is desired to use ion exchange resins in the purification process then preferably detergent should be an uncharged detergent. Chromatographic techniques which can be used in the final purification step are known in the art and include hydrophobic interaction, lectin affinity, ion exchange, dye affinity and immunoaffinity.

One strategy to maximize recombinant S. pneumoniae peptide expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., Gene Expression Technology: Methods in Enzmmology 185, Academic Press, San Diego, Calif. (1990) 119-128). Another strategy would be to alter the nucleic acid encoding an S. pneumoniae peptide to be inserted into an expression vector so that the individual codons for each amino acid would be those preferentially utilized in highly expressed E. coli proteins (Wada et al., (1992) Nuc. Acids Res. 20:2111-2118). Such alteration of nucleic acids of the invention can be carried out by standard DNA synthesis techniques.

The nucleic acids of the invention can also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (See, e.g., Itakura et al. U.S. Pat. No. 4,598,049; Caruthers et al. U.S. Pat. No. 4,458,066; and Itakura U.S. Pat. Nos. 4,401,796 and 4,373,071, incorporated by reference herein).

The present invention provides a library of S. pneumoniae-derived nucleic acid sequences. The libraries provide probes, primers, and markers which can be used as markers in epidemiological studies. The present invention also provides a library of S. pneumoniae-derived nucleic acid sequences which comprise or encode targets for therapeutic drugs.

Nucleic acids comprising any of the sequences disclosed herein or sub-sequences thereof can be prepared by standard methods using the nucleic acid sequence information provided in SEQ ID NO: 1-SEQ ID NO: 2661. For example, DNA can be chemically synthesized using, e.g., the phosphoramidite solid support method of Matteucci et al., 1981, J. Am. Chem. Soc. 103:3185, the method of Yoo et al., 1989, J. Biol. Chem. 764:17078, or other well known methods. This can be done by sequentially linking a series of oligonucleotide cassettes comprising pairs of synthetic oligonucleotides, as described below.

Of course, due to the degeneracy of the genetic code, many different nucleotide sequences can encode polypeptides having the amino acid sequences defined by SEQ ID NO: 2662-SEQ ID NO: 5322 or sub-sequences thereof. The codons can be selected for optimal expression in prokaryotic or eukaryotic systems. Such degenerate variants are also encompassed by this invention.

Insertion of nucleic acids (typically DNAs) encoding the polypeptides of the invention into a vector is easily accomplished when the termini of both the DNAs and the vector comprise compatible restriction sites. If this cannot be done, it may be necessary to modify the termini of the DNAs and/or vector by digesting back single-stranded DNA overhangs generated by restriction endonuclease cleavage to produce blunt ends, or to achieve the same result by filling in the single-stranded termini with an appropriate DNA polymerase.

Alternatively, any site desired may be produced, e.g., by ligating nucleotide sequences (linkers) onto the termini. Such linkers may comprise specific oligonucleotide sequences that define desired restriction sites. Restriction sites can also be generated by the use of the polymerase chain reaction (PCR). See, e.g., Saiki et al., 1988, Science 239:48. The cleaved vector and the DNA fragments may also be modified if required by homopolymeric tailing.

In certain embodiments, the invention encompasses isolated nucleic acid fragments comprising all or part of the individual nucleic acid sequences disclosed herein. The fragments are at least about 8 nucleotides in length, preferably at least about 12 nucleotides in length, and most preferably at least about 15-20 nucleotides in length.

The nucleic acids may be isolated directly from cells. Alternatively, the polymerase chain reaction (PCR) method can be used to produce the nucleic acids of the invention, using either chemically synthesized strands or genomic material as templates. Primers used for PCR can be synthesized using the sequence information provided herein and can further be designed to introduce appropriate new restriction sites, if desirable, to facilitate incorporation into a given vector for recombinant expression.

The nucleic acids of the present invention may be flanked by natural S. pneumoniae regulatory sequences, or may be associated with heterologous sequences, including promoters, enhancers, response elements, signal sequences, polyadenylation sequences, introns, 5′- and 3′-noncoding regions, and the like. The nucleic acids may also be modified by many means known in the art. Non-limiting examples of such modifications include methylation, “caps”, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoroamidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.). Nucleic acids may contain one or more additional covalently linked moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), intercalators (e.g., acridine, psoralen, etc.), chelators (e.g., metals, radioactive metals, iron, oxidative metals, etc.), and alkylators. PNAs are also included. The nucleic acid may be derivatized by formation of a methyl or ethyl phosphotriester or an alkyl phosphoramidate linkage. Furthermore, the nucleic acid sequences of the present invention may also be modified with a label capable of providing a detectable signal, either directly or indirectly. Exemplary labels include radioisotopes, fluorescent molecules, biotin, and the like.

The invention also provides nucleic acid vectors comprising the disclosed S. pneumoniae-derived sequences or derivatives or fragments thereof. A large number of vectors, including plasmid and fungal vectors, have been described for replication and/or expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple cloning or protein expression.

The encoded S. pneumoniae polypeptides may be expressed by using many known vectors, such as pUC plasmids, pET plasmids (Novagen, Inc., Madison, Wis.), or pRSET or pREP (Invitrogen, San Diego, Calif.), and many appropriate host cells, using methods disclosed or cited herein or otherwise known to those skilled in the relevant art. The particular choice of vector/host is not critical to the practice of the invention.

Recombinant cloning vectors will often include one or more replication systems for cloning or expression, one or more markers for selection in the host, e.g. antibiotic resistance, and one or more expression cassettes. The inserted S. pneumoniae coding sequences may be synthesized by standard methods, isolated from natural sources, or prepared as hybrids, etc. Ligation of the S. pneumoniae coding sequences to transcriptional regulatory elements and/or to other amino acid coding sequences may be achieved by known methods. Suitable host cells may be transformed/transfected/infected as appropriate by any suitable method including electroporation, CaCl₂ mediated DNA uptake, fungal infection, microinjection, microprojectile, or other established methods.

Appropriate host cells include bacteria, archebacteria, fungi, especially yeast, and plant and animal cells, especially mammalian cells. Of particular interest are S. pneumoniae, E. coli, B. Subtilis, Saccharomyces cerevisiae, Saccharomyces carlsbergensis, Schizosaccharomyces pombi, SF9 cells, C129 cells, 293 cells, Neurospora, and CHO cells, COS cells, HeLa cells, and immortalized mammalian myeloid and lymphoid cell lines. Preferred replication systems include M13, ColE1, SV40, baculovirus, lambda, adenovirus, and the like. A large number of transcription initiation and termination regulatory regions have been isolated and shown to be effective in the transcription and translation of heterologous proteins in the various hosts. Examples of these regions, methods of isolation, manner of manipulation, etc. are known in the art. Under appropriate expression conditions, host cells can be used as a source of recombinantly produced S. pneumoniae-derived peptides and polypeptides.

Advantageously, vectors may also include a transcription regulatory element (i.e., a promoter) operably linked to the S. pneumoniae portion. The promoter may optionally contain operator portions and/or ribosome binding sites. Non-limiting examples of bacterial promoters compatible with E. coli include: b-lactamase (penicillinase) promoter; lactose promoter; tryptophan (trp) promoter; araBAD (arabinose) operon promoter; lambda-derived P₁ promoter and N gene ribosome binding site; and the hybrid tac promoter derived from sequences of the trp and lac UV5 promoters. Non-limiting examples of yeast promoters include 3-phosphoglycerate kinase promoter, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter, galactokinase (GAL1) promoter, galactoepimerase promoter, and alcohol dehydrogenase (ADH) promoter. Suitable promoters for mammalian cells include without limitation viral promoters such as that from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus (ADV), and bovine papilloma virus (BPV). Mammalian cells may also require terminator sequences, polyA addition sequences and enhancer sequences to increase expression. Sequences which cause amplification of the gene may also be desirable. Furthermore, sequences that facilitate secretion of the recombinant product from cells, including, but not limited to, bacteria, yeast, and animal cells, such as secretory signal sequences and/or prohormone pro region sequences, may also be included. These sequences are well described in the art.

Nucleic acids encoding wild-type or variant S. pneumoniae-derived polypeptides may also be introduced into cells by recombination events. For example, such a sequence can be introduced into a cell, and thereby effect homologous recombination at the site of an endogenous gene or a sequence with substantial identity to the gene. Other recombination-based methods such as nonhomologous recombinations or deletion of endogenous genes by homologous recombination may also be used.

The nucleic acids of the present invention find use as templates for the recombinant production of S. pneumoniae-derived peptides or polypeptides.

Identification and Use of S. pneumoniae Nucleic Acid Sequences

The disclosed S. pneumoniae polypeptide and nucleic acid sequences, or other sequences that are contained within ORFs, including complete protein-coding sequences, of which any of the disclosed S. pneumoniae-specific sequences forms a part, are useful as target components for diagnosis and/or treatment of S. pneumoniae-caused infection

It will be understood that the sequence of an entire protein-coding sequence of which each disclosed nucleic acid sequence forms a part can be isolated and identified based on each disclosed sequence. This can be achieved, for example, by using an isolated nucleic acid encoding the disclosed sequence, or fragments thereof, to prime a sequencing reaction with genomic S. pneumoniae DNA as template; this is followed by sequencing the amplified product. The isolated nucleic acid encoding the disclosed sequence, or fragments thereof, can also be hybridized to S. pneumoniae genomic libraries to identify clones containing additional complete segments of the protein-coding sequence of which the shorter sequence forms a part. Then, the entire protein-coding sequence, or fragments thereof, or nucleic acids encoding all or part of the sequence, or sequence-conservative or function-conservative variants thereof, may be employed in practicing the present invention.

Preferred sequences are those that are useful in diagnostic and/or therapeutic applications. Diagnostic applications include without limitation nucleic-acid-based and antibody-based methods for detecting bacterial infection. Therapeutic applications include without limitation vaccines, passive immunotherapy, and drug treatments directed against gene products that are both unique to bacteria and essential for growth and/or replication of bacteria.

Identification of Nucleic Acids Encoding Vaccine Components and Targets for Agents Effective Against S. pneumoniae

The disclosed S. pneumoniae genome sequence includes segments that direct the synthesis of ribonucleic acids and polypeptides, as well as origins of replication, promoters, other types of regulatory sequences, and intergenic nucleic acids. The invention encompasses nucleic acids encoding immunogenic components of vaccines and targets for agents effective against S. pneumoniae. Identification of said immunogenic components involved in the determination of the function of the disclosed sequences, which can be achieved using a variety of approaches. Non-limiting examples of these approaches are described briefly below.

Homology to Known Sequences:

Computer-assisted comparison of the disclosed S. pneumoniae sequences with previously reported sequences present in publicly available databases is useful for identifying functional S. pneumoniae nucleic acid and polypeptide sequences. It will be understood that protein-coding sequences, for example, may be compared as a whole, and that a high degree of sequence homology between two proteins (such as, for example, >80-90%) at the amino acid level indicates that the two proteins also possess some degree of functional homology, such as, for example, among enzymes involved in metabolism, DNA synthesis, or cell wall synthesis, and proteins involved in transport, cell division, etc. In addition, many structural features of particular protein classes have been identified and correlate with specific consensus sequences, such as, for example, binding domains for nucleotides, DNA, metal ions, and other small molecules; sites for covalent modifications such as phosphorylation, acylation, and the like; sites of protein:protein interactions, etc. These consensus sequences may be quite short and thus may represent only a fraction of the entire protein-coding sequence. Identification of such a feature in an S. pneumoniae sequence is therefore useful in determining the function of the encoded protein and identifying useful targets of antibacterial drugs.

Of particular relevance to the present invention are structural features that are common to secretory, transmembrane, and surface proteins, including secretion signal peptides and hydrophobic transmembrane domains. S. pneumoniae proteins identified as containing putative signal sequences and/or transmembrane domains are useful as immunogenic components of vaccines.

Targets for therapeutic drugs according to the invention include, but are not limited to, polypeptides of the invention, whether unique to S. pneumoniae or not, that are essential for growth and/or viability of S. pneumoniae under at least one growth condition. Polypeptides essential for growth and/or viability can be determined by examining the effect of deleting and/or disrupting the genes, i.e., by so-called gene “knockout”. Alternatively, genetic footprinting can be used (Smith et al., 1995, Proc. Natl. Acad. Sci. USA 92:5479-6433; Published International Application WO 94/26933; U.S. Pat. No. 5,612,180). Still other methods for assessing essentiality includes the ability to isolate conditional lethal mutations in the specific gene (e.g., temperature sensitive mutations). Other useful targets for therapeutic drugs, which include polypeptides that are not essential for growth or viability per se but lead to loss of viability of the cell, can be used to target therapeutic agents to cells.

Strain-Specific Sequences:

Because of the evolutionary relationship between different S. pneumoniae strains, it is believed that the presently disclosed S. pneumoniae sequences are useful for identifying, and/or discriminating between, previously known and new S. pneumoniae strains. It is believed that other S. pneumoniae strains will exhibit at least 70% sequence homology with the presently disclosed sequence. Systematic and routine analyses of DNA sequences derived from samples containing S. pneumoniae strains, and comparison with the present sequence allows for the identification of sequences that can be used to discriminate between strains, as well as those that are common to all S. pneumoniae strains. In one embodiment, the invention provides nucleic acids, including probes, and peptide and polypeptide sequences that discriminate between different strains of S. pneumoniae. Strain-specific components can also be identified functionally by their ability to elicit or react with antibodies that selectively recognize one or more S. pneumoniae strains.

In another embodiment, the invention provides nucleic acids, including probes, and peptide and polypeptide sequences that are common to all S. pneumoniae strains but are not found in other bacterial species.

S. pneumoniae Polypeptides

This invention encompasses isolated S. pneumoniae polypeptides encoded by the disclosed S. pneumoniae genomic sequences, including the polypeptides of the invention contained in the Sequence Listing. Polypeptides of the invention are preferably at least 5 amino acid residues in length. Using the DNA sequence information provided herein, the amino acid sequences of the polypeptides encompassed by the invention can be deduced using methods well-known in the art. It will be understood that the sequence of an entire nucleic acid encoding an S. pneumoniae polypeptide can be isolated and identified based on an ORF that encodes only a fragment of the cognate protein-coding region. This can be achieved, for example, by using the isolated nucleic acid encoding the ORF, or fragments thereof, to prime a polymerase chain reaction with genomic S. pneumoniae DNA as template; this is followed by sequencing the amplified product.

The polypeptides of the present invention, including function-conservative variants of the disclosed ORFs, may be isolated from wild-type or mutant S. pneumoniae cells, or from heterologous organisms or cells (including, but not limited to, bacteria, fungi, insect, plant, and mammalian cells) including S. pneumoniae into which a S. pneumoniae-derived protein-coding sequence has been introduced and expressed. Furthermore, the polypeptides may be part of recombinant fusion proteins.

S. pneumoniae polypeptides of the invention can be chemically synthesized using commercially automated procedures such as those referenced herein, including, without limitation, exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis. The polypeptides are preferably prepared by solid phase peptide synthesis as described by Merrifield, 1963, J. Am. Chem. Soc. 85:2149. The synthesis is carried out with amino acids that are protected at the alpha-amino terminus. Trifunctional amino acids with labile side-chains are also protected with suitable groups to prevent undesired chemical reactions from occurring during the assembly of the polypeptides. The alpha-amino protecting group is selectively removed to allow subsequent reaction to take place at the amino-terminus. The conditions for the removal of the alpha-amino protecting group do not remove the side-chain protecting groups.

The alpha-amino protecting groups are those known to be useful in the art of stepwise polypeptide synthesis. Included are acyl type protecting groups, e.g., formyl, trifluoroacetyl, acetyl, aromatic urethane type protecting groups, e.g., benzyloxycarbonyl (Cbz), substituted benzyloxycarbonyl and 9-fluorenylmethyloxycarbonyl (Fmoc), aliphatic urethane protecting groups, e.g., t-butyloxycarbonyl (Boc), isopropyloxycarbonyl, cyclohexyloxycarbonyl, and alkyl type protecting groups, e.g., benzyl, triphenylmethyl. The preferred protecting group is Boc. The side-chain protecting groups for Tyr include tetrahydropyranyl, tert-butyl, trityl, benzyl, Cbz, 4-Br-Cbz and 2,6-dichlorobenzyl. The preferred side-chain protecting group for Tyr is 2,6-dichlorobenzyl. The side-chain protecting groups for Asp include benzyl, 2,6-dichlorobenzyl, methyl, ethyl and cyclohexyl. The preferred side-chain protecting group for Asp is cyclohexyl. The side-chain protecting groups for Thr and Ser include acetyl, benzoyl, trityl, tetrahydropyranyl, benzyl, 2,6-dichlorobenzyl and Cbz. The preferred protecting group for Thr and Ser is benzyl. The side-chain protecting groups for Arg include nitro, Tos, Cbz, adamantyloxycarbonyl and Boc. The preferred protecting group for Arg is Tos. The side-chain amino group of Lys may be protected with Cbz, 2-Cl-Cbz, Tos or Boc. The 2-Cl-Cbz group is the preferred protecting group for Lys.

The side-chain protecting groups selected must remain intact during coupling and not be removed during the deprotection of the amino-terminus protecting group or during coupling conditions. The side-chain protecting groups must also be removable upon the completion of synthesis, using reaction conditions that will not alter the finished polypeptide.

Solid phase synthesis is usually carried out from the carboxy-terminus by coupling the alpha-amino protected (side-chain protected) amino acid to a suitable solid support. An ester linkage is formed when the attachment is made to a chloromethyl or hydroxymethyl resin, and the resulting polypeptide will have a free carboxyl group at the C-terminus. Alternatively, when a benzhydrylamine or p-methylbenzhydrylamine resin is used, an amide bond is formed and the resulting polypeptide will have a carboxamide group at the C-terminus. These resins are commercially available, and their preparation was described by Stewart et al., 1984, Solid Phase Peptide Synthesis (2nd Edition), Pierce Chemical Co., Rockford, Ill.

The C-terminal amino acid, protected at the side chain if necessary and at the alpha-amino group, is coupled to the benzhydrylamine resin using various activating agents including dicyclohexylcarbodiimide (DCC), N,N′-diisopropyl-carbodiimide and carbonyldiimidazole. Following the attachment to the resin support, the alpha-amino protecting group is removed using trifluoroacetic acid (TFA) or HCl in dioxane at a temperature between 0 and 25° C. Dimethylsulfide is added to the TFA after the introduction of methionine (Met) to suppress possible S-alkylation. After removal of the alpha-amino protecting group, the remaining protected amino acids are coupled stepwise in the required order to obtain the desired sequence.

Various activating agents can be used for the coupling reactions including DCC, N,N′-diisopropyl-carbodiimide, benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium hexa-fluorophosphate (BOP) and DCC-hydroxybenzotriazole (HOBt). Each protected amino acid is used in excess (>2.0 equivalents), and the couplings are usually carried out in N-methylpyrrolidone (NMP) or in DMF, CH₂Cl₂ or mixtures thereof. The extent of completion of the coupling reaction is monitored at each stage, e.g., by the ninhydrin reaction as described by Kaiser et al., 1970, Anal. Biochem. 34:595. In cases where incomplete coupling is found, the coupling reaction is repeated. The coupling reactions can be performed automatically with commercially available instruments.

After the entire assembly of the desired polypeptide, the polypeptide-resin is cleaved with a reagent such as liquid HF for 1-2 hours at 0° C., which cleaves the polypeptide from the resin and removes all side-chain protecting groups. A scavenger such as anisole is usually used with the liquid HF to prevent cations formed during the cleavage from alkylating the amino acid residues present in the polypeptide. The polypeptide-resin may be deprotected with TFA/dithioethane prior to cleavage if desired.

Side-chain to side-chain cyclization on the solid support requires the use of an orthogonal protection scheme which enables selective cleavage of the side-chain functions of acidic amino acids (e.g., Asp) and the basic amino acids (e.g., Lys). The 9-fluorenylmethyl (Fm) protecting group for the side-chain of Asp and the 9-fluorenylmethyloxycarbonyl (Fmoc) protecting group for the side-chain of Lys can be used for this purpose. In these cases, the side-chain protecting groups of the Boc-protected polypeptide-resin are selectively removed with piperidine in DMF. Cyclization is achieved on the solid support using various activating agents including DCC, DCC/HOBt or BOP. The HF reaction is carried out on the cyclized polypeptide-resin as described above.

Methods for polypeptide purification are well-known in the art, including, without limitation, preparative disc-gel electrophoresis, isoelectric focusing, HPLC, reversed-phase HPLC, gel filtration, ion exchange and partition chromatography, and countercurrent distribution. For some purposes, it is preferable to produce the polypeptide in a recombinant system in which the S. pneumoniae protein contains an additional sequence tag that facilitates purification, such as, but not limited to, a polyhistidine sequence. The polypeptide can then be purified from a crude lysate of the host cell by chromatography on an appropriate solid-phase matrix. Alternatively, antibodies produced against a S. pneumoniae protein or against peptides derived therefrom can be used as purification reagents. Other purification methods are possible.

The present invention also encompasses derivatives and homologues of S. pneumoniae-encoded polypeptides. For some purposes, nucleic acid sequences encoding the peptides may be altered by substitutions, additions, or deletions that provide for functionally equivalent molecules, i.e., function-conservative variants. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of similar properties, such as, for example, positively charged amino acids (arginine, lysine, and histidine); negatively charged amino acids (aspartate and glutamate); polar neutral amino acids; and non-polar amino acids. The isolated polypeptides may be modified by, for example, phosphorylation, sulfation, acylation, or other protein modifications. They may also be modified with a label capable of providing a detectable signal, either directly or indirectly, including, but not limited to, radioisotopes and fluorescent compounds.

To identify S. pneumoniae-derived polypeptides for use in the present invention, essentially the complete genomic sequence of a virulent, methicillin-resistant isolate of Streptococcus pneumoniae isolate was analyzed. While, in very rare instances, a nucleic acid sequencing error may be revealed, resolving a rare sequencing error is well within the art, and such an occurrence will not prevent one skilled in the art from practicing the invention.

Also encompassed are any S. pneumoniae polypeptide sequences that are contained within the open reading frames (ORFs), including complete protein-coding sequences, of which any of SEQ ID NO: 2662-SEQ ID NO: 5322 forms a part. Table 2, which is appended herewith and which forms part of the present specification, provides a putative identification of the particular function of a polypeptide which is encoded by each ORF. As a result, one skilled in the art can use the polypeptides of the present invention for commercial and industrial purposes consistent with the type of putative identification of the polypeptide.

The present invention provides a library of S. pneumoniae-derived polypeptide sequences, and a corresponding library of nucleic acid sequences encoding the polypeptides, wherein the polypeptides themselves, or polypeptides contained within ORFs of which they form a part, comprise sequences that are contemplated for use as components of vaccines. Non-limiting examples of such sequences are listed by SEQ ID NO in Table 2, which is appended herewith and which forms part of the present specification.

The present invention also provides a library of S. pneumoniae-derived polypeptide sequences, and a corresponding library of nucleic acid sequences encoding the polypeptides, wherein the polypeptides themselves, or polypeptides contained within ORFs of which they form a part, comprise sequences lacking homology to any known prokaryotic or eukaryotic sequences. Such libraries provide probes, primers, and markers which can be used to diagnose S. pneumoniae infection, including use as markers in epidemiological studies. Non-limiting examples of such sequences are listed by SEQ ID NO in Table 2, which is appended

The present invention also provides a library of S. pneumoniae-derived polypeptide sequences, and a corresponding library of nucleic acid sequences encoding the polypeptides, wherein the polypeptides themselves, or polypeptides contained within ORFs of which they form a part, comprise targets for therapeutic drugs.

Specific Example: Determination of Candidate Protein Antigens for Antibody and Vaccine Development

The selection of candidate protein antigens for vaccine development can be derived from the nucleic acids encoding S. pneumoniae polypeptides. First, the ORF's can be analyzed for homology to other known exported or membrane proteins and analyzed using the discriminant analysis described by Klein, et al. (Klein, P., Kanehsia, M., and DeLisi, C. (1985) Biochimica et Biophysica Acta 815, 468-476) for predicting exported and membrane proteins.

Homology searches can be performed using the BLAST algorithm contained in the Wisconsin Sequence Analysis Package (Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711) to compare each predicted ORF amino acid sequence with all sequences found in the current GenBank, SWISS-PROT and PIR databases. BLAST searches for local alignments between the ORF and the databank sequences and reports a probability score which indicates the probability of finding this sequence by chance in the database. ORF's with significant homology (e.g. probabilities lower than 1×10⁻⁶ that the homology is only due to random chance) to membrane or exported proteins represent protein antigens for vaccine development. Possible functions can be provided to S. pneumoniae genes based on sequence homology to genes cloned in other organisms.

Discriminant analysis (Klein, et al. supra) can be used to examine the ORF amino acid sequences. This algorithm uses the intrinsic information contained in the ORF amino acid sequence and compares it to information derived from the properties of known membrane and exported proteins. This comparison predicts which proteins will be exported, membrane associated or cytoplasmic. ORF amino acid sequences identified as exported or membrane associated by this algorithm are likely protein antigens for vaccine development.

Production of Fragments and Analogs of S. pneumoniae Nucleic Acids and Polypeptides

Based on the discovery of the S. pneumoniae gene products of the invention provided in the Sequence Listing, one skilled in the art can alter the disclosed structure (of S. pneumoniae genes), e.g., by producing fragments or analogs, and test the newly produced structures for activity. Examples of techniques known to those skilled in the relevant art which allow the production and testing of fragments and analogs are discussed below. These, or analogous methods can be used to make and screen libraries of polypeptides, e.g., libraries of random peptides or libraries of fragments or analogs of cellular proteins for the ability to bind S. pneumoniae polypeptides. Such screens are useful for the identification of inhibitors of S. pneumoniae.

Generation of Fragments

Fragments of a protein can be produced in several ways, e.g., recombinantly, by proteolytic digestion, or by chemical synthesis. Internal or terminal fragments of a polypeptide can be generated by removing one or more nucleotides from one end (for a terminal fragment) or both ends (for an internal fragment) of a nucleic acid which encodes the polypeptide. Expression of the mutagenized DNA produces polypeptide fragments. Digestion with “end-nibbling” endonucleases can thus generate DNA's which encode an array of fragments. DNA's which encode fragments of a protein can also be generated by random shearing, restriction digestion or a combination of the above-discussed methods.

Fragments can also be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. For example, peptides of the present invention may be arbitrarily divided into fragments of desired length with no overlap of the fragments, or divided into overlapping fragments of a desired length.

Alteration of Nucleic Acids and Polypeptides: Random Methods

Amino acid sequence variants of a protein can be prepared by random mutagenesis of DNA which encodes a protein or a particular domain or region of a protein. Useful methods include PCR mutagenesis and saturation mutagenesis. A library of random amino acid sequence variants can also be generated by the synthesis of a set of degenerate oligonucleotide sequences. (Methods for screening proteins in a library of variants are elsewhere herein).

PCR Mutagenesis

In PCR mutagenesis, reduced Taq polymerase fidelity is used to introduce random mutations into a cloned fragment of DNA (Leung et al., 1989, Technique 1:11-15). The DNA region to be mutagenized is amplified using the polymerase chain reaction (PCR) under conditions that reduce the fidelity of DNA synthesis by Taq DNA polymerase, e.g., by using a dGTP/dATP ratio of five and adding Mn²⁺ to the PCR reaction. The pool of amplified DNA fragments are inserted into appropriate cloning vectors to provide random mutant libraries.

Saturation Mutagenesis

Saturation mutagenesis allows for the rapid introduction of a large number of single base substitutions into cloned DNA fragments (Mayers et al., 1985, Science 229:242). This technique includes generation of mutations, e.g., by chemical treatment or irradiation of single-stranded DNA in vitro, and synthesis of a complimentary DNA strand. The mutation frequency can be modulated by modulating the severity of the treatment, and essentially all possible base substitutions can be obtained. Because this procedure does not involve a genetic selection for mutant fragments both neutral substitutions, as well as those that alter function, are obtained. The distribution of point mutations is not biased toward conserved sequence elements.

Degenerate Oligonucleotides

A library of homologs can also be generated from a set of degenerate oligonucleotide sequences. Chemical synthesis of a degenerate sequences can be carried out in an automatic DNA synthesizer, and the synthetic genes then ligated into an appropriate expression vector. The synthesis of degenerate oligonucleotides is known in the art (see for example, Narang, S A (1983) Tetrahedron 39:3; Itakura et al. (1981) Recombinant DNA, Proc 3rd Cleveland Sympos. Macromolecules, ed. A G Walton, Amsterdam: Elsevier pp 273-289; Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477. Such techniques have been employed in the directed evolution of other proteins (see, for example, Scott et al. (1990) Science 249:386-390; Roberts et al. (1992) PNAS 89:2429-2433; Devlin et al. (1990) Science 249: 404-406; Cwirla et al. (1990) PNAS 87: 6378-6382; as well as U.S. Pat. Nos. 5,223,409, 5,198,346, and 5,096,815).

Alteration of Nucleic Acids and Polypeptides: Methods for Directed Mutagenesis

Non-random or directed, mutagenesis techniques can be used to provide specific sequences or mutations in specific regions. These techniques can be used to create variants which include, e.g., deletions, insertions, or substitutions, of residues of the known amino acid sequence of a protein. The sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conserved amino acids and then with more radical choices depending upon results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3.

Alanine Scanning Mutagenesis

Alanine scanning mutagenesis is a useful method for identification of certain residues or regions of the desired protein that are preferred locations or domains for mutagenesis, Cunningham and Wells (Science 244:1081-1085, 1989). In alanine scanning, a residue or group of target residues are identified (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine). Replacement of an amino acid can affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensitivity to the substitutions are then refined by introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to optimize the performance of a mutation at a given site, alanine scanning or random mutagenesis may be conducted at the target codon or region and the expressed desired protein subunit variants are screened for the optimal combination of desired activity.

Oligonucleotide-Mediated Mutagenesis

Oligonucleotide-mediated mutagenesis is a useful method for preparing substitution, deletion, and insertion variants of DNA, see, e.g., Adelman et al., (DNA 2:183, 1983). Briefly, the desired DNA is altered by hybridizing an oligonucleotide encoding a mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of the desired protein. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the desired protein DNA. Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea et al. (Proc. Natl. Acad. Sci. USA, 75: 5765[1978]).

Cassette Mutagenesis

Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells et al. (Gene, 34:315[1985]). The starting material is a plasmid (or other vector) which includes the protein subunit DNA to be mutated. The codon(s) in the protein subunit DNA to be mutated are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction sites exist, they may be generated using the above-described oligonucleotide-mediated mutagenesis method to introduce them at appropriate locations in the desired protein subunit DNA. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have 3′ and 5′ ends that are comparable with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid. This plasmid now contains the mutated desired protein subunit DNA sequence.

Combinatorial Mutagenesis

Combinatorial mutagenesis can also be used to generate mutants (Ladner et al., WO 88/06630). In this method, the amino acid sequences for a group of homologs or other related proteins are aligned, preferably to promote the highest homology possible. All of the amino acids which appear at a given position of the aligned sequences can be selected to create a degenerate set of combinatorial sequences. The variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level, and is encoded by a variegated gene library. For example, a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential sequences are expressible as individual peptides, or alternatively, as a set of larger fusion proteins containing the set of degenerate sequences.

Other Modifications of S. pneumoniae Nucleic Acids and Polypeptides

It is possible to modify the structure of an S. pneumoniae polypeptide for such purposes as increasing solubility, enhancing stability (e.g., shelf life ex vivo and resistance to proteolytic degradation in vivo). A modified S. pneumoniae protein or peptide can be produced in which the amino acid sequence has been altered, such as by amino acid substitution, deletion, or addition as described herein.

An S. pneumoniae peptide can also be modified by substitution of cysteine residues preferably with alanine, serine, threonine, leucine or glutamic acid residues to minimize dimerization via disulfide linkages. In addition, amino acid side chains of fragments of the protein of the invention can be chemically modified. Another modification is cyclization of the peptide.

In order to enhance stability and/or reactivity, an S. pneumoniae polypeptide can be modified to incorporate one or more polymorphisms in the amino acid sequence of the protein resulting from any natural allelic variation. Additionally, D-amino acids, non-natural amino acids, or non-amino acid analogs can be substituted or added to produce a modified protein within the scope of this invention. Furthermore, an S. pneumoniae polypeptide can be modified using polyethylene glycol (PEG) according to the method of A. Sehon and co-workers (Wie et al., supra) to produce a protein conjugated with PEG. In addition, PEG can be added during chemical synthesis of the protein. Other modifications of S. pneumoniae proteins include reduction/alkylation (Tarr, Methods of Protein Microcharacterization, J. E. Silver ed., Humana Press, Clifton N.J. 155-194 (1986)); acylation (Tarr, supra); chemical coupling to an appropriate carrier (Mishell and Shiigi, eds, Selected Methods in Cellular Immunology, WH Freeman, San Francisco, Calif. (1980), U.S. Pat. No. 4,939,239; or mild formalin treatment (Marsh, (1971) Int. Arch. of Allergy and Appl. Immunol, 41: 199-215).

To facilitate purification and potentially increase solubility of an S. pneumoniae protein or peptide, it is possible to add an amino acid fusion moiety to the peptide backbone. For example, hexa-histidine can be added to the protein for purification by immobilized metal ion affinity chromatography (Hochuli, E. et al., (1988) Bio/Technology, 6: 1321-1325). In addition, to facilitate isolation of peptides free of irrelevant sequences, specific endoprotease cleavage sites can be introduced between the sequences of the fusion moiety and the peptide.

To potentially aid proper antigen processing of epitopes within an S. pneumoniae polypeptide, canonical protease sensitive sites can be engineered between regions, each comprising at least one epitope via recombinant or synthetic methods. For example, charged amino acid pairs, such as KK or RR, can be introduced between regions within a protein or fragment during recombinant construction thereof. The resulting peptide can be rendered sensitive to cleavage by cathepsin and/or other trypsin-like enzymes which would generate portions of the protein containing one or more epitopes. In addition, such charged amino acid residues can result in an increase in the solubility of the peptide.

Primary Methods for Screening Polypeptides and Analogs

Various techniques are known in the art for screening generated mutant gene products. Techniques for screening large gene libraries often include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the genes under conditions in which detection of a desired activity, e.g., in this case, binding to S. pneumoniae polypeptide or an interacting protein, facilitates relatively easy isolation of the vector encoding the gene whose product was detected. Each of the techniques described below is amenable to high through-put analysis for screening large numbers of sequences created, e.g., by random mutagenesis techniques.

Two Hybrid Systems

Two hybrid assays such as the system described above (as with the other screening methods described herein), can be used to identify polypeptides, e.g., fragments or analogs of a naturally-occurring S. pneumoniae polypeptide, e.g., of cellular proteins, or of randomly generated polypeptides which bind to an S. pneumoniae protein. (The S. pneumoniae domain is used as the bait protein and the library of variants are expressed as prey fusion proteins.) In an analogous fashion, a two hybrid assay (as with the other screening methods described herein), can be used to find polypeptides which bind a S. pneumoniae polypeptide.

Display Libraries

In one approach to screening assays, the candidate peptides are displayed on the surface of a cell or viral particle, and the ability of particular cells or viral particles to bind an appropriate receptor protein via the displayed product is detected in a “panning assay”. For example, the gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein detected by panning (Ladner et al., WO 88/06630; Fuchs et al. (1991) Bio/Technology 9:1370-1371; and Goward et al. (1992) TIBS 18:136-140). In a similar fashion, a detectably labeled ligand can be used to score for potentially functional peptide homologs. Fluorescently labeled ligands, e.g., receptors, can be used to detect homologs which retain ligand-binding activity. The use of fluorescently labeled ligands, allows cells to be visually inspected and separated under a fluorescence microscope, or, where the morphology of the cell permits, to be separated by a fluorescence-activated cell sorter.

A gene library can be expressed as a fusion protein on the surface of a viral particle. For instance, in the filamentous phage system, foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits. First, since these phage can be applied to affinity matrices at concentrations well over 10¹³ phage per milliliter, a large number of phage can be screened at one time. Second, since each infectious phage displays a gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection. The group of almost identical E. coli filamentous phages M13, fd., and f1 are most often used in phage display libraries. Either of the phage gIII or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle. Foreign epitopes can be expressed at the NH₂-terminal end of pIII and phage bearing such epitopes recovered from a large excess of phage lacking this epitope (Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) J. Biol. Chem. 267:16007-16010; Griffiths et al. (1993) EMBO J. 12:725-734; Clackson et al. (1991) Nature 352:624-628; and Barbas et al. (1992) PNAS 89:4457-4461).

A common approach uses the maltose receptor of E. coli (the outer membrane protein, LamB) as a peptide fusion partner (Charbit et al. (1986) EMBO 5, 3029-3037). Oligonucleotides have been inserted into plasmids encoding the LamB gene to produce peptides fused into one of the extracellular loops of the protein. These peptides are available for binding to ligands, e.g., to antibodies, and can elicit an immune response when the cells are administered to animals. Other cell surface proteins, e.g., OmpA (Schorr et al. (1991) Vaccines 91, pp. 387-392), PhoE (Agterberg, et al. (1990) Gene 88, 37-45), and PAL (Fuchs et al. (1991) Bio/Tech 9, 1369-1372), as well as large bacterial surface structures have served as vehicles for peptide display. Peptides can be fused to pilin, a protein which polymerizes to form the pilus-a conduit for interbacterial exchange of genetic information (Thiry et al. (1989) Appl. Environ. Microbiol. 55, 984-993). Because of its role in interacting with other cells, the pilus provides a useful support for the presentation of peptides to the extracellular environment. Another large surface structure used for peptide display is the bacterial motive organ, the flagellum. Fusion of peptides to the subunit protein flagellin offers a dense array of many peptide copies on the host cells (Kuwajima et al. (1988) Bio/Tech. 6, 1080-1083). Surface proteins of other bacterial species have also served as peptide fusion partners. Examples include the Staphylococcus protein A and the outer membrane IgA protease of Neisseria (Hansson et al. (1992) J. Bacteriol. 174, 4239-4245 and Klauser et al. (1990) EMBO J. 9, 1991-1999).

In the filamentous phage systems and the LamB system described above, the physical link between the peptide and its encoding DNA occurs by the containment of the DNA within a particle (cell or phage) that carries the peptide on its surface. Capturing the peptide captures the particle and the DNA within. An alternative scheme uses the DNA-binding protein LacI to form a link between peptide and DNA (Cull et al. (1992) PNAS USA 89:1865-1869). This system uses a plasmid containing the LacI gene with an oligonucleotide cloning site at its 3′-end. Under the controlled induction by arabinose, a LacI-peptide fusion protein is produced. This fusion retains the natural ability of LacI to bind to a short DNA sequence known as LacO operator (LacO). By installing two copies of LacO on the expression plasmid, the LacI-peptide fusion binds tightly to the plasmid that encoded it. Because the plasmids in each cell contain only a single oligonucleotide sequence and each cell expresses only a single peptide sequence, the peptides become specifically and stablely associated with the DNA sequence that directed its synthesis. The cells of the library are gently lysed and the peptide-DNA complexes are exposed to a matrix of immobilized receptor to recover the complexes containing active peptides. The associated plasmid DNA is then reintroduced into cells for amplification and DNA sequencing to determine the identity of the peptide ligands. As a demonstration of the practical utility of the method, a large random library of dodecapeptides was made and selected on a monoclonal antibody raised against the opioid peptide dynorphin B. A cohort of peptides was recovered, all related by a consensus sequence corresponding to a six-residue portion of dynorphin B. (Cull et al. (1992) Proc. Natl. Acad. Sci. U.S.A. 89-1869)

This scheme, sometimes referred to as peptides-on-plasmids, differs in two important ways from the phage display methods. First, the peptides are attached to the C-terminus of the fusion protein, resulting in the display of the library members as peptides having free carboxy termini. Both of the filamentous phage coat proteins, pIII and pVIII, are anchored to the phage through their C-termini, and the guest peptides are placed into the outward-extending N-terminal domains. In some designs, the phage-displayed peptides are presented right at the amino terminus of the fusion protein. (Cwirla, et al. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 6378-6382) A second difference is the set of biological biases affecting the population of peptides actually present in the libraries. The LacI fusion molecules are confined to the cytoplasm of the host cells. The phage coat fusions are exposed briefly to the cytoplasm during translation but are rapidly secreted through the inner membrane into the periplasmic compartment, remaining anchored in the membrane by their C-terminal hydrophobic domains, with the N-termini, containing the peptides, protruding into the periplasm while awaiting assembly into phage particles. The peptides in the LacI and phage libraries may differ significantly as a result of their exposure to different proteolytic activities. The phage coat proteins require transport across the inner membrane and signal peptidase processing as a prelude to incorporation into phage. Certain peptides exert a deleterious effect on these processes and are underrepresented in the libraries (Gallop et al. (1994) J. Med. Chem. 37(9):1233-1251). These particular biases are not a factor in the LacI display system.

The number of small peptides available in recombinant random libraries is enormous. Libraries of 10⁷-10⁹ independent clones are routinely prepared. Libraries as large as 10¹¹ recombinants have been created, but this size approaches the practical limit for clone libraries. This limitation in library size occurs at the step of transforming the DNA containing randomized segments into the host bacterial cells. To circumvent this limitation, an in vitro system based on the display of nascent peptides in polysome complexes has recently been developed. This display library method has the potential of producing libraries 3-6 orders of magnitude larger than the currently available phage/phagemid or plasmid libraries. Furthermore, the construction of the libraries, expression of the peptides, and screening, is done in an entirely cell-free format.

In one application of this method (Gallop et al. (1994) J. Med. Chem. 37(9):1233-1251), a molecular DNA library encoding 1012 decapeptides was constructed and the library expressed in an E. coli S30 in vitro coupled transcription/translation system. Conditions were chosen to stall the ribosomes on the mRNA, causing the accumulation of a substantial proportion of the RNA in polysomes and yielding complexes containing nascent peptides still linked to their encoding RNA. The polysomes are sufficiently robust to be affinity purified on immobilized receptors in much the same way as the more conventional recombinant peptide display libraries are screened. RNA from the bound complexes is recovered, converted to cDNA, and amplified by PCR to produce a template for the next round of synthesis and screening. The polysome display method can be coupled to the phage display system. Following several rounds of screening, cDNA from the enriched pool of polysomes was cloned into a phagemid vector. This vector serves as both a peptide expression vector, displaying peptides fused to the coat proteins, and as a DNA sequencing vector for peptide identification. By expressing the polysome-derived peptides on phage, one can either continue the affinity selection procedure in this format or assay the peptides on individual clones for binding activity in a phage ELISA, or for binding specificity in a completion phage ELISA (Barret, et al. (1992) Anal. Biochem 204, 357-364). To identify the sequences of the active peptides one sequences the DNA produced by the phagemid host.

Secondary Screening of Polypeptides and Analogs

The high through-put assays described above can be followed by secondary screens in order to identify further biological activities which will, e.g., allow one skilled in the art to differentiate agonists from antagonists. The type of a secondary screen used will depend on the desired activity that needs to be tested. For example, an assay can be developed in which the ability to inhibit an interaction between a protein of interest and its respective ligand can be used to identify antagonists from a group of peptide fragments isolated though one of the primary screens described above.

Therefore, methods for generating fragments and analogs and testing them for activity are known in the art. Once the core sequence of interest is identified, it is routine for one skilled in the art to obtain analogs and fragments.

Peptide Mimetics of S. pneumoniae Polypeptides

The invention also provides for reduction of the protein binding domains of the subject S. pneumoniae polypeptides to generate mimetics, e.g. peptide or non-peptide agents. The peptide mimetics are able to disrupt binding of a polypeptide to its counter ligand, e.g., in the case of an S. pneumoniae polypeptide binding to a naturally occurring ligand. The critical residues of a subject S. pneumoniae polypeptide which are involved in molecular recognition of a polypeptide can be determined and used to generate S. pneumoniae-derived peptidomimetics which competitively or noncompetitively inhibit binding of the S. pneumoniae polypeptide with an interacting polypeptide (see, for example, European patent applications EP-412,762A and EP-B31,080A).

For example, scanning mutagenesis can be used to map the amino acid residues of a particular S. pneumoniae polypeptide involved in binding an interacting polypeptide, peptidomimetic compounds (e.g. diazepine or isoquinoline derivatives) can be generated which mimic those residues in binding to an interacting polypeptide, and which therefore can inhibit binding of an S. pneumoniae polypeptide to an interacting polypeptide and thereby interfere with the function of S. pneumoniae polypeptide. For instance, non-hydrolyzable peptide analogs of such residues can be generated using benzodiazepine (e.g., see Freidinger et al. in Peptides: Chemistry and Biology, G. R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), azepine (e.g., see Huffman et al. in Peptides: Chemistry and Biology, G. R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gama lactam rings (Garvey et al. in Peptides: Chemistry and Biology, G. R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson et al. (1986) J Med Chem 29:295; and Ewenson et al. in Peptides: Structure and Function (Proceedings of the 9th American Peptide Symposium) Pierce Chemical Co. Rockland, Ill., 1985), b-turn dipeptide cores (Nagai et al. (1985) Tetrahedron Lett 26:647; and Sato et al. (1986) J Chem Soc Perkin Trans 1:1231), and b-aminoalcohols (Gordon et al. (1985) Biochem Biophys Res Commun 126:419; and et al. (1986) Biochem Biophys Res Commun 134:71).

Vaccine Formulations for S. pneumoniae Nucleic Acids and Polypeptides

This invention also features vaccine compositions for protection against infection by S. pneumoniae or for treatment of S. pneumoniae infection, a gram-negative spiral microaerophilic bacterium. In one embodiment, the vaccine compositions contain one or more immunogenic components such as a surface protein from S. pneumoniae, or portion thereof, and a pharmaceutically acceptable carrier. Nucleic acids within the scope of the invention are exemplified by the nucleic acids of the invention contained in the Sequence Listing which encode S. pneumoniae surface proteins. Any nucleic acid encoding an immunogenic S. pneumoniae protein, or portion thereof, which is capable of expression in a cell, can be used in the present invention. These vaccines have therapeutic and prophylactic utilities.

One aspect of the invention provides a vaccine composition for protection against infection by S. pneumoniae which contains at least one immunogenic fragment of an S. pneumoniae protein and a pharmaceutically acceptable carrier. Preferred fragments include peptides of at least about 10 amino acid residues in length, preferably about 10-20 amino acid residues in length, and more preferably about 12-16 amino acid residues in length.

Immunogenic components of the invention can be obtained, for example, by screening polypeptides recombinantly produced from the corresponding fragment of the nucleic acid encoding the full-length S. pneumoniae protein. In addition, fragments can be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry.

In one embodiment, immunogenic components are identified by the ability of the peptide to stimulate T cells. Peptides which stimulate T cells, as determined by, for example, T cell proliferation or cytokine secretion are defined herein as comprising at least one T cell epitope. T cell epitopes are believed to be involved in initiation and perpetuation of the immune response to the protein allergen which is responsible for the clinical symptoms of allergy. These T cell epitopes are thought to trigger early events at the level of the T helper cell by binding to an appropriate HLA molecule on the surface of an antigen presenting cell, thereby stimulating the T cell subpopulation with the relevant T cell receptor for the epitope. These events lead to T cell proliferation, lymphokine secretion, local inflammatory reactions, recruitment of additional immune cells to the site of antigen/T cell interaction, and activation of the B cell cascade, leading to the production of antibodies. A T cell epitope is the basic element, or smallest unit of recognition by a T cell receptor, where the epitope comprises amino acids essential to receptor recognition (e.g., approximately 6 or 7 amino acid residues). Amino acid sequences which mimic those of the T cell epitopes are within the scope of this invention.

Screening immunogenic components can be accomplished using one or more of several different assays. For example, in vitro, peptide T cell stimulatory activity is assayed by contacting a peptide known or suspected of being immunogenic with an antigen presenting cell which presents appropriate MHC molecules in a T cell culture. Presentation of an immunogenic S. pneumoniae peptide in association with appropriate MHC molecules to T cells in conjunction with the necessary co-stimulation has the effect of transmitting a signal to the T cell that induces the production of increased levels of cytokines, particularly of interleukin-2 and interleukin-4. The culture supernatant can be obtained and assayed for interleukin-2 or other known cytokines. For example, any one of several conventional assays for interleukin-2 can be employed, such as the assay described in Proc. Natl. Acad. Sci USA, 86: 1333 (1989) the pertinent portions of which are incorporated herein by reference. A kit for an assay for the production of interferon is also available from Genzyme Corporation (Cambridge, Mass.).

Alternatively, a common assay for T cell proliferation entails measuring tritiated thymidine incorporation. The proliferation of T cells can be measured in vitro by determining the amount of ³H-labeled thymidine incorporated into the replicating DNA of cultured cells. Therefore, the rate of DNA synthesis and, in turn, the rate of cell division can be quantified.

Vaccine compositions of the invention containing immunogenic components (e.g., S. pneumoniae polypeptide or fragment thereof or nucleic acid encoding an S. pneumoniae polypeptide or fragment thereof) preferably include a pharmaceutically acceptable carrier. The term “pharmaceutically acceptable carrier” refers to a carrier that does not cause an allergic reaction or other untoward effect in patients to whom it is administered. Suitable pharmaceutically acceptable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the antibody. For vaccines of the invention containing S. pneumoniae polypeptides, the polypeptide is co-administered with a suitable adjuvant.

It will be apparent to those of skill in the art that the therapeutically effective amount of DNA or protein of this invention will depend, inter alia, upon the administration schedule, the unit dose of antibody administered, whether the protein or DNA is administered in combination with other therapeutic agents, the immune status and health of the patient, and the therapeutic activity of the particular protein or DNA.

Vaccine compositions are conventionally administered parenterally, e.g., by injection, either subcutaneously or intramuscularly. Methods for intramuscular immunization are described by Wolff et al. (1990) Science 247: 1465-1468 and by Sedegah et al. (1994) Immunology 91: 9866-9870. Other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications. Oral immunization is preferred over parenteral methods for inducing protection against infection by S. pneumoniae. Cain et. al. (1993) Vaccine 11: 637-642. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like.

The vaccine compositions of the invention can include an adjuvant, including, but not limited to aluminum hydroxide; N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP); N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP); N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine (CGP 19835A, referred to a MTP-PE); RIBI, which contains three components from bacteria; monophosphoryl lipid A; trehalose dimycoloate; cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion; and cholera toxin. Others which may be used are non-toxic derivatives of cholera toxin, including its B subunit, and/or conjugates or genetically engineered fusions of the S. pneumoniae polypeptide with cholera toxin or its B subunit, procholeragenoid, fungal polysaccharides, including schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of E. coli, non-S. pneumoniae bacterial lysates, block polymers or saponins.

Other suitable delivery methods include biodegradable microcapsules or immuno-stimulating complexes (ISCOMs), cochleates, or liposomes, genetically engineered attenuated live vectors such as viruses or bacteria, and recombinant (chimeric) virus-like particles, e.g., bluetongue. The amount of adjuvant employed will depend on the type of adjuvant used. For example, when the mucosal adjuvant is cholera toxin, it is suitably used in an amount of 5 mg to 50 mg, for example 10 mg to 35 mg. When used in the form of microcapsules, the amount used will depend on the amount employed in the matrix of the microcapsule to achieve the desired dosage. The determination of this amount is within the skill of a person of ordinary skill in the art.

Carrier systems in humans may include enteric release capsules protecting the antigen from the acidic environment of the stomach, and including S. pneumoniae polypeptide in an insoluble form as fusion proteins. Suitable carriers for the vaccines of the invention are enteric coated capsules and polylactide-glycolide microspheres. Suitable diluents are 0.2 N NaHCO3 and/or saline.

Vaccines of the invention can be administered as a primary prophylactic agent in adults or in children, as a secondary prevention, after successful eradication of S. pneumoniae in an infected host, or as a therapeutic agent in the aim to induce an immune response in a susceptible host to prevent infection by S. pneumoniae. The vaccines of the invention are administered in amounts readily determined by persons of ordinary skill in the art. Thus, for adults a suitable dosage will be in the range of 10 mg to 10 g, preferably 10 mg to 100 mg. A suitable dosage for adults will also be in the range of 5 mg to 500 mg. Similar dosage ranges will be applicable for children. Those skilled in the art will recognize that the optimal dose may be more or less depending upon the patient's body weight, disease, the route of administration, and other factors. Those skilled in the art will also recognize that appropriate dosage levels can be obtained based on results with known oral vaccines such as, for example, a vaccine based on an E. coli lysate (6 mg dose daily up to total of 540 mg) and with an enterotoxigenic E. coli purified antigen (4 doses of 1 mg) (Schulman et al., J. Urol. 150:917-921 (1993); Boedecker et al., American Gastroenterological Assoc. 999:A-222 (1993)). The number of doses will depend upon the disease, the formulation, and efficacy data from clinical trials. Without intending any limitation as to the course of treatment, the treatment can be administered over 3 to 8 doses for a primary immunization schedule over 1 month (Boedeker, American Gastroenterological Assoc. 888:A-222 (1993)).

In a preferred embodiment, a vaccine composition of the invention can be based on a killed whole E. coli preparation with an immunogenic fragment of an S. pneumoniae protein of the invention expressed on its surface or it can be based on an E. coli lysate, wherein the killed E. coli acts as a carrier or an adjuvant.

It will be apparent to those skilled in the art that some of the vaccine compositions of the invention are useful only for preventing S. pneumoniae infection, some are useful only for treating S. pneumoniae infection, and some are useful for both preventing and treating S. pneumoniae infection. In a preferred embodiment, the vaccine composition of the invention provides protection against S. pneumoniae infection by stimulating humoral and/or cell-mediated immunity against S. pneumoniae. It should be understood that amelioration of any of the symptoms of S. pneumoniae infection is a desirable clinical goal, including a lessening of the dosage of medication used to treat S. pneumoniae-caused disease, or an increase in the production of antibodies in the serum or mucous of patients.

Antibodies Reactive with S. pneumoniae Polypeptides

The invention also includes antibodies specifically reactive with the subject S. pneumoniae polypeptide. Anti-protein/anti-peptide antisera or monoclonal antibodies can be made by standard protocols (See, for example, Antibodies: A Laboratory Manual ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)). A mammal such as a mouse, a hamster or rabbit can be immunized with an immunogenic form of the peptide. Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers or other techniques well known in the art. An immunogenic portion of the subject S. pneumoniae polypeptide can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of antibodies.

In a preferred embodiment, the subject antibodies are immunospecific for antigenic determinants of the S. pneumoniae polypeptides of the invention, e.g. antigenic determinants of a polypeptide of the invention contained in the Sequence Listing, or a closely related human or non-human mammalian homolog (e.g., 90% homologous, more preferably at least 95% homologous). In yet a further preferred embodiment of the invention, the anti-S. pneumoniae antibodies do not substantially cross react (i.e., react specifically) with a protein which is for example, less than 80% percent homologous to a sequence of the invention contained in the Sequence Listing. By “not substantially cross react”, it is meant that the antibody has a binding affinity for a non-homologous protein which is less than 10 percent, more preferably less than 5 percent, and even more preferably less than 1 percent, of the binding affinity for a protein of the invention contained in the Sequence Listing. In a most preferred embodiment, there is no cross-reactivity between bacterial and mammalian antigens.

The term antibody as used herein is intended to include fragments thereof which are also specifically reactive with S. pneumoniae polypeptides. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab′)₂ fragments can be generated by treating antibody with pepsin. The resulting F(ab′)₂ fragment can be treated to reduce disulfide bridges to produce Fab′ fragments. The antibody of the invention is further intended to include bispecific and chimeric molecules having an anti-S. pneumoniae portion.

Both monoclonal and polyclonal antibodies (Ab) directed against S. pneumoniae polypeptides or S. pneumoniae polypeptide variants, and antibody fragments such as Fab′ and F(ab′)₂, can be used to block the action of S. pneumoniae polypeptide and allow the study of the role of a particular S. pneumoniae polypeptide of the invention in aberrant or unwanted intracellular signaling, as well as the normal cellular function of the S. pneumoniae and by microinjection of anti-S. pneumoniae polypeptide antibodies of the present invention.

Antibodies which specifically bind S. pneumoniae epitopes can also be used in immunohistochemical staining of tissue samples in order to evaluate the abundance and pattern of expression of S. pneumoniae antigens. Anti S. pneumoniae polypeptide antibodies can be used diagnostically in immuno-precipitation and immuno-blotting to detect and evaluate S. pneumoniae levels in tissue or bodily fluid as part of a clinical testing procedure. Likewise, the ability to monitor S. pneumoniae polypeptide levels in an individual can allow determination of the efficacy of a given treatment regimen for an individual afflicted with such a disorder. The level of an S. pneumoniae polypeptide can be measured in cells found in bodily fluid, such as in urine samples or can be measured in tissue, such as produced by gastric biopsy. Diagnostic assays using anti-S. pneumoniae antibodies can include, for example, immunoassays designed to aid in early diagnosis of S. pneumoniae infections. The present invention can also be used as a method of detecting antibodies contained in samples from individuals infected by this bacterium using specific S. pneumoniae antigens.

Another application of anti-S. pneumoniae polypeptide antibodies of the invention is in the immunological screening of cDNA libraries constructed in expression vectors such as lgt11, lgt18-23, IZAP, and lORF8. Messenger libraries of this type, having coding sequences inserted in the correct reading frame and orientation, can produce fusion proteins. For instance, lgt11 will produce fusion proteins whose amino termini consist of β-galactosidase amino acid sequences and whose carboxy termini consist of a foreign polypeptide. Antigenic epitopes of a subject S. pneumoniae polypeptide can then be detected with antibodies, as, for example, reacting nitrocellulose filters lifted from infected plates with anti-S. pneumoniae polypeptide antibodies. Phage, scored by this assay, can then be isolated from the infected plate. Thus, the presence of S. pneumoniae gene homologs can be detected and cloned from other species, and alternate isoforms (including splicing variants) can be detected and cloned.

Kits Containing Nucleic Acids Polypeptides or Antibodies of the Invention

The nucleic acid, polypeptides and antibodies of the invention can be combined with other reagents and articles to form kits. Kits for diagnostic purposes typically comprise the nucleic acid, polypeptides or antibodies in vials or other suitable vessels. Kits typically comprise other reagents for performing hybridization reactions, polymerase chain reactions (PCR), or for reconstitution of lyophilized components, such as aqueous media, salts, buffers, and the like. Kits may also comprise reagents for sample processing such as detergents, chaotropic salts and the like. Kits may also comprise immobilization means such as particles, supports, wells, dipsticks and the like. Kits may also comprise labeling means such as dyes, developing reagents, radioisotopes, fluorescent agents, luminescent or chemiluminescent agents, enzymes, intercalating agents and the like. With the nucleic acid and amino acid sequence information provided herein, individuals skilled in art can readily assemble kits to serve their particular purpose. Kits further can include instructions for use.

Bio Chips and Microarrays

The nucleic acid sequence of the present invention may be used to detect S. pneumoniae or other species of Streptococcus acid sequence using bio chip technology. Bio chips containing arrays of nucleic acid sequence can also be used to measure expression of genes of S. pneumoniae or other species of Streptococcus. For example, to diagnose a patient with a S. pneumoniae or other Streptococcus infection, a sample from a human or animal can be used as a probe on a bio chip containing an array of nucleic acid sequence from the present invention. In addition, a sample from a disease state can be compared to a sample from a non-disease state which would help identify a gene that is up-regulated or expressed in the disease state. This would provide valuable insight as to the mechanism by which the disease manifests. Changes in gene expression can also be used to identify critical pathways involved in drug transport or metabolism, and may enable the identification of novel targets involved in virulence or host cell interactions involved in maintenance of an infection. Procedures using such techniques have been described by Brown et al., 1995, Science 270: 467-470.

Bio chips can also be used to monitor the genetic changes of potential therapeutic compounds including, deletions, insertions or mismatches. Once the therapeutic is added to the patient, changes to the genetic sequence can be evaluated for its efficacy. In addition, the nucleic acid sequence of the present invention can be used to determine essential genes in cell cycling. As described in Iyer et al., 1999 (Science, 283:83-87) genes essential in the cell cycle can be identified using bio chips. Furthermore, the present invention provides nucleic acid sequence which can be used with bio chip technology to understand regulatory networks in bacteria, measure the response to environmental signals or drugs as in drug screening, and study virulence induction. (Mons et al., 1998, Nature Biotechnology, 16: 45-48. Patents teaching this technology include U.S. Pat. Nos. 5,445,934, 5,744,305, and 5,800,992.

Drug Screening Assays Using S. pneumoniae Polypeptides

By making available purified and recombinant S. pneumoniae polypeptides, the present invention provides assays which can be used to screen for drugs which are either agonists or antagonists of the normal cellular function, in this case, of the subject S. pneumoniae polypeptides, or of their role in intracellular signaling. Such inhibitors or potentiators may be useful as new therapeutic agents to combat S. pneumoniae infections in humans. A variety of assay formats will suffice and, in light of the present inventions, will be comprehended by the skilled artisan.

In many drug screening programs which test libraries of compounds and natural extracts, high throughput assays are desirable in order to maximize the number of compounds surveyed in a given period of time. Assays which are performed in cell-free systems, such as may be derived with purified or semi-purified proteins, are often preferred as “primary” screens in that they can be generated to permit rapid development and relatively easy detection of an alteration in a molecular target which is mediated by a test compound. Moreover, the effects of cellular toxicity and/or bioavailability of the test compound can be generally ignored in the in vitro system, the assay instead being focused primarily on the effect of the drug on the molecular target as may be manifest in an alteration of binding affinity with other proteins or change in enzymatic properties of the molecular target. Accordingly, in an exemplary screening assay of the present invention, the compound of interest is contacted with an isolated and purified S. pneumoniae polypeptide.

Screening assays can be constructed in vitro with a purified S. pneumoniae polypeptide or fragment thereof, such as an S. pneumoniae polypeptide having enzymatic activity, such that the activity of the polypeptide produces a detectable reaction product. The efficacy of the compound can be assessed by generating dose response curves from data obtained using various concentrations of the test compound. Moreover, a control assay can also be performed to provide a baseline for comparison. Suitable products include those with distinctive absorption, fluorescence, or chemi-luminescence properties, for example, because detection may be easily automated. A variety of synthetic or naturally occurring compounds can be tested in the assay to identify those which inhibit or potentiate the activity of the S. pneumoniae polypeptide. Some of these active compounds may directly, or with chemical alterations to promote membrane permeability or solubility, also inhibit or potentiate the same activity (e.g., enzymatic activity) in whole, live S. pneumoniae cells.

Overexpression Assays

Overexpression assays are based on the premise that overproduction of a protein would lead to a higher level of resistance to compounds that selectively interfere with the function of that protein. Overexpression assays may be used to identify compounds that interfere with the function of virtually any type of protein, including without limitation enzymes, receptors, DNA- or RNA-binding proteins, or any proteins that are directly or indirectly involved in regulating cell growth.

Typically, two bacterial strains are constructed. One contains a single copy of the gene of interest, and a second contains several copies of the same gene. Identification of useful inhibitory compounds of this type of assay is based on a comparison of the activity of a test compound in inhibiting growth and/or viability of the two strains. The method involves constructing a nucleic acid vector that directs high level expression of a particular target nucleic acid. The vectors are then transformed into host cells in single or multiple copies to produce strains that express low to moderate and high levels of protein encoding by the target sequence (strain A and B, respectively). Nucleic acid comprising sequences encoding the target gene can, of course, be directly integrated into the host cell.

Large numbers of compounds (or crude substances which may contain active compounds) are screened for their effect on the growth of the two strains. Agents which interfere with an unrelated target equally inhibit the growth of both strains. Agents which interfere with the function of the target at high concentration should inhibit the growth of both strains. It should be possible, however, to titrate out the inhibitory effect of the compound in the overexpressing strain. That is, if the compound is affecting the particular target that is being tested, it should be possible to inhibit the growth of strain A at a concentration of the compound that allows strain B to grow.

Alternatively, a bacterial strain is constructed that contains the gene of interest under the control of an inducible promoter. Identification of useful inhibitory agents using this type of assay is based on a comparison of the activity of a test compound in inhibiting growth and/or viability of this strain under both inducing and non-inducing conditions. The method involves constructing a nucleic acid vector that directs high-level expression of a particular target nucleic acid. The vector is then transformed into host cells that are grown under both non-inducing and inducing conditions (conditions A and B, respectively).

Large numbers of compounds (or crude substances which may contain active compounds) are screened for their effect on growth under these two conditions. Agents that interfere with the function of the target should inhibit growth under both conditions. It should be possible, however, to titrate out the inhibitory effect of the compound in the overexpressing strain. That is, if the compound is affecting the particular target that is being tested, it should be possible to inhibit growth under condition A at a concentration that allows the strain to grow under condition B.

Ligand-Binding Assays

Many of the targets according to the invention have functions that have not yet been identified. Ligand-binding assays are useful to identify inhibitor compounds that interfere with the function of a particular target, even when that function is unknown. These assays are designed to detect binding of test compounds to particular targets. The detection may involve direct measurement of binding. Alternatively, indirect indications of binding may involve stabilization of protein structure or disruption of a biological function. Non-limiting examples of useful ligand-binding assays are detailed below.

A useful method for the detection and isolation of binding proteins is the Biomolecular Interaction Assay (BLAcore) system developed by Pharmacia Biosensor and described in the manufacturer's protocol (LKB Pharmacia, Sweden). The BIAcore system uses an affinity purified anti-GST antibody to immobilize GST-fusion proteins onto a sensor chip. The sensor utilizes surface plasmon resonance which is an optical phenomenon that detects changes in refractive indices. In accordance with the practice of the invention, a protein of interest is coated onto a chip and test compounds are passed over the chip. Binding is detected by a change in the refractive index (surface plasmon resonance).

A different type of ligand-binding assay involves scintillation proximity assays (SPA, described in U.S. Pat. No. 4,568,649).

Another type of ligand binding assay, also undergoing development, is based on the fact that proteins containing mitochondrial targeting signals are imported into isolated mitochondria in vitro (Hurt et al., 1985, Embo J 4:2061-2068; Eilers and Schatz, Nature, 1986, 322:228-231). In a mitochondrial import assay, expression vectors are constructed in which nucleic acids encoding particular target proteins are inserted downstream of sequences encoding mitochondrial import signals. The chimeric proteins are synthesized and tested for their ability to be imported into isolated mitochondria in the absence and presence of test compounds. A test compound that binds to the target protein should inhibit its uptake into isolated mitochondria in vitro.

Another ligand-binding assay is the yeast two-hybrid system (Fields and Song, 1989, Nature 340:245-246). The yeast two-hybrid system takes advantage of the properties of the GAL4 protein of the yeast Saccharomyces cerevisiae. The GAL4 protein is a transcriptional activator required for the expression of genes encoding enzymes of galactose utilization. This protein consists of two separable and functionally essential domains: an N-terminal domain which binds to specific DNA sequences (UAS_(G)); and a C-terminal domain containing acidic regions, which is necessary to activate transcription. The native GAL4 protein, containing both domains, is a potent activator of transcription when yeast are grown on galactose media. The N-terminal domain binds to DNA in a sequence-specific manner but is unable to activate transcription. The C-terminal domain contains the activating regions but cannot activate transcription because it fails to be localized to UAS_(G). In the two-hybrid system, a system of two hybrid proteins containing parts of GAL4: (1) a GAL4 DNA-binding domain fused to a protein ‘X’ and (2) a GAL4 activation region fused to a protein ‘Y’. If X and Y can form a protein-protein complex and reconstitute proximity of the GAL4 domains, transcription of a gene regulated by UAS_(G) occurs. Creation of two hybrid proteins, each containing one of the interacting proteins X and Y, allows the activation region of UAS_(G) to be brought to its normal site of action.

The binding assay described in Fodor et al., 1991, Science 251:767-773, which involves testing the binding affinity of test compounds for a plurality of defined polymers synthesized on a solid substrate, may also be useful.

Compounds which bind to the polypeptides of the invention are potentially useful as antibacterial agents for use in therapeutic compositions.

Pharmaceutical formulations suitable for antibacterial therapy comprise the antibacterial agent in conjunction with one or more biologically acceptable carriers. Suitable biologically acceptable carriers include, but are not limited to, phosphate-buffered saline, saline, deionized water, or the like. Preferred biologically acceptable carriers are physiologically or pharmaceutically acceptable carriers.

The antibacterial compositions include an antibacterial effective amount of active agent. Antibacterial effective amounts are those quantities of the antibacterial agents of the present invention that afford prophylactic protection against bacterial infections or which result in amelioration or cure of an existing bacterial infection. This antibacterial effective amount will depend upon the agent, the location and nature of the infection, and the particular host. The amount can be determined by experimentation known in the art, such as by establishing a matrix of dosages and frequencies and comparing a group of experimental units or subjects to each point in the matrix.

The antibacterial active agents or compositions can be formed into dosage unit forms, such as for example, creams, ointments, lotions, powders, liquids, tablets, capsules, suppositories, sprays, aerosols or the like. If the antibacterial composition is formulated into a dosage unit form, the dosage unit form may contain an antibacterial effective amount of active agent. Alternatively, the dosage unit form may include less than such an amount if multiple dosage unit forms or multiple dosages are to be used to administer a total dosage of the active agent. Dosage unit forms can include, in addition, one or more excipient(s), diluent(s), disintegrant(s), lubricant(s), plasticizer(s), colorant(s), dosage vehicle(s), absorption enhancer(s), stabilizer(s), bactericide(s), or the like.

For general information concerning formulations, see, e.g., Gilman et al. (eds.), 1990, Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed., 1990, Mack Publishing Co., Easton, Pa.; Avis et al. (eds.), 1993, Pharmaceutical Dosage Forms: Parenteral Medications, Dekker, New York; Lieberman et al (eds.), 1990, Pharmaceutical Dosage Forms: Disperse Systems, Dekker, New York.

The antibacterial agents and compositions of the present invention are useful for preventing or treating S. pneumoniae infections. Infection prevention methods incorporate a prophylactically effective amount of an antibacterial agent or composition. A prophylactically effective amount is an amount effective to prevent S. pneumoniae infection and will depend upon the specific bacterial strain, the agent, and the host. These amounts can be determined experimentally by methods known in the art and as described above.

S. pneumoniae infection treatment methods incorporate a therapeutically effective amount of an antibacterial agent or composition. A therapeutically effective amount is an amount sufficient to ameliorate or eliminate the infection. The prophylactically and/or therapeutically effective amounts can be administered in one administration or over repeated administrations. Therapeutic administration can be followed by prophylactic administration, once the initial bacterial infection has been resolved.

The antibacterial agents and compositions can be administered topically or systemically. Topical application is typically achieved by administration of creams, ointments, lotions, or sprays as described above. Systemic administration includes both oral and parental routes. Parental routes include, without limitation, subcutaneous, intramuscular, intraperitoneal, intravenous, transdermal, inhalation and intranasal administration.

EXEMPLIFICATION

I. Cloning and Sequencing of S. pneumoniae DNA

S. pneumoniae chromosomal DNA was isolated according to a basic DNA protocol outlined in Schleif R. F. and Wensink P. C., Practical Methods in Molecular Biology, p. 98, Springer-Verlag, NY., 1981, with minor modifications. Briefly, cells were pelleted, resuspended in TE (10 mM Tris, 1 mM EDTA, pH 7.6) and GES lysis buffer (5.1 M guanidium thiocyanate, 0.1 M EDTA, pH 8.0, 0.5% N-laurylsarcosine) was added. Suspension was chilled and ammonium acetate (NH4Ac) was added to final concentration of 2.0 M. DNA was extracted, first with chloroform, then with phenol-chloroform, and reextracted with chloroform. DNA was precipitated with isopropanol, washed twice with 70% EtOH, dried and resuspended in TE.

Following isolation whole genomic S. pneumoniae DNA was nebulized (Bodenteich et al., Automated DNA Sequencing and Analysis (J. C. Venter, ed.), Academic Press, 1994) to a median size of 2000 bp. After nebulization, the DNA was concentrated and separated on a standard 1% agarose gel. Several fractions, corresponding to approximate sizes 1000-1500 bp, 1500-2000 bp, 2000-2500 bp, 2500-3000 bp, were excised from the gel and purified by the GeneClean procedure (Bio101, Inc.).

The purified DNA fragments were then blunt-ended using T4 DNA polymerase. The healed DNA was then ligated to unique BstXI-linker adapters (5′ GTCTTCACCACGGGG (SEQ ID NO: 5323) and 5′ GTGGTGAAGAC (SEQ ID NO: 5324) in 100-1000 fold molar excess). These linkers are complimentary to the BstXI-cut pMPX vectors, while the overhang is not self-complimentary. Therefore, the linkers will not concatemerize nor will the cut-vector religate itself easily. The linker-adopted inserts were separated from the unincorporated linkers on a 1% agarose gel and purified using GeneClean. The linker-adopted inserts were then ligated to each of 20 pMPX vectors to construct a series of “shotgun” subclone libraries. Blunt ended vector was used for cloning into the PUC19 vector. The vectors contain an out-of-frame lacZ gene at the cloning site which becomes in-frame in the event that an adapter-dimer is cloned, allowing these to be avoided by their blue-color.

All subsequent steps were based either on the multiplex DNA sequencing protocols outlined in Church G. M. and Kieffer-Higgins S., Science 240:185-188, 1988 or by ABI377 automated DNA sequencing methods. Only major modifications to the protocols are highlighted. Briefly, each of the 20 vectors was then transformed into DH5a competent cells (Gibco/BRL, DH5a transformation protocol). The libraries were assessed by plating onto antibiotic plates containing ampicillin, methicillin and IPTG/Xgal. The plates were incubated overnight at 37° C. Successful transformants were then used for plating of clones and pooling into the multiplex pools. The clones were picked and pooled into 40 ml growth medium cultures. The cultures were grown overnight at 37° C. DNA was purified using the Qiagen Midi-prep kits and Tip-100 columns (Qiagen, Inc.). In this manner, 100 mg of DNA was obtained per pool.

These purified DNA samples were then sequenced either using the multiplex DNA sequencing based on chemical degradation methods (Church G. M. and Kieffer-Higgins S., Science 240:185-188, 1988) or by Sequithrem (Epicenter Technologies) dideoxy sequencing protocols or by ABI dye-terminator chemistry. For the multiplex portion the sequencing reactions were electrophoresed and transferred onto nylon membranes by direct transfer electrophoresis from 40 cm gels (Richterich P. and Church G. M., Methods in Enzymology 218:187-222, 1993). The DNA was covalently bound to the membranes by exposure to ultraviolet light, and hybridized with labeled oligonucleotides complimentary to tag sequences on the vectors (Church, supra). The membranes were washed to rinse off non-specifically bound probe, and exposed to X-ray film to visualize individual sequence ladders. After autoradiography, the hybridized probe was removed by incubation at 65° C., and the hybridization cycle repeated with another tag sequence until the membrane had been probed 41 times. Thus, each gel produced a large number of films, each containing new sequencing information. Whenever a new blot was processed, it was initially probed for an internal standard sequence added to each of the pools. Digital images of the films were generated using a laser-scanning densitometer (Molecular Dynamics, Sunnyvale, Calif.). The digitized images were processed on computer workstations (VaxStation 4000's) using the program REPLICA™ (Church et al., Automated DNA Sequencing and Analysis (J. C. Venter, ed.), Academic Press, 1994). Image processing included lane straightening, contrast adjustment to smooth out intensity differences, and resolution enhancement by iterative gaussian deconvolution. The sequences were then converted to an SCF format so that processing and assembly could proceed on UNIX machines. The ABI dye terminator sequence reads were run on ABI377 machines and the data was directly transferred to UNIX machines following lane tracking of the gels. All multiplex and ABI reads were assembled using PHRAP (P. Green, Abstracts of DOE Human Genome Program Contractor-Grantee Workshop V, January 1996, p. 157) with default parameters and not using quality scores. The initial assembly was done at 7fold coverage and yielded 511 contigs. Short read length fragments of 200 bp or less found on the ends of contigs facing in the appropriate direction were used to extend off the end of the contigs. These reads were then resequenced with primers using ABI technology to give sequences with a read length of 500 or more bases. This allowed end extensions to be performed without ordering new primers. In addition, missing mates (sequences from clones that only gave one strand reads) were identified and sequenced with ABI technology to allow the identification of additional overlapping contigs.

End-sequencing of randomly picked genomic lambda was also performed. Sequencing on a both sides was done for all lambda sequences. The lambda library backbone helped to verify the integrity of the assembly and allowed closure of some of the physical gaps.

To identify S. pneumoniae polypeptides the complete genomic sequence of S. pneumoniae were analyzed essentially as follows: First, all possible stop-to-stop open reading frames (ORFs) greater than 180 nucleotides in all six reading frames were translated into amino acid sequences. Second, the identified ORFs were analyzed for homology to known (archeabacter, prokaryotic and eukaryotic) protein sequences. Third, the predicted coding regions of the sequences and start codons were evaluated with the programs GENEMARK™ (Borodovsky and Mclninch, 1993, Comp. Chem. 17:123) and Glimmer (Fraser et al, Nature, 1997).

Identification, Cloning and Expression of S. pneumoniae Nucleic Acids

Expression and purification of the S. pneumoniae polypeptides of the invention can be performed essentially as outlined below.

To facilitate the cloning, expression and purification of membrane and secreted proteins from S. pneumoniae, a gene expression system, such as the pET System (Novagen), for cloning and expression of recombinant proteins in E. coli, is selected. Also, a DNA sequence encoding a peptide tag, the His-Tag, is fused to the 3′ end of DNA sequences of interest in order to facilitate purification of the recombinant protein products. The 3′ end is selected for fusion in order to avoid alteration of any 5′ terminal signal sequence.

PCR Amplification and Cloning of Nucleic Acids Containing ORF's Encoding Enzymes

Nucleic acids chosen (for example, from the nucleic acids set forth in SEQ ID NO: 1-SEQ ID NO: 2661) for cloning from the 14453 strain of S. pneumoniae are prepared for amplification cloning by polymerase chain reaction (PCR). Synthetic oligonucleotide primers specific for the 5′ and 3′ ends of open reading frames (ORFs) are designed and purchased from GibcoBRL Life Technologies (Gaithersburg, Md., USA). All forward primers (specific for the 5′ end of the sequence) are designed to include an NcoI cloning site at the extreme 5′ terminus. These primers are designed to permit initiation of protein translation at a methionine residue followed by a valine residue and the coding sequence for the remainder of the native S. pneumoniae DNA sequence. All reverse primers (specific for the 3′ end of any S. pneumoniae ORF) include a EcoRI site at the extreme 5′ terminus to permit cloning of each S. pneumoniae sequence into the reading frame of the pET-28b. The pET-28b vector provides sequence encoding an additional 20 carboxy-terminal amino acids including six histidine residues (at the extreme C-terminus), which comprise the His-Tag.

Genomic DNA prepared from strain 14453 of S. pneumoniae is used as the source of template DNA for PCR amplification reactions (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). To amplify a DNA sequence containing an S. pneumoniae ORF, genomic DNA (50 nanograms) is introduced into a reaction vial containing 2 mM MgCl₂, 1 micromolar synthetic oligonucleotide primers (forward and reverse primers) complementary to and flanking a defined S. pneumoniae ORF, 0.2 mM of each deoxynucleotide triphosphate; dATP, dGTP, dCTP, dTTP and 2.5 units of heat stable DNA polymerase (Amplitaq, Roche Molecular Systems, Inc., Branchburg, N.J., USA) in a final volume of 100 microliters.

Upon completion of thermal cycling reactions, each sample of amplified DNA is washed and purified using the Qiaquick Spin PCR purification kit (Qiagen, Gaithersburg, Md., USA). All amplified DNA samples are subjected to digestion with the restriction endonucleases, e.g., NcoI and EcoRI (New England BioLabs, Beverly, Mass., USA)(Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). DNA samples are then subjected to electrophoresis on 1.0% NuSeive (FMC BioProducts, Rockland, Me. USA) agarose gels. DNA is visualized by exposure to ethidium bromide and long wave uv irradiation. DNA contained in slices isolated from the agarose gel is purified using the Bio 101 GeneClean Kit protocol (Bio 101 Vista, Calif., USA).

Cloning of S. pneumoniae Nucleic Acids into an Expression Vector

The pET-28b vector is prepared for cloning by digestion with endonucleases, e.g., NcoI and EcoRI (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). The pET-28a vector, which encodes a His-Tag that can be fused to the 5′ end of an inserted gene, is prepared by digestion with appropriate restriction endonucleases.

Following digestion, DNA inserts are cloned (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994) into the previously digested pET-28b expression vector. Products of the ligation reaction are then used to transform the BL21 strain of E. coli (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994) as described below.

Transformation of Competent Bacteria With Recombinant Plasmids

Competent bacteria, E. coli strain BL21 or E. coli strain BL21(DE3), are transformed with recombinant pET expression plasmids carrying the cloned S. pneumoniae sequences according to standard methods (Current Protocols in Molecular, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). Briefly, 1 microliter of ligation reaction is mixed with 50 microliters of electrocompetent cells and subjected to a high voltage pulse, after which, samples are incubated in 0.45 milliliters SOC medium (0.5% yeast extract, 2.0% tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 20, mM glucose) at 37° C. with shaking for 1 hour. Samples are then spread on LB agar plates containing 25 microgram/ml kanamycin sulfate for growth overnight. Transformed colonies of BL21 are then picked and analyzed to evaluate cloned inserts as described below.

Identification of Recombinant Expression Vectors With S. pneumoniae Nucleic Acids

Individual BL21 clones transformed with recombinant pET-28b S. pneumoniae ORFs are analyzed by PCR amplification of the cloned inserts using the same forward and reverse primers, specific for each S. pneumoniae sequence, that were used in the original PCR amplification cloning reactions. Successful amplification verifies the integration of the S. pneumoniae sequences in the expression vector (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994).

Isolation and Preparation of Nucleic Acids from Transformants

Individual clones of recombinant pET-28b vectors carrying properly cloned S. pneumoniae ORFs are picked and incubated in 5 mls of LB broth plus 25 microgram/ml kanamycin sulfate overnight. The following day plasmid DNA is isolated and purified using the Qiagen plasmid purification protocol (Qiagen Inc., Chatsworth, Calif., USA).

Expression of Recombinant S. pneumoniae Sequences in E. coli

The pET vector can be propagated in any E. coli K-12 strain e.g. HMS174, HB101, JM109, DH5, etc. for the purpose of cloning or plasmid preparation. Hosts for expression include E. coli strains containing a chromosomal copy of the gene for T7 RNA polymerase. These hosts are lysogens of bacteriophage DE3, a lambda derivative that carries the lacI gene, the lacUV5 promoter and the gene for T7 RNA polymerase. T7 RNA polymerase is induced by addition of isopropyl-B-D-thiogalactoside (IPTG), and the T7 RNA polymerase transcribes any target plasmid, such as pET-28b, carrying its gene of interest. Strains used include: BL21(DE3) (Studier, F. W., Rosenberg, A. H., Dunn, J. J., and Dubendorff, J. W. (1990) Meth. Enzymol. 185, 60-89).

To express recombinant S. pneumoniae sequences, 50 nanograms of plasmid DNA isolated as described above is used to transform competent BL21(DE3) bacteria as described above (provided by Novagen as part of the pET expression system kit). The lacZ gene (beta-galactosidase) is expressed in the pET-System as described for the S. pneumoniae recombinant constructions. Transformed cells are cultured in SOC medium for 1 hour, and the culture is then plated on LB plates containing 25 micrograms/ml kanamycin sulfate. The following day, bacterial colonies are pooled and grown in LB medium containing kanamycin sulfate (25 micrograms/ml) to an optical density at 600 nM of 0.5 to 1.0 O.D. units, at which point, I millimolar IPTG was added to the culture for 3 hours to induce gene expression of the S. pneumoniae recombinant DNA constructions.

After induction of gene expression with IPTG, bacteria are pelleted by centrifugation in a Sorvall RC-3B centrifuge at 3500×g for 15 minutes at 4° C. Pellets are resuspended in 50 milliliters of cold 10 mM Tris-HCl, pH 8.0, 0.1 M NaCl and 0.1 mM EDTA (STE buffer). Cells are then centrifuged at 2000×g for 20 min at 4° C. Wet pellets are weighed and frozen at −80° C. until ready for protein purification.

A variety of methodologies known in the art can be utilized to purify the isolated proteins. (Current Protocols in Protein Science, John Wiley and Sons, Inc., J. E. Coligan et al., eds., 1995). For example, the frozen cells may be thawed, resupended in buffer and ruptured by several passages through a small volume microfluidizer (Model M-110S, Microfluidics International Corporation, Newton, Mass.). The resultant homogenate may be centrifuged to yield a clear supernatant (crude extract) and following filtration the crude extract may be fractionated over columns. Fractions may be monitored by absorbance at OD₂₈₀ nm. and peak fractions may analyzed by SDS-PAGE.

The concentrations of purified protein preparations may be quantified spectrophotometrically using absorbance coefficients calculated from amino acid content (Perkins, S. J. 1986 Eur. J. Biochem. 157, 169-180). Protein concentrations are also measured by the method of Bradford, M. M. (1976) Anal. Biochem. 72, 248-254, and Lowry, O. H., Rosebrough, N., Farr, A. L. & Randall, R. J. (1951) J. Biol. Chem. 193, pages 265-275, using bovine serum albumin as a standard.

SDS-polyacrylamide gels of various concentrations may be purchased from BioRad (Hercules, Calif., USA), and stained with Coomassie blue. Molecular weight markers may include rabbit skeletal muscle myosin (200 kDa), E. coli (-gal actosidase (116 kDa), rabbit muscle phosphorylase B (97.4 kDa), bovine serum albumin (66.2 kDa), ovalbumin (45 kDa), bovine carbonic anhydrase (31 kDa), soybean trypsin inhibitor (21.5 kDa), egg white lysozyme (14.4 kDa) and bovine aprotinin (6.5 kDa).

EQUIVALENTS

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

ORF NT AA AA NT NAME ID ID LN LN SCORE P-VALUE DESCRIPTION SPX0001 1 2662 111 333 552 2.20E−74 [GI:2804700] [LN:AF030361] [AC:AF030361] [PN:transposase] [OR:Streptococcus pneumoniae] 87 SPX0002 2 2663 173 519 885 3.60E−120 [GI:663278] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae (strain RX1) DNA] 138 SPX0003 3 2664 109 327 281 1.40E−34 [GI:2804700] [LN:AF030361] [AC:AF030361] [PN:transposase] [OR:Streptococcus pneumoniae] 87 SPX0004 4 2665 190 570 948 7.40E−131 [GI:663279] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae (strain RX1) DNA] 138 SPX0005 5 2666 122 366 NO-HIT 6 SPX0006 6 2667 401 1203 815 7.40E−125 [LN:RS1_LEULA] [AC:P50889:P71450] [GN:RPS1] [OR:Leuconostoc lactis] [DE:40S RIBOSOMAL PROTEIN S1] [SP:P50889:P71450] 116 SPX0007 7 2668 79 237 89 2.90E−05 [LN:E64801] [AC:E64801] [PN:hypothetical protein b0663] [OR:Escherichia coli] 77 SPX0008 8 2669 77 231 NO-HIT 6 SPX0009 9 2670 215 645 832 6.30E−114 [LN:PCP_STRPY] [AC:Q01328] [GN:PCP] [OR:Streptococcus pyogenes] [EC:3.4.19.3] 149 [DE:PEPTIDASE) (PYROGLUTAMYL-PEPTIDASE I) (PGP-I) (PYRASE)] [SP:Q01328] SPX0010 10 2671 308 924 234 3.90E−61 [LN:A81402] [AC:A81402] [PN:probable integral membrane protein Cj0553 [imported]] [GN:Cj0553] [OR:Campylobacter jejuni] 119 SPX0011 11 2672 237 711 208 1.30E−37 [GI:6002226] [LN:SC51A] [AC:AL121596] [PN:possible integral membrane protein] [GN:SCF51A.18c] [OR:Streptomyces coelicolor A3(2)] 128 SPX0012 12 2673 235 705 213 1.30E−53 [GI:2804687] [LN:AF030359] [AC:AF030359] [PN:oligopeptide binding protein] [GN:aliA] [OR:Streptococcus pneumoniae] 114 SPX0013 13 2674 341 1023 1359 9.60E−184 [GI:6979306] [LN:AF164204] [AC:AF164204] [PN:branched-chain amino acid aminotransferase] [GN:bcaT] [FN:catalyzes the first reaction in the catabolism] 190 [OR:Lactococcus lactis subsp. cremoris] SPX0014 14 2675 824 2472 4143 0 [GI:6851038] [LN:SPPARCETP] [AC:Z67739] [PN:DNA topoisomerase IV] [GN:parC] [OR:Streptococcus pneumoniae] 105 SPX0015 15 2676 648 1944 3318 0 [GI:6851037] [LN:SPPARCETP] [AC:Z67739] [PN:DNA topoisomerase IV] [GN:parE] [OR:Streptococcus pneumoniae] 105 SPX0016 16 2677 214 642 1073 2.50E−150 [LN:YPAE_STRPN] [AC:Q54916] [OR:Streptococcus pneumoniae] [DE:HYPOTHETICAL 23.0 KD PROTEIN IN PARE 5′REGION (ORF2)] 127 [SP:Q54916] SPX0017 17 2678 410 1230 1044 8.20E−270 [GI:2804700] [LN:AF030361] [AC:AF030361] [PN:transposase] [OR:Streptococcus pneumoniae] 87 SPX0018 18 2679 278 834 591 9.50E−139 [LN:A33595] [AC:A33595:A30868] [PN:probable transposase] [CL:transposase IS3] [OR:Streptococcus agalactiae] 107 SPX0019 19 2680 191 573 422 2.30E−53 [LN:B30868] [AC:B30868] [PN:hypothetical protein 1] [OR:Streptococcus agalactiae] 81 SPX0020 20 2681 34 102 124 5.30E−12 [LN:B30868] [AC:B30868] [PN:hypothetical protein 1] [OR:Streptococcus agalactiae] 81 SPX0021 21 2682 319 957 1002 3.80E−138 [LN:F70009] [AC:F70009] [PN:conserved hypothetical protein yufQ] [GN:yufQ] [CL:probable ribose ABC transporter rbsC-2] [OR:Bacillus subtilis] 141 SPX0022 22 2683 362 1086 385 3.70E−85 [LN:E70009] [AC:E70009] [PN:conserved hypothetical protein yufP] [GN:yufP] [OR:Bacillus subtilis] 97 SPX0023 23 2684 512 1536 1623 2.30E−217 [LN:D70009] [AC:D70009] [PN:probable ABC transporter yufO] [GN:yufO] [CL:Bacillus subtilis probable ABC transporter 174 yufO:ATP-binding cassette homology] [OR:Bacillus subtilis] SPX0024 24 2685 140 420 83 1.80E−06 [LN:G72493] [AC:G72493] [PN:hypothetical protein APE2590] [GN:APE2590] [OR:Aeropyrum pernix] 92 SPX0025 25 2686 364 1092 354 8.80E−82 [LN:YUFN_BACSU] [AC:O05252] [GN:YUFN] [OR:Bacillus subtilis] [DE:HYPOTHETICAL LIPOPROTEIN YUFN PRECURSOR] [SP:O05252] 117 SPX0026 26 2687 130 390 324 5.40E−40 [GI:6478520] [LN:AF187304] [AC:AF187304] [PN:cytidine deaminase] [GN:cdd] [OR:Bacillus caldolyticus] 100 SPX0027 27 2688 100 300 276 2.40E−33 [LN:D75424] [AC:D75424] [PN:deoxyribose-phosphate aldolase] [GN:DR1205] [CL:deoxyribose-phosphate aldolase] [OR:Deinococcus radiodurans] 136 SPX0028 28 2689 61 183 NO-HIT 6 SPX0029 29 2690 119 357 344 3.30E−42 [LN:DEOC_BACSU] [AC:P39121] [GN:DRA] [OR:Bacillus subtilis] [EC:4.1.2.4] [DE:(DEOXYRIBOALDOLASE)] [SP:P39121] 109 SPX0030 30 2691 426 1278 921 9.70E−147 “[LN:PDP_BACST] [AC:P77836] [GN:PYN] [OR:Bacillus stearothermophilus] [EC:2.4.2.2] [DE:PYRIMIDINE−NUCLEOSIDE PHOSPHORYLASE, 144 (PYNP)] [SP:P77836]” SPX0031 31 2692 197 591 250 2.00E−56 [LN:S59955] [AC:S59955] [PN:hypothetical protein 202] [CL:hypothetical protein MJ0882] [OR:Staphylococcus aureus] 113 SPX0032 32 2693 73 219 NO-HIT 6 SPX0033 33 2694 100 300 NO-HIT 6 SPX0034 34 2695 317 951 345 3.80E−79 [GI:6960352] [LN:STYSTMF1] [AC:AF170176] [PN:96% identity over 316 amino acids with E. coli] [GN:coaA] [OR:Salmonella typhimurium LT2] 134 SPX0035 35 2696 79 237 98 8.40E−17 [LN:R3EC20] [AC:A30425:A02748:S40547:G64722:S07374] [PN:ribosomal protein S20/L26 [validated]:ribosomal protein L26:ribosomal protein S20] 214 [GN:rpsT] [CL:Escherichia coli ribosomal protein S20] [OR:Escherichia coli] SPX0036 36 2697 175 525 270 6.30E−50 [GI:6434823] [LN:SPU78969] [AC:U78969] [PN:FlaR] [GN:flaR] [OR:Streptococcus pyogenes] 86 SPX0037 37 2698 237 711 1042 4.10E−140 [LN:DEOD_STRTR] [AC:Q56037] [GN:DEOD] [OR:Streptococcus thermophilus] [EC:2.4.2.1] [DE:(PNP) (FRAGMENT)] [SP:Q56037] 116 SPX0038 38 2699 171 513 271 1.10E−30 [GI:6729344] [LN:AB029317] [AC:AB029317] [PN:intermedilysin] [GN:ily] [OR:Streptococcus intermedius] 150 [SR:Streptococcus intermedius (strain:UNS46) DNA] SPX0039 39 2700 192 576 117 2.80E−07 “[LN:PXN1_XENLA] [AC:P49263] [GN:PXN1] [OR:Xenopus laevis] [SR:,African clawed frog] [DE:PENTRAXIN FUSION PROTEIN 137 PRECURSOR] [SP:P49263]” SPX0040 40 2701 136 408 92 0.00026 “[LN:CP23_CHICK] [AC:P23614] [OR:Gallus gallus] [SR:,Chicken] [DE:23 KD CORTICAL CYTOSKELETON-ASSOCIATED PROTEIN (CAP-23)] 135 [SP:P23614]” SPX0041 41 2702 270 810 395 1.40E−105 [LN:DEOD_BACSU] [AC:P46354] [GN:DEOD:PNP] [OR:Bacillus subtilis] [EC:2.4.2.1] [DE:(PNP)] [SP:P46354] 100 SPX0042 42 2703 181 543 NO-HIT 6 SPX0043 43 2704 404 1212 736 2.30E−199 “[LN:DEOB_LACLC] [AC:O32808] [GN:DEOB] [OR:Lactococcus lactis] [SR:,subspcremoris:Streptococcus cremoris] 181 [EC:5.4.2.7] [DE:PHOSPHOPENTOMUTASE, (PHOSPHODEOXYRIBOMUTASE)] [SP:O32808]” SPX0044 44 2705 247 741 206 1.40E−52 [LN:G69180] [AC:G69180] [PN:ribose 5-phosphate isomerase] [GN:MTH608] [CL:Haemophilus influenzae ribose-5-phosphate isomerase] 168 [OR:Methanobacterium thermoautotrophicum] SPX0045 45 2706 62 186 NO-HIT 6 SPX0046 46 2707 291 873 386 5.80E−99 [LN:YFOL_STRTR] [AC:P96051] [OR:Streptococcus thermophilus] [DE:(ORF1091)] [SP:P96051] 86 SPX0047 47 2708 307 921 1049 3.00E−140 [LN:FOLD_STRTR] [AC:P96050] [GN:FOLD] [OR:Streptococcus thermophilus] [EC:1.5.1.5:3.5.4.9] [DE:(EC 3.5.4.9)]] [SP:P96050] 121 SPX0048 48 2709 72 216 99 5.40E−08 [LN:G72510] [AC:G72510] [PN:hypothetical protein APE2061] [GN:APE2061] [OR:Aeropyrum pernix] 92 SPX0049 49 2710 245 735 796 7.00E−105 [LN:H69334] [AC:H69334] [PN:glutamine transport protein glnQ] [GN:glnQ] [CL:inner membrane protein malK:ATP-binding cassette homology] 162 [OR:Archaeoglobus fulgidus] SPX0050 50 2711 128 384 88 5.60E−05 [LN:D72757] [AC:D72757] [PN:hypothetical protein APE0049] [GN:APE0049] [OR:Aeropyrum pernix] 92 SPX0051 51 2712 228 684 314 1.10E−52 “[LN:H69278] [AC:H69278] [PN:glutamine ABC transporter, permease protein (glnP) homolog] [CL:histidine permease protein M] 151 [OR:Archaeoglobus fulgidus]” SPX0052 52 2713 77 231 89 8.60E−09 [LN:G69865] [AC:G69865] [PN:hypothetical protein ykuJ] [GN:ykuJ] [OR:Bacillus subtilis] 87 SPX0053 53 2714 753 2259 2641 0 [GI:4103470] [LN:AF023421] [AC:AF023421] [PN:ClpE] [GN:clpE] [OR:Lactococcus lactis] 84 SPX0054 54 2715 83 249 116 9.50E−10 [GI:4098132] [LN:MBU73653] [AC:U73653] [PN:63 kDa protein] [OR:Mycobacterium bovis] 83 SPX0055 55 2716 61 183 NO-HIT 6 SPX0056 56 2717 70 210 NO-HIT 6 SPX0057 57 2718 114 342 477 2.00E−73 [GI:5019553] [LN:SPN239004] [AC:AJ239004] [PN:putative transposase] [OR:Streptococcus pneumoniae] 97 SPX0058 58 2719 116 348 569 6.90E−75 [GI:4200438] [LN:AF026471] [AC:AF026471] [PN:putative transposase] [OR:Streptococcus pneumoniae] 96 SPX0059 59 2720 141 423 101 5.60E−07 [LN:A70315] [AC:A70315] [PN:AP4A hydrolase] [GN:apfA] [CL:Methanococcus jannaschii mutator protein mutT:mutT domain homology] 147 [OR:Aquifex aeolicus] SPX0060 60 2721 100 300 NO-HIT 6 SPX0061 61 2722 198 594 597 3.80E−95 [LN:A33595] [AC:A33595:A30868] [PN:probable transposase] [CL:transposase IS3] [OR:Streptococcus agalactiae] 107 SPX0062 62 2723 88 264 308 1.70E−38 [LN:A33595] [AC:A33595:A30868] [PN:probable transposase] [CL:transposase IS3] [OR:Streptococcus agalactiae] 107 SPX0063 63 2724 34 102 126 2.60E−12 [LN:B30868] [AC:B30868] [PN:hypothetical protein 1] [OR:Streptococcus agalactiae] 81 SPX0064 64 2725 117 351 210 5.10E−24 “[LN:JC1151] [AC:JC1151] [PN:hypothetical protein, 20.3K] [OR:Agrobacterium tumefaciens]” 89 SPX0065 65 2726 102 306 154 5.60E−19 [GI:722339] [LN:AXU22323] [AC:U22323] [PN:unknown] [OR:Acetobacter xylinus] [SR:Acetobacter xylinum] 100 SPX0066 66 2727 89 267 NO-HIT 6 SPX0067 67 2728 576 1728 285 5.20E−53 [LN:G70002] [AC:G70002] [PN:hypothetical protein ytwP] [GN:ytwP] [OR:Bacillus subtilis] 87 SPX0068 68 2729 649 1947 3322 0 [GI:1490397] [LN:SPGYRBORF] [AC:Z67740] [PN:DNA gyrase] [GN:gyrB] [OR:Streptococcus pneumoniae] 95 SPX0069 69 2730 191 573 709 2.40E−93 [GI:1052803] [LN:SPGYRBG] [AC:X83917] [GN:orflgyrb] [OR:Streptococcus pneumoniae] 81 SPX0070 70 2731 185 555 118 9.00E−28 “[LN:D70177] [AC:D70177] [PN:4-methyl-5(b-hydroxyethyl)-thiazole monophosphate biosynthesis protein (thiJ) homolog] [CL:signal transduction 211 protein DJ-1] [OR:Borrelia burgdorferi] [SR:, Lyme disease spirochete]” SPX0071 71 2732 417 1251 398 1.00E−50 [LN:S22738] [AC:S22738:S22728] [PN:hypothetical protein] [OR:Streptococcus salivarius] 86 SPX0072 72 2733 817 2451 203 3.80E−66 [LN:DING_BACSU] [AC:P54394] [GN:DING] [OR:Bacillus subtilis] [DE:PROBABLE ATP-DEPENDENT HELICASE DING HOMOLOG] [SP:P54394] 122 SPX0073 73 2734 310 930 189 6.20E−42 [LN:G69979] [AC:G69979] [PN:proteinase homolog yrrN] [GN:yrrN] [OR:Bacillus subtilis] 85 SPX0074 74 2735 96 288 NO-HIT 6 SPX0075 75 2736 445 1335 2202 4.50E−301 “[LN:CIAH_STRPN] [AC:Q54955] [GN:CIAH] [OR:Streptococcus pneumoniae] [EC:2.7.3.-] [DE:SENSOR PROTEIN CIAH,] [SP:Q54955]” 120 SPX0076 76 2737 225 675 1130 1.70E−152 [LN:CIAR_STRPN] [AC:Q54954] [GN:CIAR] [OR:Streptococcus pneumoniae] [DE:TRANSCRIPTIONAL REGULATORY PROTEIN CIAR] [SP:Q54954] 124 SPX0077 77 2738 849 2547 1653 0 [GI:5524752] [LN:STH007700] [AC:AJ007700] [PN:aminopeptidase N] [GN:pepN] [OR:Streptococcus thermophilus] 105 SPX0078 78 2739 147 441 176 1.80E−20 [LN:T35570] [AC:T35570] [PN:hypothetical protein SC6G4.19c SC6G4.19c] [GN:SC6G4.19c] [OR:Streptomyces coelicolor] 113 SPX0079 79 2740 292 876 80 8.00E−10 [LN:PPSA_PYRFU] [AC:P42850:Q59672] [GN:PPSA] [OR:Pyrococcus furiosus] [EC:2.7.9.2] [DE:DIKINASE) (PEP SYNTHASE)] 131 SPX0080 80 2741 243 729 NO-HIT 6 SPX0081 81 2742 160 480 113 1.60E−07 [LN:C72513] [AC:C72513] [PN:hypothetical protein APE2080] [GN:APE2080] [OR:Aeropyrum pernix] 92 SPX0082 82 2743 76 228 NO-HIT 6 SPX0083 83 2744 233 699 231 3.20E−28 [LN:GNO_GLUOX] [AC:P50199] [GN:GNO] [OR:Gluconobacter oxydans] [EC:1.1.1.69] [DE:REDUCTASE)] [SP:P50199] 104 SPX0084 84 2745 89 267 NO-HIT 6 SPX0085 85 2746 309 927 210 2.40E−41 [LN:YDHF_ECOLI] [AC:P76187] [GN:YDHF] [OR:Escherichia coli] [DE:HYPOTHETICAL OXIDOREDUCTASE IN SODC-NEMA INTERGENIC 135 REGION] [SP:P76187] SPX0086 86 2747 272 816 114 3.70E−09 [GI:3043880] [LN:LLU95841] [AC:U95841] [PN:transmembrane protein Tmp6] [OR:Lactococcus lactis] 94 SPX0087 87 2748 72 216 146 1.50E−15 [GI:3582220] [LN:AE001272] [AC:AE001272] [PN:conserved hypothetical protein] [GN:ORF00047] [OR:Lactococcus lactis] 114 SPX0088 88 2749 79 237 NO-HIT 6 SPX0089 89 2750 82 246 269 2.80E−32 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX0090 90 2751 680 2040 734 6.10E−239 [LN:SYM_BACST] [AC:P23920] [GN:METS] [OR:Bacillus stearothermophilus] [EC:6.1.1.10] [DE:(METRS)] [SP:P23920] 108 SPX0091 91 2752 420 1260 287 2.30E−62 [LN:E69858] [AC:E69858] [PN:conserved hypothetical protein yknZ] [GN:yknZ] [OR:Bacillus subtilis] 97 SPX0092 92 2753 234 702 663 9.00E−86 [GI:2822199] [LN:SCU96166] [AC:U96166:AF227987] [PN:ATP-binding cassette protein] [GN:tptC] [OR:Streptococcus cristatus] 120 SPX0093 93 2754 400 1200 144 5.60E−36 [LN:C69858] [AC:C69858] [PN:conserved hypothetical protein yknX] [GN:yknX] [OR:Bacillus subtilis] 97 SPX0094 94 2755 449 1347 730 1.70E−192 “[LN:S41386] [AC:S41386] [PN:glutathione reductase (NADPH),] [CL:dihydrolipoamide dehydrogenase:dihydrolipoamide dehydrogenase homology] 182 [OR:Streptococcus thermophilus] [EC:1.6.4.2]” SPX0095 95 2756 179 537 218 6.90E−30 [LN:H72334] [AC:H72334] [PN:bioY protein] [GN:TM0799] [OR:Thermotoga maritima] 78 SPX0096 96 2757 112 336 NO-HIT 6 SPX0097 97 2758 80 240 171 1.50E−18 [LN:Y352_TREPA] [AC:O83371] [GN:TP0352] [OR:Treponema pallidum] [DE:HYPOTHETICAL PROTEIN TP0352] [SP:O83371] 108 SPX0098 98 2759 107 321 NO-HIT 6 SPX0099 99 2760 113 339 109 1.40E−12 [GI:4098081] [LN:LLU73336] [AC:U73336] [PN:anaerobic ribonucleotide reductase] [GN:nrdD] [OR:Lactococcus lactis subsp. cremoris] 128 SPX0100 100 2761 240 720 372 1.30E−85 [LN:TRMD_BACSU] [AC:O31741] [GN:TRMD] [OR:Bacillus subtilis] [EC:2.1.1.31] [DE:METHYLTRANSFERASE) (TRNA [GM37] 142 METHYLTRANSFERASE)] [SP:O31741] SPX0101 101 2762 173 519 292 5.20E−61 [LN:RIMM_BACSU] [AC:O31740] [GN:RIMM] [OR:Bacillus subtilis] [DE:PROBABLE 16S RRNA PROCESSING PROTEIN RIMM] [SP:O31740] 119 SPX0102 102 2763 267 801 NO-HIT 6 SPX0103 103 2764 80 240 141 9.70E−15 [LN:C69880] [AC:C69880] [PN:conserved hypothetical protein ylqC] [GN:ylqC] [CL:Bacillus conserved hypothetical protein ylqC] [OR:Bacillus subtilis] 147 SPX0104 104 2765 91 273 315 5.10E−39 [LN:C47154] [AC:C47154:S11366:G69700] [PN:ribosomal protein S16 (BS17) rpsP:ribosomal protein BS17] [GN:rpsP] [CL:Escherichia coli 176 ribosomal protein S16] [OR:Bacillus subtilis] SPX0105 105 2766 70 210 NO-HIT 6 SPX0106 106 2767 135 405 NO-HIT 6 SPX0107 107 2768 71 213 NO-HIT 6 SPX0108 108 2769 268 804 243 3.60E−38 [LN:T41399] [AC:T41399] [PN:probable cyclophilin-related peptidyl prolyl cis-trans isomerase] [GN:SPCC553.04] [OR:Schizosaccharomyces pombe] 140 SPX0109 109 2770 120 360 83 5.110E−05 [GI:1773206] [LN:ECU82664] [AC:U82664] [OR:Escherichia coli] 60 SPX0110 110 2771 514 1542 1502 3.70E−258 [LN:D69813] [AC:D69813] [PN:ABC transporter (ATP-binding protein) homolog yfmM] [GN:yfmM] [CL:unassigned ATP-binding cassette 188 proteins:ATP-binding cassette homology] [OR:Bacillus subtilis] SPX0111 111 2772 161 483 88 2.20E−11 [GI:7110140] [LN:AF155139] [AC:AF155139:AF019976] [PN:VanZF] [GN:vanZF] [OR:Paenibacillus popilliae] 100 SPX0112 112 2773 362 1086 452 1.30E−135 [LN:YLON_BACSU] [AC:O34617] [GN:YLON] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 41.6 KD PROTEIN IN FMT-SPOVM INTERGENIC 137 REGION] [SP:O34617] SPX0113 113 2774 177 531 152 3.20E−25 [LN:F70023] [AC:F70023] [PN:hypothetical protein yutD] [GN:yutD] [CL:Bacillus subtilis hypothetical protein yutD] [OR:Bacillus subtilis] 136 SPX0114 114 2775 202 606 1034 4.90E−138 [GI:5758312] [LN:AF162664] [AC:AF162664] [PN:manganese co-factored superoxide dismutase] [GN:sodA] [FN:removes superoxide] [OR:Streptococcus 152 pneumoniae] SPX0115 115 2776 346 1038 952 2.60E−127 [GI:2765186] [LN:SASODA] [AC:Y12224] [PN:hypothetical protein] [OR:Streptococcus agalactiae] 92 SPX0116 116 2777 312 936 1616 3.20E−220 [GI:5578893] [LN:SPN131985] [AC:AJ131985] [PN:dihydroorotate dehydrogenase] [GN:pyrDA] [OR:Streptococcus pneumoniae] 116 SPX0117 117 2778 397 1191 1399 3.90E−187 [LN:METK_STAAU] [AC:P50307] [GN:METK] [OR:Staphylococcus aureus] [EC:2.5.1.6] [DE:ADENOSYLTRANSFERASE) (ADOMET 135 SYNTHETASE)] [SP:P50307] SPX0118 118 2779 448 1344 972 1.00E−140 [LN:YQFR_BACSU] [AC:P54475] [GN:YQFR] [OR:Bacillus subtilis] [DE:PROBABLE RNA HELICASE IN CCCA-SODA INTERGENIC 130 REGION] [SP:P54475] SPX0119 119 2780 272 816 NO-HIT 6 SPX0120 120 2781 88 264 NO-HIT 6 SPX0121 121 2782 727 2181 735 4.60E−182 [GI:4098489] [LN:SMU78600] [AC:U78600] [PN:putative ptsG protein] [OR:Streptococcus mutans] 91 SPX0122 122 2783 312 936 330 2.80E−63 [LN:G69627] [AC:G69627] [PN:cell-division protein ftsX] [GN:ftsX] [OR:Bacillus subtilis] 88 SPX0123 123 2784 69 207 NO-HIT 6 SPX0124 124 2785 231 693 798 9.90E−106 [LN:D69627] [AC:D69627] [PN:cell-division ATP-binding protein ftsE] [GN:ftsE] [CL:unassigned ATP-binding cassette proteins:ATP-binding 176 cassette homology] [OR:Bacillus subtilis] SPX0125 125 2786 75 225 94 1.10E−07 [LN:A71007] [AC:A71007] [PN:hypothetical protein PH1351] [GN:PH1351] [OR:Pyrococcus horikoshii] 95 SPX0126 126 2787 307 921 936 6.80E−124 [LN:RF2_BACSU] [AC:P28367:O34444] [GN:PRFB] [OR:Bacillus subtilis] [DE:PEPTIDE CHAIN RELEASE FACTOR 2 (RF-2)] [SP:P28367:O34444] 128 SPX0127 127 2788 219 657 279 3.40E−41 [LN:H72290] [AC:H72290] [PN:conserved hypothetical protein] [GN:TM1140] [OR:Thermotoga maritima] 96 SPX0128 128 2789 237 711 711 7.60E−93 [LN:T35757] [AC:T35757] [PN:probable branched chain amino acid transport ATP-binding protein] [GN:SC7H2.26] [CL:unassigned ATP-binding 212 cassette proteins:ATP-binding cassette homology] [OR:Streptomyces coelicolor] SPX0129 129 2790 67 201 109 6.60E−10 [LN:G72485] [AC:G72485] [PN:hypothetical protein APE2527] [GN:APE2527] [OR:Aeropyrum pernix] 92 SPX0130 130 2791 255 765 387 4.20E−90 “[LN:F72290] [AC:F72290] [PN:branched chain amino acid ABC transporter, ATP-binding protein] [GN:TM1138] [CL:unassigned ATP-binding 206 cassette proteins:ATP-binding cassette homology] [OR:Thermotoga maritima]” SPX0131 131 2792 319 957 334 1.10E−63 [LN:E81303] [AC:E81303] [PN:probable branched-chain amino-acid ABC transport system permease protein Cj1016c [imported]] [GN:livM:Cj1016c] 164 [OR:Campylobacter jejuni] SPX0132 132 2793 293 879 325 1.30E−90 “[LN:D72290] [AC:D72290] [PN:branched chain amino acid ABC transporter, permease protein] [GN:TM1136] [CL:leucine transport protein livH] 163 [OR:Thermotoga maritima]” SPX0133 133 2794 387 1161 193 5.70E−39 [LN:H81303] [AC:H81303] [PN:branched-chain amino-acid ABC transport system periplasmic binding protein Cj1019c [imported]] [GN:livJ:Cj1019c] 166 [OR:Campylobacter jejuni] SPX0134 134 2795 150 450 NO-HIT 6 SPX0135 135 2796 83 249 116 2.40E−11 [LN:D69874] [AC:D69874] [PN:conserved hypothetical protein ylbG] [GN:ylbG] [OR:Bacillus subtilis] 97 SPX0136 136 2797 197 591 933 8.10E−124 [LN:CLPP_STRSL] [AC:P36398] [GN:CLPP] [OR:Streptococcus salivarius] [EC:3.4.21.92] [DE:(ENDOPEPTIDASE CLP)] [SP:P36398] 119 SPX0137 137 2798 217 651 961 5.20E−129 [LN:UPP_STRSL] [AC:P36399] [GN:UPP] [OR:Streptococcus salivarius] [EC:2.4.2.9] [DE:PYROPHOSPHORYLASE) (UPRTASE)] [SP:P36399] 124 SPX0138 138 2799 54 162 O-HIT 6 SPX0139 139 2800 156 468 265 4.40E−49 [LN:CME2_BACSU] [AC:P32393] [GN:COMEB:COME2] [OR:Bacillus subtilis] [DE:COME OPERON PROTEIN 2] [SP:P32393] 106 SPX0140 140 2801 186 558 114 1.10E−07 [LN:G70325] [AC:G70325] [PN:transcription regulator TetR/AcrR family] [GN:acrR3] [OR:Aquifex aeolicus] 102 SPX0141 141 2802 282 846 813 2.60E−107 [GI:4580621] [LN:AF118389] [AC:AF118389] [PN:unknown] [OR:Streptococcus suis] 77 SPX0142 142 2803 392 1176 330 1.60E−83 [GI:2293312] [LN:AF008220] [AC:AF008220] [PN:YtfP] [GN:ytfP] [OR:Bacillus subtilis] 83 SPX0143 143 2804 152 456 106 6.50E−12 [LN:G70031] [AC:G70031] [PN:mutator MutT protein homolog yvcI] [GN:yvcI] [CL:mutT domain homology] [OR:Bacillus subtilis] 121 SPX0144 144 2805 173 519 876 2.10E−115 [GI:6179679] [LN:SPN239034] [AC:AJ239034] [PN:regulator of pmrA] [GN:mta] [FN:regulator of pmrA expression] [OR:Streptococcus pneumoniae] 137 SPX0145 145 2806 490 1470 805 5.40E−151 [LN:F69825] [AC:F69825] [PN:sodium-dependent transporter homolog yhdH] [GN:yhdH] [CL:gamma-aminobutyric acid transporter] [OR:Bacillus subtilis] 144 SPX0146 146 2807 315 945 1165 3.00E−155 [LN:MANA_STRMU] [AC:Q59935] [GN:PMI] [OR:Streptococcus mutans] [EC:5.3.1.8] [DE:(PMI) (PHOSPHOHEXOMUTASE)] [SP:Q59935] 118 SPX0147 147 2808 134 402 NO-HIT 6 SPX0148 148 2809 110 330 270 1.80E−43 [LN:JE0396] [AC:JE0396] [PN:phospho-beta-galactosidase II] [CL:Agrobacterium beta-glucosidase] [OR:Lactobacillus gasseri] 121 SPX0149 149 2810 89 267 NO-HIT 6 SPX0150 150 2811 218 654 154 1.00E−20 [GI:722339] [LN:AXU22323] [AC:U22323] [PN:unknown] [OR:Acetobacter xylinus] [SR:Acetobacter xylinum] 100 SPX0151 151 2812 116 348 NO-HIT 6 SPX0152 152 2813 592 1776 3033 0 “[LN:POXB_STRPN] [AC:Q54970] [GN:SPXB] [OR:Streptococcus pneumoniae] [EC:1.2.3.3] [DE:PYRUVATE OXIDASE, 141 (PYRUVIC OXIDASE) (POX)] [SP:Q54970]” SPX0153 153 2814 67 201 149 2.30E−14 [GI:1513069] [LN:LMU15554] [AC:U15554] [PN:P-type adenosine triphosphatase] [GN:ctpA] [FN:involved in cation transport] 147 [OR:Listeria monocytogenes] SPX0154 154 2815 733 2199 648 8.80E−202 [GI:1513069] [LN:LMU15554] [AC:U15554] [PN:P-type adenosine triphosphatase] [GN:ctpA] [FN:involved in cation transport] 147 [OR:Listeria monocytogenes] SPX0155 155 2816 85 255 107 2.40E−09 [LN:H72624] [AC:H72624] [PN:hypothetical protein APE1456] [GN:APE1456] [OR:Aeropyrum pernix] 92 SPX0156 156 2817 61 183 NO-HIT 6 SPX0157 157 2818 124 372 70 6.10E−06 “[LN:H69267] [AC:H69267] [PN:cytochrome-c oxidase, chain II AF0144] [CL:cytochrome-c oxidase chain II:cytochrome-c oxidase chain II homology] 183 [OR:Archaeoglobus fulgidus] [EC:1.9.3.1]” SPX0158 158 2819 142 426 240 1.00E−28 [LN:COPY_ENTHR] [AC:Q47839] [GN:COPY] [OR:Enterococcus hirae] [DE:COPAB ATPASES METAL-FIST TYPE REPRESSOR] [SP:Q47839] 118 SPX0159 159 2820 269 807 308 4.00E−99 [GI:6707002] [LN:AF109218] [AC:AF109218:U96108] [PN:ThiD] [GN:thiD] [OR:Staphylococcus carnosus] 96 SPX0160 160 2821 211 633 245 8.10E−55 [LN:D75087] [AC:D75087] [PN:thiamin phosphate pyrophosphorylase (thie) PAB1645] [GN:PAB1645] [CL:probable thiamin-phosphate 210 pyrophosphorylase:thiamin-phosphate pyrophosphorylase homology] [OR:Pyrococcus abyssi] SPX0161 161 2822 269 807 228 2.70E−27 [LN:THIM_ECOLI] [AC:P76423] [GN:THIM] [OR:Escherichia coli] [EC:2.7.1.50] [DE:HYDROXYETHYLTHIAZOLE KINASE) (THZ KINASE) 144 (TH KINASE)] [SP:P76423] SPX0162 162 2823 175 525 NO-HIT 6 SPX0163 163 2824 231 693 384 2.00E−48 [LN:TENA_BACSU] [AC:P25052] [GN:TENA] [OR:Bacillus subtilis] [DE:TRANSCRIPTIONAL ACTIVATOR TENA] [SP:P25052] 108 SPX0164 164 2825 217 651 112 1.10E−13 [GI:1296823] [LN:LHPEPIGN] [AC:Z56283] [GN:orf2] [OR:Lactobacillus helveticus] 78 SPX0165 165 2826 462 1386 279 4.50E−59 [GI:1296822] [LN:LHPEPIGN] [AC:Z56283] [GN:orf1] [OR:Lactobacillus helveticus] 78 SPX0166 166 2827 187 561 203 2.20E−27 [LN:A69859] [AC:A69859] [PN:hypothetical protein ykoE] [GN:ykoE] [OR:Bacillus subtilis] 87 SPX0167 167 2828 75 225 NO-HIT 6 SPX0168 168 2829 69 207 NO-HIT 6 SPX0169 169 2830 210 630 520 4.10E−72 [GI:6707004] [LN:AF109218] [AC:AF109218:U96108] [PN:ThiE] [GN:thiE] [OR:Staphylococcus carnosus] 96 SPX0170 170 2831 268 804 523 4.60E−67 [GI:6707003] [LN:AF109218] [AC:AF109218:U96108] [PN:ThiM] [GN:thiM] [OR:Staphylococcus carnosus] 96 SPX0171 171 2832 137 411 114 2.00E−08 [LN:H71057] [AC:H71057] [PN:hypothetical protein PH1158] [GN:PH1158] [OR:Pyrococcus horikoshii] 95 SPX0172 172 2833 82 246 NO-HIT 6 SPX0173 173 2834 75 225 203 1.90E−23 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX0174 174 2835 223 669 127 6.60E−15 “[LN:PT18_YEAST] [AC:P25362] [GN:PET18:HIT2:YCR020C:YCR20C] [OR:Saccharomyces cerevisiae] [SR:,Baker's yeast] 141 [DE:PET18 PROTEIN] [SP:P25362]” SPX0175 175 2836 379 1137 1379 5.20E−216 [GI:2239174] [LN:SILCT] [AC:Y07622] [PN:lactate oxidase] [GN:lctO] [FN:lactate utilisation] [OR:Streptococcus iniae] 116 SPX0176 176 2837 497 1491 1157 1.60E−228 “[LN:SYK_BACSU] [AC:P37477] [GN:LYSS] [OR:Bacillus subtilis] [EC:6.1.1.6] [DE:LYSYL-TRNA SYNTHETASE, (LYSINE-TRNA LIGASE) 144 (LYSRS)] [SP:P37477]” SPX0177 177 2838 227 681 351 2.10E−70 “[LN:D71849] [AC:D71849] [PN:amino acid ABC transporter, permease protein] [GN:jhp1096] [CL:histidine permease protein M] [OR:Helicobacter 195 pylori] [SR:strain J99, , strain J99] [SR:strain J99, ]” SPX0178 178 2839 127 381 279 2.10E−35 “[LN:B64666] [AC:B64666] [PN:glutamine ABC transporter, permease protein] [CL:histidine permease protein M] [OR:Helicobacter pylori]” 133 SPX0179 179 2840 96 288 249 4.10E−30 “[LN:B64666] [AC:B64666] [PN:glutamine ABC transporter, permease protein] [CL:histidine permease protein M] [OR:Helicobacter pylori]” 133 SPX0180 180 2841 71 213 92 5.90E−05 [GI:4163988] [LN:AF082511] [AC:AF082511] [PN:putative ATP-binding protein MglA] [GN:mglA] [OR:Treponema denticola] 114 SPX0181 181 2842 169 507 531 5.00E−70 [LN:H81391] [AC:H81391] [PN:amino-acid ABC transporter ATP-binding protein Cj0469 [imported]] [GN:Cj0469] [OR:Campylobacter jejuni] 131 SPX0182 182 2843 67 201 72 3.30E−07 [LN:G72510] [AC:G72510] [PN:hypothetical protein APE2061] [GN:APE2061] [OR:Aeropyrum pernix] 92 SPX0183 183 2844 81 243 132 5.50E−12 [GI:4204972] [LN:LLU60994] [AC:U60994] [FN:transport systems for basic amino acids and] [OR:Leuconostoc lactis] 111 SPX0184 184 2845 185 555 531 1.40E−67 [LN:C81373] [AC:C81373] [PN:probable amino-acid transporter periplasmic solute-binding protein Cj0982c [imported]] [GN:Cj0982c] 153 [OR:Campylobacter jejuni] SPX0185 185 2846 216 648 353 6.60E−51 [LN:YYBJ_BACSU] [AC:P37494] [GN:YYBJ] [OR:Bacillus subtilis] [DE:INTERGENIC REGION] [SP:P37494] 95 SPX0186 186 2847 235 705 NO-HIT 6 SPX0187 187 2848 68 204 NO-HIT 6 SPX0188 188 2849 269 807 NO-HIT 6 SPX0189 189 2850 255 765 NO-HIT 6 SPX0190 190 2851 117 351 NO-HIT 6 SPX0191 191 2852 211 633 1057 1.30E−140 [GI:4009484] [LN:AF068902] [AC:AF068902] [PN:orotate phosphoribosyltransferase PyrE] [GN:pyrE] [OR:Streptococcus pneumoniae] 124 SPX0192 192 2853 234 702 1173 1.80E−157 [GI:4009483] [LN:AF068902] [AC:AF068902] [PN:orotidine-5′-decarboxylase PyrF] [GN:pyrF] [OR:Streptococcus pneumoniae] 117 SPX0193 193 2854 67 201 NO-HIT 6 SPX0194 194 2855 400 1200 1946 3.00E−251 [GI:4009482] [LN:AF068902] [AC:AF068902] [PN:cell division protein DivIB] [GN:divIB] [OR:Streptococcus pneumoniae] 114 SPX0195 195 2856 148 444 110 2.20E−07 “[GI:6473880] [LN:AB027890] [AC:AB027890] [PN:Hypothetical protein] [GN:SPBC3D5.14C] [OR:Schizosaccharomyces pombe] [SR: 180 Schizosaccharomyces pombe (strain:968 h90) DNA, clone:TA46]” SPX0196 196 2857 353 1059 1780 1.40E−242 [GI:4009481] [LN:AF068902] [AC:AF068902] [PN:undecaprenyl-PP-MurNAc-pentapeptide-UDPGlcNAc] [GN:murG] [OR:Streptococcus pneumoniae] 131 SPX0197 197 2858 451 1353 2206 1.20E−297 [GI:4009480] [LN:AF068902] [AC:AF068902] [PN:D-glutamic acid adding enzyme MurD] [GN:murD] [OR:Streptococcus pneumoniae] 120 SPX0198 198 2859 214 642 1062 1.20E−142 [GI:4009479] [LN:AF068902] [AC:AF068902] [PN:unknown] [OR:Streptococcus pneumoniae] 83 SPX0199 199 2860 674 2022 2263 0 [GI:4009478] [LN:AF068902] [AC:AF068902] [PN:unknown] [OR:Streptococcus pneumoniae] 83 SPX0200 200 2861 135 405 86 1.80E−05 [GI:7576923] [LN:AF242367] [AC:AF242367] [PN:lactococcin 972] [GN:lclA] [OR:Lactococcus lactis subsp. lactis] 109 SPX0201 201 2862 73 219 NO-HIT 6 SPX0202 202 2863 85 255 89 2.50E−05 [LN:T20916] [AC:T20916] [PN:hypothetical protein F14F8.3] [GN:F14F8.3] [OR:Caenorhabditis elegans] 98 SPX0203 203 2864 621 1863 1706 0 [LN:TYPA_BACSU] [AC:O07631] [GN:TYPA] [OR:Bacillus subtilis] [DE:GTP-BINDING PROTEIN TYPA/BIPA HOMOLOG] [SP:O07631] 115 SPX0204 204 2865 242 726 154 3.00E−34 [GI:7328274] [LN:SAY14816] [AC:Y14816] [PN:hypothetical protein] [GN:ORF231] [OR:Staphylococcus aureus] 103 SPX0205 205 2866 66 198 NO-HIT 6 SPX0206 206 2867 127 381 174 3.80E−28 [LN:YQHL_BACSU] [AC:P54510] [GN:YQHL] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 14.6 KD PROTEIN IN GCVT-SPOIIIAA INTERGENIC 141 REGION] [SP:P54510] SPX0207 207 2868 74 222 158 1.80E−17 [LN:T44786] [AC:T44786] [PN:hypothetical protein 1 [imported]] [OR:Bacillus megaterium] 87 SPX0208 208 2869 303 909 1241 5.30E−168 [LN:T44638] [AC:T44638] [PN:capsular polysaccharide biosynthesis protein cpsY [imported]] [GN:cpsY] [CL:probable transcription regulator lsyR] 172 [OR:Streptococcus agalactiae] SPX0209 209 2870 252 756 476 5.30E−66 [LN:YQJQ_BACSU] [AC:P54554] [GN:YQJQ] [OR:Bacillus subtilis] [EC:1.-.-.-] [DE:(EC 1.-.-.-)] [SP:P54554] 103 SPX0210 210 2871 310 930 368 9.50E−98 [LN:YQJK_BACSU] [AC:P54548] [GN:YQJK] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 34.0 KD PROTEIN IN GLNQ-ANSR INTERGENIC REGION] [SP:P54548] 137 SPX0211 211 2872 208 624 NO-HIT 6 SPX0212 212 2873 413 1239 792 1.40E−103 [LN:B69888] [AC:B69888] [PN:GTP-binding protein proteinase modulator homolog ynbA] [GN:ynbA] [CL:GTP-binding protein hflX:translation 187 elongation factor Tu homology] [OR:Bacillus subtilis] SPX0213 213 2874 312 936 317 7.10E−70 [LN:G69657] [AC:G69657] [PN:tRNA isopentenylpyrophosphate transferase miaA] [GN:miaA] [CL:delta(2)-isopentenylpyrophosphate transferase] 159 [OR:Bacillus subtilis] SPX0214 214 2875 63 189 NO-HIT 6 SPX0215 215 2876 66 198 129 6.10E−12 “[LN:TYSY_LACLA] [AC:P19368] [GN:THYA] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:2.1.1.45] 160 [DE:THYMIDYLATE SYNTHASE, (TS)] [SP:P19368]” SPX0216 216 2877 221 663 318 1.20E−39 [GI:7328278] [LN:SAY14816] [AC:Y14816] [PN:hypothetical protein] [GN:ORF242] [OR:Staphylococcus aureus] 103 SPX0217 217 2878 212 636 691 4.80E−91 [LN:B69997] [AC:B69997] [PN:conserved hypothetical protein ytmQ] [GN:ytmQ] [CL:hypothetical protein HI0340] [OR:Bacillus subtilis] 130 SPX0218 218 2879 89 267 NO-HIT 6 SPX0219 219 2880 103 309 215 6.90E−25 [LN:YLXS_BACSU] [AC:P32726] [GN:YLXS] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 17.6 KD PROTEIN IN NUSA 5′REGION (P15A) (ORF1)] [SP:P32726] 137 SPX0220 220 2881 379 1137 715 6.00E−122 [GI:2634032] [LN:BSUB0009] [AC:Z99112:AL009126] [GN:nusA] [FN:transcription termination] [OR:Bacillus subtilis] 111 SPX0221 221 2882 98 294 220 1.70E−25 [LN:YLXR_BACSU] [AC:P32728] [GN:YLXR] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 10.4 KD PROTEIN IN NUSA-INFB INTERGENIC 144 REGION (ORF3)] [SP:P32728] SPX0222 222 2883 100 300 259 3.80E−31 “[LN:YLXQ_ENTFC] [AC:P55768] [OR:Enterococcus faecium] [SR:,Streptococcus faecium] [DE:PROBABLE RIBOSOMAL PROTEIN IN INFB 144 5′ REGION] [SP:P55768]” SPX0223 223 2884 165 495 NO-HIT 6 SPX0224 224 2885 931 2793 2768 0 [GI:3947714] [LN:SAAJ3164] [AC:AJ003164] [PN:initiation factor IF2] [GN:infB] [FN:translation initiation factor] [OR:Streptococcus agalactiae] 142 SPX0225 225 2886 82 246 NO-HIT 6 SPX0226 226 2887 117 351 478 2.00E−61 [GI:3947715] [LN:SAAJ3164] [AC:AJ003164] [PN:ribosome binding factor A] [GN:rbfA] [FN:ribosome maturation] [OR:Streptococcus agalactiae] 136 SPX0227 227 2888 260 780 217 3.30E−40 [LN:T35040] [AC:T35040] [PN:hypothetical protein SC4G2.05 SC4G2.05] [GN:SC4G2.05] [OR:Streptomyces coelicolor] 110 SPX0228 228 2889 84 252 NO-HIT 6 SPX0229 229 2890 74 222 NO-HIT 6 SPX0230 230 2891 65 195 202 2.70E−24 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX0231 231 2892 78 234 102 4.60E−08 [LN:A69271] [AC:A69271] [PN:hypothetical protein AF0169] [CL:Archaeoglobus fulgidus hypothetical protein AF0169] [OR:Archaeoglobus fulgidus] 140 SPX0232 232 2893 445 1335 123 1.30E−41 [LN:B69271] [AC:B69271] [PN:hypothetical protein AF0170] [OR:Archaeoglobus fulgidus] 84 SPX0233 233 2894 85 255 NO-HIT 6 SPX0234 234 2895 132 396 NO-HIT 6 SPX0235 235 2896 69 207 NO-HIT 6 SPX0236 236 2897 150 450 NO-HIT 6 SPX0237 237 2898 186 558 148 2.10E−18 [LN:YP20_BACLI] [AC:P05332] [GN:P20] [OR:Bacillus licheniformis] [DE:HYPOTHETICAL P20 PROTEIN] [SP:P05332] 106 SPX0238 238 2899 321 963 NO-HIT 6 SPX0239 239 2900 884 2652 1594 0 “[LN:SYV_BACSU] [AC:Q05873] [GN:VALS] [OR:Bacillus subtilis] [EC:6.1.1.9] [DE:VALYL-TRNA SYNTHETASE, (VALINE-TRNA LIGASE) 144 (VALRS)] [SP:Q05873]” SPX0240 240 2901 252 756 642 7.80E−85 “[LN:B71947] [AC:B71947] [PN:hypothetical protein jhp0330] [GN:jhp0330] [OR:Helicobacter pylori] [SR:strain J99, , strain J99] [SR:strain J99, ]” 145 SPX0241 241 2902 268 804 91 1.80E−05 “[LN:Y4LH_RHISN] [AC:P55548] [GN:Y4LH] [OR:Rhizobium sp] [SR:,strain NGR234] [DE:HYPOTHETICAL 22.4 KD PROTEIN Y4LH] [SP:P55548]” 128 SPX0242 242 2903 95 285 387 3.10E−49 [GI:1490399] [LN:SPPARCETP] [AC:Z67739] [PN:DNA transposase] [OR:Streptococcus pneumoniae] 90 SPX0243 243 2904 102 306 323 2.70E−40 [GI:1490399] [LN:SPPARCETP] [AC:Z67739] [PN:DNA transposase] [OR:Streptococcus pneumoniae] 90 SPX0244 244 2905 91 273 315 2.50E−39 [LN:A33595] [AC:A33595:A30868] [PN:probable transposase] [CL:transposase IS3] [OR:Streptococcus agalactiae] 107 SPX0245 245 2906 92 276 135 3.80E−13 [LN:B30868] [AC:B30868] [PN:hypothetical protein 1] [OR:Streptococcus agalactiae] 81 SPX0246 246 2907 422 1266 NO-HIT 6 SPX0247 247 2908 399 1197 109 9.90E−10 [GI:6689196] [LN:SCE20] [AC:AL136058] [PN:putative helicase] [GN:SCE20.37] [OR:Streptomyces coelicolor A3(2)] 109 SPX0248 248 2909 98 294 NO-HIT 6 SPX0249 249 2910 280 840 489 2.30E−81 [LN:LICT_BACSU] [AC:P39805] [GN:LICT:N15A] [OR:Bacillus subtilis] [DE:TRANSCRIPTION ANTITERMINATOR LICT] [SP:P39805] 116 SPX0250 250 2911 613 1839 534 8.10E−147 “[LN:PTBA_BACSU] [AC:P40739:Q45661] [GN:BGLP:N17C] [OR:Bacillus subtilis] [EC:2.7.1.69] [DE:ENZYME II, ABC COMPONENT), 149 (EII-BGL)] [SP:P40739:Q45661]” SPX0251 251 2912 472 1416 1046 3.70E−228 “[LN:ABGA_CLOLO] [AC:Q46130] [GN:ABGA] [OR:Clostridium longisporum] [EC:3.2.1.86] [DE:6-PHOSPHO-BETA-GLUCOSIDASE,] 127 [SP:Q46130]” SPX0252 252 2913 349 1047 656 3.10E−156 [LN:SYFA_BACSU] [AC:P17921:P94539] [GN:PHES] [OR:Bacillus subtilis] [EC:6.1.1.20] [DE:-TRNA LIGASE ALPHA CHAIN) (PHERS)] 139 [SP:P17921:P94539] SPX0253 253 2914 331 993 NO-HIT 6 SPX0254 254 2915 170 510 333 1.80E−41 “[LN:YPIP_LACDL] [AC:P46543] [OR:Lactobacillus delbrueckii] [SR:,subsplactis] [DE:HYPOTHETICAL 19.8 KD PROTEIN IN PEPI 3′REGION] 141 [SP:P46543]” SPX0255 255 2916 801 2403 312 2.20E−132 “[LN:SYFB_SYNY3] [AC:P74296] [GN:PHET:SLL1553] [OR:Synechocystis sp] [SR:,strain PCC 6803] [EC:6.1.1.20] [DE:TRNA LIGASE 154 BETA CHAIN) (PHERS)] [SP:P74296]” SPX0256 256 2917 296 888 NO-HIT 6 SPX0257 257 2918 149 447 437 4.90E−55 [GI:517210] [LN:SPU11799] [AC:U11799] [OR:Streptococcus pyogenes] 65 SPX0258 258 2919 89 267 245 2.00E−28 [LN:Y659_HAEIN] [AC:P44030] [GN:HI0659] [OR:Haemophilus influenzae] [DE:HYPOTHETICAL PROTEIN HI0659] [SP:P44030] 112 SPX0259 259 2920 99 297 NO-HIT 6 SPX0260 260 2921 750 2250 1309 6.60E−297 “[LN:C81326] [AC:C81326] [PN:5-methyltetrahydropteroyltriglutamate-homocystei methyltransferase, Cj1201 [imported]] [GN:metE:Cj1201] 175 [OR:Campylobacter jejuni] [EC:2.1.1.14]” SPX0261 261 2922 289 867 261 3.90E−77 “[LN:D81326] [AC:D81326] [PN:5,10-methylenetetrahydrofolate reductase, Cj1202 [imported]] [GN:metF:Cj1202] [OR:Campylobacter jejuni] [EC:1.7.99.5]” 147 SPX0262 262 2923 90 270 NO-HIT 6 SPX0263 263 2924 738 2214 1323 3.80E−298 [LN:PNPA_BACSU] [AC:P50849] [GN:PNPA:COMR] [OR:Bacillus subtilis] [EC:2.7.7.8] [DE:PHOSPHORYLASE) (PNPASE) (VEGETATIVE 151 PROTEIN 15) (VEG15)] [SP:P50849] SPX0264 264 2925 206 618 493 1.20E−63 [GI:6899995] [LN:CST130879] [AC:AJ130879] [PN:serine acetyltransferase] [GN:cysE] [OR:Clostridium sticklandii] 110 SPX0265 265 2926 295 885 113 3.80E−07 [LN:E69786] [AC:E69786] [PN:ribosomal-protein-alanine N-acetyltransfer homolog ydiD] [GN:ydiD] [CL:Escherichia coli ribosomal-protein-alanine 190 N-acetyltransferase rimI] [OR:Bacillus subtilis] SPX0266 266 2927 152 456 NO-HIT 6 SPX0267 267 2928 448 1344 570 9.00E−167 [GI:6899996] [LN:CST130879] [AC:AJ130879] [PN:cysteinyl tRNA synthetase] [GN:cysRS] [OR:Clostridium sticklandii] 112 SPX0268 268 2929 129 387 316 6.30E−39 [LN:C69742] [AC:C69742] [PN:conserved hypothetical protein yazC] [GN:yazC] [OR:Bacillus subtilis] 97 SPX0269 269 2930 295 885 224 3.10E−30 [LN:LRPR_STREQ] [AC:Q54087] [GN:LRP] [OR:Streptococcus equisimilis] [DE:LEUCINE RICH PROTEIN] [SP:Q54087] 105 SPX0270 270 2931 88 264 NO-HIT 6 SPX0271 271 2932 200 600 NO-HIT 6 SPX0272 272 2933 52 156 87 3.30E−06 [LN:D75542] [AC:D75542] [PN:hypothetical protein] [GN:DR0254] [OR:Deinococcus radiodurans] 90 SPX0273 273 2934 82 246 247 1.10E−29 [LN:F81737] [AC:F81737] [PN:hypothetical protein TC0129 [imported]] [GN:TC0129] [OR:Chlamydia muridarum:Chlamydia trachomatis MoPn] 131 SPX0274 274 2935 78 234 143 4.90E−15 [LN:F71245] [AC:F71245] [PN:hypothetical protein PHS004] [GN:PHS004] [OR:Pyrococcus horikoshii] 95 SPX0275 275 2936 72 216 NO-HIT 6 SPX0276 276 2937 63 189 68 2.40E−07 [LN:C64571] [AC:C64571] [PN:hypothetical protein HP0411] [CL:Helicobacter pylori hypothetical protein HP0411] [OR:Helicobacter pylori] 134 SPX0277 277 2938 312 936 194 2.60E−36 “[GI:773349] [LN:BSU20445] [AC:U20445] [PN:BirA protein] [GN:birA] [FN:biotin protein ligase, biotin operon repressor] [OR:Bacillus subtilis]” 142 SPX0278 278 2939 287 861 255 1.70E−56 [LN:MSMR_STRMU] [AC:Q00753] [GN:MSMR] [OR:Streptococcus mutans] [DE:MSM OPERON REGULATORY PROTEIN] [SP:Q00753] 110 SPX0279 279 2940 721 2163 2528 0 “[LN:AGAL_STRMU] [AC:P27756] [GN:AGA] [OR:Streptococcus mutans] [EC:3.2.1.22] [DE:ALPHA-GALACTOSIDASE, (MELIBIASE)] [SP:P27756]” 128 SPX0280 280 2941 420 1260 1106 2.40E−180 [LN:MSME_STRMU] [AC:Q00749] [GN:MSME] [OR:Streptococcus mutans] [DE:MULTIPLE SUGAR-BINDING PROTEIN PRECURSOR] [SP:Q00749] 121 SPX0281 281 2942 82 246 NO-HIT 6 SPX0282 282 2943 289 867 1188 1.40E−166 [LN:MSMF_STRMU] [AC:Q00750] [GN:MSMF] [OR:Streptococcus mutans] [DE:MULTIPLE SUGAR-BINDING TRANSPORT SYSTEM PERMEASE 142 PROTEIN MSMF] [SP:Q00750] SPX0283 283 2944 278 834 1174 3.40E−164 [LN:MSMG_STRMU] [AC:Q00751] [GN:MSMG] [OR:Streptococcus mutans] [DE:MULTIPLE SUGAR-BINDING TRANSPORT SYSTEM PERMEASE 142 PROTEIN MSMG] [SP:Q00751] SPX0284 284 2945 482 1446 2154 6.70E−294 “[LN:A27626] [AC:A27626] [PN:sucrose phosphorylase,] [CL:gtfA protein] [OR:Streptococcus mutans] [EC:2.4.1.7]” 110 SPX0285 285 2946 398 1194 NO-HIT 6 SPX0286 286 2947 134 402 NO-HIT 6 SPX0287 287 2948 662 1986 3341 0 [LN:AMIA_STRPN] [AC:P18791:P18792] [GN:AMIA] [OR:Streptococcus pneumoniae] [DE:OLIGOPEPTIDE−BINDING PROTEIN AMIA 142 PRECURSOR] [SP:P18791:P18792] SPX0288 288 2949 499 1497 2538 0 [LN:AMIC_STRPN] [AC:P18793] [GN:AMIC] [OR:Streptococcus pneumoniae] [DE:OLIGOPEPTIDE TRANSPORT PERMEASE PROTEIN AMIC] 129 [SP:P18793] SPX0289 289 2950 309 927 1564 1.10E−217 [LN:AMID_STRPN] [AC:P18794] [GN:AMID] [OR:Streptococcus pneumoniae] [DE:OLIGOPEPTIDE TRANSPORT PERMEASE PROTEIN AMID] 129 [SP:P18794] SPX0290 290 2951 356 1068 1806 2.10E−245 [LN:AMIE_STRPN] [AC:P18765] [GN:AMIE] [OR:Streptococcus pneumoniae] [DE:OLIGOPEPTIDE TRANSPORT ATP-BINDING PROTEIN AMIE] 132 [SP:P18765] SPX0291 291 2952 113 339 NO-HIT 6 SPX0292 292 2953 309 927 1534 5.40E−208 [LN:AMIF_STRPN] [AC:P18766] [GN:AMIF] [OR:Streptococcus pneumoniae] [DE:OLIGOPEPTIDE TRANSPORT ATP-BINDING PROTEIN AMIF] 132 [SP:P18766] SPX0293 293 2954 419 1257 2039 1.30E−284 [GI:2804700] [LN:AF030361] [AC:AF030361] [PN:transposase] [OR:Streptococcus pneumoniae] 87 SPX0294 294 2955 96 288 274 1.10E−34 [GI:663279] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae (strain RX1) DNA] 138 SPX0295 295 2956 173 519 840 6.50E−114 [GI:663278] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae (strain RX1) DNA] 138 SPX0296 296 2957 237 711 471 2.40E−60 [LN:TRER_BACSU] [AC:P39796] [GN:TRER] [OR:Bacillus subtilis] [DE:TREHALOSE OPERON TRANSCRIPTIONAL REPRESSOR] [SP:P39796] 120 SPX0297 297 2958 656 1968 383 7.20E−135 [LN:PTTB_ECOLI] [AC:P36672] [GN:TREB] [OR:Escherichia coli] [EC:2.7.1.69] [DE:(EC 2.7.1.69) (EII-TRE)] [SP:P36672] 114 SPX0298 298 2959 542 1626 1617 2.00E−272 [GI:2208998] [LN:SSU35633] [AC:U35633] [PN:dextran glucosidase DexS] [GN:dexS] [OR:Streptococcus suis] 102 SPX0299 299 2960 60 180 125 2.30E−12 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX0300 300 2961 84 252 104 4.40E−09 [GI:6899236] [LN:AE002123] [AC:AE002123:AF222894] [PN:conserved hypothetical] [GN:UU265] [OR:Ureaplasma urealyticum] 116 SPX0301 301 2962 265 795 476 2.60E−84 [GI:2462097] [LN:BCBCTLGLR] [AC:Y10927] [PN:glutamate racemase] [GN:bcglr] [OR:Bacillus cereus] 95 SPX0302 302 2963 297 891 273 9.10E−35 [LN:C69986] [AC:C69986] [PN:conserved hypothetical protein ysnA] [GN:ysnA] [CL:Methanococcus jannaschii conserved hypothetical protein MJ0226] 165 [OR:Bacillus subtilis] SPX0303 303 2964 74 222 158 1.60E−15 [LN:YGGV_ECOLI] [AC:P52061] [GN:YGGV] [OR:Escherichia coli] [DE:HYPOTHETICAL 21.0 KD PROTEIN IN GSHB-ANSB INTERGENIC 143 REGION (O197)] [SP:P52061] SPX0304 304 2965 174 522 229 8.10E−27 [LN:YSNB_BACSU] [AC:P94559] [GN:YSNB] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 19.2 KD PROTEIN IN RPH-ILVB INTERGENIC 136 REGION] [SP:P94559] SPX0305 305 2966 154 462 75 8.30E−08 [LN:A69866] [AC:A69866] [PN:hypothetical protein ykuL] [GN:ykuL] [CL:Bacillus subtilis hypothetical protein ykuL] [OR:Bacillus subtilis] 136 SPX0306 306 2967 247 741 61 0.0006 [LN:A75153] [AC:A75153] [PN:integrase/recombinase xerd PAB0255] [GN:xerD-like:PAB0255] [CL:probable site-specific integrase/recombinase XerC] 164 [OR:Pyrococcus abyssi] SPX0307 307 2968 243 729 233 1.60E−40 [LN:YPUG_BACSU] [AC:P35154] [GN:YPUG] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 29.6 KD PROTEIN IN RIBT-DACB INTERGENIC 145 REGION (ORFX7)] [SP:P35154] SPX0308 308 2969 190 570 216 2.00E−28 [LN:Y214_MYCPN] [AC:P75477] [OR:Mycoplasma pneumoniae] [DE:HYPOTHETICAL PROTEIN MG214 HOMOLOG] [SP:P75477] 106 SPX0309 309 2970 241 723 660 5.60E−86 [LN:RLUB_BACSU] [AC:P35159] [GN:RLUB] [OR:Bacillus subtilis] [EC:4.2.1.70] [DE:(PSEUDOURIDYLATE SYNTHASE) (URACIL 138 HYDROLYASE)] [SP:P35159] SPX0310 310 2971 81 243 166 1.10E−32 [LN:G72251] [AC:G72251] [PN:conserved hypothetical protein] [GN:TM1462] [CL:conserved hypothetical protein HI1000] [OR:Thermotoga maritima] 139 SPX0311 311 2972 175 525 NO-HIT 6 SPX0312 312 2973 322 966 218 2.70E−57 [LN:E69763] [AC:E69763] [PN:probable ferrichrome ABC transporter yclQ] [GN:yclQ] [CL:iron(III) dicitrate transport protein] [OR:Bacillus subtilis] 146 SPX0313 313 2974 251 753 702 2.90E−92 [LN:D69763] [AC:D69763] [PN:ferrichrome ABC transporter (ATP-binding p) homolog yclP] [GN:yclP] [CL:unassigned ATP-binding cassette 194 proteins:ATP-binding cassette homology] [OR:Bacillus subtilis] SPX0314 314 2975 67 201 89 6.60E−07 [LN:G72510] [AC:G72510] [PN:hypothetical protein APE2061] [GN:APE2061] [OR:Aeropyrum pernix] 92 SPX0315 315 2976 319 957 474 8.60E−64 [LN:C69763] [AC:C69763] [PN:ferrichrome ABC transporter (permease) homolog yclO] [GN:yclO] [CL:ferrichrome ABC transporter] 146 [OR:Bacillus subtilis] SPX0316 316 2977 320 960 625 2.80E−84 [LN:B69763] [AC:B69763] [PN:ferrichrome ABC transporter (permease) homolog yclN] [GN:yclN] [CL:vitamin B12 transport protein btuC] 153 [OR:Bacillus subtilis] SPX0317 317 2978 136 408 288 3.50E−36 [GI:6707010] [LN:AF109295] [AC:AF109295:AF022796] [PN:GalE] [GN:galE] [OR:Staphylococcus carnosus] 98 SPX0318 318 2979 81 243 164 6.20E−18 [GI:3703059] [LN:AF082009] [AC:AF082009] [PN:UDP-galactose-4-epimerase] [GN:galE] [OR:Lactococcus lactis] 105 SPX0319 319 2980 354 1062 388 8.30E−143 “[LN:PEPA_LACLC] [AC:Q48677] [GN:PEPA] [OR:Lactococcus lactis] [SR:,subspcremoris:Streptococcus cremoris] [EC:3.4.11.7] 162 [DE:GLUTAMYL-AMINOPEPTIDASE,] [SP:Q48677]” SPX0320 320 2981 99 297 NO-HIT 6 SPX0321 321 2982 63 189 NO-HIT 6 SPX0322 322 2983 148 444 87 0.00059 [GI:2791904] [LN:SSK3MECA1] [AC:Y13052] [GN:ORF145] [OR:Staphylococcus sciuri] 78 SPX0323 323 2984 255 765 NO-HIT 6 SPX0324 324 2985 243 729 1211 8.40E−163 [GI:5579394] [LN:AF162655] [AC:AF162655] [PN:choline transporter] [GN:proV] [FN:ATPase] [OR:Streptococcus pneumoniae] 117 SPX0325 325 2986 29 87 NO-HIT 6 SPX0326 326 2987 311 933 1434 2.40E−200 [LN:T44634] [AC:T44634] [PN:choline transporter [imported]] [GN:proWX] [OR:Streptococcus pneumoniae] 100 SPX0327 327 2988 210 630 1042 3.30E−137 [LN:T44634] [AC:T44634] [PN:choline transporter [imported]] [GN:proWX] [OR:Streptococcus pneumoniae] 100 SPX0328 328 2989 270 810 125 1.90E−15 [LN:YA7B_HAEIN] [AC:Q57425:P96338] [GN:HI1077.1] [OR:Haemophilus influenzae] [DE:HYPOTHETICAL PROTEIN HI1077.1] 130 [SP:Q57425:P96338] SPX0329 329 2990 179 537 150 8.10E−17 [GI:5881867] [LN:SC5G9] [AC:AL117385] [PN:putative tetR-family transcriptional regulator] [GN:SC5G9.19c] 139 [OR:Streptomyces coelicolor A3(2)] SPX0330 330 2991 300 900 202 5.60E−39 [GI:1944409] [LN:D87026] [AC:D87026:D28136] [PN:membrane protein] [OR:Bacillus stearothermophilus] [SR:Bacillus stearothermophilus 151 (strain:TRBE14) DNA] SPX0331 331 2992 118 354 282 3.60E−34 [LN:B69970] [AC:B69970] [PN:transcription regulator MerR family homolog yraB] [GN:yraB] [CL:transcription repressor glnR] [OR:Bacillus subtilis] 144 SPX0332 332 2993 346 1038 403 3.80E−82 [LN:T44975] [AC:T44975] [PN:dehydrogenase [imported]] [CL:alcohol dehydrogenase:long-chain alcohol dehydrogenase homology] [OR:Haloferax volcanii] 146 SPX0333 333 2994 336 1008 729 4.00E−144 [GI:4097439] [LN:STU61402] [AC:U61402] [PN:GalR] [GN:galR] [OR:Streptococcus thermophilus] 90 SPX0334 334 2995 393 1179 1674 3.10E−227 [GI:4097440] [LN:STU61402] [AC:U61402] [PN:galactokinase] [GN:galK] [FN:galactose metabolism] [OR:Streptococcus thermophilus] 125 SPX0335 335 2996 494 1482 1612 1.90E−230 [GI:4097441] [LN:STU61402] [AC:U61402] [PN:gal-1-P uridylyltransferase] [GN:galT] [FN:galactose metabolism] [OR:Streptococcus thermophilus] 139 SPX0336 336 2997 135 405 467 1.10E−60 [GI:1196924] [LN:STRDPN2A] [AC:M14339] [PN:unknown] [OR:Streptococcus pneumoniae] 81 SPX0337 337 2998 296 888 1461 6.00E−199 [LN:MT21_STRPN] [AC:P04043] [GN:DPNM] [OR:Streptococcus pneumoniae] [EC:2.1.1.72] [DE:METHYLTRANSFERASE DPNII 1) (M.DPNII 1)] 137 [SP:P04043] SPX0338 338 2999 257 771 1366 2.60E−183 [LN:MT22_STRPN] [AC:P09358] [GN:DPNA] [OR:Streptococcus pneumoniae] [EC:2.1.1.72] [DE:METHYLTRANSFERASE DPNII 2) (M.DPNII 2)] 137 [SP:P09358] SPX0339 339 3000 289 867 1492 5.50E−202 [LN:T2D2_STRPN] [AC:P09357] [GN:DPNB] [OR:Streptococcus pneumoniae] [EC:3.1.21.4] [DE:(R.DPNII)] [SP:P09357] 108 SPX0340 340 3001 119 357 462 1.20E−61 [GI:6978345] [LN:STRDPN2A] [AC:M14339] [PN:unknown] [OR:Streptococcus pneumoniae] 81 SPX0341 341 3002 283 849 436 8.70E−87 [LN:YUNK_BACSU] [AC:O32140] [GN:YUNK] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 44.9 KD PROTEIN IN HOM-MRGA INTERGENIC 136 REGION] [SP:O32140] SPX0342 342 3003 194 582 786 3.40E−105 [GI:7160242] [LN:SPN272465] [AC:AJ272465] [PN:xanthine phosphoribosyltransferase] [GN:xpt] [OR:Streptococcus pneumoniae] 120 SPX0343 343 3004 58 174 79 7.70E−11 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX0344 344 3005 80 240 113 5.90E−10 [LN:C75408] [AC:C75408] [PN:hypothetical protein] [GN:DR1341] [OR:Deinococcus radiodurans] 90 SPX0345 345 3006 276 828 1432 8.60E−192 “[LN:EXOA_STRPN] [AC:P21998] [GN:EXOA] [OR:Streptococcus pneumoniae] [EC:3.1.11.2] [DE:EXODEOXYRIBONUCLEASE,] [SP:P21998]” 122 SPX0346 346 3007 76 228 NO-HIT 6 SPX0347 347 3008 90 270 NO-HIT 6 SPX0348 348 3009 177 531 132 9.60E−19 [LN:F69972] [AC:F69972] [PN:probable membrane protein yrbG] [GN:yrbG] [CL:probable membrane protein ycaP] [OR:Bacillus subtilis] 128 SPX0349 349 3010 79 237 129 5.90E−21 [GI:1914870] [LN:SPZ82001] [AC:Z82001] [PN:unknown] [OR:Streptococcus pneumoniae] 81 SPX0350 350 3011 582 1746 685 1.90E−170 [LN:A69829] [AC:A69829] [PN:ABC transporter (ATP-binding protein) homolog yheI] [GN:yheI] [CL:unassigned ATP- 188 binding cassette proteins:ATP-binding cassette homology] [OR:Bacillus subtilis] SPX0351 351 3012 294 882 364 6.80E−49 [LN:H69828] [AC:H69828] [PN:ABC transporter (ATP-binding protein) homolog yheH] [GN:yheH] [CL:unassigned ATP- 188 binding cassette proteins:ATP-binding cassette homology] [OR:Bacillus subtilis] SPX0352 352 3013 69 207 82 0.00022 [LN:H69828] [AC:H69828] [PN:ABC transporter (ATP-binding protein) homolog yheH] [GN:yheH] [CL:unassigned ATP- 188 binding cassette proteins:ATP-binding cassette homology] [OR:Bacillus subtilis] SPX0353 353 3014 264 792 383 3.90E−79 [LN:H69828] [AC:H69828] [PN:ABC transporter (ATP-binding protein) homolog yheH] [GN:yheH] [CL:unassigned ATP- 188 binding cassette proteins:ATP-binding cassette homology] [OR:Bacillus subtilis] SPX0354 354 3015 232 696 632 1.10E−83 [GI:6601354] [LN:AF164515] [AC:AF164515] [PN:putative glycosyltransferase Cps7F] [GN:cps7F] [OR:Streptococcus suis] 115 SPX0355 355 3016 409 1227 973 4.70E−214 [GI:6601355] [LN:AF164515] [AC:AF164515] [PN:Cps7G] [GN:cps7G] [OR:Streptococcus suis] 86 SPX0356 356 3017 63 189 NO-HIT 6 SPX0357 357 3018 89 267 NO-HIT 6 SPX0358 358 3019 709 2127 107 4.60E−08 [GI:2952545] [LN:AF051898] [AC:AF051898] [PN:coronin binding protein] [GN:DB10] [OR:Dictyostelium discoideum] 109 SPX0359 359 3020 82 246 NO-HIT 6 SPX0360 360 3021 69 207 NO-HIT 6 SPX0361 361 3022 95 285 NO-HIT 6 SPX0362 362 3023 96 288 289 6.60E−34 [GI:43589] [LN:HILIC3] [AC:X57315] [PN:UDP-galactose-4-epimerase] [GN:galE] [OR:Haemophilus influenzae] 103 SPX0363 363 3024 66 198 NO-HIT 6 SPX0364 364 3025 220 660 NO-HIT 6 SPX0365 365 3026 356 1068 286 2.20E−30 “[LN:Y4FP_RHISN] [AC:P55454] [GN:Y4FP] [OR:Rhizobium sp] [SR:,strain NGR234] [DE:PROBABLE ABC TRANSPORTER PERIPLASMIC 162 BINDING PROTEIN Y4FP PRECURSOR] [SP:P55454]” SPX0366 366 3027 337 1011 395 3.30E−90 “[LN:A70180] [AC:A70180] [PN:spermidine/putrescine ABC transporter, ATP-binding protein (potA) homolog] [CL:unassigned ATP-binding 237 cassette proteins:ATP-binding cassette homology] [OR:Borrelia burgdorferi] [SR:, Lyme disease spirochete]””” SPX0367 367 3028 564 1692 433 1.50E−93 “[LN:Y4FN_RHISN] [AC:P55452] [GN:Y4FN] [OR:Rhizobium sp] [SR:,strain NGR234] [DE:PROBABLE ABC TRANSPORTER PERMEASE 141 PROTEIN Y4FN] [SP:P55452]” SPX0368 368 3029 237 711 192 4.80E−28 [LN:Y647_HAEIN] [AC:Q57424:O05028] [GN:HI0647] [OR:Haemophilus influenzae] [DE:HYPOTHETICAL PROTEIN HI0647] [SP:Q57424:O05028] 126 SPX0369 369 3030 103 309 NO-HIT 6 SPX0370 370 3031 334 1002 144 3.70E−25 [LN:CCPA_BACME] [AC:P46828] [GN:CCPA] [OR:Bacillus megaterium] [DE:GLUCOSE-RESISTANCE AMYLASE 145 REGULATOR (CATABOLITE CONTROL PROTEIN)] [SP:P46828] SPX0371 371 3032 66 198 NO-HIT 6 SPX0372 372 3033 69 207 NO-HIT 6 SPX0373 373 3034 488 1464 1100 2.50E−173 “[LN:TRPE_LACLA] [AC:Q02001] [GN:TRPE] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:4.1.3.27] [DE:ANTHRANILATE 168 SYNTHASE COMPONENT I,] [SP:Q02001]” SPX0374 374 3035 67 201 108 6.30E−10 [LN:C72489] [AC:C72489] [PN:hypothetical protein APE2554] [GN:APE2554] [OR:Aeropyrum pernix] 92 SPX0375 375 3036 189 567 440 8.80E−75 “[LN:TRPG_LACLA] [AC:Q02003] [GN:TRPG] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:4.1.3.27] [DE:TRANSFERASE)] 146 [SP:Q02003]” SPX0376 376 3037 335 1005 1008 9.70E−134 “[LN:TRPD_LACLA] [AC:Q02000] [GN:TRPD] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:2.4.2.18] [DE:ANTHRANILATE 173 PHOSPHORIBOSYLTRANSFERASE,] [SP:Q02000]” SPX0377 377 3038 256 768 446 6.20E−107 “[LN:TRPC_LACLA] [AC:Q01999] [GN:TRPC] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:4.1.1.48] [DE:INDOLE-3- 178 GLYCEROL PHOSPHATE SYNTHASE, (IGPS)] [SP:Q01999]” SPX0378 378 3039 210 630 225 3.50E−49 “[LN:TRPF_LACLA] [AC:Q02002] [GN:TRPF] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:5.3.1.24] [DE:N-(5′- 185 PHOSPHORIBOSYL)ANTHRANILATE ISOMERASE, (PRAI)] [SP:Q02002]” SPX0379 379 3040 408 1224 930 9.00E−225 “[LN:TRPB_LACLA] [AC:Q01998] [GN:TRPB] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:4.2.1.20] [DE:TRYPTOPHAN 165 SYNTHASE BETA CHAIN,] [SP:Q01998]” SPX0380 380 3041 278 834 1137 5.00E−153 [GI:5231181] [LN:AF157817] [AC:AF157817] [PN:tryptophan synthase alpha chain] [GN:trpA] [OR:Streptococcus pneumoniae] 117 SPX0381 381 3042 68 204 NO-HIT 6 SPX0382 382 3043 244 732 NO-HIT 6 SPX0383 383 3044 384 1152 92 2.70E−13 [LN:H70940] [AC:H70940] [PN:probable helix-turn-helix motif at aa 18-39] [GN:Rv2017] [OR:Mycobacterium tuberculosis] 116 SPX0384 384 3045 220 660 109 1.00E−14 [LN:B72220] [AC:B72220] [PN:type IV prepilin peptidase] [GN:TM1696] [CL:type IV prepilin peptidase] [OR:Thermotoga maritima] 124 SPX0385 385 3046 149 447 92 0.00011 [LN:E72312] [AC:E72312] [PN:conserved hypothetical protein] [GN:TM0968] [CL:Escherichia coli ribosomal-protein-alanine N-acetyltransferase 169 rimJ] [OR:Thermotoga maritima] SPX0386 386 3047 104 312 138 1.30E−12 “[GI:6332767] [LN:AB033763] [AC:AB033763:AB014419:AB014429:AB014439] [PN:hypothetical protein] [OR:Staphylococcus aureus] 194 [SR:Staphylococcus aureus (strain:NCTC10442) DNA, clone_lib:Lambda das]” SPX0387 387 3048 68 204 98 8.10E−08 [GI:2772940] [LN:AF034574] [AC:AF034574] [PN:putative cruciform DNA binding protein] [GN:Gv1] [OR:Glomus versiforme] 116 SPX0388 388 3049 203 609 515 8.70E−64 [GI:727436] [LN:LLU23376] [AC:U23376] [OR:Lactococcus lactis] 61 SPX0389 389 3050 191 573 NO-HIT 6 SPX0390 390 3051 513 1539 193 6.90E−35 “[GI:6782400] [LN:STC133440] [AC:AJ133440] [PN:multigene regulator protein Mgc, putative] [GN:mgc] [FN:gene regulatory function, 171 putative] [OR:Streptococcus dysgalactiae]” SPX0391 391 3052 334 1002 185 3.80E−46 [LN:SCRR_STRMU] [AC:Q54430] [GN:SCRR] [OR:Streptococcus mutans] [DE:SUCROSE OPERON REPRESSOR (SCR OPERON REGULATORY 137 PROTEIN)] [SP:Q54430] SPX0392 392 3053 315 945 376 2.50E−89 [LN:A69653] [AC:A69653] [PN:transmembrane lipoprotein lplB] [GN:lplB] [CL:inner membrane protein ugpA] [OR:Bacillus subtilis] 125 SPX0393 393 3054 306 918 450 1.20E−73 [LN:LPLC_BACSU] [AC:P39129] [GN:LPLC] [OR:Bacillus subtilis] [DE:LPLC PROTEIN] [SP:P39129] 90 SPX0394 394 3055 539 1617 167 2.90E−15 [GI:4056657] [LN:AF098273] [AC:AF098273] [PN:peripheral protein] [GN:glucuronic acid catabolism operon] [OR:Bacillus stearothermophilus] 136 SPX0395 395 3056 141 423 NO-HIT 6 SPX0396 396 3057 440 1320 305 2.30E−76 “[LN:RAFD_ECOLI] [AC:P16553] [GN:RAFD] [OR:Escherichia coli] [EC:3.2.1.26] [DE:RAFFINOSE INVERTASE, (INVERTASE)] [SP:P16553]” 125 SPX0397 397 3058 424 1272 722 7.10E−167 [LN:D69981] [AC:D69981] [PN:conserved hypothetical protein yrvN] [GN:yrvN] [CL:Haemophilus influenzae conserved hypothetical protein HI1590] 163 [OR:Bacillus subtilis] SPX0398 398 3059 74 222 NO-HIT 6 SPX0399 399 3060 60 180 NO-HIT 6 SPX0400 400 3061 84 252 NO-HIT 6 SPX0401 401 3062 151 453 92 4.90E−09 [LN:T13557] [AC:T13557] [PN:hypothetical protein 17] [CL:Archaeoglobus fulgidus conserved hypothetical protein AF1072] [OR:Bacillus phage phi-105] 146 SPX0402 402 3063 157 471 NO-HIT 6 SPX0403 403 3064 363 1089 NO-HIT 6 SPX0404 404 3065 345 1035 130 8.00E−15 [GI:758793] [LN:ECU23723] [AC:U23723] [FN:unknown] [OR:Escherichia coli] 72 SPX0405 405 3066 748 2244 68 0.00048 [GI:758794] [LN:ECU23723] [AC:U23723] [FN:unknown] [OR:Escherichia coli] 72 SPX0406 406 3067 340 1020 NO-HIT 6 SPX0407 407 3068 317 951 395 1.40E−81 “[LN:T43740] [AC:T43740] [PN:probable ribosomal protein L11 methyltransferase, [imported]:hypothetical protein 35] [CL:ribosomal protein L11 215 methyltransferase:bioC homology] [OR:Listeria monocytogenes] [EC:2.1.1.-]” SPX0408 408 3069 248 744 461 1.90E−64 [LN:T43741] [AC:T43741] [PN:conserved hypothetical protein orf29 [imported]] [OR:Listeria monocytogenes] 104 SPX0409 409 3070 599 1797 300 2.10E−57 “[LN:PEPF_BACSU] [AC:O31605] [GN:YJBG] [OR:Bacillus subtilis] [EC:3.4.24.-] [DE:OLIGOENDOPEPTIDASE F HOMOLOG,] [SP:O31605]” 123 SPX0410 410 3071 226 678 312 1.80E−58 [LN:D69780] [AC:D69780] [PN:hypothetical protein ydfF] [GN:ydfF] [OR:Bacillus subtilis] 87 SPX0411 411 3072 217 651 394 1.40E−54 [LN:G69803] [AC:G69803] [PN:ABC transporter (ATP-binding protein) homolog yfiL] [GN:yfiL] [CL:unassigned ATP-binding cassette 188 proteins:ATP-binding cassette homology] [OR:Bacillus subtilis] SPX0412 412 3073 255 765 346 4.20E−44 “[LN:NODJ_RHILV] [AC:P06755] [GN:NODJ] [OR:Rhizobium leguminosarum] [SR:,biovar viciae] [DE:NODULATION PROTEIN J] [SP:P06755]” 126 SPX0413 413 3074 264 792 NO-HIT 6 SPX0414 414 3075 210 630 257 3.90E−39 “[LN:A69428] [AC:A69428] [PN:glycerol uptake facilitator, MIP channel (glpF) homolog] [CL:nodulin-26] [OR:Archaeoglobus fulgidus]” 130 SPX0415 415 3076 60 180 NO-HIT 6 SPX0416 416 3077 191 573 467 1.10E−60 [LN:D69868] [AC:D69868] [PN:conserved hypothetical protein ykvM] [GN:ykvM] [CL:hypothetical protein ykvM] [OR:Bacillus subtilis] 128 SPX0417 417 3078 105 315 193 1.80E−43 [GI:5640117] [LN:LMO133006] [AC:AJ133006] [PN:thioredoxin] [GN:trxA] [FN:thiol:disulfide interchange] [OR:Listeria monocytogenes] 129 SPX0418 418 3079 101 303 NO-HIT 6 SPX0419 419 3080 67 201 NO-HIT 6 SPX0420 420 3081 75 225 NO-HIT 6 SPX0421 421 3082 318 954 433 2.70E−56 [LN:YQJA_BACSU] [AC:P54538] [GN:YQJA] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 37.1 KD PROTEIN IN BMRU-ANSR INTERGENIC 137 REGION] [SP:P54538] SPX0422 422 3083 287 861 745 1.50E−100 [LN:YGJU_HAEIN] [AC:P45246] [GN:HI1545] [OR:Haemophilus influenzae] [DE:HYPOTHETICAL SYMPORTER HI1545] [SP:P45246] 114 SPX0423 423 3084 75 225 153 4.00E−15 [LN:YGJU_ECOLI] [AC:P42602] [GN:YGJU] [OR:Escherichia coli] [DE:HYPOTHETICAL 43.5 KD PROTEIN IN EBGC-UXAA INTERGENIC 143 REGION (O414)] [SP:P42602] SPX0424 424 3085 140 420 163 2.90E−17 “[GI:2828366] [LN:AB010789] [AC:AB010789] [OR:Lactococcus lactis] [SR:Lactococcus lactis (sub_species:lactis, strain:01-7) DNA]” 128 SPX0425 425 3086 66 198 102 1.80E−07 [LN:A69867] [AC:A69867] [PN:conserved hypothetical protein ykuT] [GN:ykuT] [CL:Escherichia coli hypothetical 30.9K protein (sbm-fba intergenic 174 region)] [OR:Bacillus subtilis] SPX0426 426 3087 59 177 NO-HIT 6 SPX0427 427 3088 303 909 270 1.70E−35 [GI:5123526] [LN:AF036485] [AC:AF036485:AF036486:AF036487:U93364] [PN:hypothetical protein] [OR:Plasmid pNZ4000] 112 SPX0428 428 3089 176 528 326 9.70E−41 [LN:YQEG_BACSU] [AC:P54452] [GN:YQEG] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 20.1 KD PROTEIN IN NUCB-AROD INTERGENIC 137 REGION] [SP:P54452] SPX0429 429 3090 369 1107 1037 1.30E−164 [LN:YQEH_BACSU] [AC:P54453] [GN:YQEH] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 41.0 KD PROTEIN IN NUCB-AROD INTERGENIC 137 REGION] [SP:P54453] SPX0430 430 3091 104 312 211 5.20E−24 [LN:YQEI_BACSU] [AC:P54454] [GN:YQEI] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 10.8 KD PROTEIN IN AROD-COMER INTERGENIC 138 REGION] [SP:P54454] SPX0431 431 3092 205 615 491 1.30E−63 [LN:YQEJ_BACSU] [AC:P54455] [GN:YQEJ] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 22.2 KD PROTEIN IN AROD-COMER INTERGENIC 138 REGION] [SP:P54455] SPX0432 432 3093 198 594 375 2.90E−47 [LN:YQEK_BACSU] [AC:P54456] [GN:YQEK] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 21.3 KD PROTEIN IN AROD-COMER INTERGENIC 138 REGION] [SP:P54456] SPX0433 433 3094 167 501 110 4.90E−10 [GI:7160132] [LN:SC5C11] [AC:AL158060] [PN:putative isochorismatase.] [GN:SC5C11.12] [OR:Streptomyces coelicolor A3(2)] 119 SPX0434 434 3095 118 354 267 7.00E−32 [LN:YQEL_BACSU] [AC:P54457] [GN:YQEL] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 13.3 KD PROTEIN IN AROD-COMER INTERGENIC 138 REGION] [SP:P54457] SPX0435 435 3096 247 741 287 4.60E−55 [LN:YQEM_BACSU] [AC:P54458] [GN:YQEM] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 28.3 KD PROTEIN IN AROD-COMER INTERGENIC 138 REGION] [SP:P54458] SPX0436 436 3097 188 564 NO-HIT 6 SPX0437 437 3098 366 1098 222 9.30E−38 [LN:B69875] [AC:B69875] [PN:conserved hypothetical protein ylbM] [GN:ylbM] [OR:Bacillus subtilis] 97 SPX0438 438 3099 63 189 NO-HIT 6 SPX0439 439 3100 916 2748 86 1.00E−10 [GI:1890605] [LN:RMEXPGNS] [AC:Z79692] [PN:ORF25] [OR:Sinorhizobium meliloti] 77 SPX0440 440 3101 537 1611 1547 2.30E−211 [GI:6984124] [LN:AF228345] [AC:AF228345] [PN:unknown] [OR:Listeria monocytogenes] 81 SPX0441 441 3102 209 627 614 1.40E−80 [LN:B69878] [AC:B69878] [PN:guanylate kinase homolog yloD] [GN:yloD] [CL:guanylate kinase:guanylate kinase homology] [OR:Bacillus subtilis] 139 SPX0442 442 3103 105 315 91 1.00E−09 [LN:C69878] [AC:C69878] [PN:hypothetical protein yloH] [GN:yloH] [OR:Bacillus subtilis] 87 SPX0443 443 3104 799 2397 953 2.70E−237 [LN:PRIA_BACSU] [AC:P94461:O34941] [GN:PRIA] [OR:Bacillus subtilis] [DE:PRIMOSOMAL PROTEIN N′ (REPLICATION FACTOR Y)] 136 [SP:P94461:O34941] SPX0444 444 3105 312 936 434 1.70E−64 [GI:1772500] [LN:BSPRIADFS] [AC:Y10304] [PN:Met-tRNAi formyl transferase] [GN:fmt] [OR:Bacillus subtilis] 105 SPX0445 445 3106 176 528 248 1.40E−39 [GI:1772501] [LN:BSPRIADFS] [AC:Y10304] [GN:sun] [OR:Bacillus subtilis] 71 SPX0446 446 3107 139 417 130 1.30E−09 [GI:4210751] [LN:LLA132604] [AC:AJ132604] [PN:sunL protein] [GN:sunL] [OR:Lactococcus lactis] 93 SPX0447 447 3108 233 699 606 2.70E−80 [GI:4210751] [LN:LLA132604] [AC:AJ132604] [PN:sunL protein] [GN:sunL] [OR:Lactococcus lactis] 93 SPX0448 448 3109 247 741 371 1.50E−85 [GI:4210752] [LN:LLA132604] [AC:AJ132604] [PN:pppL protein] [GN:pppL] [FN:putative phosphoprotein phosphatase] [OR:Lactococcus lactis] 134 SPX0449 449 3110 660 1980 985 1.70E−128 [GI:4210753] [LN:LLA132604] [AC:AJ132604] [PN:hypothetical protein] [OR:Lactococcus lactis] 91 SPX0450 450 3111 68 204 NO-HIT 6 SPX0451 451 3112 74 222 NO-HIT 6 SPX0452 452 3113 170 510 125 1.80E−09 [LN:YJJP_ECOLI] [AC:P39402] [GN:YJJP] [OR:Escherichia coli] [DE:HYPOTHETICAL 30.5 KD PROTEIN IN DNAT-BGLJ INTERGENIC 143 REGION (F277)] [SP:P39402] SPX0453 453 3114 112 336 94 4.60E−07 [LN:G81321] [AC:G81321] [PN:probable integral membrane protein Cj1165c [imported]] [GN:Cj1165c] [OR:Campylobacter jejuni] 121 SPX0454 454 3115 67 201 217 3.80E−24 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX0455 455 3116 130 390 362 7.00E−46 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX0456 456 3117 96 288 NO-HIT 6 SPX0457 457 3118 391 1173 775 1.30E−101 [GI:4096796] [LN:SCU40157] [AC:U40157] [OR:Staphylococcus carnosus] 67 SPX0458 458 3119 425 1275 354 8.70E−92 [LN:MVAA_PSEMV] [AC:P13702] [GN:MVAA] [OR:Pseudomonas mevalonii] [EC:1.1.1.88] [DE:REDUCTASE)] [SP:P13702] 106 SPX0459 459 3120 322 966 1108 1.00E−150 [LN:SCRR_STRMU] [AC:Q54430] [GN:SCRR] [OR:Streptococcus mutans] [DE:SUCROSE OPERON REPRESSOR (SCR OPERON 137 REGULATORY PROTEIN)] [SP:Q54430] SPX0460 460 3121 485 1455 1691 3.60E−229 “[LN:S68598] [AC:S68598] [PN:sucrose-6-phosphate hydrolase ScrB] [GN:scrB] [CL:sucrose-6-phosphate hydrolase] [OR:Streptococcus sobrinus] 189 [SR:strain 6715, , strain 6715] [SR:strain 6715, ]” SPX0461 461 3122 77 231 NO-HIT 6 SPX0462 462 3123 66 198 NO-HIT 6 SPX0463 463 3124 628 1884 717 6.70E−255 “[LN:S68599] [AC:S68599] [PN:phosphotransferase system enzyme II,, sucrose-specific:sucrose-specific enzyme II:sucrose-specific enzyme II] [GN:scrA] 177 [OR:Streptococcus sobrinus]” SPX0464 464 3125 296 888 701 3.80E−158 “[LN:SCRK_STRMU] [AC:Q07211] [GN:SCRK] [OR:Streptococcus mutans] [EC:2.7.1.4] [DE:FRUCTOKINASE,] [SP:Q07211]” 109 SPX0465 465 3126 71 213 NO-HIT 6 SPX0466 466 3127 200 600 103 2.90E−07 [LN:YDJZ_ECOLI] [AC:P76221] [GN:YDJZ] [OR:Escherichia coli] [DE:HYPOTHETICAL 26.2 KD PROTEIN IN XTHA-GDHA INTERGENIC 136 REGION] [SP:P76221] SPX0467 467 3128 75 225 200 1.30E−21 [GI:517210] [LN:SPU11799] [AC:U11799] [OR:Streptococcus pyogenes] 65 SPX0468 468 3129 84 252 NO-HIT 6 SPX0469 469 3130 76 228 187 3.50E−21 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX0470 470 3131 298 894 460 1.20E−78 [GI:3688825] [LN:AF084104] [AC:AF084104] [PN:NatA] [GN:natA] [OR:Bacillus firmus] 81 SPX0471 471 3132 400 1200 200 4.70E−36 [GI:1150487] [LN:LSLASAMPT] [AC:Z54312] [PN:unknown] [GN:orf414] [OR:Lactobacillus sakei] 89 SPX0472 472 3133 56 168 NO-HIT 6 SPX0473 473 3134 283 849 NO-HIT 6 SPX0474 474 3135 241 723 460 1.50E−58 “[LN:G71842] [AC:G71842] [PN:probable ABC transporter, ATP-binding protein] [GN:jhp1141] [CL:unassigned ATP-binding cassette 238 proteins:ATP-binding cassette homology] [OR:Helicobacter pylori] [SR:strain J99, , strain J99] [SR:strain J99, ]” SPX0475 475 3136 70 210 95 4.40E−07 [LN:E72756] [AC:E72756] [PN:hypothetical protein APE0042] [GN:APE0042] [OR:Aeropyrum pernix] 92 SPX0476 476 3137 122 366 256 3.70E−30 [GI:5822822] [LN:AB024564] [AC:AB024564] [PN:YHCF] [GN:yhcF] [OR:Bacillus halodurans] [SR:Bacillus halodurans (strain:C-125) DNA] 129 SPX0477 477 3138 158 474 405 8.00E−51 [LN:E72221] [AC:E72221] [PN:conserved hypothetical protein] [GN:TM1707] [CL:conserved hypothetical protein HI0943] [OR:Thermotoga maritima] 139 SPX0478 478 3139 390 1170 NO-HIT 6 SPX0479 479 3140 299 897 300 2.40E−58 [LN:DNAI_BACSU] [AC:P06567] [GN:DNAI] [OR:Bacillus subtilis] [DE:PRIMOSOMAL PROTEIN DNAI] [SP:P06567] 101 SPX0480 480 3141 238 714 239 3.90E−35 “[LN:CHRR_PSESP] [AC:P96977] [GN:CHRR] [OR:Pseudomonas sp] [SR:,strain G-1] [DE:CR(VI) REDUCTASE] [SP:P96977]” 110 SPX0481 481 3142 437 1311 1986 1.10E−270 “[GI:6681650] [LN:AB016077] [AC:AB016077] [PN:phosphoglycerate dehydrogenase] [GN:pgdA] [OR:Streptococcus mutans] [SR:Streptococcus 174 mutans (strain:MT8148) DNA, clone:pYT570]” SPX0482 482 3143 115 345 NO-HIT 6 SPX0483 483 3144 118 354 NO-HIT 6 SPX0484 484 3145 64 192 NO-HIT 6 SPX0485 485 3146 284 852 103 3.00E−11 [GI:4102023] [LN:AF007761] [AC:AF007761] [PN:MutR] [GN:mutR] [FN:positive transcriptional regulator of mutA] [OR:Streptococcus mutans] 134 SPX0486 486 3147 131 393 NO-HIT 6 SPX0487 487 3148 264 792 NO-HIT 6 SPX0488 488 3149 226 678 NO-HIT 6 SPX0489 489 3150 211 633 282 3.20E−42 [LN:YYBJ_BACSU] [AC:P37494] [GN:YYBJ] [OR:Bacillus subtilis] [DE:INTERGENIC REGION] [SP:P37494] 95 SPX0490 490 3151 96 288 NO-HIT 6 SPX0491 491 3152 838 2514 989 0 [LN:SECA_LISMO] [AC:P47847] [GN:SECA] [OR:Listeria monocytogenes] [DE:PREPROTEIN TRANSLOCASE SECA SUBUNIT] [SP:P47847] 118 SPX0492 492 3153 344 1032 156 7.30E−47 [GI:7380801] [LN:NMA7Z2491] [AC:AL162758:AL157959] [PN:phospho-2-dehydr-3-deoxyheptonate aldolase] [GN:aroG] [OR:Neisseria meningitidis] 136 SPX0493 493 3154 215 645 178 3.50E−34 [LN:AROF_ECOLI] [AC:P00888] [GN:AROF] [OR:Escherichia coli] [EC:4.1.2.15] [DE:SYNTHETASE) (3-DEOXY-D-ARABINO- 157 HEPTULOSONATE 7-PHOSPHATE SYNTHASE)] [SP:P00888] SPX0494 494 3155 111 333 NO-HIT 6 SPX0495 495 3156 89 267 132 2.60E−14 [GI:7380801] [LN:NMA7Z2491] [AC:AL162758:AL157959] [PN:phospho-2-dehydr-3-deoxyheptonate aldolase] [GN:aroG] [OR:Neisseria meningitidis] 136 SPX0496 496 3157 121 363 177 1.70E−30 “[LN:H69772] [AC:H69772] [PN:holo-[acyl-carrier-protein]synthase,] [GN:ydcB] [CL:holo-ACP synthase] [OR:Bacillus subtilis] [EC:2.7.8.7]” 137 SPX0497 497 3158 368 1104 1852 1.10E−252 [GI:5759209] [LN:AF171873] [AC:AF171873] [PN:alanine racemase] [GN:alr] [OR:Streptococcus pneumoniae] 101 SPX0498 498 3159 672 2016 3357 0 “[LN:RECG_STRPN] [AC:Q54900] [GN:RECG:MMSA] [OR:Streptococcus pneumoniae] [EC:3.6.1.-] [DE:ATP-DEPENDENT DNA HELICASE 137 RECG,] [SP:Q54900]” SPX0499 499 3160 89 267 263 2.70E−32 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX0500 500 3161 68 204 NO-HIT 6 SPX0501 501 3162 327 981 447 1.40E−92 [GI:2353697] [LN:AF001926] [AC:AF001926] [PN:xylan esterase 1] [GN:axe1] [OR:Thermoanaerobacterium sp. ‘JW/SL YS485’] 117 SPX0502 502 3163 206 618 355 1.20E−44 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX0503 503 3164 168 504 172 1.10E−15 [GI:4101572] [LN:AF004842] [AC:AF004842] [PN:major royal jelly protein MRJP5] [GN:MRJP5] [OR:Apis mellifera] [SR:honeybee] 122 SPX0504 504 3165 76 228 371 3.40E−50 [LN:T30286] [AC:T30286:S26297] [PN:hypothetical protein 76] [OR:Streptococcus pneumoniae] 89 SPX0505 505 3166 938 2814 4378 0 “[LN:NANA_STRPN] [AC:Q59959:Q54722] [GN:NANA] [OR:Streptococcus pneumoniae] [EC:3.2.1.18] [DE:SIALIDASE A PRECURSOR, 155 (NEURAMINIDASE A)] [SP:Q59959:Q54722]” SPX0506 506 3167 72 216 NO-HIT 6 SPX0507 507 3168 151 453 773 6.10E−103 [GI:1163111] [LN:SPU43526] [AC:U43526] [OR:Streptococcus pneumoniae] 68 SPX0508 508 3169 446 1338 2307 0 [GI:1163112] [LN:SPU43526] [AC:U43526] [OR:Streptococcus pneumoniae] 68 SPX0509 509 3170 295 885 1542 2.00E−218 [GI:1163113] [LN:SPU43526] [AC:U43526] [OR:Streptococcus pneumoniae] 68 SPX0510 510 3171 278 834 1375 3.80E−192 [GI:1163114] [LN:SPU43526] [AC:U43526] [OR:Streptococcus pneumoniae] 68 SPX0511 511 3172 254 762 1250 1.40E−167 “[LN:NANB_STRPN] [AC:Q54727] [GN:NANB] [OR:Streptococcus pneumoniae] [EC:3.2.1.18] [DE:SIALIDASE B PRECURSOR, 141 (NEURAMINIDASE B)] [SP:Q54727]” SPX0512 512 3173 126 378 333 1.60E−40 [GI:517210] [LN:SPU11799] [AC:U11799] [OR:Streptococcus pyogenes] 65 SPX0513 513 3174 211 633 762 7.90E−101 [GI:517210] [LN:SPU11799] [AC:U11799] [OR:Streptococcus pyogenes] 65 SPX0514 514 3175 467 1401 2363 0 “[LN:NANB_STRPN] [AC:Q54727] [GN:NANB] [OR:Streptococcus pneumoniae] [EC:3.2.1.18] [DE:SIALIDASE B PRECURSOR, 141 (NEURAMINIDASE B)] [SP:Q54727]” SPX0515 515 3176 368 1104 1838 1.30E−249 [LN:YJHC_STRPN] [AC:Q54728] [OR:Streptococcus pneumoniae] [DE:HYPOTHETICAL PROTEIN IN NANB 3′ REGION (ORF-5) (FRAGMENT)] 131 [SP:Q54728] SPX0516 516 3177 130 390 NO-HIT 6 SPX0517 517 3178 233 699 331 1.90E−64 “[LN:C70180] [AC:C70180] [PN:conserved hypothetical protein BB0644] [OR:Borrelia burgdorferi] [SR:, Lyme disease spirochete]” 125 SPX0518 518 3179 506 1518 839 2.60E−178 “[LN:D70180] [AC:D70180] [PN:phosphotransferase system enzyme II,, glucose-specific, factor II] [OR:Borrelia burgdorferi] [SR:, Lyme disease 167 spirochete] [EC:2.7.1.69]” SPX0519 519 3180 443 1329 110 1.90E−09 [GI:6137033] [LN:SCF11] [AC:AL132662] [PN:putative sugar transporter sugar binding] [GN:SCF11.11] [OR:Streptomyces coelicolor A3(2)] 132 SPX0520 520 3181 296 888 211 1.60E−50 “[LN:E72357] [AC:E72357] [PN:sugar ABC transporter, permease protein] [GN:TM0596] [CL:inner membrane protein malF] [OR:Thermotoga maritima]” 140 SPX0521 521 3182 280 840 434 1.10E−65 “[LN:F72379] [AC:F72379] [PN:sugar ABC transporter, permease protein] [GN:TM0430] [CL:maltose transport protein malG] [OR:Thermotoga maritima]” 143 SPX0522 522 3183 151 453 109 2.60E−13 [LN:YJGK_ECOLI] [AC:P39335] [GN:YJGK] [OR:Escherichia coli] [DE:HYPOTHETICAL 17.3 KD PROTEIN IN PYRL-ARGI INTERGENIC 144 REGION (O153B)] [SP:P39335] SPX0523 523 3184 118 354 NO-HIT 6 SPX0524 524 3185 66 198 NO-HIT 6 SPX0525 525 3186 215 645 NO-HIT 6 SPX0526 526 3187 220 660 830 1.30E−109 [GI:2385360] [LN:CTSIALIDA] [AC:Y08695] [PN:putative acylneuraminate lyase] [OR:Clostridium tertium] 100 SPX0527 527 3188 100 300 68 0.00016 [GI:42131] [LN:ECNPL] [AC:X03345] [OR:Escherichia coli] 55 SPX0528 528 3189 295 885 423 2.50E−53 [LN:YNGA_CLOPE] [AC:P26832] [OR:Clostridium perfringens] [DE:HYPOTHETICAL PROTEIN IN NAGH 5′REGION (ORFA) (FRAGMENT)] 129 [SP:P26832] SPX0529 529 3190 283 849 170 2.10E−25 [LN:Y143_HAEIN] [AC:P44540] [GN:HI0143] [OR:Haemophilus influenzae] [DE:HYPOTHETICAL PROTEIN HI0143] [SP:P44540] 112 SPX0530 530 3191 681 2043 3365 0 [GI:4009463] [LN:AF068901] [AC:AF068901] [PN:penicillin-binding protein 2b] [GN:pbp2b] [OR:Streptococcus pneumoniae] 116 SPX0531 531 3192 119 357 524 5.00E−69 [GI:49383] [LN:SPPBP2BH] [AC:Z21808] [PN:internal region of the penicillin-binding] [FN:penicillin-resistantance] [OR:Streptococcus pneumoniae] 143 SPX0532 532 3193 171 513 625 4.80E−83 [GI:4009464] [LN:AF068901] [AC:AF068901] [PN:RecM] [GN:recM] [OR:Streptococcus pneumoniae] 90 SPX0533 533 3194 348 1044 1766 1.30E−239 [GI:4009465] [LN:AF068901] [AC:AF068901] [PN:D-Ala-D-Ala ligase] [GN:ddl] [OR:Streptococcus pneumoniae] 103 SPX0534 534 3195 458 1374 2278 0 [GI:4009466] [LN:AF068901] [AC:AF068901] [PN:D-Ala-D-Ala adding enzyme] [GN:murF] [OR:Streptococcus pneumoniae] 111 SPX0535 535 3196 449 1347 403 3.50E−76 [GI:5822769] [LN:AB024553] [AC:AB024553] [OR:Bacillus halodurans] [SR:Bacillus halodurans (strain:C-125) DNA] 109 SPX0536 536 3197 192 576 954 1.80E−127 [GI:4009467] [LN:AF068901] [AC:AF068901] [PN:MutT] [GN:mutT] [OR:Streptococcus pneumoniae] 90 SPX0537 537 3198 199 597 1003 1.80E−140 [GI:4009468] [LN:AF068901] [AC:AF068901] [PN:unknown] [OR:Streptococcus pneumoniae] 83 SPX0538 538 3199 87 261 NO-HIT 6 SPX0539 539 3200 458 1374 2266 0 [GI:4009469] [LN:AF068901] [AC:AF068901] [PN:cell division protein FtsA] [GN:ftsA] [OR:Streptococcus pneumoniae] 112 SPX0540 540 3201 419 1257 2094 4.10E−280 [GI:4009470] [LN:AF068901] [AC:AF068901] [PN:cell division protein FtsZ] [GN:ftsZ] [OR:Streptococcus pneumoniae] 112 SPX0541 541 3202 79 237 178 2.40E−19 [LN:A71218] [AC:A71218] [PN:hypothetical protein PH0004] [GN:PH0004] [OR:Pyrococcus horikoshii] 95 SPX0542 542 3203 224 672 1101 6.20E−148 [GI:4009471] [LN:AF068901] [AC:AF068901] [PN:YlmE] [GN:ylmE] [OR:Streptococcus pneumoniae] 90 SPX0543 543 3204 180 540 920 1.10E−122 [GI:4009472] [LN:AF068901] [AC:AF068901] [PN:YlmF] [GN:ylmF] [OR:Streptococcus pneumoniae] 90 SPX0544 544 3205 88 264 431 1.50E−58 [GI:4009473] [LN:AF068901] [AC:AF068901] [PN:YlmG] [GN:ylmG] [OR:Streptococcus pneumoniae] 90 SPX0545 545 3206 262 786 1318 2.10E−179 [GI:4009474] [LN:AF068901] [AC:AF068901] [PN:YlmH] [GN:ylmH] [OR:Streptococcus pneumoniae] 90 SPX0546 546 3207 263 789 1297 1.90E−171 [GI:4009475] [LN:AF068901] [AC:AF068901] [PN:cell division protein DivIVA] [GN:divIVA] [OR:Streptococcus pneumoniae] 116 SPX0547 547 3208 931 2793 4840 0 [GI:4009476] [LN:AF068901] [AC:AF068901] [PN:isoleucine-tRNA synthetase] [GN:ileS] [OR:Streptococcus pneumoniae] 112 SPX0548 548 3209 62 186 82 0.00016 “[LN:A56034] [AC:A56034] [PN:insulin activator factor] [CL:human insulin activator factor] [OR:Homo sapiens] [SR:, man]” 120 SPX0549 549 3210 87 261 192 2.20E−20 “[LN:A56034] [AC:A56034] [PN:insulin activator factor] [CL:human insulin activator factor] [OR:Homo sapiens] [SR:, man]” 120 SPX0550 550 3211 63 189 NO-HIT 6 SPX0551 551 3212 72 216 NO-HIT 6 SPX0552 552 3213 231 693 1201 1.00E−160 [GI:5578891] [LN:SPN131985] [AC:AJ131985] [PN:phosphoglyceromutase] [GN:gpmA] [OR:Streptococcus pneumoniae] 107 SPX0553 553 3214 804 2412 232 2.70E−95 [GI:5912520] [LN:SCF12] [AC:AL117669] [PN:putative large secreted protein] [GN:SCF12.20c] [OR:Streptomyces coelicolor A3(2)] 124 SPX0554 554 3215 237 711 642 7.20E−84 “[LN:B69477] [AC:B69477] [PN:ABC transporter, ATP-binding protein homolog] [CL:unassigned ATP-binding cassette proteins:ATP-binding cassette 179 homology] [OR:Archaeoglobus fulgidus]” SPX0555 555 3216 925 2775 106 1.10E−16 [LN:C69477] [AC:C69477] [PN:hypothetical protein AF1820] [OR:Archaeoglobus fulgidus] 84 SPX0556 556 3217 173 519 878 1.10E−117 [GI:4193357] [LN:AF055088] [AC:AF055088:AF055087] [PN:putative hydrophobic transmembrane protein] [GN:psaD] [OR:Streptococcus pneumoniae] 137 SPX0557 557 3218 310 930 1579 2.30E−209 [GI:3258602] [LN:SPU40786] [AC:U40786] [PN:surface antigen A variant precursor] [GN:psaA] [FN:putative fimbrial adhesin] 150 [OR:Streptococcus pneumoniae] SPX0558 558 3219 283 849 1171 8.00E−165 [LN:P29K_STRGC] [AC:P42361] [OR:Streptococcus gordonii challis] [DE:29 KD MEMBRANE PROTEIN IN PSAA 5′ REGION (ORF1)] [SP:P42361] 127 SPX0559 559 3220 252 756 1208 2.80E−164 [GI:4193356] [LN:AF055088] [AC:AF055088:AF055087] [PN:ATP-binding cassette] [GN:psaB] [OR:Streptococcus pneumoniae] 115 SPX0560 560 3221 651 1953 1477 0 [GI:5139244] [LN:AF116532] [AC:AF116532] [PN:endopeptidase O] [GN:pepO] [OR:Streptococcus parasanguinis] 104 SPX0561 561 3222 210 630 181 2.90E−36 [LN:YQGX_BACSU] [AC:P54501] [GN:YQGX] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 23.2 KD PROTEIN IN SODA-COMGA 138 INTERGENIC REGION] [SP:P54501] SPX0562 562 3223 67 201 131 2.00E−13 [GI:1914870] [LN:SPZ82001] [AC:Z82001] [PN:unknown] [OR:Streptococcus pneumoniae] 81 SPX0563 563 3224 81 243 NO-HIT 6 SPX0564 564 3225 741 2223 1601 0 [LN:RELA_STREQ] [AC:Q54089] [GN:RELA:REL] [OR:Streptococcus equisimilis] [EC:2.7.6.5] [DE:PROTEIN)] [SP:Q54089] 111 SPX0565 565 3226 81 243 70 0.0001 [LN:Q3ECS7] [AC:A30374:Q90796] [PN:hypothetical 77K protein (spoT 3′ region)] [CL:Escherichia coli hypothetical 77K protein (spoT 163 3′ region)] [OR:Escherichia coli] SPX0566 566 3227 148 444 585 2.40E−76 [LN:S39974] [AC:S39974] [PN:hypothetical protein] [CL:conserved hypothetical protein HI0670] [OR:Streptococcus equisimilis] 123 SPX0567 567 3228 76 228 NO-HIT 6 SPX0568 568 3229 141 423 NO-HIT 6 SPX0569 569 3230 236 708 NO-HIT 6 SPX0570 570 3231 140 420 433 7.90E−56 [GI:6694218] [LN:AF182402] [AC:AF182402] [PN:metalloregulator RmtA] [GN:rmtA] [OR:Streptococcus gordonii] 105 SPX0571 571 3232 80 240 307 4.00E−38 [GI:6694218] [LN:AF182402] [AC:AF182402] [PN:metalloregulator RmtA] [GN:rmtA] [OR:Streptococcus gordonii] 105 SPX0572 572 3233 281 843 125 2.00E−13 [LN:G75297] [AC:G75297] [PN:conserved hypothetical protein] [GN:DR2233] [CL:probable phosphoesterase MJ0912:phosphoesterase core homology] 167 [OR:Deinococcus radiodurans] SPX0573 573 3234 65 195 NO-HIT 6 SPX0574 574 3235 105 315 142 7.90E−15 [LN:D70063] [AC:D70063] [PN:hypothetical protein ywnA] [GN:ywnA] [OR:Bacillus subtilis] 87 SPX0575 575 3236 73 219 129 2.40E−12 [LN:D70063] [AC:D70063] [PN:hypothetical protein ywnA] [GN:ywnA] [OR:Bacillus subtilis] 87 SPX0576 576 3237 101 303 NO-HIT 6 SPX0577 577 3238 358 1074 NO-HIT 6 SPX0578 578 3239 226 678 1146 1.70E−157 [GI:5830520] [LN:SPAJ6391] [AC:AJ006391] [PN:response regulator] [GN:rr01] [OR:Streptococcus pneumoniae] 104 SPX0579 579 3240 325 975 1628 3.20E−226 [GI:5830521] [LN:SPAJ6391] [AC:AJ006391] [PN:histidine kinase] [GN:hk01] [OR:Streptococcus pneumoniae] 102 SPX0580 580 3241 661 1983 1149 2.20E−274 [LN:SYT1_BACSU] [AC:P18255:P06570] [GN:THRS:THRSV] [OR:Bacillus subtilis] [EC:6.1.1.3] [DE:(THRRS)] [SP:P18255:P06570] 118 SPX0581 581 3242 130 390 NO-HIT 6 SPX0582 582 3243 97 291 NO-HIT 6 SPX0583 583 3244 70 210 NO-HIT 6 SPX0584 584 3245 210 630 371 1.30E−60 [LN:E70063] [AC:E70063] [PN:hypothetical protein ywnB] [GN:ywnB] [OR:Bacillus subtilis] 87 SPX0585 585 3246 90 270 311 1.10E−38 [LN:F69700] [AC:F69700:S11365:S70690] [PN:ribosomal protein S15 (rpsO):ribosomal protein BS18] [GN:rpsO] [CL:Escherichia coli ribosomal 214 protein S15:eubacterial ribosomal protein S15 homology] [OR:Bacillus subtilis] SPX0586 586 3247 75 225 NO-HIT 6 SPX0587 587 3248 159 477 243 1.30E−38 [GI:1916729] [LN:AF134905] [AC:AF134905:U76550] [PN:CadD] [GN:cadD] [OR:Staphylococcus aureus] 94 SPX0588 588 3249 250 750 165 1.10E−23 [LN:E69826] [AC:E69826] [PN:1-acylglycerol-3-phosphate O-acyltransfera homolog yhdO] [GN:yhdO] [OR:Bacillus subtilis] 117 SPX0589 589 3250 779 2337 414 1.80E−126 “[LN:CTPE_MYCTU] [AC:O08365] [GN:CTPE:RV0908:MTCY21C12.02] [OR:Mycobacterium tuberculosis] [EC:3.6.1.-] [DE:PROBABLE 160 CATION-TRANSPORTING ATPASE E,] [SP:O08365]” SPX0590 590 3251 77 231 NO-HIT 6 SPX0591 591 3252 488 1464 122 9.60E−23 [GI:1480429] [LN:BSU18943] [AC:U18943:X99465] [GN:MtlR] [OR:Bacillus stearothermophilus] 88 SPX0592 592 3253 143 429 60 0.00018 [GI:2317740] [LN:AF013987] [AC:AF013987] [PN:nitrogen regulatory IIA protein] [GN:ptsN] [OR:Vibrio cholerae] 108 SPX0593 593 3254 151 453 223 5.60E−24 “[LN:HRSA_ECOLI] [AC:P54745] [GN:HRSA] [OR:Escherichia coli] [EC:2.7.1.69] [DE:HRSA PROTEIN,] [SP:P54745]” 106 SPX0594 594 3255 104 312 236 1.30E−27 “[LN:PTWB_ECOLI] [AC:P32673] [GN:FRWB] [OR:Escherichia coli] [EC:2.7.1.69] [DE:II, B COMPONENT),] [SP:P32673]” 110 SPX0595 595 3256 369 1107 398 8.00E−60 “[LN:PTFB_XANCP] [AC:P23355] [GN:FRUA] [OR:Xanthomonas campestris] [SR:,pvcampestris] [EC:2.7.1.69] [DE:(EC 2.7.1.69) 141 (EII-FRU)] [SP:P23355]” SPX0596 596 3257 232 696 560 6.50E−74 “[LN:ALSE_ECOLI] [AC:P32719] [GN:ALSE] [OR:Escherichia coli] [EC:5.1.3.-] [DE:D-ALLULOSE−6-PHOSPHATE 3-EPIMERASE,] [SP:P32719]” 127 SPX0597 597 3258 657 1971 1371 2.00E−292 “[LN:TKT_STRPN] [AC:P22976] [GN:RECP] [OR:Streptococcus pneumoniae] [EC:2.2.1.1] [DE:PROBABLE TRANSKETOLASE, (TK)] [SP:P22976]” 127 SPX0598 598 3259 191 573 422 2.30E−53 [LN:B30868] [AC:B30868] [PN:hypothetical protein 1] [OR:Streptococcus agalactiae] 81 SPX0599 599 3260 191 573 422 2.30E−53 [LN:B30868] [AC:B30868] [PN:hypothetical protein 1] [OR:Streptococcus agalactiae] 81 SPX0600 600 3261 278 834 587 1.60E−140 [LN:A33595] [AC:A33595:A30868] [PN:probable transposase] [CL:transposase IS3] [OR:Streptococcus agalactiae] 107 SPX0601 601 3262 177 531 NO-HIT 6 SPX0602 602 3263 139 417 138 1.40E−10 [LN:T35180] [AC:T35180] [PN:hypothetical protein SC5A7.31] [GN:SC5A7.31] [CL:Streptomyces coelicolor hypothetical protein SC5A7.31] 160 [OR:Streptomyces coelicolor] SPX0603 603 3264 226 678 612 1.10E−79 [GI:1813343] [LN:D78182] [AC:D78182] [GN:ORF3] [OR:Streptococcus mutans] [SR:Streptococcus mutans (strain:Xc) DNA] 114 SPX0604 604 3265 266 798 344 5.40E−120 [GI:1813344] [LN:D78182] [AC:D78182] [GN:ORF4] [OR:Streptococcus mutans] [SR:Streptococcus mutans (strain:Xc) DNA] 114 SPX0605 605 3266 368 1104 335 4.50E−71 [LN:YURR_BACSU] [AC:O32159] [GN:YURR] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 39.4 KD OXIDOREDUCTASE IN HOM-MRGA 143 INTERGENIC REGION] [SP:O32159] SPX0606 606 3267 64 192 NO-HIT 6 SPX0607 607 3268 340 1020 1167 7.10E−156 [LN:GALE_BACSU] [AC:P55180] [GN:GALE] [OR:Bacillus subtilis] [EC:5.1.3.2] [DE:GALACTOSE 4-EPIMERASE)] [SP:P55180] 113 SPX0608 608 3269 318 954 441 7.80E−87 [LN:CSBB_BACSU] [AC:Q45539] [GN:CSBB] [OR:Bacillus subtilis] [DE:CSBB PROTEIN] [SP:Q45539] 90 SPX0609 609 3270 222 666 NO-HIT 6 SPX0610 610 3271 69 207 55 0.00029 “[LN:FER_MOOTH] [AC:P00203] [OR:Moorella thermoacetica] [SR:,Clostridium thermoaceticum] [DE:FERREDOXIN] [SP:P00203]” 117 SPX0611 611 3272 159 477 NO-HIT 6 SPX0612 612 3273 224 672 413 6.00E−74 [LN:KCY_BACSU] [AC:P38493] [GN:CMK:JOFC] [OR:Bacillus subtilis] [EC:2.7.4.14] [DE:(CMP KINASE)] [SP:P38493] 107 SPX0613 613 3274 113 339 432 5.60E−55 [LN:PHNA_ECOLI] [AC:P16680] [GN:PHNA] [OR:Escherichia coli] [DE:PHNA PROTEIN] [SP:P16680] 89 SPX0614 614 3275 210 630 NO-HIT 6 SPX0615 615 3276 76 228 192 3.60E−23 [GI:1914870] [LN:SPZ82001] [AC:Z82001] [PN:unknown] [OR:Streptococcus pneumoniae] 81 SPX0616 616 3277 384 1152 68 6.80E−05 [LN:C81266] [AC:C81266] [PN:probable efflux protein Cj1687 [imported]] [GN:Cj1687] [OR:Campylobacter jejuni] 108 SPX0617 617 3278 250 750 309 4.30E−69 [LN:TRUA_BACSU] [AC:P70973] [GN:TRUA] [OR:Bacillus subtilis] [EC:4.2.1.70] [DE:I) (PSEUDOURIDINE SYNTHASE I) (URACIL 141 HYDROLYASE)] [SP:P70973]> SPX0618 618 3279 258 774 155 3.70E−39 [LN:THID_BACSU] [AC:P39610] [GN:THID:IPA-52R] [OR:Bacillus subtilis] [EC:2.7.4.7] [DE:(HMP-P KINASE)] [SP:P39610] 113 SPX0619 619 3280 154 462 69 5.80E−12 [LN:G75153] [AC:G75153] [PN:hypothetical protein PAB2090] [GN:PAB2090] [OR:Pyrococcus abyssi] 93 SPX0620 620 3281 191 573 422 2.30E−53 [LN:B30868] [AC:B30868] [PN:hypothetical protein 1] [OR:Streptococcus agalactiae] 81 SPX0621 621 3282 91 273 288 2.30E−35 [LN:A33595] [AC:A33595:A30868] [PN:probable transposase] [CL:transposase IS3] [OR:Streptococcus agalactiae] 107 SPX0622 622 3283 198 594 583 9.30E−95 [LN:A33595] [AC:A33595:A30868] [PN:probable transposase] [CL:transposase IS3] [OR:Streptococcus agalactiae] 107 SPX0623 623 3284 159 477 NO-HIT 6 SPX0624 624 3285 361 1083 1016 1.20E−136 [GI:2323341] [LN:AF014460] [AC:AF014460] [PN:PepQ] [FN:hydrolysis of Leu-Pro] [OR:Streptococcus mutans] 103 SPX0625 625 3286 261 783 147 5.10E−36 [LN:T31439] [AC:T31439] [PN:probable cobyric acid synthase CobQ] [OR:Heliobacillus mobilis] 91 SPX0626 626 3287 448 1344 137 1.30E−46 [LN:T31440] [AC:T31440] [PN:UDP-N-acetylmuramyl tripeptide synthetase homolog murC] [OR:Heliobacillus mobilis] 110 SPX0627 627 3288 439 1317 797 4.80E−136 [LN:YKGC_ECOLI] [AC:P77212] [GN:YKGC] [OR:Escherichia coli] [DE:INTERGENIC REGION] [SP:P77212] 94 SPX0628 628 3289 291 873 711 3.70E−137 [GI:7107009] [LN:AF168363] [AC:AF168363] [PN:oxalate:formate antiporter] [OR:Lactococcus lactis] 96 SPX0629 629 3290 82 246 193 5.00E−21 [GI:7107009] [LN:AF168363] [AC:AF168363] [PN:oxalate:formate antiporter] [OR:Lactococcus lactis] 96 SPX0630 630 3291 525 1575 1329 1.80E−184 [GI:4409804] [LN:AF091502] [AC:AF091502] [PN:autoaggregation-mediating protein] [GN:aggH] [OR:Lactobacillus reuteri] 116 SPX0631 631 3292 263 789 547 3.10E−74 [LN:CODY_BACSU] [AC:P39779] [GN:CODY] [OR:Bacillus subtilis] [DE:CODY PROTEIN (VEGETATIVE PROTEIN 286B) (VEG286B)] 126 [SP:P39779] SPX0632 632 3293 69 207 174 1.30E−18 [LN:C70008] [AC:C70008] [PN:pyrazinamidase/nicotinamidase homolog yueJ] [GN:yueJ] [CL:hypothetical protein b1011] [OR:Bacillus subtilis] 136 SPX0633 633 3294 152 456 253 1.50E−30 [LN:C70008] [AC:C70008] [PN:pyrazinamidase/nicotinamidase homolog yueJ] [GN:yueJ] [CL:hypothetical protein b1011] [OR:Bacillus subtilis] 136 SPX0634 634 3295 78 234 328 1.70E−40 [GI:600072] [LN:SEDEXB] [AC:X72832] [PN:ABC transporter] [GN:abc] [OR:Streptococcus equisimilis] 96 SPX0635 635 3296 52 156 113 2.50E−10 [LN:E72756] [AC:E72756] [PN:hypothetical protein APE0042] [GN:APE0042] [OR:Aeropyrum pernix] 92 SPX0636 636 3297 285 855 731 1.70E−136 [LN:MSMK_STRMU] [AC:Q00752] [GN:MSMK] [OR:Streptococcus mutans] [DE:MULTIPLE SUGAR-BINDING 138 TRANSPORT ATP-BINDING PROTEIN MSMK] [SP:Q00752] SPX0637 637 3298 253 759 485 3.90E−95 [LN:Y095_HAEIN] [AC:Q57060:O05007] [GN:HI0095] [OR:Haemophilus influenzae] [DE:HYPOTHETICAL PROTEIN HI0095] [SP:Q57060:O05007] 126 SPX0638 638 3299 177 531 603 2.90E−79 “[LN:B69587] [AC:B69587] [PN:adenine phosphoribosyltransferase,:AMP pyrophosphorylase:transphosphoribosidase] [GN:apt] [CL:adenine 194 phosphoribosyltransferase] [OR:Bacillus subtilis] [EC:2.4.2.7]” SPX0639 639 3300 315 945 567 6.90E−116 [LN:C72324] [AC:C72324] [PN:homoserine O-succinyltransferase] [GN:TM0881] [CL:homoserine succinyltransferase] [OR:Thermotoga maritima] 134 SPX0640 640 3301 226 678 357 5.50E−90 [GI:1813342] [LN:D78182] [AC:D78182] [GN:ORF2] [OR:Streptococcus mutans] [SR:Streptococcus mutans (strain:Xc) DNA] 114 SPX0641 641 3302 125 375 NO-HIT 6 SPX0642 642 3303 253 759 864 1.30E−113 “[LN:TPIS_LACDE] [AC:O32757] [GN:TPIA:TPI] [OR:Lactobacillus delbrueckii] [SR:,subspbulgaricus] [EC:5.3.1.1] [DE:TRIOSEPHOSPHATE 159 ISOMERASE, (TIM)] [SP:O32757]” SPX0643 643 3304 502 1506 2728 0 “[GI:4218526] [LN:SPAJ9639] [AC:AJ009639] [PN:1,4-beta-N-acetylmuramidase] [GN:lytC] [FN:lysis of cell wall peptidoglycan] 153 [OR:Streptococcus pneumoniae]” SPX0644 644 3305 173 519 800 2.60E−105 [GI:3513547] [LN:AF055720] [AC:AF055720] [PN:unknown] [OR:Streptococcus pneumoniae] 83 SPX0645 645 3306 213 639 NO-HIT 6 SPX0646 646 3307 169 507 882 2.00E−118 [GI:2196662] [LN:HSZ84379] [AC:Z84379] [PN:dihydrofolate reductase] [GN:dfr] [FN:trimethoprim resistance] [OR:Streptococcus pneumoniae] 135 SPX0647 647 3308 69 207 NO-HIT 6 SPX0648 648 3309 411 1233 1251 4.80E−206 [GI:7546983] [LN:AF236863] [AC:AF236863] [PN:protease ClpX] [GN:clpX] [OR:Lactococcus lactis] 93 SPX0649 649 3310 196 588 807 9.70E−107 [GI:7546984] [LN:AF236863] [AC:AF236863] [PN:hypothetical GTP-binding protein] [OR:Lactococcus lactis] 102 SPX0650 650 3311 127 381 392 2.30E−49 “[LN:ALDR_LACLA] [AC:O34133] [GN:ALDR] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [DE:PUTATIVE REGULATOR ALDR] 143 [SP:O34133]” SPX0651 651 3312 297 891 337 2.00E−91 [GI:7328270] [LN:SAY14324] [AC:Y14324] [PN:hypothetical protein] [OR:Staphylococcus aureus] 91 SPX0652 652 3313 326 978 268 1.30E−62 [LN:YVCK_BACSU] [AC:O06974] [GN:YVCK] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 34.7 KD PROTEIN IN CRH-TRXB INTERGENIC 136 REGION] [SP:O06974] SPX0653 653 3314 304 912 424 5.50E−81 [GI:7328272] [LN:SAY14324] [AC:Y14324] [OR:Staphylococcus aureus] 65 SPX0654 654 3315 323 969 422 5.00E−99 [LN:B70015] [AC:B70015] [PN:thioredoxin reductase homolog yumC] [GN:yumC] [CL:thioredoxin reductase:thioredoxin reductase homology] 154 [OR:Bacillus subtilis] SPX0655 655 3316 272 816 419 8.50E−81 [LN:H69744] [AC:H69744] [PN:conserved hypothetical protein ybbP] [GN:ybbP] [CL:hypothetical protein ybbP] [OR:Bacillus subtilis] 128 SPX0656 656 3317 260 780 104 2.70E−10 [LN:A69745] [AC:A69745] [PN:hypothetical protein ybbR] [GN:ybbR] [OR:Bacillus subtilis] 87 SPX0657 657 3318 64 192 NO-HIT 6 SPX0658 658 3319 451 1353 655 2.00E−180 [GI:3892895] [LN:SAARGFEMD] [AC:Y15477] [PN:phosphoglucosamine-mutase] [GN:glmM] [OR:Staphylococcus aureus] 107 SPX0659 659 3320 121 363 NO-HIT 6 SPX0660 660 3321 283 849 239 6.50E−25 [LN:DEGV_BACSU] [AC:P32436] [GN:DEGV] [OR:Bacillus subtilis] [DE:DEGV PROTEIN] [SP:P32436] 90 SPX0661 661 3322 256 768 614 6.50E−89 “[LN:DAPB_BACSU] [AC:P42976] [GN:DAPB] [OR:Bacillus subtilis] [EC:1.3.1.26] [DE:DIHYDRODIPICOLINATE REDUCTASE,] [SP:P42976]” 124 SPX0662 662 3323 400 1200 601 8.40E−92 “[LN:PAPS_BACSU] [AC:P42977] [GN:PAPS] [OR:Bacillus subtilis] [EC:2.7.7.19] [DE:POLY(A) POLYMERASE, (PAP)] [SP:P42977]” 119 SPX0663 663 3324 624 1872 669 1.80E−162 [LN:A69814] [AC:A69814] [PN:ABC transporter (ATP-binding protein) homolog yfmR] [GN:yfmR] [CL:unassigned ATP-binding cassette proteins: 188 ATP-binding cassette homology] [OR:Bacillus subtilis] SPX0664 664 3325 144 432 NO-HIT 6 SPX0665 665 3326 394 1182 629 1.90E−82 [LN:YEAB_BACSU] [AC:P46348:O05001] [GN:YEAB] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 31.8 KD PROTEIN IN GABP-GUAA 158 INTERGENIC REGION (ORFX)] [SP:P46348:O05001] SPX0666 666 3327 899 2697 601 1.20E−189 “[LN:S77052] [AC:S77052] [PN:cation-transporting ATPase, pacL-1:protein sll0672:protein sll0672] [GN:pacL-1] [CL:Na+/K+-transporting ATPase 218 alpha chain:ATPase nucleotide-binding domain homology] [OR:Synechocystis sp.]” SPX0667 667 3328 97 291 NO-HIT 6 SPX0668 668 3329 83 249 73 0.00016 [LN:H72624] [AC:H72624] [PN:hypothetical protein APE1456] [GN:APE1456] [OR:Aeropyrum pernix] 92 SPX0669 669 3330 264 792 713 2.30E−105 [LN:YGHU_ECOLI] [AC:Q46845] [GN:YGHU] [OR:Escherichia coli] [DE:HYPOTHETICAL 34.2 KD PROTEIN IN GSP-HYBG INTERGENIC 135 REGION] [SP:Q46845] SPX0670 670 3331 152 456 368 3.30E−46 “[LN:DEF_CLOBE] [AC:O08450] [GN:DEF:FMS] [OR:Clostridium beijerinckii] [SR:,Clostridium MP] [EC:3.5.1.31] [DE:DEFORMYLASE)] 136 [SP:O08450]” SPX0671 671 3332 532 1596 NO-HIT 6 SPX0672 672 3333 60 180 NO-HIT 6 SPX0673 673 3334 243 729 473 1.20E−60 [GI:4580623] [LN:AF118389] [AC:AF118389] [PN:unknown] [OR:Streptococcus suis] 77 SPX0674 674 3335 210 630 111 2.10E−12 [GI:6562870] [LN:SCM1] [AC:AL133422] [PN:putative secreted protein.] [GN:SCM1.21] [OR:Streptomyces coelicolor A3(2)] 116 SPX0675 675 3336 163 489 68 0.00021 [LN:YPMB_BACSU] [AC:P54396] [GN:YPMB] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 17.9 KD PROTEIN IN DING-ASPB INTERGENIC 137 REGION] [SP:P54396] SPX0676 676 3337 396 1188 1400 2.80E−187 [GI:6465901] [LN:AF035157] [AC:AF035157] [PN:aspartate aminotransferase] [GN:aspC] [OR:Lactococcus lactis] 106 SPX0677 677 3338 124 372 178 1.90E−27 [LN:T03486] [AC:T03486] [PN:conserved hypothetical protein] [OR:Rhodobacter capsulatus] 87 SPX0678 678 3339 448 1344 703 1.60E−180 [LN:SYN_BACSU] [AC:P39772] [GN:ASNS] [OR:Bacillus subtilis] [EC:6.1.1.22] [DE:(ASNRS)] [SP:P39772] 98 SPX0679 679 3340 129 387 NO-HIT 6 SPX0680 680 3341 97 291 236 7.30E−39 [LN:RS6_BACSU] [AC:P21468] [GN:RPSF] [OR:Bacillus subtilis] [DE:30S RIBOSOMAL PROTEIN S6 (BS9)] [SP:P21468] 107 SPX0681 681 3342 157 471 481 5.20E−71 [GI:6716352] [LN:AF145054] [AC:AF145054:AF001793:AF118440:U89246] [PN:ORF9] [GN:orf9] [OR:Streptococcus thermophilus bacteriophage 7201] 136 SPX0682 682 3343 87 261 134 1.30E−13 [LN:RS18_BACST] [AC:P10806] [GN:RPSR] [OR:Bacillus stearothermophilus] [DE:30S RIBOSOMAL PROTEIN S18 (BS21)] [SP:P10806] 120 SPX0683 683 3344 112 336 NO-HIT 6 SPX0684 684 3345 467 1401 270 7.50E−47 [GI:4678225] [LN:AC007135] [AC:AC007135:AE002093] [PN:cyclophilin-like protein] [GN:At2g36130] [OR:Arabidopsis thaliana] [SR:thale cress] 137 SPX0685 685 3346 84 252 172 6.10E−19 [LN:YABR_BACSU] [AC:P37560] [GN:YABR] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 14.2 KD PROTEIN IN DIVIC-SPOIIE INTERGENIC 140 REGION] [SP:P37560] SPX0686 686 3347 87 261 96 1.40E−15 [LN:YABB_BACSU] [AC:P37543] [GN:YABB] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 28.3 KD PROTEIN IN XPAC-ABRB INTERGENIC 137 REGION] [SP:P37543] SPX0687 687 3348 67 201 109 3.00E−09 [LN:YABB_BACSU] [AC:P37543] [GN:YABB] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 28.3 KD PROTEIN IN XPAC-ABRB INTERGENIC 137 REGION] [SP:P37543] SPX0688 688 3349 129 387 267 1.40E−39 [LN:YABB_BACSU] [AC:P37543] [GN:YABB] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 28.3 KD PROTEIN IN XPAC-ABRB INTERGENIC 137 REGION] [SP:P37543] SPX0689 689 3350 93 279 224 1.50E−26 [LN:A69742] [AC:A69742] [PN:conserved hypothetical protein yazA] [GN:yazA] [CL:hypothetical protein 312] [OR:Bacillus subtilis] 127 SPX0690 690 3351 60 180 143 5.60E−14 [GI:1743856] [LN:SGU57759] [AC:U57759] [PN:intrageneric coaggregation-relevant adhesin] [OR:Streptococcus gordonii] 115 SPX0691 691 3352 222 666 955 2.60E−126 [GI:1743856] [LN:SGU57759] [AC:U57759] [PN:intrageneric coaggregation-relevant adhesin] [OR:Streptococcus gordonii] 115 SPX0692 692 3353 171 513 NO-HIT 6 SPX0693 693 3354 105 315 140 1.80E−21 [GI:2952534] [LN:AF051356] [AC:AF051356] [PN:unknown] [OR:Streptococcus mutans] 79 SPX0694 694 3355 95 285 NO-HIT 6 SPX0695 695 3356 65 195 74 0.00038 [GI:2772940] [LN:AF034574] [AC:AF034574] [PN:putative cruciform DNA binding protein] [GN:Gv1] [OR:Glomus versiforme] 116 SPX0696 696 3357 504 1512 172 1.50E−35 [LN:MURE_BACSU] [AC:Q03523] [GN:MURE] [OR:Bacillus subtilis] [EC:6.3.2.13] [DE:DIAMINOPIMELATE−ADDING ENZYME)] [SP:Q03523] 122 SPX0697 697 3358 192 576 172 9.40E−16 [LN:MURE_BACSU] [AC:Q03523] [GN:MURE] [OR:Bacillus subtilis] [EC:6.3.2.13] [DE:DIAMINOPIMELATE−ADDING ENZYME)] [SP:Q03523] 122 SPX0698 698 3359 541 1623 187 2.90E−75 [LN:G69992] [AC:G69992] [PN:spore cortex protein homolog ytgP] [GN:ytgP] [OR:Bacillus subtilis] 95 SPX0699 699 3360 653 1959 3335 0 [LN:ALIB_STRPN] [AC:Q51933] [GN:ALIB] [OR:Streptococcus pneumoniae] [DE:OLIGOPEPTIDE-BINDING PROTEIN ALIB PRECURSOR] 128 [SP:Q51933] SPX0700 700 3361 185 555 282 2.00E−38 [GI:1125685] [LN:SADNAS55] [AC:X87104] [GN:mdr] [FN:multiple grug resistance] [OR:Staphylococcus aureus] 104 SPX0701 701 3362 180 540 179 9.60E−18 [LN:S58356] [AC:S66651:S58356] [PN:pepT protein] [GN:pepT] [CL:unassigned ATP-binding cassette proteins:ATP-binding cassette homology] 166 [OR:Staphylococcus epidermidis] SPX0702 702 3363 182 546 444 4.80E−55 [GI:1262136] [LN:SAPBP4GEN] [AC:X91786] [PN:ATP-binding cassette transporter A] [GN:abcA] [OR:Staphylococcus aureus] 116 SPX0703 703 3364 365 1095 681 2.80E−123 [LN:A69847] [AC:A69847] [PN:cystathionine gamma-synthase homolog yjcI] [GN:yjcI] [CL:O-succinylhomoserine (thiol)-lyase] [OR:Bacillus subtilis] 143 SPX0704 704 3365 389 1167 582 1.60E−99 “[LN:PATB_BACSU] [AC:Q08432] [GN:PATB] [OR:Bacillus subtilis] [EC:2.6.1.-] [DE:PUTATIVE AMINOTRANSFERASE B,] [SP:Q08432]” 121 SPX0705 705 3366 1033 3099 552 1.00E−129 [GI:1769947] [LN:BCX98455] [AC:X98455] [GN:SNF] [OR:Bacillus cereus] 68 SPX0706 706 3367 206 618 NO-HIT 6 SPX0707 707 3368 445 1335 491 2.00E−154 [LN:MURC_BACSU] [AC:P40778] [GN:MURC] [OR:Bacillus subtilis] [EC:6.3.2.8] [DE:ACETYLMURANOYL-L-ALANINE SYNTHETASE)] [SP:P40778] 127 SPX0708 708 3369 155 465 NO-HIT 6 SPX0709 709 3370 119 357 56 7.70E−05 “[LN:A64491] [AC:A64491] [PN:N-terminal acetyltransferase complex, subunit ARD1 homolog] [CL:Escherichia coli ribosomal-protein-alanine 192 N-acetyltransferase rimI] [OR:Methanococcus jannaschii]” SPX0710 710 3371 71 213 NO-HIT 6 SPX0711 711 3372 502 1506 185 2.10E−43 [LN:E69979] [AC:E69979] [PN:folate metabolism homolog yrrL] [GN:yrrL] [CL:yceG protein] [OR:Bacillus subtilis] 110 SPX0712 712 3373 161 483 271 3.60E−55 [LN:GREA_BACSU] [AC:P80240] [GN:GREA] [OR:Bacillus subtilis] [DE:GREA) (GENERAL STRESS PROTEIN 20M) (GSP20M)] [SP:P80240] 121 SPX0713 713 3374 61 183 121 2.50E−12 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX0714 714 3375 163 489 152 1.50E−24 [LN:S31638] [AC:S31638] [PN:hypothetical protein] [OR:Lactobacillus curvatus] 77 SPX0715 715 3376 66 198 NO-HIT 6 SPX0716 716 3377 70 210 89 0.0001 [GI:4966270] [LN:CELK09H11] [AC:U97002] [GN:K09H11.1] [OR:Caenorhabditis elegans] 81 SPX0717 717 3378 148 444 419 7.50E−56 [GI:517210] [LN:SPU11799] [AC:U11799] [OR:Streptococcus pyogenes] 65 SPX0718 718 3379 164 492 484 1.40E−63 [GI:517210] [LN:SPU11799] [AC:U11799] [OR:Streptococcus pyogenes] 65 SPX0719 719 3380 67 201 331 3.00E−44 “[LN:S49404] [AC:S49404:S38206] [PN:H+-transporting ATP synthase, chain c] [GN:atpC] [CL:H+-transporting ATP synthase lipid-binding protein] 185 [OR:Streptococcus pneumoniae] [EC:3.6.1.34]” SPX0720 720 3381 239 717 1205 5.00E−168 “[LN:ATP6_STRPN] [AC:Q59954] [GN:ATPB:ATPA] [OR:Streptococcus pneumoniae] [EC:3.6.1.34] [DE:ATP SYNTHASE A CHAIN, (PROTEIN 6)] 139 [SP:Q59954]” SPX0721 721 3382 165 495 769 2.90E−100 “[LN:ATPF_STRPN] [AC:Q59952:Q59955] [GN:ATPF:ATPB] [OR:Streptococcus pneumoniae] [EC:3.6.1.34] [DE:ATP SYNTHASE B CHAIN, 153 (SUBUNIT I)] [SP:Q59952:Q59955]” SPX0722 722 3383 179 537 509 8.40E−66 [GI:4100654] [LN:AF001955] [AC:AF001955] [PN:proton-translocating ATPase delta subunit] [GN:uncH] [OR:Streptococcus sanguinis] 126 SPX0723 723 3384 502 1506 2347 0 [GI:4100655] [LN:AF001955] [AC:AF001955] [PN:proton-translocating ATPase alpha subunit] [GN:uncA] [OR:Streptococcus sanguinis] 126 SPX0724 724 3385 293 879 1011 1.70E−169 [GI:4100656] [LN:AF001955] [AC:AF001955] [PN:proton-translocating ATPase gamma subunit] [OR:Streptococcus sanguinis] 116 SPX0725 725 3386 469 1407 2287 0 [GI:4100657] [LN:AF001955] [AC:AF001955] [PN:proton-translocating ATPase beta subunit] [GN:uncD] [OR:Streptococcus sanguinis] 125 SPX0726 726 3387 140 420 581 1.40E−76 [GI:4100658] [LN:AF001955] [AC:AF001955] [PN:proton-translocating ATPase epsilon subunit] [GN:uncC] [OR:Streptococcus sanguinis] 128 SPX0727 727 3388 251 753 175 2.70E−42 [GI:6746427] [LN:AF179847] [AC:AF179847] [PN:putative transposase] [OR:Lactococcus lactis] 90 SPX0728 728 3389 65 195 NO-HIT 6 SPX0729 729 3390 182 546 107 1.20E−15 [GI:3849798] [LN:U91581] [AC:U91581:U04057] [PN:putative transposase] [GN:tpase] [OR:Lactococcus lactis subsp. lactis] 118 SPX0730 730 3391 338 1014 444 1.50E−117 [GI:3242228] [LN:LLCADHE] [AC:AJ001007] [GN:orfB] [OR:Lactococcus lactis] 73 SPX0731 731 3392 78 234 NO-HIT 6 SPX0732 732 3393 389 1167 1141 1.60E−158 [GI:4098497] [LN:SMU78604] [AC:U78604] [PN:putative membrane protein] [OR:Streptococcus mutans] 95 SPX0733 733 3394 410 1230 457 6.20E−71 “[GI:473901] [LN:LACALS] [AC:L16975] [OR:Lactococcus lactis] [SR:Lactococcus lactis (strain DSM 20384, sub_species lactis) DNA]” 128 SPX0734 734 3395 214 642 351 1.70E−45 “[LN:A72357] [AC:A72357] [PN:amino acid ABC transporter, permease protein] [GN:TM0592] [CL:histidine permease protein M] 146 [OR:Thermotoga maritima]” SPX0735 735 3396 210 630 367 2.90E−65 [GI:1649037] [LN:STU73111] [AC:U73111] [PN:glutamine transport ATP-binding protein GLNQ] [OR:Salmonella typhimurium] 116 SPX0736 736 3397 279 837 1411 4.70E−188 [GI:5929889] [LN:AF165218] [AC:AF165218] [PN:AatB] [GN:aatB] [OR:Streptococcus pneumoniae] 90 SPX0737 737 3398 116 348 578 1.80E−76 [GI:5929888] [LN:AF165218] [AC:AF165218] [PN:Bta] [GN:bta] [OR:Streptococcus pneumoniae] 88 SPX0738 738 3399 573 1719 2903 0 [GI:5929887] [LN:AF165218] [AC:AF165218] [PN:Pgm] [GN:pgm] [OR:Streptococcus pneumoniae] 88 SPX0739 739 3400 109 327 129 8.30E−12 [GI:4200438] [LN:AF026471] [AC:AF026471] [PN:putative transposase] [OR:Streptococcus pneumoniae] 96 SPX0740 740 3401 100 300 245 5.10E−30 [GI:5019553] [LN:SPN239004] [AC:AJ239004] [PN:putative transposase] [OR:Streptococcus pneumoniae] 97 SPX0741 741 3402 95 285 NO-HIT 6 SPX0742 742 3403 85 255 NO-HIT 6 SPX0743 743 3404 71 213 NO-HIT 6 SPX0744 744 3405 371 1113 NO-HIT 6 SPX0745 745 3406 174 522 72 1.10E−05 “[LN:I38170] [AC:I38170] [PN:gene hr44 protein] [GN:hr44] [OR:Homo sapiens] [SR:, man]” 87 SPX0746 746 3407 290 870 335 2.40E−72 [LN:B72254] [AC:B72254] [PN:glycerol uptake facilitator protein] [GN:TM1429] [CL:glycerol facilitator protein] [OR:Thermotoga maritima] 135 SPX0747 747 3408 399 1197 2022 6.40E−273 [LN:EFTU_STROR] [AC:P33170] [GN:TUF] [OR:Streptococcus oralis] [DE:ELONGATION FACTOR TU (EF-TU)] [SP:P33170] 108 SPX0748 748 3409 128 384 104 1.80E−06 [LN:H71023] [AC:H71023] [PN:hypothetical protein PH1485] [GN:PH1485] [OR:Pyrococcus horikoshii] 95 SPX0749 749 3410 138 414 99 6.40E−06 [LN:S31840] [AC:S31840] [PN:probable transposase] [OR:Bacillus stearothermophilus] 82 SPX0750 750 3411 62 186 NO-HIT 6 SPX0751 751 3412 218 654 163 3.90E−21 [GI:722339] [LN:AXU22323] [AC:U22323] [PN:unknown] [OR:Acetobacter xylinus] [SR:Acetobacter xylinum] 100 SPX0752 752 3413 361 1083 272 2.20E−72 [LN:C69813] [AC:C69813] [PN:RNA helicase homolog yfmL] [GN:yfmL] [CL:unassigned DEAD/H box helicases:DEAD/H box helicase homology] 153 [OR:Bacillus subtilis] SPX0753 753 3414 354 1062 197 3.10E−44 [LN:YGJR_ECOLI] [AC:P42599:P42600:P76661] [GN:YGJR] [OR:Escherichia coli] [DE:HYPOTHETICAL 36.2 KD PROTEIN IN EBGC-UXAA 164 INTERGENIC REGION] [SP:P42599:P42600:P76661] SPX0754 754 3415 62 186 77 0.00028 “[LN:S67482] [AC:S67482:S52150] [PN:serine O-acetyltransferase,, cytosolic:serine acetyltransferase:serine acetyltransferase] [OR:Arabidopsis thaliana]” 152 SPX0755 755 3416 126 378 NO-HIT 6 SPX0756 756 3417 481 1443 485 5.60E−59 “[LN:G69849] [AC:G69849] [PN:endo-1,4-beta-xylanase homolog yjeA] [GN:yjeA] [CL:nodB homology] [OR:Bacillus subtilis]” 118 SPX0757 757 3418 256 768 357 5.70E−83 [LN:C70040] [AC:C70040] [PN:plant-metabolite dehydrogenase homolog yvgN] [GN:yvgN] [CL:aldehyde reductase] [OR:Bacillus subtilis] 129 SPX0758 758 3419 77 231 NO-HIT 6 SPX0759 759 3420 254 762 NO-HIT 6 SPX0760 760 3421 306 918 1187 3.50E−159 [LN:SYGA_BACSU] [AC:P54380] [GN:GLYQ] [OR:Bacillus subtilis] [EC:6.1.1.14] [DE:ALPHA CHAIN) (GLYRS)] [SP:P54380] 112 SPX0761 761 3422 679 2037 1334 6.50E−179 [LN:SYGB_BACSU] [AC:P54381] [GN:GLYS] [OR:Bacillus subtilis] [EC:6.1.1.14] [DE:BETA CHAIN) (GLYRS)] [SP:P54381] 111 SPX0762 762 3423 86 258 218 1.20E−24 [LN:E69894] [AC:E69894] [PN:hypothetical protein ynzC] [GN:ynzC] [OR:Bacillus subtilis] 87 SPX0763 763 3424 415 1245 97 5.10E−08 [LN:YIEF_ECOLI] [AC:P31465] [GN:YIEF] [OR:Escherichia coli] [DE:HYPOTHETICAL 20.4 KD PROTEIN IN TNAB-BGLB INTERGENIC 136 REGION] [SP:P31465] SPX0764 764 3425 79 237 NO-HIT 6 SPX0765 765 3426 202 606 110 2.80E−13 [LN:YIEF_ECOLI] [AC:P31465] [GN:YIEF] [OR:Escherichia coli] [DE:HYPOTHETICAL 20.4 KD PROTEIN IN TNAB-BGLB INTERGENIC 136 REGION] [SP:P31465] SPX0766 766 3427 308 924 172 3.10E−41 [LN:APBE_TREPA] [AC:O83774] [GN:APBE:TP0796] [OR:Treponema pallidum] [DE:THIAMINE BIOSYNTHESIS LIPOPROTEIN APBE 134 PRECURSOR] [SP:O83774] SPX0767 767 3428 91 273 NO-HIT 6 SPX0768 768 3429 460 1380 2342 0 [GI:4416519] [LN:AF014458] [AC:AF014458] [PN:NADH oxidase] [OR:Streptococcus pneumoniae] 88 SPX0769 769 3430 298 894 1411 3.40E−191 [LN:YG47_HAEIN] [AC:P45293] [GN:HI1647] [OR:Haemophilus influenzae] [DE:HYPOTHETICAL PROTEIN HI1647] [SP:P45293] 112 SPX0770 770 3431 78 234 125 3.00E−12 [LN:F71007] [AC:F71007] [PN:hypothetical protein PH1356] [GN:PH1356] [CL:Pyrococcus horikoshii hypothetical protein PH1356] 150 [OR:Pyrococcus horikoshii] SPX0771 771 3432 63 189 157 1.20E−15 [LN:F72782] [AC:F72782] [PN:hypothetical protein APE0247] [GN:APE0247] [OR:Aeropyrum pernix] 92 SPX0772 772 3433 52 156 159 4.30E−16 [LN:F72782] [AC:F72782] [PN:hypothetical protein APE0247] [GN:APE0247] [OR:Aeropyrum pernix] 92 SPX0773 773 3434 194 582 720 2.40E−95 [LN:YG48_HAEIN] [AC:P45294] [GN:HI1648] [OR:Haemophilus influenzae] [DE:HYPOTHETICAL PROTEIN HI1648] [SP:P45294] 112 SPX0774 774 3435 216 648 183 5.00E−34 [LN:YA37_TREPA] [AC:O84000] [GN:TP1037] [OR:Treponema pallidum] [DE:HYPOTHETICAL PROTEIN TP1037] [SP:O84000] 108 SPX0775 775 3436 151 453 NO-HIT 6 SPX0776 776 3437 165 495 94 2.80E−12 [LN:G81269] [AC:G81269] [PN:probable acetyltransferase Cj1715 [imported]] [GN:Cj1715] [OR:Campylobacter jejuni] 111 SPX0777 777 3438 177 531 167 1.80E−29 [GI:3694956] [LN:AF091508] [AC:AF091508] [PN:O-6-methylguanine DNA methyltransferase] [GN:ogt] [OR:Salmonella muenster] 119 SPX0778 778 3439 119 357 272 2.10E−32 [LN:B70021] [AC:B70021] [PN:arsenate reductase homolog yusI] [GN:yusI] [CL:hypothetical protein yjbD] [OR:Bacillus subtilis] 124 SPX0779 779 3440 126 378 NO-HIT 6 SPX0780 780 3441 267 801 284 2.10E−54 [LN:YXEN_BACSU] [AC:P54953] [GN:YXEN:LP9F] [OR:Bacillus subtilis] [DE:INTERGENIC REGION] [SP:P54953] 100 SPX0781 781 3442 248 744 468 5.80E−82 [GI:666983] [LN:BSPAAT] [AC:X77636] [PN:putative ATP binding subunit] [GN:ORF3] [OR:Bacillus subtilis] 102 SPX0782 782 3443 79 237 NO-HIT 6 SPX0783 783 3444 74 222 NO-HIT 6 SPX0784 784 3445 266 798 542 4.60E−98 “[LN:TRXB_LISMO] [AC:O32823] [GN:TRXB] [OR:Listeria monocytogenes] [EC:1.6.4.5] [DE:THIOREDOXIN REDUCTASE,] [SP:O32823]” 120 SPX0785 785 3446 254 762 322 1.30E−58 “[LN:YACO_BACSU] [AC:Q06753] [GN:YACO] [OR:Bacillus subtilis] [EC:2.1.1.-] [DE:HYPOTHETICAL TRNA/RRNA METHYLTRANSFERASE 139 YACO,] [SP:Q06753]” SPX0786 786 3447 204 612 394 4.10E−93 “[GI:806487] [LN:LACLPAGAP] [AC:L36907] [FN:unknown] [OR:Lactococcus lactis] [SR:Lactococcus lactis (individual_isolate LM0230, sub_specie]” 140 SPX0787 787 3448 84 252 NO-HIT 6 SPX0788 788 3449 161 483 136 6.00E−14 [LN:H70069] [AC:H70069:JC7099] [PN:poly-gamma-glutamic synthesis PgsA protein] [GN:ywtB:pgsA] [OR:Bacillus subtilis] 116 SPX0789 789 3450 126 378 NO-HIT 6 SPX0790 790 3451 276 828 242 8.80E−42 [LN:F64819] [AC:F64819] [PN:hypothetical protein b0822] [CL:Methanobacterium thermoautotrophicum conserved hypothetical protein MTH1071] 158 [OR:Escherichia coli] SPX0791 791 3452 212 636 NO-HIT 6 SPX0792 792 3453 242 726 1196 1.80E−160 [GI:5001711] [LN:AF112358] [AC:AF112358] [PN:C3-degrading proteinase] [GN:cppA] [OR:Streptococcus pneumoniae] 109 SPX0793 793 3454 312 936 117 4.00E−22 [GI:6469268] [LN:SCC75A] [AC:AL133220] [PN:possible secreted esterase] [GN:SCC75A.29c] [OR:Streptomyces coelicolor A3(2)] 121 SPX0794 794 3455 299 897 487 1.00E−64 [LN:YICL_ECOLI] [AC:P31437] [GN:YICL] [OR:Escherichia coli] [DE:HYPOTHETICAL 33.1 KD PROTEIN IN SELC-NLPA 136 INTERGENIC REGION] [SP:P31437] SPX0795 795 3456 233 699 294 7.80E−49 [LN:D70044] [AC:D70044] [PN:transcription regulator GntR family homolog yvoA] [GN:yvoA] [CL:transcription regulator GntR] [OR:Bacillus subtilis] 144 SPX0796 796 3457 521 1563 1721 3.40E−294 [GI:4321715] [LN:AF058326] [AC:AF058326] [PN:GMP synthase] [GN:guaA] [OR:Lactococcus lactis] 92 SPX0797 797 3458 62 186 NO-HIT 6 SPX0798 798 3459 96 288 204 2.90E−23 “[LN:JC1151] [AC:JC1151] [PN:hypothetical protein, 20.3K] [OR:Agrobacterium tumefaciens]” 89 SPX0799 799 3460 65 195 NO-HIT 6 SPX0800 800 3461 130 390 91 0.00062 “[GI:5824139] [LN:POL245436] [AC:AJ245436:J04618:J04619:S50571:X52935:X65936] [PN:hypothetical protein, 57.8 kD] [OR:Pseudomonas putida]” 137 SPX0801 801 3462 143 429 84 9.20E−08 “[GI:6009407] [LN:AB024946] [AC:AB024946] [GN:orf31] [OR:Escherichia coli] [SR:Escherichia coli (sub_species:enteropathogenic, strain:B171]” 140 SPX0802 802 3463 150 450 94 3.20E−15 “[LN:Y4HP_RHISN] [AC:P50360] [GN:Y4HP] [OR:Rhizobium sp] [SR:,strain NGR234] [DE:HYPOTHETICAL 61.7 KD PROTEIN Y4HP] [SP:P50360]” 128 SPX0803 803 3464 78 234 87 0.00033 “[GI:5824139] [LN:POL245436] [AC:AJ245436:J04618:J04619:S50571:X52935:X65936] [PN:hypothetical protein, 57.8 kD] [OR:Pseudomonas putida]” 137 SPX0804 804 3465 455 1365 253 2.70E−62 “[LN:D69159] [AC:D69159] [PN:methyl coenzyme M reductase system, component A2 homolog] [GN:MTH454] [CL:unassigned ATP-binding cassette 217 proteins:ATP-binding cassette homology] [OR:Methanobacterium thermoautotrophicum]” SPX0805 805 3466 74 222 NO-HIT 6 SPX0806 806 3467 232 696 88 1.90E−07 [LN:E72202] [AC:E72202] [PN:conserved hypothetical protein] [GN:TM1868] [OR:Thermotoga maritima] 96 SPX0807 807 3468 195 585 NO-HIT 6 SPX0808 808 3469 582 1746 554 3.00E−83 [GI:4097162] [LN:PMU46488] [AC:U46488] [PN:NrpB] [GN:nrpB] [OR:Proteus mirabilis] 81 SPX0809 809 3470 587 1761 526 2.60E−78 [GI:4097161] [LN:PMU46488] [AC:U46488] [PN:NrpA] [GN:nrpA] [OR:Proteus mirabilis] 81 SPX0810 810 3471 159 477 131 3.30E−12 [LN:SOXS_ECOLI] [AC:P22539] [GN:SOXS] [OR:Escherichia coli] [DE:REGULATORY PROTEIN SOXS] [SP:P22539] 100 SPX0811 811 3472 69 207 NO-HIT 6 SPX0812 812 3473 397 1191 889 2.70E−126 [GI:2995646] [LN:AF051092] [AC:AF051092] [PN:DNA modification methyltransferase M.XbaI] [GN:xbaIM] [FN:recognizes ds DNA sequence 177 TCTAGA; thought to] [OR:Xanthomonas campestris] SPX0813 813 3474 63 189 128 1.30E−17 [GI:2995645] [LN:AF051092] [AC:AF051092] [PN:restriction endonuclease R.XbaI] [GN:xbaIR] [FN:recognizes ds DNA sequence TCTAGA; 169 cleaves both] [OR:Xanthomonas campestris] SPX0814 814 3475 61 183 199 4.80E−22 [GI:2995645] [LN:AF051092] [AC:AF051092] [PN:restriction endonuclease R.XbaI] [GN:xbaIR] [FN:recognizes ds DNA sequence TCTAGA; 169 cleaves both] [OR:Xanthomonas campestris] SPX0815 815 3476 71 213 NO-HIT 6 SPX0816 816 3477 429 1287 681 4.70E−147 [LN:H69979] [AC:H69979] [PN:proteinase homolog yrrO] [GN:yrrO] [CL:collagenase prtC] [OR:Bacillus subtilis] 107 SPX0817 817 3478 243 729 251 6.20E−58 [LN:H69979] [AC:H69979] [PN:proteinase homolog yrrO] [GN:yrrO] [CL:collagenase prtC] [OR:Bacillus subtilis] 107 SPX0818 818 3479 241 723 225 4.40E−26 [LN:YCBN_BACSU] [AC:P42246] [GN:YCBN] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 31.7 KD PROTEIN IN GLTP-CWLJ INTERGENIC 145 REGION (ORF13)] [SP:P42246] SPX0819 819 3480 243 729 NO-HIT 6 SPX0820 820 3481 80 240 152 2.50E−16 [GI:1536960] [LN:SOORFS] [AC:Z79691] [GN:yorfE] [FN:putative transcription regulator] [OR:Streptococcus pneumoniae] 115 SPX0821 821 3482 163 489 NO-HIT 6 SPX0822 822 3483 487 1461 981 1.70E−215 [LN:D70008] [AC:D70008] [PN:nicotinate phosphoribosyltransferase homolog yueK] [GN:yueK] [OR:Bacillus subtilis] 111 SPX0823 823 3484 275 825 923 1.70E−122 [LN:NADE_ECOLI] [AC:P18843:P78235] [GN:NADE:EFG:NTRL] [OR:Escherichia coli] [EC:6.3.5.1] [DE:PROTEIN)] [SP:P18843:P78235] 121 SPX0824 824 3485 66 198 NO-HIT 6 SPX0825 825 3486 184 552 135 1.80E−13 [GI:7635982] [LN:SCE6] [AC:AL353832] [PN:putative acetyltransferase.] [GN:SCE6.13] [OR:Streptomyces coelicolor A3(2)] 117 SPX0826 826 3487 250 750 66 0.00023 [GI:4185565] [LN:AF115379] [AC:AF115379] [PN:surface protein Pls] [GN:pls] [OR:Staphylococcus aureus] 101 SPX0827 827 3488 130 390 306 1.70E−36 [LN:A41971] [AC:A41971:A60282:A33134] [PN:surface protein pspA precursor:pneumococcal surface protein A] [GN:pspA] [CL:cpl repeat homology] 169 [OR:Streptococcus pneumoniae] SPX0828 828 3489 347 1041 1229 5.30E−166 [LN:QUEA_BACSU] [AC:O32054] [GN:QUEA] [OR:Bacillus subtilis] [EC:5.-.-.-] [DE:(QUEUOSINE BIOSYNTHESIS PROTEIN QUEA)] 128 [SP:O32054] SPX0829 829 3490 236 708 336 3.00E−66 [LN:NAGB_BACSU] [AC:O35000] [GN:NAGB] [OR:Bacillus subtilis] [EC:5.3.1.10] [DE:PHOSPHATE DEAMINASE) (GNPDA) (GLCN6P 139 DEAMINASE)] [SP:O35000] SPX0830 830 3491 67 201 248 1.00E−29 [LN:T43742] [AC:T43742] [PN:ribosomal protein S21 [imported]] [OR:Listeria monocytogenes] 89 SPX0831 831 3492 313 939 1224 7.60E−165 [GI:4884536] [LN:AB027460] [AC:AB027460] [PN:Hpr kinase] [OR:Streptococcus bovis] [SR:Streptococcus bovis (strain:JB1) DNA] 123 SPX0832 832 3493 192 576 608 1.30E−84 “[LN:T11569] [AC:T11569] [PN:prolipoprotein diacylglyceryl transferase,] [GN:lgt] [CL:prolipoprotein diacylglyceryl transferase] [OR:Streptococcus 169 mutans] [EC:2.4.99.-]” SPX0833 833 3494 128 384 333 1.50E−41 [LN:T11570] [AC:T11570] [PN:hypothetical protein 1] [OR:Streptococcus mutans] 77 SPX0834 834 3495 110 330 NO-HIT 6 SPX0835 835 3496 130 390 164 5.70E−17 [LN:T11571] [AC:T11571] [PN:hypothetical protein 2] [OR:Streptococcus mutans] 77 SPX0836 836 3497 377 1131 596 4.30E−126 “[LN:B69640] [AC:B69640] [PN:coproporphyrinogen oxidase, III, oxygen-independent hemN] [GN:hemN] [CL:oxygen-independent 184 coproporphyrinogen oxidase] [OR:Bacillus subtilis] [EC:1.3.3.3]” SPX0837 837 3498 166 498 NO-HIT 6 SPX0838 838 3499 246 738 96 7.20E−11 [GI:4704640] [LN:AF110462] [AC:AF110462] [PN:oleoyl-ACP thioesterase] [OR:Elaeis guineensis] 92 SPX0839 839 3500 203 609 466 3.10E−59 [LN:H70023] [AC:H70023] [PN:N-acetyl-glucosamine catabolism homolog yutF] [GN:yutF] [CL:nagD protein] [OR:Bacillus subtilis] 124 SPX0840 840 3501 217 651 NO-HIT 6 SPX0841 841 3502 108 324 NO-HIT 6 SPX0842 842 3503 134 402 447 5.60E−58 [LN:D69843] [AC:D69843] [PN:conserved hypothetical protein yjbD] [GN:yjbD] [CL:hypothetical protein yjbD] [OR:Bacillus subtilis] 128 SPX0843 843 3504 93 279 216 2.40E−24 [LN:C69864] [AC:C69864] [PN:hypothetical protein yktA] [GN:yktA] [OR:Bacillus subtilis] 87 SPX0844 844 3505 283 849 207 1.30E−46 [LN:SUHB_BACSU] [AC:Q45499] [GN:SUHB] [OR:Bacillus subtilis] [DE:EXTRAGENIC SUPPRESSOR PROTEIN SUHB HOMOLOG] [SP:Q45499] 120 SPX0845 845 3506 113 339 NO-HIT 6 SPX0846 846 3507 305 915 143 8.30E−21 [LN:YEBU_ECOLI] [AC:P76273:O07980] [GN:YEBU] [OR:Escherichia coli] [DE:HYPOTHETICAL 53.2 KD PROTEIN IN PRC-PRPA 149 INTERGENIC REGION] [SP:P76273:O07980] SPX0847 847 3508 76 228 NO-HIT 6 SPX0848 848 3509 56 168 NO-HIT 6 SPX0849 849 3510 78 234 NO-HIT 6 SPX0850 850 3511 293 879 465 1.40E−80 [LN:YQGG_BACSU] [AC:P46338] [GN:YQGG] [OR:Bacillus subtilis] [DE:REGION PRECURSOR (ORF108)] [SP:P46338] 103 SPX0851 851 3512 306 918 403 1.00E−99 [LN:YQGH_BACSU] [AC:P46339] [GN:YQGH] [OR:Bacillus subtilis] [DE:REGION (ORF72)] [SP:P46339] 92 SPX0852 852 3513 295 885 842 2.80E−114 [LN:YQGI_BACSU] [AC:P46340] [GN:YQGI] [OR:Bacillus subtilis] [DE:REGION (ORF73)] [SP:P46340] 92 SPX0853 853 3514 268 804 796 1.10E−105 [LN:PSTB_METJA] [AC:Q58418] [GN:PSTB:MJ1012] [OR:Methanococcus jannaschii] [DE:PROBABLE PHOSPHATE TRANSPORT 145 ATP-BINDING PROTEIN PSTB] [SP:Q58418] SPX0854 854 3515 253 759 763 7.10E−100 [LN:T43868] [AC:T43868] [PN:phosphate transport system peripheral membrane protein B [imported]] [GN:pstB] [CL:inner membrane 193 protein malK:ATP-binding cassette homology] [OR:Pseudomonas putida] SPX0855 855 3516 218 654 212 3.70E−40 [GI:4530451] [LN:AF118229] [AC:AF118229] [PN:PhoU] [GN:phoU] [OR:Streptococcus pneumoniae] 90 SPX0856 856 3517 272 816 190 2.40E−30 “[LN:B72357] [AC:B72357] [PN:amino acid ABC transporter, periplasmic amino acid-binding protein] [GN:TM0593] [CL:lysine-arginine- 181 ornithine-binding protein] [OR:Thermotoga maritima]” SPX0857 857 3518 424 1272 778 4.20E−129 [GI:4580622] [LN:AF118389] [AC:AF118389] [PN:unknown] [OR:Streptococcus suis] 77 SPX0858 858 3519 57 171 NO-HIT 6 SPX0859 859 3520 171 513 340 3.10E−77 [GI:1524117] [LN:LLALDB] [AC:X82620] [PN:alpha-acetolactate decarboxylase] [GN:aldB] [OR:Lactococcus lactis] 108 SPX0860 860 3521 67 201 265 2.40E−33 [GI:1808671] [LN:SGCSHAG] [AC:X65164:S52427] [PN:putative alpha-acetolactate decarboxylase] [GN:aldB] [OR:Streptococcus gordonii] 129 SPX0861 861 3522 243 729 106 1.50E−25 [LN:A69830] [AC:A69830] [PN:hypothetical protein yhfC] [GN:yhfC] [OR:Bacillus subtilis] 87 SPX0862 862 3523 302 906 212 5.60E−55 [LN:MURB_BACSU] [AC:P18579:P16669:P37581] [GN:MURB] [OR:Bacillus subtilis] [EC:1.1.1.158] [DE:ACETYLMURAMATE 150 DEHYDROGENASE)] [SP:P18579:P16669:P37581] SPX0863 863 3524 379 1137 792 1.80E−114 “[LN:A70180] [AC:A70180] [PN:spermidine/putrescine ABC transporter, ATP-binding protein (potA) homolog] [CL:unassigned ATP-binding cassette 237 proteins:ATP-binding cassette homology] [OR:Borrelia burgdorferi] [SR:, Lyme disease spirochete]” SPX0864 864 3525 109 327 NO-HIT 6 SPX0865 865 3526 211 633 324 4.20E−44 “[LN:H70179] [AC:H70179] [PN:spermidine/putrescine ABC transporter, permease protein (potB) homolog] [CL:spermidine/putrescine transport 224 system permease protein potH] [OR:Borrelia burgdorferi] [SR:, Lyme disease spirochete]” SPX0866 866 3527 258 774 346 7.00E−66 “[LN:G70179] [AC:G70179] [PN:spermidine/putrescine ABC transporter, permease protein (potC) homolog] [CL:spermidine/putrescine transport 224 system permease protein potI] [OR:Borrelia burgdorferi] [SR:, Lyme disease spirochete]” SPX0867 867 3528 226 678 173 5.20E−48 [LN:POTD_ECOLI] [AC:P23861] [GN:POTD] [OR:Escherichia coli] [DE:SPERMIDINE/PUTRESCINE−BINDING PERIPLASMIC PROTEIN 143 PRECURSOR (SPBP)] [SP:P23861] SPX0868 868 3529 125 375 197 1.30E−20 [LN:POTD_ECOLI] [AC:P23861] [GN:POTD] [OR:Escherichia coli] [DE:SPERMIDINE/PUTRESCINE−BINDING PERIPLASMIC PROTEIN 143 PRECURSOR (SPBP)] [SP:P23861] SPX0869 869 3530 80 240 NO-HIT 6 SPX0870 870 3531 73 219 NO-HIT 6 SPX0871 871 3532 163 489 159 4.70E−15 [LN:G70079] [AC:G70079] [PN:hypothetical protein yxjI] [GN:yxjI] [CL:Bacillus subtilis hypothetical protein yxjI] [OR:Bacillus subtilis] 136 SPX0872 872 3533 89 267 332 2.40E−39 “[LN:SYA_BACSU] [AC:O34526] [GN:ALAS] [OR:Bacillus subtilis] [EC:6.1.1.7] [DE:ALANYL-TRNA SYNTHETASE, (ALANINE- 146 TRNA LIGASE) (ALARS)] [SP:O34526]” SPX0873 873 3534 787 2361 570 1.20E−202 “[LN:SYA_BACSU] [AC:O34526] [GN:ALAS] [OR:Bacillus subtilis] [EC:6.1.1.7] [DE:ALANYL-TRNA SYNTHETASE, (ALANINE- 146 TRNA LIGASE) (ALARS)] [SP:O34526]” SPX0874 874 3535 485 1455 1726 2.50E−257 [GI:2760119] [LN:AB000830] [AC:AB000830] [PN:alpha-amylase precursor] [OR:Streptococcus bovis] [SR:Streptococcus bovis (strain:148) DNA] 136 SPX0875 875 3536 64 192 NO-HIT 6 SPX0876 876 3537 250 750 489 1.10E−62 “[LN:H75077] [AC:H75077] [PN:abc transporter, ATP-binding protein PAB1696] [GN:PAB1696] [CL:unassigned ATP-binding cassette 187 proteins:ATP-binding cassette homology] [OR:Pyrococcus abyssi]” SPX0877 877 3538 545 1635 NO-HIT 6 SPX0878 878 3539 388 1164 468 2.20E−96 [LN:YWBD_BACSU] [AC:P39587] [GN:YWBD:IPA-19D] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 44.4 KD PROTEIN IN EPR-GALK INTERGENIC 144 REGION] [SP:P39587] SPX0879 879 3540 226 678 165 6.60E−27 [GI:5919207] [LN:AF184963] [AC:AF184963] [PN:3-dehydroquinase] [GN:aroD] [OR:Salmonella enteritidis] 100 SPX0880 880 3541 285 855 680 5.70E−89 [GI:3821433] [LN:SPN232281] [AC:AJ232281] [PN:shikimate dehydrogenase] [GN:aroE] [OR:Streptococcus pneumoniae] 110 SPX0881 881 3542 356 1068 439 3.10E−84 “[LN:AROB_SYNY3] [AC:P73997] [GN:AROB:SLR2130] [OR:Synechocystis sp] [SR:,strain PCC 6803] [EC:4.6.1.3] [DE:3-DEHYDROQUINATE 148 SYNTHASE,] [SP:P73997]” SPX0882 882 3543 389 1167 790 1.40E−142 [LN:AROC_BACSU] [AC:P31104] [GN:AROF] [OR:Bacillus subtilis] [EC:4.6.1.4] [DE:PHOSPHOLYASE) (VEGETATIVE PROTEIN 216) 138 (VEG216)] [SP:P31104] SPX0883 883 3544 368 1104 402 2.40E−127 “[LN:TYRA_LACLA] [AC:P43901] [GN:TYRA] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:1.3.1.12] [DE:PREPHENATE 165 DEHYDROGENASE, (PDH)] [SP:P43901]” SPX0884 884 3545 113 339 152 7.80E−16 [GI:3688819] [LN:AF084104] [AC:AF084104] [PN:hypothetical protein] [OR:Bacillus firmus] 87 SPX0885 885 3546 428 1284 2094 1.40E−284 [GI:5616525] [LN:AF169483] [AC:AF169483] [PN:5-enolpyruvylshikimate-3-phosphate synthase] [GN:aroA] [OR:Streptococcus pneumoniae] 129 SPX0886 886 3547 159 477 262 3.60E−40 “[LN:AROK_LACLA] [AC:P43906] [GN:AROK] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:2.7.1.71] [DE:SHIKIMATE 156 KINASE, (SK)] [SP:P43906]” SPX0887 887 3548 282 846 707 3.20E−98 “[LN:PHEA_LACLA] [AC:P43909] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:4.2.1.51] [DE:PREPHENATE 153 DEHYDRATASE, (PDT)] [SP:P43909]” SPX0888 888 3549 231 693 91 7.60E−09 [GI:7160813] [LN:EFA276231] [AC:AJ276231] [PN:PSR protein] [GN:psr] [FN:unknown] [OR:Enterococcus faecalis] 107 SPX0889 889 3550 200 600 268 9.10E−46 [GI:7160813] [LN:EFA276231] [AC:AJ276231] [PN:PSR protein] [GN:psr] [FN:unknown] [OR:Enterococcus faecalis] 107 SPX0890 890 3551 282 846 172 1.10E−24 [LN:LICD_HAEIN] [AC:P14184] [GN:LICD] [OR:Haemophilus influenzae] [DE:LICD PROTEIN] [SP:P14184] 95 SPX0891 891 3552 134 402 NO-HIT 6 SPX0892 892 3553 386 1158 244 1.70E−28 [LN:F70441] [AC:F70441] [PN:capsular polysaccharide biosynthsis protein] [GN:cap] [OR:Aquifex aeolicus] 103 SPX0893 893 3554 329 987 327 4.10E−51 [GI:3320393] [LN:AF030373] [AC:AF030373] [PN:galactosyl transferase] [GN:cps23FU] [OR:Streptococcus pneumoniae] 111 SPX0894 894 3555 478 1434 96 0.00022 [GI:5931973] [LN:AF125164] [AC:AF125164] [PN:putative polymerase] [GN:wzy] [OR:Bacteroides fragilis] 100 SPX0895 895 3556 151 453 NO-HIT 6 SPX0896 896 3557 202 606 NO-HIT 6 SPX0897 897 3558 99 297 NO-HIT 6 SPX0898 898 3559 185 555 349 1.10E−42 [GI:5360696] [LN:AB022909] [AC:AB022909] [PN:negative regulator of genetic competence] [GN:mecA] [OR:Streptococcus mutans] [SR:Streptococcus 164 mutans (strain:Xc) DNA] SPX0899 899 3560 128 384 NO-HIT 6 SPX0900 900 3561 71 213 127 1.70E−11 [GI:5360696] [LN:AB022909] [AC:AB022909] [PN:negative regulator of genetic competence] [GN:mecA] [OR:Streptococcus mutans] [SR:Streptococcus 164 mutans (strain:Xc) DNA] SPX0901 901 3562 429 1287 1425 2.60E−191 “[LN:DHOM_LACLA] [AC:P52985] [GN:HOM] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:1.1.1.3] [DE:HOMOSERINE 163 DEHYDROGENASE, (HDH)] [SP:P52985]” SPX0902 902 3563 290 870 1439 4.70E−194 “[LN:KHSE_STRPN] [AC:P72535] [GN:THRB] [OR:Streptococcus pneumoniae] [EC:2.7.1.39] [DE:HOMOSERINE KINASE, (HK)] [SP:P72535]” 124 SPX0903 903 3564 142 426 NO-HIT 6 SPX0904 904 3565 75 225 192 8.30E−23 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX0905 905 3566 86 258 366 6.80E−46 [LN:PMSR_STRPN] [AC:P35593] [GN:MSRA:EXP3] [OR:Streptococcus pneumoniae] [DE:(EXPORTED PROTEIN 3)] [SP:P35593] 110 SPX0906 906 3567 256 768 1236 9.90E−167 [LN:PMSR_STRPN] [AC:P35593] [GN:MSRA:EXP3] [OR:Streptococcus pneumoniae] [DE:(EXPORTED PROTEIN 3)] [SP:P35593] 110 SPX0907 907 3568 103 309 123 6.70E−10 “[LN:E72396] [AC:E72396] [PN:ABC transporter, ATP-binding protein] [GN:TM0287] [CL:unassigned ATP-binding cassette proteins:ATP-binding 180 cassette homology] [OR:Thermotoga maritima]” SPX0908 908 3569 488 1464 472 3.40E−92 “[LN:E72396] [AC:E72396] [PN:ABC transporter, ATP-binding protein] [GN:TM0287] [CL:unassigned ATP-binding cassette proteins:ATP-binding 180 cassette homology] [OR:Thermotoga maritima]” SPX0909 909 3570 62 186 NO-HIT 6 SPX0910 910 3571 584 1752 722 7.90E−145 [LN:Y08A_MYCTU] [AC:Q11047] [GN:MTCY50.10] [OR:Mycobacterium tuberculosis] [DE:HYPOTHETICAL ABC TRANSPORTER ATP-BINDING 148 PROTEIN CY50.10] [SP:Q11047] SPX0911 911 3572 86 258 325 5.10E−41 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX0912 912 3573 129 387 95 8.00E−06 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX0913 913 3574 64 192 NO-HIT 6 SPX0914 914 3575 74 222 NO-HIT 6 SPX0915 915 3576 69 207 NO-HIT 6 SPX0916 916 3577 65 195 NO-HIT 6 SPX0917 917 3578 99 297 NO-HIT 6 SPX0918 918 3579 295 885 447 1.10E−56 [LN:A70039] [AC:A70039] [PN:ABC transporter (ATP-binding protein) homolog yvfR] [GN:yvfR] [CL:unassigned ATP-binding cassette 188 proteins:ATP-binding cassette homology] [OR:Bacillus subtilis] SPX0919 919 3580 246 738 289 1.00E−39 [GI:6759480] [LN:BCE243712] [AC:AJ243712] [PN:YVFS protein] [GN:yvfS] [OR:Bacillus cereus] 90 SPX0920 920 3581 366 1098 1715 5.40E−238 [GI:5830547] [LN:SPAJ6400] [AC:AJ006400] [PN:histidine kinase] [GN:hk11] [OR:Streptococcus pneumoniae] 102 SPX0921 921 3582 200 600 932 2.00E−123 [GI:5830548] [LN:SPAJ6400] [AC:AJ006400] [PN:response regulator] [GN:rr11] [OR:Streptococcus pneumoniae] 104 SPX0922 922 3583 337 1011 1328 1.10E−176 [GI:7328454] [LN:AB028599] [AC:AB028599] [PN:catabolite control protein A] [GN:ccpA] [OR:Streptococcus bovis] [SR:Streptococcus bovis 151 (strain:JB1) DNA] SPX0923 923 3584 131 393 270 4.60E−32 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX0924 924 3585 113 339 89 5.70E−05 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX0925 925 3586 321 963 295 8.70E−56 [LN:G75283] [AC:G75283] [PN:L-asparaginase] [GN:DR2353] [CL:asparaginase] [OR:Deinococcus radiodurans] 102 SPX0926 926 3587 463 1389 213 9.90E−43 [LN:C69862] [AC:C69862] [PN:conserved hypothetical protein ykrA] [GN:ykrA] [CL:Methanobacterium thermoautotrophicum conserved 178 hypothetical protein MTH1071] [OR:Bacillus subtilis] SPX0927 927 3588 151 453 127 6.20E−14 [LN:A69220] [AC:A69220] [PN:conserved hypothetical protein MTH898] [GN:MTH898] [CL:Escherichia coli ybdQ protein] 155 [OR:Methanobacterium thermoautotrophicum] SPX0928 928 3589 97 291 NO-HIT 6 SPX0929 929 3590 239 717 819 4.70E−109 “[LN:YFBQ_HAEIN] [AC:P71348] [GN:HI0286] [OR:Haemophilus influenzae] [EC:2.6.1.-] [DE:PROBABLE AMINOTRANSFERASE HI0286,] 133 [SP:P71348]” SPX0930 930 3591 111 333 NO-HIT 6 SPX0931 931 3592 125 375 385 1.70E−48 “[LN:YFBQ_HAEIN] [AC:P71348] [GN:HI0286] [OR:Haemophilus influenzae] [EC:2.6.1.-] [DE:PROBABLE AMINOTRANSFERASE HI0286,] 133 [SP:P71348]” SPX0932 932 3593 45 135 170 7.60E−20 [LN:RL34_BACST] [AC:P23376] [GN:RPMH] [OR:Bacillus stearothermophilus] [DE:50S RIBOSOMAL PROTEIN L34] [SP:P23376] 113 SPX0933 933 3594 67 201 NO-HIT 6 SPX0934 934 3595 218 654 116 9.60E−07 [GI:546643] [LN:S70345] [AC:S70345] [PN:SpaA] [GN:SpaA] [OR:Streptococcus sobrinus] [SR:Streptococcus sobrinus MUCOB 263] 121 SPX0935 935 3596 75 225 180 6.20E−19 [LN:YABD_BACSU] [AC:P37545] [GN:YABD] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 29.2 KD PROTEIN IN METS-KSGA INTERGENIC 137 REGION] [SP:P37545] SPX0936 936 3597 181 543 469 3.60E−60 [LN:YABD_BACSU] [AC:P37545] [GN:YABD] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 29.2 KD PROTEIN IN METS-KSGA INTERGENIC 137 REGION] [SP:P37545] SPX0937 937 3598 187 561 235 2.70E−52 [LN:YABF_BACSU] [AC:P37547] [GN:YABF] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 20.7 KD PROTEIN IN METS-KSGA INTERGENIC 137 REGION] [SP:P37547] SPX0938 938 3599 304 912 NO-HIT 6 SPX0939 939 3600 99 297 149 3.30E−15 [GI:7576923] [LN:AF242367] [AC:AF242367] [PN:lactococcin 972] [GN:lclA] [OR:Lactococcus lactis subsp. lactis] 109 SPX0940 940 3601 269 807 65 5.50E−08 [GI:3355783] [LN:LLJ002203] [AC:AJ002203] [PN:putative immunity] [GN:orf2] [OR:Lactococcus lactis] 98 SPX0941 941 3602 450 1350 357 1.30E−89 [GI:4009478] [LN:AF068902] [AC:AF068902] [PN:unknown] [OR:Streptococcus pneumoniae] 83 SPX0942 942 3603 214 642 667 2.50E−87 [GI:4009479] [LN:AF068902] [AC:AF068902] [PN:unknown] [OR:Streptococcus pneumoniae] 83 SPX0943 943 3604 103 309 NO-HIT 6 SPX0944 944 3605 169 507 NO-HIT 6 SPX0945 945 3606 291 873 781 3.80E−104 [LN:KSGA_BACSU] [AC:P37468] [GN:KSGA] [OR:Bacillus subtilis] [EC:2.1.1.-] [DE:DIMETHYLTRANSFERASE)] [SP:P37468] 111 SPX0946 946 3607 293 879 394 5.10E−100 [LN:A69879] [AC:A69879] [PN:conserved hypothetical protein yloQ] [GN:yloQ] [CL:conserved hypothetical protein HI1714] [OR:Bacillus subtilis] 140 SPX0947 947 3608 301 903 460 1.20E−69 “[LN:RPE_RHOCA] [AC:P51012] [GN:CBBE] [OR:Rhodobacter capsulatus] [SR:,Rhodopseudomonas capsulata] [EC:5.1.3.1] [DE:EPIMERASE) 154 (PPE) (R5P3E)] [SP:P51012]” SPX0948 948 3609 221 663 143 3.50E−18 [LN:C69879] [AC:C69879] [PN:hypothetical protein yloS] [GN:yloS] [OR:Bacillus subtilis] 87 SPX0949 949 3610 405 1215 91 5.10E−07 [LN:E81528] [AC:E81528] [PN:conserved hypothetical protein CP0874 [imported]] [GN:CP0874] [OR:Chlamydophila pneumoniae:Chlamydia pneumoniae] 140 SPX0950 950 3611 314 942 453 1.00E−88 [LN:G69818] [AC:G69818] [PN:CMP-binding factor homolog yhaM] [GN:yhaM] [OR:Bacillus subtilis] 93 SPX0951 951 3612 276 828 498 2.80E−98 [GI:2706406] [LN:LLAJ642] [AC:AJ222642] [GN:purR] [FN:activator of purine biosynthetic genes] [OR:Lactococcus lactis] 117 SPX0952 952 3613 70 210 83 0.00046 “[LN:TABA_PSESZ] [AC:P31851] [GN:TABA] [OR:Pseudomonas syringae] [SR:,pvtabaci] [DE:TABA PROTEIN] [SP:P31851]” 110 SPX0953 953 3614 128 384 199 3.60E−21 “[LN:TABA_PSESZ] [AC:P31851] [GN:TABA] [OR:Pseudomonas syringae] [SR:,pvtabaci] [DE:TABA PROTEIN] [SP:P31851]” 110 SPX0954 954 3615 100 300 NO-HIT 6 SPX0955 955 3616 335 1005 371 8.10E−63 “[LN:TABA_PSESZ] [AC:P31851] [GN:TABA] [OR:Pseudomonas syringae] [SR:,pvtabaci] [DE:TABA PROTEIN] [SP:P31851]” 110 SPX0956 956 3617 265 795 1121 8.40E−152 [LN:PFLA_STRMU] [AC:O68575] [GN:ACT:PFLC] [OR:Streptococcus mutans] [EC:1.97.1.4] [DE:ENZYME)] [SP:O68575] 106 SPX0957 957 3618 309 927 140 6.90E−32 [GI:6117974] [LN:AF139908] [AC:AF139908] [PN:membrane protein homolog] [OR:Listeria monocytogenes] 98 SPX0958 958 3619 93 279 108 9.80E−09 [LN:T35660] [AC:T35660] [PN:probable acylphosphatase] [GN:SC7A1.20] [OR:Streptomyces coelicolor] 96 SPX0959 959 3620 253 759 217 1.10E−43 [LN:G69984] [AC:G69984] [PN:rRNA methylase homolog ysgA] [GN:ysgA] [CL:conserved hypothetical protein HI0860] [OR:Bacillus subtilis] 132 SPX0960 960 3621 228 684 433 1.10E−57 [GI:3171165] [LN:AF064763] [AC:AF064763] [PN:putative membrane spanning protein] [OR:Lactococcus lactis subsp. cremoris] 120 SPX0961 961 3622 72 216 NO-HIT 6 SPX0962 962 3623 331 993 1387 1.70E−186 “[LN:ASNA_HAEIN] [AC:P44338] [GN:ASNA:HI0564] [OR:Haemophilus influenzae] [EC:6.3.1.1] [DE:ASPARTATE−-AMMONIA LIGASE, 157 (ASPARAGINE SYNTHETASE A)] [SP:P44338]” SPX0963 963 3624 180 540 279 1.30E−33 [LN:E69874] [AC:E69874] [PN:conserved hypothetical protein ylbH] [GN:ylbH] [CL:Escherichia coli hypothetical 21.7K protein (ftsY-nikA intergenic 176 region)] [OR:Bacillus subtilis] SPX0964 964 3625 123 369 184 3.00E−25 [LN:G81347] [AC:G81347] [PN:3-deoxy-D-manno-octulosonic-acid transferase Cj0767c [imported]] [GN:kdtB:Cj0767c] [OR:Campylobacter jejuni] 136 SPX0965 965 3626 239 717 184 7.20E−17 [LN:A69875] [AC:A69875] [PN:hypothetical protein ylbL] [GN:ylbL] [OR:Bacillus subtilis] 87 SPX0966 966 3627 78 234 101 1.90E−16 [LN:A69875] [AC:A69875] [PN:hypothetical protein ylbL] [GN:ylbL] [OR:Bacillus subtilis] 87 SPX0967 967 3628 95 285 NO-HIT 6 SPX0968 968 3629 428 1284 620 3.20E−133 [LN:MURA_ACICA] [AC:P33986] [GN:MURA:MURZ] [OR:Acinetobacter calcoaceticus] [EC:2.5.1.7] [DE:TRANSFERASE) (EPT)] [SP:P33986] 124 SPX0969 969 3630 75 225 320 4.60E−41 [LN:EPUA_STRPN] [AC:Q03159] [GN:EPUA] [OR:Streptococcus pneumoniae] [DE:EPUA PROTEIN] [SP:Q03159] 97 SPX0970 970 3631 275 825 1392 2.50E−182 “[LN:NUCE_STRPN] [AC:Q03158] [GN:ENDA] [OR:Streptococcus pneumoniae] [EC:3.1.30.-] [DE:DNA-ENTRY NUCLEASE (COMPETENCE- 151 SPECIFIC NUCLEASE),] [SP:Q03158]” SPX0971 971 3632 328 984 1168 4.20E−160 [GI:2952527] [LN:AF051356] [AC:AF051356] [PN:putative hemolysin] [GN:hlyX] [OR:Streptococcus mutans] 100 SPX0972 972 3633 95 285 266 6.50E−33 [GI:2952527] [LN:AF051356] [AC:AF051356] [PN:putative hemolysin] [GN:hlyX] [OR:Streptococcus mutans] 100 SPX0973 973 3634 1204 3612 1921 0 [LN:T44375] [AC:T44375] [PN:rpoB protein [imported]] [CL:DNA-directed RNA polymerase beta chain] [OR:Bacillus halodurans] 121 SPX0974 974 3635 116 348 NO-HIT 6 SPX0975 975 3636 57 171 NO-HIT 6 SPX0976 976 3637 1226 3678 4009 0 [LN:RPOC_STRPY] [AC:P95816] [GN:RPOC] [OR:Streptococcus pyogenes] [EC:2.7.7.6] [DE:BETA′ CHAIN) (RNA POLYMERASE BETA′ 150 SUBUNIT) (FRAGMENT)] [SP:P95816] SPX0977 977 3638 131 393 NO-HIT 6 SPX0978 978 3639 138 414 192 4.30E−48 [GI:1655704] [LN:XLNM23] [AC:X97899] [PN:NM23/nucleoside diphosphate kinase] [OR:Xenopus laevis] [SR:African clawed frog] 121 SPX0979 979 3640 93 279 NO-HIT 6 SPX0980 980 3641 211 633 472 1.50E−87 [GI:4009479] [LN:AF068902] [AC:AF068902] [PN:unknown] [OR:Streptococcus pneumoniae] 83 SPX0981 981 3642 672 2016 277 4.50E−70 [GI:4009478] [LN:AF068902] [AC:AF068902] [PN:unknown] [OR:Streptococcus pneumoniae] 83 SPX0982 982 3643 65 195 NO-HIT 6 SPX0983 983 3644 288 864 110 2.30E−09 [LN:JC6007] [AC:JC6007] [PN:transcription activator plcR] [GN:plcR] [CL:Bacillus thuringiensis transcription activator plcR] 152 [OR:Bacillus thuringiensis] SPX0984 984 3645 137 411 NO-HIT 6 SPX0985 985 3646 159 477 166 2.20E−36 [LN:C69786] [AC:C69786] [PN:conserved hypothetical protein ydiB] [GN:ydiB] [CL:hypothetical protein HI0065] [OR:Bacillus subtilis] 130 SPX0986 986 3647 173 519 149 7.60E−28 [LN:D72360] [AC:D72360] [PN:conserved hypothetical protein] [GN:TM0577] [OR:Thermotoga maritima] 96 SPX0987 987 3648 339 1017 182 6.50E−46 [LN:LYTR_BACSU] [AC:Q02115] [GN:LYTR] [OR:Bacillus subtilis] [DE:MEMBRANE−BOUND PROTEIN LYTR] [SP:Q02115] 105 SPX0988 988 3649 419 1257 2015 1.70E−272 [LN:CINA_STRPN] [AC:P54184:Q54853] [GN:CINA:EXP10] [OR:Streptococcus pneumoniae] [DE:PUTATIVE COMPETENCE-DAMAGE 161 PROTEIN (EXPORTED PROTEIN 10)] [SP:P54184:Q54853] SPX0989 989 3650 389 1167 1928 6.10E−256 [LN:RECA_STRPN] [AC:P30758] [GN:RECA] [OR:Streptococcus pneumoniae] [DE:RECA PROTEIN] [SP:P30758] 97 SPX0990 990 3651 457 1371 2252 0 [GI:2398825] [LN:SPCINREC] [AC:Z34303] [PN:DinF protein] [GN:dinF] [OR:Streptococcus pneumoniae] 96 SPX0991 991 3652 319 957 1786 1.50E−240 [LN:ALYS_STRPN] [AC:P06653] [GN:LYTA] [OR:Streptococcus pneumoniae] [EC:3.5.1.28] [DE:HYDROLASE) (MUCOPEPTIDE 160 AMINOHYDROLASE) (CELL WALL HYDROLASE)] [SP:P06653] SPX0992 992 3653 79 237 NO-HIT 6 SPX0993 993 3654 81 243 NO-HIT 6 SPX0994 994 3655 120 360 NO-HIT 6 SPX0995 995 3656 142 426 NO-HIT 6 SPX0996 996 3657 75 225 NO-HIT 6 SPX0997 997 3658 332 996 676 4.50E−129 [GI:2398827] [LN:SPCINREC] [AC:Z34303] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 94 SPX0998 998 3659 82 246 NO-HIT 6 SPX0999 999 3660 90 270 NO-HIT 6 SPX1000 1000 3661 87 261 NO-HIT 6 SPX1001 1001 3662 101 303 296 7.00E−36 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX1002 1002 3663 44 132 108 5.70E−09 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX1003 1003 3664 153 459 NO-HIT 6 SPX1004 1004 3665 203 609 NO-HIT 6 SPX1005 1005 3666 137 411 NO-HIT 6 SPX1006 1006 3667 472 1416 2426 0 [LN:A28568] [AC:A28568:S12829] [PN:pneumolysin] [CL:dipeptide transport protein] [OR:Streptococcus pneumoniae] 110 SPX1007 1007 3668 239 717 915 1.30E−119 [LN:A64963] [AC:A64963] [PN:conserved hypothetical protein b1983] [CL:hypothetical protein MG332] [OR:Escherichia coli] 119 SPX1008 1008 3669 150 450 104 9.20E−07 [LN:C72329] [AC:C72329] [PN:hypothetical protein TM0816] [GN:TM0816] [OR:Thermotoga maritima] 93 SPX1009 1009 3670 291 873 309 1.20E−35 [GI:6759558] [LN:SC7A8] [AC:AL137187] [PN:putative ABC transporter] [GN:SC7A8.02] [OR:Streptomyces coelicolor A3(2)] 116 SPX1010 1010 3671 344 1032 335 7.80E−76 [GI:6759559] [LN:SC7A8] [AC:AL137187] [PN:putative ABC transporter] [GN:SC7A8.03] [OR:Streptomyces coelicolor A3(2)] 116 SPX1011 1011 3672 121 363 NO-HIT 6 SPX1012 1012 3673 168 504 130 2.10E−10 [LN:Y374_METJA] [AC:Q57819] [GN:MJ0374] [OR:Methanococcus jannaschii] [DE:HYPOTHETICAL PROTEIN MJ0374] [SP:Q57819] 114 SPX1013 1013 3674 150 450 NO-HIT 6 SPX1014 1014 3675 225 675 NO-HIT 6 SPX1015 1015 3676 74 222 125 8.00E−13 [GI:1914870] [LN:SPZ82001] [AC:Z82001] [PN:unknown] [OR:Streptococcus pneumoniae] 81 SPX1016 1016 3677 100 300 NO-HIT 6 SPX1017 1017 3678 106 318 276 6.70E−34 [LN:G69998] [AC:G69998] [PN:thioredoxin H1 homolog ytpP] [GN:ytpP] [CL:thioredoxin:thioredoxin homology] [OR:Bacillus subtilis] 127 SPX1018 1018 3679 126 378 NO-HIT 6 SPX1019 1019 3680 209 627 217 5.30E−44 [LN:A69999] [AC:A69999] [PN:phenylalanyl-tRNA synthetase (beta subunit) homolog ytpR] [GN:ytpR] [CL:Mycoplasma genitalium hypothetical 172 protein MG449] [OR:Bacillus subtilis] SPX1020 1020 3681 254 762 354 4.20E−67 [GI:2425123] [LN:AF019986] [AC:AF019986] [PN:PksB] [GN:pksB] [OR:Dictyostelium discoideum] 90 SPX1021 1021 3682 132 396 227 1.20E−34 [GI:6716352] [LN:AF145054] [AC:AF145054:AF001793:AF118440:U89246] [PN:ORF9] [GN:orf9] [OR:Streptococcus thermophilus bacteriophage 7201] 136 SPX1022 1022 3683 95 285 460 1.90E−58 [GI:4566772] [LN:AF117741] [AC:AF117741] [PN:cochaperonin GroES] [GN:groES] [OR:Streptococcus pneumoniae] 105 SPX1023 1023 3684 203 609 344 8.20E−43 [GI:1196510] [LN:MSGTCWPA] [AC:M15467] [PN:unknown protein] [OR:Mycobacterium tuberculosis] [SR:Mycobacterium tuberculosis 143 (strain Erdman) DNA] SPX1024 1024 3685 541 1623 2611 0 [GI:4566773] [LN:AF117741] [AC:AF117741] [PN:chaperonin GroEL] [GN:groEL] [OR:Streptococcus pneumoniae] 103 SPX1025 1025 3686 70 210 70 3.30E−06 [LN:C71647] [AC:C71647] [PN:hypothetical protein RP851] [GN:RP851] [OR:Rickettsia prowazekii] 93 SPX1026 1026 3687 84 252 139 1.80E−13 [LN:F72338] [AC:F72338] [PN:conserved hypothetical protein] [GN:TM0731] [OR:Thermotoga maritima] 96 SPX1027 1027 3688 64 192 NO-HIT 6 SPX1028 1028 3689 258 774 129 6.70E−09 [LN:T33885] [AC:T33885] [PN:hypothetical protein H14E04.1] [GN:H14E04.1] [CL:24-sterol C-methyltransferase:bioC homology] 149 [OR:Caenorhabditis elegans] SPX1029 1029 3690 113 339 133 1.50E−11 [LN:AB025228] [AC:AB025228] [GN:rgg] [OR:Streptococcus oralis] [SR:Streptococcus oralis (strain:ATCC10557) DNA] 111 SPX1030 1030 3691 116 348 90 8.90E−06 [LN:AB025228] [AC:AB025228] [GN:rgg] [OR:Streptococcus oralis] [SR:Streptococcus oralis (strain:ATCC10557) DNA] 111 SPX1031 1031 3692 178 534 294 4.90E−36 [LN:F69815] [AC:F69815] [PN:hypothetical protein ygaC] [GN:ygaC] [CL:Bacillus subtilis hypothetical protein ygaC] [OR:Bacillus subtilis] 136 SPX1032 1032 3693 60 180 NO-HIT 6 SPX1033 1033 3694 287 861 226 3.30E−32 [LN:H69800] [AC:H69800] [PN:hypothetical protein yfhG] [GN:yfhG] [OR:Bacillus subtilis] 87 SPX1034 1034 3695 452 1356 606 1.00E−145 [LN:F69806] [AC:F69806] [PN:RNA methyltransferase homolog yfjO] [GN:yfjO] [CL:hypothetical protein HI0333] [OR:Bacillus subtilis] 129 SPX1035 1035 3696 82 246 NO-HIT 6 SPX1036 1036 3697 50 150 82 7.60E−06 [LN:G71244] [AC:G71244] [PN:hypothetical protein PH0217] [GN:PH0217] [OR:Pyrococcus horikoshii] 95 SPX1037 1037 3698 62 186 NO-HIT 6 SPX1038 1038 3699 87 261 136 3.90E−14 [LN:G81516] [AC:G81516] [PN:hypothetical protein CP0988 [imported]] [GN:CP0988] [OR:Chlamydophila pneumoniae:Chlamydia pneumoniae] 130 SPX1039 1039 3700 76 228 190 1.00E−21 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX1040 1040 3701 79 237 NO-HIT 6 SPX1041 1041 3702 94 282 301 2.00E−35 [LN:DHAS_STRMU] [AC:P10539] [GN:ASD] [OR:Streptococcus mutans] [EC:1.2.1.11] [DE:DEHYDROGENASE)] [SP:P10539] 108 SPX1042 1042 3703 92 276 325 3.80E−40 [LN:DHAS_STRMU] [AC:P10539] [GN:ASD] [OR:Streptococcus mutans] [EC:1.2.1.11] [DE:DEHYDROGENASE)] [SP:P10539] 108 SPX1043 1043 3704 222 666 590 1.20E−108 [LN:DHAS_STRMU] [AC:P10539] [GN:ASD] [OR:Streptococcus mutans] [EC:1.2.1.11] [DE:DEHYDROGENASE)] [SP:P10539] 108 SPX1044 1044 3705 312 936 192 2.60E−55 “[LN:B72246] [AC:B72246] [PN:dihydrodipicolinate synthase, TM1521 [similarity]] [GN:TM1521] [CL:Pseudomonas 5-dehydro-4-deoxyglucarate 187 dehydratase] [OR:Thermotoga maritima] [EC:4.2.1.52]” SPX1045 1045 3706 458 1374 1312 1.10E−249 [GI:6448626] [LN:SAG251564] [AC:AJ251564] [PN:thiophene degradation protein F] [GN:thdF] [FN:putative thiophene and furan oxidation gene] 167 [OR:Streptococcus agalactiae] SPX1046 1046 3707 75 225 127 1.30E−12 “[LN:A43397] [AC:A43397:S35225] [PN:4-oxalocrotonate tautomerase, xylH] [GN:xylH] [CL:4-oxalocrotonate tautomerase] [OR:Pseudomonas putida] 153 [EC:5.3.2.-]” SPX1047 1047 3708 164 492 724 7.00E−97 “[LN:KITH_STRGC] [AC:P47848] [GN:TDK] [OR:Streptococcus gordonii challis] [EC:2.7.1.21] [DE:THYMIDINE KINASE,] [SP:P47848]” 123 SPX1048 1048 3709 281 843 642 2.20E−103 [LN:RF1_BACSU] [AC:P45872] [GN:PRFA] [OR:Bacillus subtilis] [DE:PEPTIDE CHAIN RELEASE FACTOR 1 (RF-1)] [SP:P45872] 114 SPX1049 1049 3710 143 429 350 2.60E−43 [LN:RF1_BACSU] [AC:P45872] [GN:PRFA] [OR:Bacillus subtilis] [DE:PEPTIDE CHAIN RELEASE FACTOR 1 (RF-1)] [SP:P45872] 114 SPX1050 1050 3711 280 840 183 8.00E−41 [LN:HEMK_BACSU] [AC:P45873] [GN:YWKE] [OR:Bacillus subtilis] [DE:HEMK PROTEIN HOMOLOG] [SP:P45873] 98 SPX1051 1051 3712 201 603 244 1.80E−32 [GI:6015811] [LN:SSU18930] [AC:Y18930] [PN:hypothetical protein] [GN:ORF-c09_003] [OR:Sulfolobus solfataricus] 110 SPX1052 1052 3713 144 432 97 1.30E−05 [LN:PHNO_ECOLI] [AC:P16691] [GN:PHNO] [OR:Escherichia coli] [DE:PHNO PROTEIN] [SP:P16691] 89 SPX1053 1053 3714 419 1257 858 7.90E−176 [LN:GLYA_BACSU] [AC:P39148] [GN:GLYA:GLYC:IPC-34D] [OR:Bacillus subtilis] [EC:2.1.2.1] [DE:(SHMT)] [SP:P39148] 110 SPX1054 1054 3715 336 1008 130 3.90E−11 [GI:6899993] [LN:CST130879] [AC:AJ130879] [PN:hypothetical protein] [FN:unknown] [OR:Clostridium sticklandii] 109 SPX1055 1055 3716 205 615 243 1.60E−27 [LN:F69900] [AC:F69900] [PN:transposon-related protein homolog yocA] [GN:yocA] [OR:Bacillus subtilis] 101 SPX1056 1056 3717 325 975 104 7.60E−08 [LN:YPUA_BACSU] [AC:P31847:P37951] [GN:YPUA] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 31.3 KD PROTEIN IN LYSA-PPIB 160 INTERGENIC REGION (ORFX19)] [SP:P31847:P37951] SPX1057 1057 3718 548 1644 767 5.90E−131 [LN:E69793] [AC:E69793] [PN:RNA methyltransferase homolog yefA] [GN:yefA] [CL:hypothetical protein HI0333] [OR:Bacillus subtilis] 129 SPX1058 1058 3719 98 294 NO-HIT 6 SPX1059 1059 3720 83 249 NO-HIT 6 SPX1060 1060 3721 65 195 81 3.20E−08 [LN:C69931] [AC:C69931] [PN:transcription regulator homolog yozG] [GN:yozG] [OR:Bacillus subtilis] 98 SPX1061 1061 3722 80 240 NO-HIT 6 SPX1062 1062 3723 345 1035 276 3.80E−70 [GI:2276374] [LN:CDU02617] [AC:U02617] [PN:DtxR/iron regulated lipoprotein precursor] [GN:irp1] [FN:iron transport] 148 [OR:Corynebacterium diphtheriae] SPX1063 1063 3724 212 636 NO-HIT 6 SPX1064 1064 3725 336 1008 643 1.40E−86 [LN:T44797] [AC:T44797] [PN:iron transport membrane protein irp1B [imported]] [GN:irp1B] [CL:vitamin B12 transport protein btuC] 161 [OR:Corynebacterium diphtheriae] SPX1065 1065 3726 336 1008 484 1.10E−82 [LN:T44798] [AC:T44798] [PN:iron transport membrane protein irp1C [imported]] [GN:irp1C] [CL:vitamin B12 transport protein btuC] 161 [OR:Corynebacterium diphtheriae] SPX1066 1066 3727 74 222 NO-HIT 6 SPX1067 1067 3728 138 414 NO-HIT 6 SPX1068 1068 3729 265 795 694 6.10E−91 [LN:G70022] [AC:G70022] [PN:iron(III) dicitrate transport permease homolog yusV] [GN:yusV] [CL:inner membrane protein malK:ATP-binding 176 cassette homology] [OR:Bacillus subtilis] SPX1069 1069 3730 87 261 151 1.30E−14 [GI:2467226] [LN:LLLPK214] [AC:X92946:Y10522] [PN:transposase] [GN:tnpA] [OR:Lactococcus lactis] 96 SPX1070 1070 3731 152 456 137 1.10E−10 “[LN:T4BB_BACCO] [AC:Q07606] [GN:BCGIB] [OR:Bacillus coagulans] [EC:3.1.21.-] [DE:RESTRICTION ENZYME BGCI BETA SUBUNIT,] 133 [SP:Q07606]” SPX1071 1071 3732 92 276 NO-HIT 6 SPX1072 1072 3733 83 249 NO-HIT 6 SPX1073 1073 3734 70 210 NO-HIT 6 SPX1074 1074 3735 560 1680 138 3.40E−35 [GI:6681569] [LN:AB014436] [AC:AB014436] [PN:cassette chromosome recombinase B] [GN:ccrB] [OR:Staphylococcus aureus] [SR:Staphylococcus 164 aureus (strain:85/2082) DNA] SPX1075 1075 3736 204 612 NO-HIT 6 SPX1076 1076 3737 63 189 NO-HIT 6 SPX1077 1077 3738 253 759 NO-HIT 6 SPX1078 1078 3739 285 855 70 4.40E−09 [GI:7020551] [LN:AK000453] [AC:AK000453] [OR:Homo sapiens] [SR:Homo sapiens signet-ring cell carcinoma cell_line:KATO III cDNA t] 129 SPX1079 1079 3740 295 885 192 4.90E−36 [LN:F69795] [AC:F69795] [PN:conserved hypothetical protein yerQ] [GN:yerQ] [OR:Bacillus subtilis] 97 SPX1080 1080 3741 93 279 124 1.30E−19 “[LN:JS0673] [AC:JS0673] [PN:neopullulanase,] [CL:neopullulanase:alpha-amylase core homology] [OR:Bacillus sp.] [EC:3.2.1.135]” 127 SPX1081 1081 3742 485 1455 683 3.10E−176 “[LN:F70033] [AC:F70033] [PN:glucan 1,4-alpha-maltohydrolase homolog yvdF] [GN:yvdF] [CL:neopullulanase:alpha-amylase core homology] 156 [OR:Bacillus subtilis]” SPX1082 1082 3743 101 303 NO-HIT 6 SPX1083 1083 3744 143 429 249 9.00E−30 [GI:6102604] [LN:AF144880] [AC:AF144880] [PN:aminoglycoside 6′-N-acetyltransferase] [GN:aac(6′)-Iy] [OR:Salmonella enteritidis] 127 SPX1084 1084 3745 190 570 NO-HIT 6 SPX1085 1085 3746 71 213 NO-HIT 6 SPX1086 1086 3747 94 282 NO-HIT 6 SPX1087 1087 3748 65 195 184 8.80E−20 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX1088 1088 3749 410 1230 419 1.50E−74 [LN:FTSW_ENTHR] [AC:Q47866] [GN:FTSW] [OR:Enterococcus hirae] [DE:PROBABLE CELL DIVISION PROTEIN FTSW] [SP:Q47866] 114 SPX1089 1089 3750 899 2697 418 1.60E−169 [GI:144985] [LN:CORPEPC] [AC:M25819] [PN:phosphoenolpyruvate carboxylase] [OR:Corynebacterium glutamicum] [SR:Corynebacterium 176 glutamicum (clone: pTG1200.) (tissue library: ATC] SPX1090 1090 3751 102 306 NO-HIT 6 SPX1091 1091 3752 210 630 105 2.60E−05 [LN:H71693] [AC:H71693] [PN:hypothetical protein RP367] [GN:RP367] [OR:Rickettsia prowazekii] 93 SPX1092 1092 3753 223 669 163 6.00E−23 [LN:A71694] [AC:A71694] [PN:hypothetical protein RP368] [GN:RP368] [OR:Rickettsia prowazekii] 93 SPX1093 1093 3754 253 759 365 1.80E−45 [GI:1661179] [LN:SMU75471] [AC:U75471] [PN:high affinity branched chain amino acid] [GN:livG] [OR:Streptococcus mutans] 119 SPX1094 1094 3755 64 192 82 2.10E−05 [LN:A71007] [AC:A71007] [PN:hypothetical protein PH1351] [GN:PH1351] [OR:Pyrococcus horikoshii] 95 SPX1095 1095 3756 592 1776 694 1.40E−161 “[LN:PRIM_LACLA] [AC:Q04505] [GN:DNAG:DNAE] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:2.7.7.-] [DE:DNA 150 PRIMASE,] [SP:Q04505]” SPX1096 1096 3757 305 915 1452 2.30E−194 [LN:RPOD_STRPN] [AC:O08388] [GN:RPOD] [OR:Streptococcus pneumoniae] [DE:RNA POLYMERASE SIGMA FACTOR RPOD] [SP:O08388] 117 SPX1097 1097 3758 66 198 290 2.40E−35 [LN:RPOD_STRPN] [AC:O08388] [GN:RPOD] [OR:Streptococcus pneumoniae] [DE:RNA POLYMERASE SIGMA FACTOR RPOD] [SP:O08388] 117 SPX1098 1098 3759 110 330 556 5.10E−73 [GI:2108332] [LN:SPDNAGCPO] [AC:Y11463] [OR:Streptococcus pneumoniae] 69 SPX1099 1099 3760 69 207 NO-HIT 6 SPX1100 1100 3761 267 801 1357 1.40E−186 [GI:2108333] [LN:SPDNAGCPO] [AC:Y11463] [GN:cpoA] [OR:Streptococcus pneumoniae] 79 SPX1101 1101 3762 66 198 318 4.00E−38 [GI:2108333] [LN:SPDNAGCPO] [AC:Y11463] [GN:cpoA] [OR:Streptococcus pneumoniae] 79 SPX1102 1102 3763 442 1326 1475 1.70E−200 [GI:2108334] [LN:SPDNAGCPO] [AC:Y11463] [OR:Streptococcus pneumoniae] 69 SPX1103 1103 3764 59 177 151 3.70E−16 [LN:B72287] [AC:B72287] [PN:conserved hypothetical protein] [GN:TM1156] [OR:Thermotoga maritima] 96 SPX1104 1104 3765 392 1176 1021 5.10E−184 [LN:OBG_BACSU] [AC:P20964] [GN:OBG] [OR:Bacillus subtilis] [DE:SPO0B-ASSOCIATED GTP-BINDING PROTEIN] [SP:P20964] 112 SPX1105 1105 3766 420 1260 424 9.00E−142 [LN:MURA_BACSU] [AC:P19670:Q03225] [GN:MURA:MURZ] [OR:Bacillus subtilis] [EC:2.5.1.7] [DE:ENOLPYRUVYL TRANSFERASE) (EPT)] 140 [SP:P19670:Q03225] SPX1106 1106 3767 176 528 156 1.00E−17 [LN:C69895] [AC:C69895] [PN:conserved hypothetical protein yoaA] [GN:yoaA] [CL:Escherichia coli ribosomal-protein-alanine N-acetyltransferase 170 rimJ] [OR:Bacillus subtilis] SPX1107 1107 3768 426 1278 425 4.20E−85 [LN:A69998] [AC:A69998] [PN:hypothetical protein ytoI] [GN:ytoI] [OR:Bacillus subtilis] 87 SPX1108 1108 3769 287 861 345 3.30E−65 “[LN:T44405] [AC:T44405] [PN:methionyl aminopeptidase, map [imported]] [CL:Escherichia coli methionyl aminopeptidase] 158 [OR:Bacillus halodurans] [EC:3.4.11.18]” SPX1109 1109 3770 181 543 307 2.50E−38 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX1110 1110 3771 75 225 104 5.80E−08 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX1111 1111 3772 130 390 384 4.80E−49 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX1112 1112 3773 764 2292 1351 7.70E−282 [LN:E69794] [AC:E69794] [PN:ATP-dependent DNA helicase homolog yerF] [GN:yerF] [CL:helicase II] [OR:Bacillus subtilis] 118 SPX1113 1113 3774 240 720 488 2.80E−62 [LN:RADC_BACSU] [AC:Q02170] [GN:YSXA] [OR:Bacillus subtilis] [DE:DNA REPAIR PROTEIN RADC HOMOLOG (ORFB)] [SP:Q02170] 116 SPX1114 1114 3775 230 690 237 6.50E−27 “[LN:YDP3_LACLA] [AC:P22347] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [DE:HYPOTHETICAL 18.7 KD PROTEIN 162 IN PEPX 3′REGION (ORF3)] [SP:P22347]” SPX1115 1115 3776 214 642 339 2.60E−68 [LN:A69787] [AC:A69787] [PN:hypothetical protein ydiH] [GN:ydiH] [OR:Bacillus subtilis] 87 SPX1116 1116 3777 84 252 NO-HIT 6 SPX1117 1117 3778 116 348 NO-HIT 6 SPX1118 1118 3779 265 795 288 2.40E−63 [LN:E69981] [AC:E69981] [PN:iron-sulfur cofactor synthesis protein yrvO] [GN:yrvO] [CL:nitrogen fixation protein nifS] [OR:Bacillus subtilis] 141 SPX1119 1119 3780 145 435 149 4.90E−18 [GI:2289093] [LN:CAU76387] [AC:U76387] [PN:PRPP synthetase] [GN:prs] [OR:Corynebacterium ammoniagenes] 102 SPX1120 1120 3781 183 549 547 6.60E−75 [GI:2289093] [LN:CAU76387] [AC:U76387] [PN:PRPP synthetase] [GN:prs] [OR:Corynebacterium ammoniagenes] 102 SPX1121 1121 3782 190 570 164 1.20E−26 [LN:C69844] [AC:C69844] [PN:hypothetical protein yjbK] [GN:yjbK] [CL:Bacillus subtilis hypothetical protein yjbK] [OR:Bacillus subtilis] 136 SPX1122 1122 3783 168 504 338 6.80E−68 [LN:E69844] [AC:E69844] [PN:GTP pyrophosphokinase homolog yjbM] [GN:yjbM] [CL:GTP pyrophosphokinase related protein] [OR:Bacillus subtilis] 139 SPX1123 1123 3784 71 213 90 6.20E−06 [LN:E69844] [AC:E69844] [PN:GTP pyrophosphokinase homolog yjbM] [GN:yjbM] [CL:GTP pyrophosphokinase related protein] [OR:Bacillus subtilis] 139 SPX1124 1124 3785 263 789 309 4.70E−67 [LN:F69844] [AC:F69844] [PN:conserved hypothetical protein yjbN] [GN:yjbN] [CL:conserved hypothetical protein HI0072] [OR:Bacillus subtilis] 140 SPX1125 1125 3786 299 897 286 3.40E−66 [LN:YJBO_BACSU] [AC:O31613] [GN:YJBO] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 31.5 KD PROTEIN IN MECA-TENA INTERGENIC 137 REGION] [SP:O31613] SPX1126 1126 3787 325 975 867 5.10E−115 [LN:PTA_BACSU] [AC:P39646] [GN:PTA:IPA-88D] [OR:Bacillus subtilis] [EC:2.3.1.8] [DE:(PHOSPHOTRANSACETYLASE) (VEGETATIVE 152 PROTEIN 43) (VEG43)] [SP:P39646] SPX1127 1127 3788 79 237 NO-HIT 6 SPX1128 1128 3789 199 597 472 3.10E−122 [GI:663279] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae (strain RX1) DNA] 138 SPX1129 1129 3790 109 327 280 2.00E−34 [GI:2804700] [LN:AF030361] [AC:AF030361] [PN:transposase] [OR:Streptococcus pneumoniae] 87 SPX1130 1130 3791 173 519 875 3.10E−119 [GI:663278] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae (strain RX1) DNA] 138 SPX1131 1131 3792 108 324 190 3.90E−21 [LN:YAAK_BACSU] [AC:P24281] [GN:YAAK] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 11.8 KD PROTEIN IN DNAZ-RECR INTERGENIC 137 REGION] [SP:P24281] SPX1132 1132 3793 231 693 89 1.90E−05 [LN:E69896] [AC:E69896] [PN:hypothetical protein yoaK] [GN:yoaK] [OR:Bacillus subtilis] 87 SPX1133 1133 3794 105 315 360 3.20E−44 [LN:RL21_BACSU] [AC:P26908] [GN:RPLU] [OR:Bacillus subtilis] [DE:50S RIBOSOMAL PROTEIN L21 (BL20)] [SP:P26908] 110 SPX1134 1134 3795 147 441 NO-HIT 6 SPX1135 1135 3796 115 345 152 1.30E−22 [LN:YSXB_BACSU] [AC:P26942:Q45629] [GN:YSXB] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 12.3 KD PROTEIN IN RPLU-RPMA 159 INTERGENIC REGION (ORF X)] [SP:P26942:Q45629] SPX1136 1136 3797 98 294 372 1.10E−46 [LN:RL27_BACSU] [AC:P05657] [GN:RPMA] [OR:Bacillus subtilis] [DE:50S RIBOSOMAL PROTEIN L27 (BL30) (BL24)] [SP:P05657] 117 SPX1137 1137 3798 55 165 77 4.70E−09 [GI:1914870] [LN:SPZ82001] [AC:Z82001] [PN:unknown] [OR:Streptococcus pneumoniae] 81 SPX1138 1138 3799 306 918 808 1.30E−107 [GI:2289231] [LN:SAU92073] [AC:U92073] [PN:macrolide-efflux protein] [GN:mreA] [FN:resistance to 14- and 15-membered macrolides] 158 [OR:Streptococcus agalactiae] SPX1139 1139 3800 283 849 531 2.80E−71 [LN:YPJC_BACSU] [AC:P42978] [GN:YPJC:JOJC] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 23.6 KD PROTEIN IN QCRC-DAPB 142 INTERGENIC REGION] [SP:P42978] SPX1140 1140 3801 280 840 252 9.50E−36 [GI:671632] [LN:SADIRED] [AC:Z16422] [PN:unknown] [GN:ORF2] [OR:Staphylococcus aureus] 86 SPX1141 1141 3802 92 276 397 9.60E−50 [GI:5209334] [LN:L40356] [AC:L40356] [PN:histone-like DNA-binding protein] [GN:hlpA] [OR:Streptococcus gordonii] 112 SPX1142 1142 3803 634 1902 905 2.00E−202 [LN:YDIF_BACSU] [AC:O05519] [GN:YDIF] [OR:Bacillus subtilis] [DE:HYPOTHETICAL ABC TRANSPORTER ATP-BINDING PROTEIN 131 YDIF] [SP:O05519] SPX1143 1143 3804 298 894 204 8.40E−33 [GI:4102023] [LN:AF007761] [AC:AF007761] [PN:MutR] [GN:mutR] [FN:positive transcriptional regulator of mutA] [OR:Streptococcus mutans] 134 SPX1144 1144 3805 393 1179 113 5.30E−22 [LN:H72265] [AC:H72265] [PN:hypothetical protein TM1336] [GN:TM1336] [OR:Thermotoga maritima] 93 SPX1145 1145 3806 656 1968 521 1.40E−217 “[LN:F69794] [AC:F69794] [PN:DNA ligase (NAD+),] [GN:yerG] [CL:polydeoxyribonucleotide synthase (NAD+)] [OR:Bacillus subtilis] [EC:6.5.1.2]” 140 SPX1146 1146 3807 760 2280 620 2.20E−109 [GI:3089609] [LN:AF060205] [AC:AF060205] [PN:pullulanase] [GN:pul] [OR:Thermus sp. IM6501] 90 SPX1147 1147 3808 475 1425 1818 2.70E−245 [LN:GAPN_STRMU] [AC:Q59931] [GN:GAPN] [OR:Streptococcus mutans] [EC:1.2.1.9] [DE:DEHYDROGENASE)] [SP:Q59931] 108 SPX1148 1148 3809 643 1929 658 6.60E−176 “[LN:S18599] [AC:S18599] [PN:1,4-alpha-glucan branching enzyme,:glycogen branching enzyme] [CL:1,4-alpha-glucan branching enzyme] 177 [OR:Bacillus stearothermophilus] [EC:2.4.1.18]” SPX1149 1149 3810 381 1143 187 6.00E−19 [LN:CCE277601] [AC:AJ277601] [PN:ADP-glucose pyrophosphorylase] [GN:glgD] [OR:Clostridium cellulolyticum] 105 SPX1150 1150 3811 380 1140 324 4.80E−53 [LN:GLGD_BACST] [AC:O08327] [GN:GLGD] [OR:Bacillus stearothermophilus] [DE:GLYCOGEN BIOSYNTHESIS PROTEIN GLGD] [SP:O08327] 122 SPX1151 1151 3812 478 1434 813 6.80E−159 [LN:GLGA_BACSU] [AC:P39125] [GN:GLGA] [OR:Bacillus subtilis] [EC:2.4.1.21] [DE:SYNTHASE)] [SP:P39125] 101 SPX1152 1152 3813 124 372 214 7.80E−24 [LN:B69517] [AC:B69517] [PN:phosphoserine phosphatase (serB) homolog] [OR:Archaeoglobus fulgidus] 97 SPX1153 1153 3814 110 330 213 6.30E−24 “[LN:A64499] [AC:A64499] [PN:phosphoserine phosphatase,] [CL:phosphoserine phosphatase] [OR:Methanococcus jannaschii] [EC:3.1.3.3]” 131 SPX1154 1154 3815 372 1116 1670 1.30E−226 [GI:7380122] [LN:NMA5Z2491] [AC:AL162756:AL157959] [PN:hypothetical protein NMA1473] [GN:NMA1473] [OR:Neisseria meningitidis] 125 SPX1155 1155 3816 149 447 NO-HIT 6 SPX1156 1156 3817 435 1305 2119 6.30E−286 [GI:5263171] [LN:AB029313] [AC:AB029313] [PN:enolase] [GN:eno] [OR:Streptococcus intermedius] [SR:Streptococcus intermedius 148 (strain:ATCC 27335) DNA] SPX1157 1157 3818 156 468 74 6.80E−09 “[LN:T45116] [AC:T45116] [PN:phosphopyruvate hydratase, [imported]] [OR:Schizosaccharomyces pombe] [EC:4.2.1.11]” 113 SPX1158 1158 3819 44 132 75 2.00E−06 [LN:B72477] [AC:B72477] [PN:hypothetical protein APE2459] [GN:APE2459] [OR:Aeropyrum pernix] 92 SPX1159 1159 3820 169 507 174 3.60E−16 [GI:6782411] [LN:STH243106] [AC:AJ243106] [PN:integrase] [GN:int] [OR:Streptococcus thermophilus] 97 SPX1160 1160 3821 113 339 556 6.20E−74 [GI:5019553] [LN:SPN239004] [AC:AJ239004] [PN:putative transposase] [OR:Streptococcus pneumoniae] 97 SPX1161 1161 3822 116 348 573 1.80E−75 [GI:4200438] [LN:AF026471] [AC:AF026471] [PN:putative transposase] [OR:Streptococcus pneumoniae] 96 SPX1162 1162 3823 1092 3276 315 2.90E−101 [LN:T30307] [AC:T30307] [PN:rexB protein] [GN:rexB] [OR:Lactococcus lactis] 75 SPX1163 1163 3824 1217 3651 517 1.80E−246 [LN:T30308] [AC:T30308] [PN:rexA protein] [OR:Lactococcus lactis] 65 SPX1164 1164 3825 79 237 NO-HIT 6 SPX1165 1165 3826 64 192 205 2.00E−24 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX1166 1166 3827 393 1179 NO-HIT 6 SPX1167 1167 3828 111 333 NO-HIT 6 SPX1168 1168 3829 1966 5898 7485 0 [GI:1213494] [LN:SPU47687] [AC:U47687] [PN:immunoglobulin A1 protease] [GN:iga] [OR:Streptococcus pneumoniae] [SR:Streptococcus 149 pneumoniae strain=R6] SPX1169 1169 3830 76 228 138 8.00E−12 [GI:6911257] [LN:AF221126] [AC:AF221126] [PN:putative zinc metalloprotease] [GN:zmpB] [OR:Streptococcus pneumoniae] 115 SPX1170 1170 3831 284 852 707 2.50E−96 [LN:F69880] [AC:F69880] [PN:conserved hypothetical protein ylqF] [GN:ylqF] [CL:conserved hypothetical protein MG442] [OR:Bacillus subtilis] 139 SPX1171 1171 3832 260 780 615 3.40E−79 [LN:C69693] [AC:C69693] [PN:ribonuclease H rnh] [GN:rnh] [CL:ribonuclease HII] [OR:Bacillus subtilis] 101 SPX1172 1172 3833 517 1551 261 1.40E−51 [LN:YADQ_ECOLI] [AC:P37019:P77394] [GN:YADQ] [OR:Escherichia coli] [DE:HYPOTHETICAL 46.0 KD PROTEIN IN HEML-PFS INTERGENIC 149 REGION] [SP:P37019:P77394] SPX1173 1173 3834 357 1071 1529 9.60E−206 [GI:3152920] [LN:AF065141] [AC:AF065141] [PN:unknown] [OR:Streptococcus mutans] 79 SPX1174 1174 3835 330 990 577 6.60E−108 [LN:G69830] [AC:G69830] [PN:lipoate-protein ligase homolog yhfJ] [GN:yhfJ] [CL:lipoate-protein ligase] [OR:Bacillus subtilis] 125 SPX1175 1175 3836 568 1704 334 6.80E−104 [LN:I40794] [AC:I40794] [PN:dihydrolipoamide dehydrogenase] [OR:Clostridium magnum] [EC:1.8.1.4] 96 SPX1176 1176 3837 376 1128 366 8.20E−70 “[LN:I40793] [AC:I40793] [PN:dihydrolipoamide S-acetyltransferase,] [CL:dihydrolipoamide acetyltransferase: 177 lipoyl/biotin-binding homology] [OR:Clostridium magnum] [EC:2.3.1.12]” SPX1177 1177 3838 331 993 550 5.00E−108 “[LN:I40791] [AC:I40791] [PN:acetoin dehydrogenase (TPP-dependent), beta chain] [CL:pyruvate dehydrogenase (lipoamide) beta chain] 168 [OR:Clostridium magnum] [EC:1.-.-.-]” SPX1178 1178 3839 146 438 NO-HIT 6 SPX1179 1179 3840 104 312 136 6.90E−13 [LN:G72548] [AC:G72548] [PN:hypothetical protein APE1675] [GN:APE1675] [OR:Aeropyrum pernix] 92 SPX1180 1180 3841 323 969 554 6.20E−107 “[LN:I40790] [AC:I40790] [PN:acetoin dehydrogenase (TPP-dependent), alpha chain] [CL:pyruvate dehydrogenase (lipoamide) alpha chain:thiamin 216 pyrophosphate-binding domain homology] [OR:Clostridium magnum] [EC:1.-.-.-]” SPX1181 1181 3842 454 1362 482 2.40E−117 [LN:F69906] [AC:F69906] [PN:conserved hypothetical protein yojI] [GN:yojI] [CL:conserved hypothetical protein HI1612] [OR:Bacillus subtilis] 140 SPX1182 1182 3843 87 261 NO-HIT 6 SPX1183 1183 3844 423 1269 351 1.70E−86 “[LN:PYRC_LACLE] [AC:P48795] [GN:PYRC] [OR:Lactobacillus leichmannii] [EC:3.5.2.3] [DE:DIHYDROOROTASE, (DHOASE)] [SP:P48795]” 125 SPX1184 1184 3845 155 465 845 7.70E−113 “[LN:MUTX_STRPN] [AC:P41354] [GN:MUTX] [OR:Streptococcus pneumoniae] [EC:3.6.1.-] [DE:(8-OXO-DGTPASE), (DGTP 144 PYROPHOSPHOHYDROLASE)] [SP:P41354]” SPX1185 1185 3846 222 666 1123 8.50E−151 “[LN:UNG_STRPN] [AC:P23379] [GN:UNG] [OR:Streptococcus pneumoniae] [EC:3.2.2.-] [DE:URACIL-DNA GLYCOSYLASE, (UDG)] 127 [SP:P23379]” SPX1186 1186 3847 201 603 NO-HIT 6 SPX1187 1187 3848 238 714 260 5.40E−57 [LN:E69814] [AC:E69814] [PN:conserved hypothetical protein yfnB] [GN:yfnB] [CL:Alcaligenes eutrophus phosphoglycolate phosphatase] 153 [OR:Bacillus subtilis] SPX1188 1188 3849 76 228 66 1.60E−05 [LN:H75623] [AC:H75623] [PN:conserved hypothetical protein] [GN:DRB0052] [OR:Deinococcus radiodurans] 101 SPX1189 1189 3850 852 2556 412 3.10E−104 [LN:T46758] [AC:T46758] [PN:hypothetical protein [imported]] [OR:Streptococcus agalactiae] 90 SPX1190 1190 3851 830 2490 397 3.60E−100 [LN:T46758] [AC:T46758] [PN:hypothetical protein [imported]] [OR:Streptococcus agalactiae] 90 SPX1191 1191 3852 411 1233 1763 4.80E−237 [GI:4958916] [LN:AB027569] [AC:AB027569] [PN:phosphoenolpyruvate-protein phosphotransferase] [GN:ptsI] [OR:Streptococcus bovis] 169 [SR:Streptococcus bovis (strain:JB1) DNA] SPX1192 1192 3853 46 138 144 1.50E−15 [LN:YKXH_BACSU] [AC:P08876] [GN:YKXH] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 7.4 KD PROTEIN IN PTSX OPERON (PROTEIN K)] 132 [SP:P08876] SPX1193 1193 3854 88 264 402 2.30E−50 [LN:PTHP_STRMU] [AC:P45596] [GN:PTSH] [OR:Streptococcus mutans] [DE:PHOSPHOCARRIER PROTEIN HPR (HISTIDINE-CONTAINING 138 PROTEIN)] [SP:P45596] SPX1194 1194 3855 73 219 233 1.50E−27 “[LN:NRDH_LACLC] [AC:Q48708] [GN:NRDH] [OR:Lactococcus lactis] [SR:,subspcremoris:Streptococcus cremoris] [DE:GLUTAREDOXIN-LIKE 154 PROTEIN NRDH] [SP:Q48708]” SPX1195 1195 3856 720 2160 1042 2.20E−255 [GI:3077613] [LN:CANRDFGEN] [AC:Y09572] [PN:ribonucleotide reductase subunit R1E] [GN:nrdE] [OR:Corynebacterium ammoniagenes] 125 SPX1196 1196 3857 63 189 NO-HIT 6 SPX1197 1197 3858 321 963 818 2.90E−116 [GI:3068719] [LN:AF050168] [AC:AF050168] [PN:ribonucleoside diphosphate reductase small] [GN:nrdF] [OR:Corynebacterium ammoniagenes] 132 SPX1198 1198 3859 254 762 371 2.50E−80 “[LN:LACR_LACLA] [AC:P18816] [GN:LACR] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [DE:LACTOSE 163 PHOSPHOTRANSFERASE SYSTEM REPRESSOR] [SP:P18816]” SPX1199 1199 3860 84 252 NO-HIT 6 SPX1200 1200 3861 472 1416 2452 0 “[LN:LACG_LACLA] [AC:P11546] [GN:LACG] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:3.2.1.85] 180 [DE:GALACTOHYDROLASE) (PGALASE) (P-BETA-GAL) (PBG)] [SP:P11546]” SPX1201 1201 3862 565 1695 1628 4.50E−299 “[LN:PTLB_LACLA] [AC:P23531] [GN:LACE] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:2.7.1.69] [DE:(EC 2.7.1.69) 157 (EII-LAC)] [SP:P23531]” SPX1202 1202 3863 106 318 454 2.90E−58 “[LN:PTLA_LACLA] [AC:P23532] [GN:LACF] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:2.7.1.69] [DE:(EC 2.7.1.69) 158 (EIII-LAC)] [SP:P23532]” SPX1203 1203 3864 279 837 487 1.40E−75 [LN:LACT_LACCA] [AC:P24401] [GN:LACT] [OR:Lactobacillus casei] [DE:TRANSCRIPTION ANTITERMINATOR LACT] [SP:P24401] 113 SPX1204 1204 3865 270 810 1232 1.10E−164 “[LN:LACD_LACLA] [AC:P26593] [GN:LACD] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:4.1.2.40] [DE:ALDOLASE) 182 (D-TAGATOSE-1,6-BISPHOSPHATE ALDOLASE)] [SP:P26593]” SPX1205 1205 3866 273 819 810 9.10E−118 “[LN:LACC_LACLA] [AC:P23391] [GN:LACC] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:2.7.1.144] [DE:TAGATOSE- 185 6-PHOSPHATE KINASE, (PHOSPHOTAGATOKINASE)] [SP:P23391]” SPX1206 1206 3867 163 489 NO-HIT 6 SPX1207 1207 3868 172 516 810 5.00E−108 “[LN:LACB_LACLA] [AC:P23495] [GN:LACB] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:5.3.1.26] [DE:GALACTOSE- 179 6-PHOSPHATE ISOMERASE LACB SUBUNIT,] [SP:P23495]” SPX1208 1208 3869 142 426 612 2.90E−80 “[LN:LACA_LACLA] [AC:P23494] [GN:LACA] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:5.3.1.26] 179 [DE:GALACTOSE−6-PHOSPHATE ISOMERASE LACA SUBUNIT,] [SP:P23494]” SPX1209 1209 3870 97 291 57 0.00024 [GI:712785] [LN:S74218] [AC:S74218] [GN:E9] [OR:reindeer papillomavirus] 72 SPX1210 1210 3871 159 477 507 1.70E−65 “[LN:LAXP_LACLA] [AC:P23496] [GN:LACX] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [DE:LACX PROTEIN, PLASMID] 141 [SP:P23496]””” SPX1211 1211 3872 207 621 374 1.20E−65 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX1212 1212 3873 107 321 193 4.90E−21 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX1213 1213 3874 101 303 NO-HIT 6 SPX1214 1214 3875 148 444 88 1.30E−10 “[GI:4512375] [LN:AB011837] [AC:AB011837] [PN:phosphotransferase system (PTS)] [GN:fruA] [OR:Bacillus halodurans] [SR:Bacillus halodurans 181 (strain:C-125) DNA, clone_lib:lambda no.9]” SPX1215 1215 3876 431 1293 2159 2.90E−302 [GI:2804700] [LN:AF030361] [AC:AF030361] [PN:transposase] [OR:Streptococcus pneumoniae] 87 SPX1216 1216 3877 63 189 120 2.10E−12 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX1217 1217 3878 417 1251 1395 2.00E−200 “[LN:THD1_LACLA] [AC:Q02145] [GN:ILVA] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:4.2.1.16] [DE:DEAMINASE)] 144 [SP:Q02145]” SPX1218 1218 3879 119 357 NO-HIT 6 SPX1219 1219 3880 78 234 NO-HIT 6 SPX1220 1220 3881 89 267 NO-HIT 6 SPX1221 1221 3882 341 1023 1329 9.50E−179 “[LN:ILVC_LACLA] [AC:Q02138] [GN:ILVC] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:1.1.1.86] 199 [DE:ISOMEROREDUCTASE) (ALPHA-KETO-BETA-HYDROXYLACIL REDUCTOISOMERASE)] [SP:Q02138]” SPX1222 1222 3883 167 501 477 4.10E−62 “[LN:ILVN_LACLA] [AC:Q02140] [GN:ILVN] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:4.1.3.18] [DE:(ACETOHYDROXY- 182 ACID SYNTHASE SMALL SUBUNIT) (ALS)] [SP:Q02140]” SPX1223 1223 3884 567 1701 1207 2.30E−266 “““[LN:ILVB_LACLA] [AC:Q02137] [GN:ILVB] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:4.1.3.18] [DE:(ACETOHYDROXY- 182 ACID SYNTHASE LARGE SUBUNIT) (ALS)] [SP:Q02137]” SPX1224 1224 3885 679 2037 565 7.80E−167 [LN:E69879] [AC:E69879] [PN:conserved hypothetical protein yloV] [GN:yloV] [CL:Mycoplasma genitalium hypothetical protein MG369] 151 [OR:Bacillus subtilis] SPX1225 1225 3886 63 189 222 4.40E−26 [LN:RL28_BACSU] [AC:P37807] [GN:RPMB] [OR:Bacillus subtilis] [DE:50S RIBOSOMAL PROTEIN L28] [SP:P37807] 103 SPX1226 1226 3887 82 246 123 5.10E−19 [GI:6760462] [LN:AF224467] [AC:AF224467] [PN:putative glycosyl transferase] [OR:Haemophilus ducreyi] 100 SPX1227 1227 3888 66 198 157 8.80E−16 [GI:6760462] [LN:AF224467] [AC:AF224467] [PN:putative glycosyl transferase] [OR:Haemophilus ducreyi] 100 SPX1228 1228 3889 515 1545 771 2.70E−216 [GI:3256222] [LN:SAY14370] [AC:Y14370] [PN:peptide chain release factor 3] [GN:RF3] [OR:Staphylococcus aureus] 110 SPX1229 1229 3890 101 303 190 4.90E−21 [LN:A69795] [AC:A69795] [PN:conserved hypothetical protein yerL] [GN:yerL] [CL:probable glu-tRNA amidotransferase C chain] [OR:Bacillus subtilis] 145 SPX1230 1230 3891 489 1467 1333 1.60E−186 [LN:B69795] [AC:B69795] [PN:amidase homolog yerM] [GN:yerM] [CL:indoleacetamide hydrolase] [OR:Bacillus subtilis] 113 SPX1231 1231 3892 213 639 414 4.30E−94 [LN:T44293] [AC:T44293] [PN:hypothetical protein yerN [imported]] [CL:PET112 protein] [OR:Bacillus halodurans] 110 SPX1232 1232 3893 269 807 744 4.60E−97 [LN:C69795] [AC:C69795] [PN:pet112-like protein homolog yerN] [GN:yerN] [CL:PET112 protein] [OR:Bacillus subtilis] 114 SPX1233 1233 3894 348 1044 719 1.70E−145 “[LN:H69789] [AC:H69789] [PN:L-iditol 2-dehydrogenase, homolog ydjL:sorbitol dehydrogenase homolog] [GN:ydjL] [CL:alcohol dehydrogenase:long- 216 chain alcohol dehydrogenase homology] [OR:Bacillus subtilis] [EC:1.1.1.14]” SPX1234 1234 3895 67 201 138 4.80E−14 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX1235 1235 3896 187 561 430 7.10E−54 [LN:EFP_BACSU] [AC:P49778] [GN:EFP] [OR:Bacillus subtilis] [DE:ELONGATION FACTOR P (EF-P)] [SP:P49778] 102 SPX1236 1236 3897 130 390 139 8.30E−19 [LN:YQHY_BACSU] [AC:P54519] [GN:YQHY] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 14.7 KD PROTEIN IN ACCC-FOLD INTERGENIC 137 REGION] [SP:P54519] SPX1237 1237 3898 141 423 105 1.00E−12 [GI:6580774] [LN:AF088897] [AC:AF088897:AF034613:AF086792:U63733] [PN:N-utilization substance protein B] [GN:nusB] [OR:Zymomonas mobilis] 137 SPX1238 1238 3899 190 570 948 7.40E−131 [GI:663279] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae (strain RX1) DNA] 138 SPX1239 1239 3900 261 783 1075 1.10E−148 [GI:2804700] [LN:AF030361] [AC:AF030361] [PN:transposase] [OR:Streptococcus pneumoniae] 87 SPX1240 1240 3901 278 834 80 9.90E−07 [LN:E69787] [AC:E69787] [PN:hypothetical protein ydiL] [GN:ydiL] [OR:Bacillus subtilis] 87 SPX1241 1241 3902 84 252 NO-HIT 6 SPX1242 1242 3903 256 768 653 4.10E−90 [GI:285621] [LN:BACPK] [AC:D13095] [PN:undefined open reading frame] [OR:Bacillus stearothermophilus] [SR:Bacillus stearothermophilus 155 (strain:NCA1503) DNA] SPX1243 1243 3904 288 864 602 2.20E−92 “[LN:ACCD_SYNP7] [AC:Q54776] [GN:ACCD] [OR:Synechococcus sp] [SR:,strain PCC 7942:Anacystis nidulans R2] [EC:6.4.1.2] [DE:(EC 6.4.1.2) 168 (ACCASE BETA CHAIN)] [SP:Q54776]” SPX1244 1244 3905 456 1368 1101 1.50E−181 [LN:A69581] [AC:A69581] [PN:acetyl-CoA carboxylase (biotin carboxylase subunit) accC] [GN:accC] [CL:biotin carboxylase:biotin carboxylase 170 homology] [OR:Bacillus subtilis] SPX1245 1245 3906 141 423 299 1.60E−49 “[LN:D70065] [AC:D70065] [PN:(3R)-hydroxymyristoyl-[acyl carrier protein]dehydratase, ywpB] [GN:ywpB] [CL:(3R)-hydroxymyristoyl-[acyl carrier 201 protein] dehydratase] [OR:Bacillus subtilis] [EC:4.2.1.-]” SPX1246 1246 3907 162 486 248 1.10E−34 “[LN:C75558] [AC:C75558] [PN:acetyl-CoA carboxylase, bitoin carboxyl carrier protein] [GN:DR0118] [CL:biotin carboxyl carrier protein:lipoyl/biotin- 195 binding homology] [OR:Deinococcus radiodurans]” SPX1247 1247 3908 93 279 134 1.30E−13 [LN:FAB2_MYCTU] [AC:Q10525] [GN:RV2246:MTCY427.27] [OR:Mycobacterium tuberculosis] [EC:2.3.1.41] [DE:(BETA-KETOACYL-ACP 152 SYNTHASE 2) (KAS 2)] [SP:Q10525] SPX1248 1248 3909 360 1080 477 2.60E−113 “[LN:S77464] [AC:S77464] [PN:3-oxoacyl-[acyl-carrier-protein]synthase, beta chain:beta ketoacyl-acyl carrier protein synthase:protein sll1069:beta 237 ketoacyl-acyl carrier protein synthase:protein sll1069] [GN:fabF] [OR:Synechocystis sp.]” SPX1249 1249 3910 244 732 482 2.10E−76 [LN:FABG_CUPLA] [AC:P28643] [GN:CLKR27] [OR:Cuphea lanceolata] [EC:1.1.1.100] [DE:(3-KETOACYL-ACYL CARRIER PROTEIN 138 REDUCTASE)] [SP:P28643] SPX1250 1250 3911 74 222 81 9.50E−05 [LN:H72482] [AC:H72482] [PN:hypothetical protein APE2504] [GN:APE2504] [OR:Aeropyrum pernix] 92 SPX1251 1251 3912 307 921 374 1.00E−85 “[LN:B41856] [AC:B41856:A42147:S20443:A64853] [PN:[acyl-carrier-protein] S-malonyltransferase,] [GN:fabD:tfpA] [CL:[acyl-carrier-protein] 249 S-malonyltransferase:[acyl-carrier-protein] S-malonyltransferase homology] [OR:Escherichia coli] [EC:2.3.1.39]” SPX1252 1252 3913 325 975 681 5.90E−101 [LN:A72335] [AC:A72335] [PN:conserved hypothetical protein] [GN:TM0800] [OR:Thermotoga maritima] 96 SPX1253 1253 3914 75 225 80 1.80E−12 [LN:ACP_BACSU] [AC:P80643:P51832] [GN:ACPA:ACPP] [OR:Bacillus subtilis] [DE:ACYL CARRIER PROTEIN (ACP)] [SP:P80643:P51832] 122 SPX1254 1254 3915 189 567 202 6.90E−38 “[LN:S75457] [AC:S75457] [PN:beta-ketoacyl-acyl carrier protein synthase III:protein slr1511:protein slr1511] [GN:fabH] [CL:3-oxoacyl-[acyl- 236 carrier-protein]synthase III] [OR:Synechocystis sp.] [SR:PCC 6803, , PCC 6803] [SR:PCC 6803, ]” SPX1255 1255 3916 140 420 269 1.30E−46 [GI:7416010] [LN:AB025973] [AC:AB025973] [PN:3-oxoacyl-[acyl-carrier-protein] synthase III] [GN:accS] [OR:Lactobacillus plantarum] 177 [SR:Lactobacillus plantarum (strain:L137) DNA] SPX1256 1256 3917 66 198 NO-HIT 6 SPX1257 1257 3918 145 435 139 5.00E−12 [GI:4139249] [LN:AF110185] [AC:AF110185] [PN:unknown] [OR:Burkholderia pseudomallei] 84 SPX1258 1258 3919 66 198 NO-HIT 6 SPX1259 1259 3920 98 294 138 7.10E−13 [GI:3253198] [LN:AF029714] [AC:AF029714:Z71175] [PN:PhaB] [GN:phaB] [OR:Pseudomonas putida] 91 SPX1260 1260 3921 76 228 156 9.00E−18 [GI:1914870] [LN:SPZ82001] [AC:Z82001] [PN:unknown] [OR:Streptococcus pneumoniae] 81 SPX1261 1261 3922 455 1365 1240 6.10E−166 [LN:A69763] [AC:A69763] [PN:homoserine dehydrogenase homolog yclM] [GN:yclM] [CL:aspartate kinase:aspartate kinase homology] 147 [OR:Bacillus subtilis] SPX1262 1262 3923 124 372 493 2.80E−64 [GI:5669858] [LN:AF130465] [AC:AF130465] [PN:unknown] [GN:manO] [OR:Streptococcus salivarius] 93 SPX1263 1263 3924 375 1125 564 8.90E−141 “[LN:SYS_BACSU] [AC:P37464] [GN:SERS] [OR:Bacillus subtilis] [EC:6.1.1.11] [DE:SERYL-TRNA SYNTHETASE, (SERINE−-TRNA LIGASE) 145 (SERRS)] [SP:P37464]” SPX1264 1264 3925 91 273 101 6.30E−08 “[LN:SYS_MYCGE] [AC:P47251] [GN:SERS:MG005] [OR:Mycoplasma genitalium] [EC:6.1.1.11] [DE:SERYL-TRNA SYNTHETASE, 155 (SERINE-TRNA LIGASE) (SERRS)] [SP:P47251]” SPX1265 1265 3926 304 912 NO-HIT 6 SPX1266 1266 3927 69 207 NO-HIT 6 SPX1267 1267 3928 183 549 217 2.40E−57 [GI:7379894] [LN:NMA4Z2491] [AC:AL162755:AL157959] [PN:hypothetical protein NMA1203] [GN:NMA1203] [OR:Neisseria meningitidis] 125 SPX1268 1268 3929 441 1323 611 6.80E−118 “[LN:D71327] [AC:D71327] [PN:probable D-alanine glycine permease (dagA)] [GN:TP0414] [CL:sodium-dependent D-alanine/glycine transport protein] 210 [OR:Treponema pallidum subsp. pallidum] [SR:, syphilis spirochete]” SPX1269 1269 3930 779 2337 671 5.70E−155 [LN:MUS2_BACSU] [AC:P94545] [GN:MUTS2] [OR:Bacillus subtilis] [DE:MUTS2 PROTEIN] [SP:P94545] 92 SPX1270 1270 3931 251 753 175 7.10E−43 [GI:6746427] [LN:AF179847] [AC:AF179847] [PN:putative transposase] [OR:Lactococcus lactis] 90 SPX1271 1271 3932 65 195 NO-HIT 6 SPX1272 1272 3933 182 546 107 1.20E−15 [GI:3849798] [LN:U91581] [AC:U91581:U04057] [PN:putative transposase] [GN:tpase] [OR:Lactococcus lactis subsp. lactis] 118 SPX1273 1273 3934 183 549 95 4.30E−13 [LN:B69985] [AC:B69985] [PN:hypothetical protein yshB] [GN:yshB] [OR:Bacillus subtilis] 87 SPX1274 1274 3935 104 312 NO-HIT 6 SPX1275 1275 3936 294 882 1444 8.00E−194 “[LN:RNH2_STRPN] [AC:O07874] [GN:RNHB] [OR:Streptococcus pneumoniae] [EC:3.1.26.4] [DE:RIBONUCLEASE HII, (RNASE HII)] 130 [SP:O07874]” SPX1276 1276 3937 205 615 1065 6.70E−145 “[LN:LEP_STRPN] [AC:O07344] [GN:LEPB:SPI] [OR:Streptococcus pneumoniae] [EC:3.4.21.89] [DE:SIGNAL PEPTIDASE I, (SPASE I) 155 (LEADER PEPTIDASE I)] [SP:O07344]” SPX1277 1277 3938 93 279 NO-HIT 6 SPX1278 1278 3939 789 2367 738 5.80E−165 [LN:A69979] [AC:A69979] [PN:conjugation transfer protein homolog yrrC] [GN:yrrC] [OR:Bacillus subtilis] 103 SPX1279 1279 3940 428 1284 1691 1.40E−223 [GI:3549287] [LN:AF073922] [AC:AF073922] [PN:RopA] [GN:ropA] [OR:Streptococcus pyogenes] 88 SPX1280 1280 3941 379 1137 1350 2.20E−182 “[LN:MTLD_STRMU] [AC:Q02418] [GN:MTLD] [OR:Streptococcus mutans] [EC:1.1.1.17] [DE:MANNITOL-1-PHOSPHATE 5-DEHYDROGENASE,] 134 [SP:Q02418]” SPX1281 1281 3942 146 438 544 5.30E−71 [LN:PTMA_STRMU] [AC:Q02420] [GN:MTLF] [OR:Streptococcus mutans] [EC:2.7.1.69] [DE:(EC 2.7.1.69) (EIII-MTL)] [SP:Q02420] 119 SPX1282 1282 3943 652 1956 392 1.00E−47 [LN:YMTF_STRMU] [AC:Q02425] [OR:Streptococcus mutans] [DE:HYPOTHETICAL PROTEIN IN MTLF 5′REGION (ORFX) (FRAGMENT)] 126 [SP:Q02425] SPX1283 1283 3944 596 1788 1099 4.90E−194 [LN:PTMB_BACST] [AC:P50852] [GN:MTLA] [OR:Bacillus stearothermophilus] [EC:2.7.1.69] [DE:(EC 2.7.1.69) (EII-MTL)] [SP:P50852] 125 SPX1284 1284 3945 67 201 NO-HIT 6 SPX1285 1285 3946 191 573 422 2.30E−53 [LN:B30868] [AC:B30868] [PN:hypothetical protein 1] [OR:Streptococcus agalactiae] 81 SPX1286 1286 3947 278 834 582 1.50E−140 [LN:A33595] [AC:A33595:A30868] [PN:probable transposase] [CL:transposase IS3] [OR:Streptococcus agalactiae] 107 SPX1287 1287 3948 341 1023 1142 5.00E−219 [GI:1914875] [LN:SPZ82002] [AC:Z82002] [PN:PCPC] [GN:pcpC] [FN:unknown] [OR:Streptococcus pneumoniae] 101 SPX1288 1288 3949 98 294 194 3.40E−25 [GI:4586910] [LN:AB017447] [AC:AB017447] [PN:protective antigen SpaA.1] [OR:Erysipelothrix rhusiopathiae] [SR:Erysipelothrix rhusiopathiae 161 (strain:Fujisawa) DNA] SPX1289 1289 3950 219 657 104 1.50E−08 [LN:S25140] [AC:S25140] [PN:serine proteinase homolog] [CL:staphylococcal serine proteinase] [OR:Enterococcus faecalis] 119 SPX1290 1290 3951 80 240 296 8.20E−35 [GI:1914874] [LN:SPZ82002] [AC:Z82002] [PN:unknown] [OR:Streptococcus pneumoniae] 81 SPX1291 1291 3952 91 273 146 3.20E−14 [GI:4584089] [LN:BAJ10128] [AC:AJ010128] [PN:DNA alkylation repair enzyme] [GN:alkD] [FN:complements DNA alkylation repair deficiency] 155 [OR:Bacillus cereus] SPX1292 1292 3953 85 255 102 2.90E−08 [GI:4584089] [LN:BAJ10128] [AC:AJ010128] [PN:DNA alkylation repair enzyme] [GN:alkD] [FN:complements DNA alkylation repair deficiency] 155 [OR:Bacillus cereus] SPX1293 1293 3954 211 633 1040 1.50E−139 [GI:5830527] [LN:SPAJ6393] [AC:AJ006393] [PN:response regulator] [GN:rr03] [OR:Streptococcus pneumoniae] 104 SPX1294 1294 3955 332 996 1603 3.60E−220 [GI:5830526] [LN:SPAJ6393] [AC:AJ006393] [PN:histidine kinase] [GN:hk03] [OR:Streptococcus pneumoniae] 102 SPX1295 1295 3956 233 699 104 1.50E−11 [LN:G70045] [AC:G70045] [PN:hypothetical protein yvqF] [GN:yvqF] [OR:Bacillus subtilis] 87 SPX1296 1296 3957 337 1011 151 6.20E−42 [LN:D75084] [AC:D75084] [PN:carotenoid biosynthetic gene erwcrts related PAB1662] [GN:PAB1662] [CL:carotenoid biosynthesis protein homolog] 162 [OR:Pyrococcus abyssi] SPX1297 1297 3958 336 1008 67 0.00053 “[LN:KIME_METJA] [AC:Q58487] [GN:MJ1087] [OR:Methanococcus jannaschii] [EC:2.7.1.36] [DE:MEVALONATE KINASE, (MK)] [SP:Q58487]” 126 SPX1298 1298 3959 345 1035 141 5.90E−28 [GI:6625790] [LN:AF203779] [AC:AF203779] [PN:diphosphomevalonate decarboxylase MVD1] [GN:MVD1] [OR:Candida albicans] 116 SPX1299 1299 3960 293 879 134 1.60E−20 [LN:F72474] [AC:F72474] [PN:probable mevalonate kinase APE2439] [GN:APE2439] [OR:Aeropyrum pernix] 98 SPX1300 1300 3961 110 330 193 8.50E−21 [GI:1914875] [LN:SPZ82002] [AC:Z82002] [PN:PCPC] [GN:pcpC] [FN:unknown] [OR:Streptococcus pneumoniae] 101 SPX1301 1301 3962 292 876 NO-HIT 6 SPX1302 1302 3963 411 1233 97 4.90E−10 [GI:3582221] [LN:AE001272] [AC:AE001272] [PN:conserved hypothetical protein] [GN:ORF00049] [OR:Lactococcus lactis] 114 SPX1303 1303 3964 333 999 402 1.50E−124 [GI:1914875] [LN:SPZ82002] [AC:Z82002] [PN:PCPC] [GN:pcpC] [FN:unknown] [OR:Streptococcus pneumoniae] 101 SPX1304 1304 3965 371 1113 289 1.70E−89 [GI:1914875] [LN:SPZ82002] [AC:Z82002] [PN:PCPC] [GN:pcpC] [FN:unknown] [OR:Streptococcus pneumoniae] 101 SPX1305 1305 3966 230 690 212 7.30E−56 [GI:3599371] [LN:AF082668] [AC:AF082668] [PN:CsrR] [GN:csrR] [FN:negative regulator of hyaluronic acid capsule] [OR:Streptococcus pyogenes] 139 SPX1306 1306 3967 458 1374 801 5.10E−226 [GI:3033358] [LN:LLU74322] [AC:U74322] [PN:6-phosphogluconate dehydrogenase] [OR:Lactococcus lactis] 100 SPX1307 1307 3968 465 1395 109 1.10E−06 [GI:1684847] [LN:HSU77718] [AC:U77718] [PN:pinin] [OR:Homo sapiens] [SR:human] 78 SPX1308 1308 3969 386 1158 678 1.20E−133 [LN:YPSC_BACSU] [AC:P50840] [GN:YPSC] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 43.5 KD PROTEIN IN COTD-KDUD INTERGENIC 147 REGION PRECURSOR] [SP:P50840] SPX1309 1309 3970 110 330 166 6.70E−18 [LN:YPSB_BACSU] [AC:P50839] [GN:YPSB] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 11.6 KD PROTEIN IN COTD-KDUD INTERGENIC 137 REGION] [SP:P50839] SPX1310 1310 3971 176 528 147 8.20E−19 [LN:YPSA_BACSU] [AC:P50838] [GN:YPSA] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 21.1 KD PROTEIN IN COTD-KDUD INTERGENIC 137 REGION] [SP:P50838] SPX1311 1311 3972 199 597 1043 3.40E−141 [LN:YPOA_STRPN] [AC:P38034] [OR:Streptococcus pneumoniae] [DE:HYPOTHETICAL 23.1 KD PROTEIN IN PONA 5′REGION] [SP:P38034] 120 SPX1312 1312 3973 720 2160 3734 0 [GI:6563337] [LN:AF210745] [AC:AF210745] [PN:penicillin-binding protein 1A] [GN:pbp1a] [OR:Streptococcus pneumoniae] 116 SPX1313 1313 3974 68 204 NO-HIT 6 SPX1314 1314 3975 1768 5304 1762 9.10E−232 [GI:1658320] [LN:SPDEXCAP] [AC:Z47210] [GN:orf] [OR:Streptococcus pneumoniae] 77 SPX1315 1315 3976 661 1983 3378 0 LN:ALIA_STRPN] [AC:P35592:Q54782:O54620:O52228] [GN:ALIA:EXP1:PLPA] [OR:Streptococcus pneumoniae] [DE:OLIGOPEPTIDE- 201 BINDING PROTEIN ALIA PRECURSOR (EXPORTED PROTEIN 1)] [SP:P35592:Q54782:O54620:O52228] SPX1316 1316 3977 78 234 87 0.00034 “[GI:5824139] [LN:POL245436] [AC:AJ245436:J04618:J04619:S50571:X52935:X65936] [PN:hypothetical protein, 57.8 kD] [OR:Pseudomonas putida]” 137 SPX1317 1317 3978 150 450 94 3.20E−15 “[LN:Y4HP_RHISN] [AC:P50360] [GN:Y4HP] [OR:Rhizobium sp] [SR:,strain NGR234] [DE:HYPOTHETICAL 61.7 KD PROTEIN Y4HP] 128 [SP:P50360]” SPX1318 1318 3979 58 174 NO-HIT 6 SPX1319 1319 3980 86 258 80 8.90E−06 “[LN:Y4HP_RHISN] [AC:P50360] [GN:Y4HP] [OR:Rhizobium sp] [SR:,strain NGR234] [DE:HYPOTHETICAL 61.7 KD PROTEIN Y4HP] 128 [SP:P50360]” SPX1320 1320 3981 143 429 84 9.20E−08 “[GI:6009407] [LN:AB024946] [AC:AB024946] [GN:orf31] [OR:Escherichia coli] [SR:Escherichia coli (sub_species:enteropathogenic, strain:B171]” 140 SPX1321 1321 3982 284 852 1480 1.00E−198 [GI:2804705] [LN:AF030362] [AC:AF030362] [PN:dTDP-L-rhamnose synthase] [GN:cpsO] [OR:Streptococcus pneumoniae] 110 SPX1322 1322 3983 350 1050 1853 2.90E−249 [GI:4200435] [LN:AF026471] [AC:AF026471] [PN:Cps2N] [GN:cps2N] [OR:Streptococcus pneumoniae] 92 SPX1323 1323 3984 199 597 1027 4.50E−137 “[GI:3907611] [LN:AF094575] [AC:AF094575] [PN:dTDP-4-keto-6-deoxyglucose-3,5-epimerase] [GN:cps19aM] [OR:Streptococcus pneumoniae]” 131 SPX1324 1324 3985 290 870 1430 7.20E−193 [GI:4406249] [LN:AF105113] [AC:AF105113] [PN:glucose-1-phosphate thymidylyl transferase] [GN:cps19AL] [OR:Streptococcus pneumoniae] 131 SPX1325 1325 3986 476 1428 2017 3.10E−287 [GI:3907608] [LN:AF094575] [AC:AF094575] [PN:putative repeat unit transporter Cps19aJ] [GN:cps19aJ] [OR:Streptococcus pneumoniae] 129 SPX1326 1326 3987 95 285 NO-HIT 6 SPX1327 1327 3988 448 1344 148 6.90E−31 [GI:3907607] [LN:AF094575] [AC:AF094575] [PN:polysaccharide polymerase Cps19aI] [GN:cps19aI] [OR:Streptococcus pneumoniae] 122 SPX1328 1328 3989 329 987 178 2.00E−31 [LN:T00087] [AC:T00087] [PN:rhamnosyltransferase] [GN:rgpBc] [OR:Streptococcus mutans] 86 SPX1329 1329 3990 242 726 93 1.90E−06 [LN:T35395] [AC:T35395] [PN:probable transferase] [GN:SC6A5.04] [OR:Streptomyces coelicolor] 92 SPX1330 1330 3991 186 558 154 3.00E−14 [GI:2209209] [LN:AF004325] [AC:AF004325] [PN:unknown] [GN:cps19bG] [OR:Streptococcus pneumoniae] 96 SPX1331 1331 3992 315 945 96 6.50E−16 [GI:3132871] [LN:AF019375] [AC:AF019375] [PN:UDP-glucose:(glucosyl) LPS] [GN:waaR] [OR:Escherichia coli] 104 SPX1332 1332 3993 456 1368 1141 0 [GI:3907603] [LN:AF094575] [AC:AF094575] [PN:glucosyl-1-phosphate transferase Cps19aE] [GN:cps19aE] [OR:Streptococcus pneumoniae] 129 SPX1333 1333 3994 227 681 1055 4.60E−145 [GI:3907602] [LN:AF094575] [AC:AF094575] [PN:Cps19aD] [GN:cps19aD] [FN:chain length regulation and export] [OR:Streptococcus pneumoniae] 136 SPX1334 1334 3995 232 696 1061 2.00E−141 [GI:3907601] [LN:AF094575] [AC:AF094575] [PN:Cps19aC] [GN:cps19aC] [FN:chain length regulation and export] [OR:Streptococcus pneumoniae] 136 SPX1335 1335 3996 260 780 1195 2.90E−162 [GI:3907600] [LN:AF094575] [AC:AF094575] [PN:Cps19aB] [GN:cps19aB] [OR:Streptococcus pneumoniae] 96 SPX1336 1336 3997 485 1455 2238 0 [GI:3550627] [LN:SPAJ6986] [AC:AJ006986] [GN:cap33fA] [OR:Streptococcus pneumoniae] 83 SPX1337 1337 3998 358 1074 1690 9.20E−228 [LN:TRA2_STRPN] [AC:Q54513] [OR:Streptococcus pneumoniae] [DE:TRANSPOSASE FOR INSERTION SEQUENCE IS1202] [SP:Q54513] 116 SPX1338 1338 3999 120 360 581 6.60E−75 [LN:TRA2_STRPN] [AC:Q54513] [OR:Streptococcus pneumoniae] [DE:TRANSPOSASE FOR INSERTION SEQUENCE IS1202] [SP:Q54513] 116 SPX1339 1339 4000 317 951 267 3.80E−61 “““[GI:6332767] [LN:AB033763] [AC:AB033763:AB014419:AB014429:AB014439] [PN:hypothetical protein] [OR:Staphylococcus aureus] 194 [SR:Staphylococcus aureus (strain:NCTC10442) DNA, clone_lib:Lambda das]””” SPX1340 1340 4001 179 537 551 1.10E−70 [LN:B30868] [AC:B30868] [PN:hypothetical protein 1] [OR:Streptococcus agalactiae] 81 SPX1341 1341 4002 161 483 550 2.00E−80 [LN:A33595] [AC:A33595:A30868] [PN:probable transposase] [CL:transposase IS3] [OR:Streptococcus agalactiae] 107 SPX1342 1342 4003 278 834 587 1.60E−140 [LN:A33595] [AC:A33595:A30868] [PN:probable transposase] [CL:transposase IS3] [OR:Streptococcus agalactiae] 107 SPX1343 1343 4004 537 1611 2499 0 “[GI:3320387] [LN:AF030373] [AC:AF030373] [PN:alpha, 1-6-glucosidase] [GN:dexB] [OR:Streptococcus pneumoniae]” 110 SPX1344 1344 4005 495 1485 NO-HIT 6 SPX1345 1345 4006 161 483 288 9.40E−46 [LN:D75280] [AC:D75280] [PN:conserved hypothetical protein] [GN:DR2387] [CL:conserved hypothetical protein HI0491] [OR:Deinococcus radiodurans] 143 SPX1346 1346 4007 702 2106 2049 0 [GI:871784] [LN:BOVCLPAB] [AC:L34677] [PN:Clp-like ATP-dependent protease binding subunit] [OR:Bos taurus] [SR:Bos taurus calf 147 thymus cDNA to mRNA] SPX1347 1347 4008 80 240 NO-HIT 6 SPX1348 1348 4009 327 981 1619 8.40E−229 [GI:4009489] [LN:AF068903] [AC:AF068903] [PN:undecaprenyl-phosphate-UDP-MurNAc-pentapeptide] [GN:mraY] [OR:Streptococcus pneumoniae] 132 SPX1349 1349 4010 751 2253 3812 0 [LN:PBPX_STRPN] [AC:P14677] [GN:PBPX] [OR:Streptococcus pneumoniae] [DE:PENICILLIN-BINDING PROTEIN 2X (PBP-2X) (PBP2X)] 131 [SP:P14677] SPX1350 1350 4011 106 318 505 1.40E−65 [GI:4009487] [LN:AF068903] [AC:AF068903] [PN:YllD] [GN:yllD] [OR:Streptococcus pneumoniae] 90 SPX1351 1351 4012 317 951 1604 2.70E−217 [GI:4009486] [LN:AF068903] [AC:AF068903] [PN:YllC] [GN:yllC] [OR:Streptococcus pneumoniae] 90 SPX1352 1352 4013 65 195 323 1.20E−40 [GI:1536960] [LN:SOORFS] [AC:Z79691] [GN:yorfE] [FN:putative transcription regulator] [OR:Streptococcus pneumoniae] 115 SPX1353 1353 4014 142 426 291 1.40E−36 [GI:1524349] [LN:SOORFS] [AC:Z79691] [PN:OrfC] [GN:yorfC] [OR:Streptococcus pneumoniae] 87 SPX1354 1354 4015 94 282 NO-HIT 6 SPX1355 1355 4016 85 255 178 5.70E−20 [GI:1536959] [LN:SOORFS] [AC:Z79691] [PN:OrfB] [GN:yorfb] [OR:Streptococcus pneumoniae] 87 SPX1356 1356 4017 81 243 391 2.00E−51 [GI:1536959] [LN:SOORFS] [AC:Z79691] [PN:OrfB] [GN:yorfb] [OR:Streptococcus pneumoniae] 87 SPX1357 1357 4018 112 336 219 4.90E−27 [GI:1536959] [LN:SOORFS] [AC:Z79691] [PN:OrfB] [GN:yorfb] [OR:Streptococcus pneumoniae] 87 SPX1358 1358 4019 64 192 111 4.30E−10 [GI:1536959] [LN:SOORFS] [AC:Z79691] [PN:OrfB] [GN:yorfb] [OR:Streptococcus pneumoniae] 87 SPX1359 1359 4020 334 1002 1703 2.00E−229 “[GI:1536958] [LN:SOORFS] [AC:Z79691] [PN:RegR] [GN:regR] [FN:putative transcription regulator, member GalR] [OR:Streptococcus pneumoniae]” 139 SPX1360 1360 4021 634 1902 1094 3.90E−148 [GI:1524347] [LN:SOORFS] [AC:Z79691] [PN:OrfA] [GN:yorfA] [OR:Streptococcus pneumoniae] 87 SPX1361 1361 4022 98 294 96 7.80E−07 [LN:D70408] [AC:D70408] [PN:conserved hypothetical protein aq_1254] [GN:aq_1254] [CL:yajC protein] [OR:Aquifex aeolicus] 120 SPX1362 1362 4023 273 819 268 3.50E−51 “[LN:PTPD_ECOLI] [AC:P42911] [GN:AGAD] [OR:Escherichia coli] [DE:ENZYME II, D COMPONENT)] [SP:P42911]” 102 SPX1363 1363 4024 260 780 170 4.30E−27 [GI:1732200] [LN:VFU65015] [AC:U65015] [PN:PTS permease for mannose subunit IIPMan] [GN:manY] [OR:Vibrio furnissii] 115 SPX1364 1364 4025 164 492 286 3.40E−44 “[LN:PTPV_ECOLI] [AC:P42904:P76669] [GN:AGAV] [OR:Escherichia coli] [EC:2.7.1.69] [DE:ENZYME II, B COMPONENT 2),] 133 [SP:P42904:P76669]” SPX1365 1365 4026 336 1008 475 2.70E−95 [GI:5869507] [LN:AB019619] [AC:AB019619] [PN:unsaturated glucuronyl hydrolase] [GN:ugl] [OR:Bacillus sp. GL1] 148 [SR:Bacillus sp. GL1 (strain:GL1) DNA] SPX1366 1366 4027 146 438 NO-HIT 6 SPX1367 1367 4028 145 435 129 3.30E−17 [GI:5669855] [LN:AF130465] [AC:AF130465] [PN:mannose-specific phosphotransferase system] [GN:manL] [OR:Streptococcus salivarius] 128 SPX1368 1368 4029 218 654 436 1.40E−55 [LN:YJGU_ECOLI] [AC:P39345] [GN:YJGU] [OR:Escherichia coli] [EC:1.-.-.-] [DE:(EC 1.-.-.-)] [SP:P39345] 102 SPX1369 1369 4030 125 375 NO-HIT 6 SPX1370 1370 4031 98 294 169 2.50E−19 [LN:YJGU_ECOLI] [AC:P39345] [GN:YJGU] [OR:Escherichia coli] [EC:1.-.-.-] [DE:(EC 1.-.-.-)] [SP:P39345] 102 SPX1371 1371 4032 214 642 NO-HIT 6 SPX1372 1372 4033 334 1002 317 1.00E−46 [LN:G72422] [AC:G72422] [PN:2-keto-3-deoxygluconate kinase] [GN:TM0067] [CL:ribokinase] [OR:Thermotoga maritima] 112 SPX1373 1373 4034 210 630 271 6.10E−46 [LN:F72422] [AC:F72422] [PN:2-dehydro-3-deoxyphosphogluconate aldolase/4-hydroxy-2-oxoglutarate aldolase] [GN:TM0066] [CL:2-dehydro-3- 190 deoxyphosphogluconate aldolase] [OR:Thermotoga maritima] SPX1374 1374 4035 118 354 264 1.50E−50 [GI:1841332] [LN:D64071] [AC:D64071] [PN:putative protein of unknown function] [OR:Actinobacillus actinomycetemcomitans] [SR:Actinobacillus 178 actinomycetemcomitans (strain:Y4) DNA] SPX1375 1375 4036 1079 3237 4863 0 “[LN:HYSA_STRPN] [AC:Q54873:Q54874] [OR:Streptococcus pneumoniae] [EC:4.2.2.1] [DE:HYALURONATE LYASE PRECURSOR, 156 (HYALURONIDASE) (HYASE)] [SP:Q54873:Q54874]” SPX1376 1376 4037 159 477 482 1.90E−62 [GI:2598550] [LN:LLAJ109] [AC:AJ000109] [PN:gluthatione peroxidase] [GN:gpo] [OR:Lactococcus lactis] 100 SPX1377 1377 4038 738 2214 181 4.50E−33 [GI:6686567] [LN:AAC252161] [AC:AJ252161] [PN:putative alpha-glucosidase] [GN:glcA] [OR:Alicyclobacillus acidocaldarius] 120 SPX1378 1378 4039 61 183 NO-HIT 6 SPX1379 1379 4040 449 1347 231 3.40E−63 “[LN:PTCC_BACST] [AC:Q45400] [GN:CELB] [OR:Bacillus stearothermophilus] [DE:PERMEASE IIC COMPONENT) (PHOSPHOTRANSFERASE 157 ENZYME II, C COMPONENT)] [SP:Q45400]” SPX1380 1380 4041 169 507 NO-HIT 6 SPX1381 1381 4042 105 315 234 2.00E−27 [LN:PTCA_BACSU] [AC:P46319] [GN:CELC:LICA] [OR:Bacillus subtilis] [EC:2.7.1.69] [DE:(EC 2.7.1.69) (EIII-CEL)] [SP:P46319] 121 SPX1382 1382 4043 660 1980 138 9.20E−51 [LN:CELR_BACSU] [AC:P46321] [GN:CELR:LICR] [OR:Bacillus subtilis] [DE:PUTATIVE CEL OPERON REGULATOR] [SP:P46321] 112 SPX1383 1383 4044 114 342 84 2.40E−08 [LN:PTCB_BACST] [AC:Q45399] [GN:CELA] [OR:Bacillus stearothermophilus] [EC:2.7.1.69] [DE:(EC 2.7.1.69)] [SP:Q45399] 115 SPX1384 1384 4045 80 240 142 1.20E−15 [LN:Y110_METJA] [AC:Q57574] [GN:MJ0110] [OR:Methanococcus jannaschii] [DE:HYPOTHETICAL PROTEIN MJ0110] [SP:Q57574] 114 SPX1385 1385 4046 493 1479 797 2.50E−225 [LN:JE0395] [AC:JE0395] [PN:phospho-beta-galactosidase I] [CL:Agrobacterium beta-glucosidase] [OR:Lactobacillus gasseri] 120 SPX1386 1386 4047 122 366 NO-HIT 6 SPX1387 1387 4048 69 207 359 2.90E−46 [GI:5019553] [LN:SPN239004] [AC:AJ239004] [PN:putative transposase] [OR:Streptococcus pneumoniae] 97 SPX1388 1388 4049 131 393 456 1.30E−58 [LN:RS9_BACST] [AC:P07842] [GN:RPSI] [OR:Bacillus stearothermophilus] [DE:30S RIBOSOMAL PROTEIN S9 (BS10)] [SP:P07842] 118 SPX1389 1389 4050 149 447 487 2.30E−62 [LN:RL13_STACA] [AC:Q00990] [GN:RPLM] [OR:Staphylococcus carnosus] [DE:50S RIBOSOMAL PROTEIN L13] [SP:Q00990] 109 SPX1390 1390 4051 122 366 NO-HIT 6 SPX1391 1391 4052 106 318 NO-HIT 6 SPX1392 1392 4053 131 393 630 8.40E−84 “[LN:SULD_STRPN] [AC:P22291:O33697] [GN:SULD] [OR:Streptococcus pneumoniae] [EC:4.1.2.25:2.7.6.3] [DE:HYDROXYMETHYL-7,8- 181 DIHYDROPTERIN PYROPHOSPHOKINASE) (PPPK)]] [SP:P22291:O33697]” SPX1393 1393 4054 170 510 834 1.40E−111 “[LN:A36704] [AC:A36704] [PN:bifunctional folate biosynthesis enzyme sulD:6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase:7,8-dihydro- 220 6-hydroxymethylpterin pyrophosphokinase] [GN:sulD] [OR:Streptococcus pneumoniae]” SPX1394 1394 4055 185 555 938 4.90E−127 “[LN:GCH1_STRPN] [AC:P51595] [GN:SULC] [OR:Streptococcus pneumoniae] [EC:3.5.4.16] [DE:GTP CYCLOHYDROLASE I, (GTP-CH-I)] 133 [SP:P51595]” SPX1395 1395 4056 441 1323 2219 0 [GI:564018] [LN:SPU16156] [AC:U16156:M17362:M58706] [PN:dihydrofolate synthetase] [GN:sulB] [FN:folate biosynthesis] 146 [OR:Streptococcus pneumoniae] SPX1396 1396 4057 327 981 1485 7.00E−201 [LN:DHPS_STRPN] [AC:P05382] [GN:SULA] [OR:Streptococcus pneumoniae] [EC:2.5.1.15] [DE:PYROPHOSPHORYLASE)] [SP:P05382] 117 SPX1397 1397 4058 236 708 143 3.00E−13 [GI:1402529] [LN:D78257] [AC:D78257] [PN:ORF8] [GN:orf8] [OR:Enterococcus faecalis] [SR:Enterococcus faecalis plasmid:pYI17 DNA] 128 SPX1398 1398 4059 62 186 NO-HIT 6 SPX1399 1399 4060 494 1482 447 1.70E−116 [GI:6624219] [LN:AB023289] [AC:AB023289] [GN:ORFX] [OR:Pseudomonas fluorescens] [SR:Pseudomonas fluorescens (strain:No.33) DNA] 127 SPX1400 1400 4061 271 813 199 8.70E−36 [LN:F69841] [AC:F69841] [PN:conserved hypothetical protein yitU] [GN:yitU] [CL:Methanobacterium thermoautotrophicum conserved hypothetical 178 protein MTH1071] [OR:Bacillus subtilis] SPX1401 1401 4062 311 933 861 2.70E−156 [GI:7379448] [LN:NMA3Z2491] [AC:AL162754:AL157959] [PN:putative alcohol dehydrogenase] [GN:adhA] [OR:Neisseria meningitidis] 124 SPX1402 1402 4063 333 999 795 2.40E−188 [GI:5669855] [LN:AF130465] [AC:AF130465] [PN:mannose-specific phosphotransferase system] [GN:manL] [OR:Streptococcus salivarius] 128 SPX1403 1403 4064 268 804 974 1.10E−144 [GI:5669856] [LN:AF130465] [AC:AF130465] [PN:mannose-specific phosphotransferase system] [GN:manM] [OR:Streptococcus salivarius] 128 SPX1404 1404 4065 304 912 1157 3.60E−158 [GI:5669857] [LN:AF130465] [AC:AF130465] [PN:mannose-specific phosphotransferase system] [GN:manN] [OR:Streptococcus salivarius] 128 SPX1405 1405 4066 445 1335 1900 4.00E−256 “[LN:PEPC_STRTR] [AC:Q56115] [GN:PEPC] [OR:Streptococcus thermophilus] [EC:3.4.22.-] [DE:AMINOPEPTIDASE C,] [SP:Q56115]” 120 SPX1406 1406 4067 241 723 223 1.50E−59 [GI:7328274] [LN:SAY14816] [AC:Y14816] [PN:hypothetical protein] [GN:ORF231] [OR:Staphylococcus aureus] 103 SPX1407 1407 4068 137 411 328 2.80E−41 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX1408 1408 4069 77 231 NO-HIT 6 SPX1409 1409 4070 77 231 154 1.90E−17 [LN:B69770] [AC:B69770] [PN:conserved hypothetical protein ydaS] [GN:ydaS] [OR:Bacillus subtilis] 97 SPX1410 1410 4071 414 1242 1792 6.20E−241 [GI:4731022] [LN:AF102860] [AC:AF102860] [PN:aminopeptidase PepS] [GN:pepS] [OR:Streptococcus thermophilus] 107 SPX1411 1411 4072 60 180 NO-HIT 6 SPX1412 1412 4073 77 231 NO-HIT 6 SPX1413 1413 4074 93 279 110 1.90E−19 “[LN:B71883] [AC:B71883] [PN:hypothetical protein jhp0831] [GN:jhp0831] [CL:conserved hypothetical protein HI0711] [OR:Helicobacter pylori] 188 [SR:strain J99, , strain J99] [SR:strain J99, ]” SPX1414 1414 4075 88 264 80 0.00012 [LN:DINJ_ECOLI] [AC:Q47150] [GN:DINJ] [OR:Escherichia coli] [DE:DNA-DAMAGE−INDUCIBLE PROTEIN J] [SP:Q47150] 107 SPX1415 1415 4076 1464 4392 1689 0 “[GI:143342] [LN:BACPOLC] [AC:M22996] [GN:polC] [OR:Bacillus subtilis] [SR:B.subtilis SB19 DNA, clone PRO10]” 109 SPX1416 1416 4077 694 2082 2833 0 [LN:T44380] [AC:T44380] [PN:translation elongation factor EF-G fus [imported]] [GN:fus] [CL:translation elongation factor G:translation elongation 191 factor Tu homology] [OR:Bacillus halodurans] SPX1417 1417 4078 119 357 86 5.20E−10 [LN:YHA2_EIKCO] [AC:P35649] [OR:Eikenella corrodens] [DE:HYPOTHETICAL 66.3 KD PROTEIN IN HAG2 5′REGION] [SP:P35649] 115 SPX1418 1418 4079 150 450 88 1.30E−08 [LN:YHA2_EIKCO] [AC:P35649] [OR:Eikenella corrodens] [DE:HYPOTHETICAL 66.3 KD PROTEIN IN HAG2 5′REGION] [SP:P35649] 115 SPX1419 1419 4080 144 432 173 1.90E−17 [GI:7576785] [LN:AF214675] [AC:AF214675] [PN:unknown in vivo-induced protein 131-19] [OR:Pseudomonas aeruginosa] 112 SPX1420 1420 4081 157 471 633 1.10E−83 [LN:F69699] [AC:F69699:S11357] [PN:ribosomal protein S7 (rpsG):ribosomal protein BS7] [GN:rpsG] [CL:Escherichia coli ribosomal protein S7] 161 [OR:Bacillus subtilis] SPX1421 1421 4082 138 414 699 1.70E−91 [LN:RS12_STRPN] [AC:P30891] [GN:RPSL:STR] [OR:Streptococcus pneumoniae] [DE:30S RIBOSOMAL PROTEIN S12] [SP:P30891] 114 SPX1422 1422 4083 1205 3615 1478 0 [GI:1665738] [LN:D78258] [AC:D78258] [PN:alkaline amylopullulanase] [OR:Bacillus sp.] [SR:Bacillus sp. (strain:KSM-1378) DNA] 125 SPX1423 1423 4084 308 924 655 1.70E−115 “[GI:2735505] [LN:SCU96107] [AC:U96107] [PN:N5,N10-methylenetetrahydromethanopterin] [OR:Staphylococcus carnosus]” 114 SPX1424 1424 4085 603 1809 963 3.70E−194 “[LN:B69633] [AC:B69633] [PN:glutamine--fructose-6-phosphate transaminase (isomerizing), glmS] [GN:glmS] [CL:glutamine--fructose-6-phosphate 210 aminotransferase (isomerizing)] [OR:Bacillus subtilis] [EC:2.6.1.16]” SPX1425 1425 4086 460 1380 851 2.00E−207 [LN:D69785] [AC:D69785] [PN:beta-glucosidase homolog ydhP] [GN:ydhP] [CL:Agrobacterium beta-glucosidase] [OR:Bacillus subtilis] 127 SPX1426 1426 4087 347 1041 298 1.30E−82 “[LN:G69682] [AC:G69682] [PN:proline--tRNA ligase, proS:prolyl-tRNA synthetase] [GN:proS] [CL:proline--tRNA ligase] [OR:Bacillus subtilis] 153 [EC:6.1.1.15]” SPX1427 1427 4088 336 1008 691 5.20E−109 “[LN:G69682] [AC:G69682] [PN:proline--tRNA ligase, proS:prolyl-tRNA synthetase] [GN:proS] [CL:proline--tRNA ligase] [OR:Bacillus subtilis] 153 [EC:6.1.1.15]” SPX1428 1428 4089 420 1260 436 8.50E−136 [GI:5714510] [LN:AF152237] [AC:AF152237] [PN:Eep] [GN:eep] [FN:determinant for enhanced expression of] [OR:Enterococcus faecalis] 129 SPX1429 1429 4090 268 804 202 1.20E−51 [LN:CDSA_BACSU] [AC:O31752] [GN:CDSA] [OR:Bacillus subtilis] [EC:2.7.7.41] [DE:SYNTHASE)] [SP:O31752] 101 SPX1430 1430 4091 259 777 490 2.80E−90 [LN:UPPS_BACSU] [AC:O31751] [GN:UPPS] [OR:Bacillus subtilis] [EC:2.5.1.31] [DE:(DI-TRANS-POLY-CIS-DECAPRENYLCISTRANSFERASE)] 136 [SP:O31751] SPX1431 1431 4092 191 573 127 1.50E−11 [LN:S70841] [AC:S70841] [PN:hypothetical transmembrane protein (sipS 3′ region)] [CL:Bradyrhizobium japonicum hypothetical transmembrane 192 protein (sipS 3′ region)] [OR:Bradyrhizobium japonicum] SPX1432 1432 4093 333 999 1045 1.50E−140 [LN:H81105] [AC:H81105] [PN:Holliday junction DNA helicase RuvB NMB1243 [imported]] [GN:NMB1243] [OR:Neisseria meningitidis] 124 SPX1433 1433 4094 35 105 76 0.00015 [LN:H72613] [AC:H72613] [PN:hypothetical protein APE1371] [GN:APE1371] [OR:Aeropyrum pernix] 92 SPX1434 1434 4095 139 417 103 1.50E−06 [GI:5616248] [LN:AF158628] [AC:AF158628] [PN:hypothetical protein] [OR:Prochlorococcus PCC9511] 95 SPX1435 1435 4096 232 696 482 1.50E−73 “[LN:YIW2_YEAST] [AC:P40586] [GN:YIR042C] [OR:Saccharomyces cerevisiae] [SR:,Baker's yeast] [DE:HYPOTHETICAL 27.4 KD PROTEIN 155 IN HYR1 3′REGION] [SP:P40586]” SPX1436 1436 4097 64 192 NO-HIT 6 SPX1437 1437 4098 834 2502 944 0 “LN:C70131] [AC:C70131] [PN:leucine--tRNA ligase, leuS:leucyl-tRNA synthetase:leucyl-tRNA synthetase] [CL:leucine--tRNA ligase] [OR:Borrelia 199 burgdorferi] [SR:,Lyme disease spirochete] [EC:6.1.1.4]” SPX1438 1438 4099 363 1089 998 1.00E−137 “[LN:GLDA_BACST] [AC:P32816] [GN:GLDA:GLD] [OR:Bacillus stearothermophilus] [EC:1.1.1.6] [DE:GLYCEROL DEHYDROGENASE, (GLDH)] 137 [SP:P32816]” SPX1439 1439 4100 223 669 356 8.20E−53 [GI:2582658] [LN:CBAJ2527] [AC:AJ002527] [PN:OrfX] [GN:orfX] [FN:putative transaldolase (37.4% identity to talC] [OR:Clostridium beijerinckii] 142 SPX1440 1440 4101 816 2448 992 1.80E−275 [LN:PFLF_ECOLI] [AC:P75793] [GN:YBIW] [OR:Escherichia coli] [EC:2.3.1.54] [DE:LYASE 3)] [SP:P75793] 99 SPX1441 1441 4102 427 1281 337 4.90E−89 “[LN:PTCC_BACST] [AC:Q45400] [GN:CELB] [OR:Bacillus stearothermophilus] [DE:PERMEASE IIC COMPONENT) (PHOSPHOTRANSFERASE 157 ENZYME II, C COMPONENT)] [SP:Q45400]” SPX1442 1442 4103 103 309 194 3.50E−22 [LN:A69785] [AC:A69785] [PN:cellobiose phosphotransferase system enzym homolog ydhM] [GN:ydhM] [CL:phosphotransferase system enzyme II cellobiose- 189 specific factor IIB] [OR:Bacillus subtilis] SPX1443 1443 4104 107 321 186 5.70E−21 [LN:PTCA_BACSU] [AC:P46319] [GN:CELC:LICA] [OR:Bacillus subtilis] [EC:2.7.1.69] [DE:(EC 2.7.1.69) (EIII-CEL)] [SP:P46319] 121 SPX1444 1444 4105 327 981 265 2.80E−49 [LN:SORC_KLEPN] [AC:P37078] [GN:SORC] [OR:Klebsiella pneumoniae] [DE:SORBITOL OPERON REGULATOR (SOR OPERON ACTIVATOR)] 130 [SP:P37078] SPX1445 1445 4106 249 747 252 6.10E−57 [LN:YCIT_ECOLI] [AC:P76034] [GN:YCIT] [OR:Escherichia coli] [DE:HYPOTHETICAL TRANSCRIPTIONAL REGULATOR IN OSMB-RNB 145 INTERGENIC REGION] [SP:P76034] SPX1446 1446 4107 259 777 266 4.40E−55 “[LN:PFLE_ECOLI] [AC:P75794] [GN:YBIY] [OR:Escherichia coli] [EC:1.97.1.4] [DE:PUTATIVE PYRUVATE FORMATE-LYASE 3 145 ACTIVATING ENZYME,] [SP:P75794]” SPX1447 1447 4108 83 249 105 3.60E−08 [GI:7331182] [LN:AF235048] [AC:AF235048] [PN:AgpT] [GN:agpT] [OR:Sinorhizobium meliloti] 88 SPX1448 1448 4109 65 195 177 4.60E−18 [GI:6127225] [LN:SHU75349] [AC:U75349] [PN:periplasmic-iron-binding protein BitA] [GN:bit operon] [OR:Brachyspira hyodysenteriae] 129 SPX1449 1449 4110 123 369 242 1.10E−26 [GI:6127225] [LN:SHU75349] [AC:U75349] [PN:periplasmic-iron-binding protein BitA] [GN:bit operon] [OR:Brachyspira hyodysenteriae] 129 SPX1450 1450 4111 318 954 799 1.70E−113 [GI:2766194] [LN:SHU75349] [AC:U75349] [PN:putative ABC transporter BitD] [GN:bit operon] [OR:Brachyspira hyodysenteriae] 121 SPX1451 1451 4112 209 627 283 2.70E−40 [GI:2766195] [LN:SHU75349] [AC:U75349] [PN:putative permease BitE] [GN:bit operon] [OR:Brachyspira hyodysenteriae] 114 SPX1452 1452 4113 257 771 295 1.50E−68 [GI:2766196] [LN:SHU75349] [AC:U75349] [PN:putative permease BitF] [GN:bit operon] [OR:Brachyspira hyodysenteriae] 114 SPX1453 1453 4114 66 198 164 3.20E−17 [GI:2766196] [LN:SHU75349] [AC:U75349] [PN:putative permease BitF] [GN:bit operon] [OR:Brachyspira hyodysenteriae] 114 SPX1454 1454 4115 250 750 137 3.20E−10 [LN:PMGY_TREPA] [AC:P96121] [GN:GPM:PGM:TP0168] [OR:Treponema pallidum] [EC:5.4.2.1] [DE:(BPG-DEPENDENT PGAM)] [SP:P96121] 122 SPX1455 1455 4116 446 1338 855 6.60E−196 [GI:7380543] [LN:NMA6Z2491] [AC:AL162757:AL157959] [PN:conserved hypothetical protein] [GN:NMA1908] [OR:Neisseria meningitidis] 127 SPX1456 1456 4117 120 360 123 9.30E−21 [LN:E64494] [AC:E64494] [PN:hypothetical protein MJ1558] [OR:Methanococcus jannaschii] 86 SPX1457 1457 4118 129 387 282 2.20E−58 [LN:T44411] [AC:T44411] [PN:ribosomal protein L17 [imported]] [GN:rplQ] [CL:Escherichia coli ribosomal protein L17] [OR:Bacillus halodurans] 140 SPX1458 1458 4119 312 936 963 6.70E−130 [LN:RPOA_BACSU] [AC:P20429] [GN:RPOA] [OR:Bacillus subtilis] [EC:2.7.7.6] [DE:ALPHA CHAIN) (RNA POLYMERASE ALPHA SUBUNIT)] 134 [SP:P20429] SPX1459 1459 4120 134 402 NO-HIT 6 SPX1460 1460 4121 141 423 494 1.80E−63 [LN:RS11_BACSU] [AC:P04969] [GN:RPSK] [OR:Bacillus subtilis] [DE:30S RIBOSOMAL PROTEIN S11 (BS11)] [SP:P04969] 110 SPX1461 1461 4122 122 366 433 1.70E−55 [GI:1044989] [LN:BACRPLP] [AC:L47971] [PN:ribosomal protein S13] [GN:rpsM] [OR:Bacillus subtilis] 97 SPX1462 1462 4123 56 168 237 1.10E−28 [LN:S17988] [AC:S17988] [PN:translation initiation factor IF-1] [GN:infA] [CL:translation initiation factor IF-1] [OR:Lactococcus lactis subsp. lactis] 151 SPX1463 1463 4124 213 639 560 8.10E−95 “[LN:KAD_LACLA] [AC:P27143] [GN:ADK] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:2.7.4.3] [DE:ADENYLATE 177 KINASE, (ATP-AMP TRANSPHOSPHORYLASE)] [SP:P27143]” SPX1464 1464 4125 437 1311 927 4.30E−126 “[LN:SECY_LACLA] [AC:P27148] [GN:SECY] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [DE:PREPROTEIN TRANSLOCASE 155 SECY SUBUNIT] [SP:P27148]” SPX1465 1465 4126 147 441 614 7.90E−79 [LN:RL15_STAAU] [AC:O06445] [GN:RPLO] [OR:Staphylococcus aureus] [DE:50S RIBOSOMAL PROTEIN L15] [SP:O06445] 107 SPX1466 1466 4127 61 183 185 6.90E−21 [LN:RL30_STAAU] [AC:O06444] [GN:RPMD] [OR:Staphylococcus aureus] [DE:50S RIBOSOMAL PROTEIN L30] [SP:O06444] 107 SPX1467 1467 4128 165 495 621 8.70E−81 [LN:RS5_BACST] [AC:P02357] [GN:RPSE] [OR:Bacillus stearothermophilus] [DE:30S RIBOSOMAL PROTEIN S5 (BS5)] [SP:P02357] 117 SPX1468 1468 4129 119 357 232 2.60E−53 [LN:RL18_BACSU] [AC:P46899:P70969] [GN:RPLR] [OR:Bacillus subtilis] [DE:50S RIBOSOMAL PROTEIN L18] [SP:P46899:P70969] 117 SPX1469 1469 4130 175 525 478 2.00E−66 [LN:B69695] [AC:B69695] [PN:ribosomal protein L6 (BL8) rplF] [GN:rplF] [CL:Escherichia coli ribosomal protein L6] [OR:Bacillus subtilis] 136 SPX1470 1470 4131 133 399 521 2.60E−67 [GI:1044978] [LN:BACRPLP] [AC:L47971] [PN:ribosomal protein S8] [GN:rpsH] [OR:Bacillus subtilis] 96 SPX1471 1471 4132 79 237 NO-HIT 6 SPX1472 1472 4133 90 270 325 8.80E−41 [LN:F69835] [AC:F69835] [PN:ribosomal protein S14 homolog yhzA] [GN:yhzA] [CL:Escherichia coli ribosomal protein S14] [OR:Bacillus subtilis] 140 SPX1473 1473 4134 181 543 728 6.40E−96 [LN:T44395] [AC:T44395] [PN:ribosomal protein L5 [imported]] [GN:rplE] [CL:Escherichia coli ribosomal protein L5] [OR:Bacillus halodurans] 138 SPX1474 1474 4135 102 306 508 2.80E−65 [GI:4927751] [LN:AF126059] [AC:AF126059] [PN:RpL24] [GN:rplX] [OR:Streptococcus pneumoniae] 91 SPX1475 1475 4136 123 369 597 2.20E−78 [GI:4927750] [LN:AF126059] [AC:AF126059] [PN:RpL14] [GN:rplN] [OR:Streptococcus pneumoniae] 91 SPX1476 1476 4137 110 330 100 4.40E−07 [LN:E71186] [AC:E71186] [PN:hypothetical protein PH1769] [GN:PH1769] [CL:Pyrococcus horikoshii hypothetical protein PH1769] 150 [OR:Pyrococcus horikoshii] SPX1477 1477 4138 87 261 430 3.10E−55 [GI:4927749] [LN:AF126059] [AC:AF126059] [PN:RpS17] [GN:rpsQ] [OR:Streptococcus pneumoniae] 91 SPX1478 1478 4139 133 399 NO-HIT 6 SPX1479 1479 4140 69 207 324 8.90E−40 [GI:4927748] [LN:AF126059] [AC:AF126059] [PN:RpL29] [GN:rpmC] [OR:Streptococcus pneumoniae] 91 SPX1480 1480 4141 138 414 708 1.30E−94 [GI:4927747] [LN:AF126059] [AC:AF126059] [PN:RpL16] [GN:rplP] [OR:Streptococcus pneumoniae] 91 SPX1481 1481 4142 209 627 1063 2.10E−142 [GI:4927746] [LN:AF126059] [AC:AF126059] [PN:RpS3] [GN:rpsC] [OR:Streptococcus pneumoniae] 90 SPX1482 1482 4143 75 225 356 1.60E−44 [GI:4927745] [LN:AF126059] [AC:AF126059] [PN:RpL22] [GN:rplV] [OR:Streptococcus pneumoniae] 91 SPX1483 1483 4144 82 246 NO-HIT 6 SPX1484 1484 4145 94 282 492 5.20E−64 [GI:4927744] [LN:AF126059] [AC:AF126059] [PN:RpS19] [GN:rpsS] [OR:Streptococcus pneumoniae] 91 SPX1485 1485 4146 278 834 1144 2.80E−152 [LN:RL2_BACST] [AC:P04257] [GN:RPLB] [OR:Bacillus stearothermophilus] [DE:50S RIBOSOMAL PROTEIN L2] [SP:P04257] 111 SPX1486 1486 4147 99 297 162 1.30E−30 [GI:3273331] [LN:AB015722] [AC:AB015722] [PN:ribosomal protrein L23] [OR:Bacillus stearothermophilus] [SR:Bacillus stearothermophilus DNA] 138 SPX1487 1487 4148 208 624 696 6.80E−91 [LN:RL4_BACST] [AC:P28601] [GN:RPLD] [OR:Bacillus stearothermophilus] [DE:50S RIBOSOMAL PROTEIN L4] [SP:P28601] 111 SPX1488 1488 4149 209 627 496 6.60E−110 [LN:RL3_BACSU] [AC:P42920] [GN:RPLC] [OR:Bacillus subtilis] [DE:50S RIBOSOMAL PROTEIN L3 (BL3)] [SP:P42920] 107 SPX1489 1489 4150 103 309 494 3.40E−64 [LN:RS10_STRMU] [AC:P48853] [GN:RPSJ] [OR:Streptococcus mutans] [DE:30S RIBOSOMAL PROTEIN S10] [SP:P48853] 106 SPX1490 1490 4151 206 618 71 0.00018 [GI:7302797] [LN:AE003803] [AC:AE003803:AE002787] [GN:CG4798] [OR:Drosophila melanogaster] [SR:fruit fly] 105 SPX1491 1491 4152 197 591 843 3.60E−112 [GI:4098082] [LN:LLU73336] [AC:U73336] [PN:anaerobic ribonucleotide reductase activator] [GN:nrdG] [FN:activation of anaerobic] [OR:Lactococcus 167 lactis subsp. cremoris] SPX1492 1492 4153 69 207 NO-HIT 6 SPX1493 1493 4154 169 507 187 4.50E−19 [LN:G75479] [AC:G75479] [PN:hypothetical protein] [GN:DR0763] [OR:Deinococcus radiodurans] 90 SPX1494 1494 4155 155 465 NO-HIT 6 SPX1495 1495 4156 738 2214 1123 1.10E−231 [GI:4098081] [LN:LLU73336] [AC:U73336] [PN:anaerobic ribonucleotide reductase] [GN:nrdD] [OR:Lactococcus lactis subsp. cremoris] 128 SPX1496 1496 4157 519 1557 NO-HIT 6 SPX1497 1497 4158 492 1476 519 3.70E−97 [LN:YWAP_STRMU] [AC:P34001] [OR:Streptococcus mutans] [DE:HYPOTHETICAL PROTEIN IN WAPA 3′REGION (FRAGMENT)] [SP:P34001] 119 SPX1498 1498 4159 186 558 93 0.00012 “[LN:A26892] [AC:A26892] [PN:Mopa box protein] [OR:Mus musculus] [SR:, house mouse]” 84 SPX1499 1499 4160 70 210 NO-HIT 6 SPX1500 1500 4161 130 390 66 7.30E−09 [GI:1119198] [LN:BACCOMC] [AC:M30805] [PN:unknown protein] [OR:Bacillus subtilis] [SR:Bacillus subtilis (strain IS75) DNA] 122 SPX1501 1501 4162 161 483 119 5.10E−16 [LN:FOLC_LACCA] [AC:P15925] [GN:FGS] [OR:Lactobacillus casei] [EC:6.3.2.17] [DE:SYNTHETASE) (FPGS)] [SP:P15925] 111 SPX1502 1502 4163 164 492 251 2.00E−38 [LN:FOLC_BACSU] [AC:Q05865] [GN:FOLC] [OR:Bacillus subtilis] [EC:6.3.2.17] [DE:SYNTHETASE) (FPGS)] [SP:Q05865] 110 SPX1503 1503 4164 102 306 87 5.90E−11 [LN:A69982] [AC:A69982] [PN:hypothetical protein yrzB] [GN:yrzB] [OR:Bacillus subtilis] 87 SPX1504 1504 4165 140 420 327 2.00E−40 [LN:D69979] [AC:D69979] [PN:conserved hypothetical protein yrrK] [GN:yrrK] [CL:Haemophilus influenzae conserved hypothetical protein HI0305] 163 [OR:Bacillus subtilis] SPX1505 1505 4166 89 267 NO-HIT 6 SPX1506 1506 4167 190 570 NO-HIT 6 SPX1507 1507 4168 133 399 315 1.80E−38 [GI:6650536] [LN:AF103794] [AC:AF103794] [PN:unknown] [OR:Listeria monocytogenes] 81 SPX1508 1508 4169 126 378 333 1.60E−40 [GI:517210] [LN:SPU11799] [AC:U11799] [OR:Streptococcus pyogenes] 65 SPX1509 1509 4170 131 393 340 3.70E−41 [GI:517210] [LN:SPU11799] [AC:U11799] [OR:Streptococcus pyogenes] 65 SPX1510 1510 4171 296 888 1035 8.50E−139 [GI:6318592] [LN:AF146529] [AC:AF146529] [PN:aromatic amino acid aminotransferase] [GN:araT] [FN:catalyzes the last reaction in the biosynthesis] 185 [OR:Lactococcus lactis subsp. cremoris] SPX1511 1511 4172 62 186 NO-HIT 6 SPX1512 1512 4173 257 771 297 2.20E−40 [LN:YQXN_BACSU] [AC:P42095] [GN:YQXN:YQFI] [OR:Bacillus subtilis] [DE:(ORF3)] [SP:P42095] 89 SPX1513 1513 4174 331 993 623 6.80E−120 [LN:H69679] [AC:H69679] [PN:involved in fatty acid/phospholipid synthesis plsX] [GN:plsX] [CL:phospholipid synthesis protein] [OR:Bacillus subtilis] 148 SPX1514 1514 4175 112 336 NO-HIT 6 SPX1515 1515 4176 78 234 129 1.40E−17 [LN:C72349] [AC:C72349] [PN:acyl carrier protein] [GN:TM0662] [CL:acyl carrier protein:acyl carrier protein homology] 142 [OR:Thermotoga maritima] SPX1516 1516 4177 98 294 320 4.80E−40 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX1517 1517 4178 77 231 64 3.00E−06 [GI:2695624] [LN:STU93029] [AC:U93029] [PN:amphipathic pore-forming peptide precursor] [GN:thmA] [OR:Streptococcus thermophilus] 128 SPX1518 1518 4179 69 207 NO-HIT 6 SPX1519 1519 4180 720 2160 3571 0 [LN:COMA_STRPN] [AC:Q03727] [GN:COMA] [OR:Streptococcus pneumoniae] [DE:TRANSPORT ATP-BINDING PROTEIN COMA] [SP:Q03727] 119 SPX1520 1520 4181 450 1350 2184 8.20E−289 [LN:COMB_STRPN] [AC:P36498] [GN:COMB] [OR:Streptococcus pneumoniae] [DE:TRANSPORT PROTEIN COMB] [SP:P36498] 107 SPX1521 1521 4182 250 750 1189 1.40E−160 [LN:PUR7_STRPN] [AC:Q07296] [GN:PURC] [OR:Streptococcus pneumoniae] [EC:6.3.2.6] [DE:(SAICAR SYNTHETASE)] [SP:Q07296] 117 SPX1522 1522 4183 254 762 127 2.80E−08 “““[LN:C69492] [AC:C69492] [PN:phosphoribosylformylglycinamidine synthase, component II:formylglycinamide ribotide amidotransferase: 217 phosphoribosylformylglycinamidine synthetase] [OR:Archaeoglobus fulgidus] [EC:6.3.5.3]””” SPX1523 1523 4184 95 285 155 3.80E−15 [GI:4928281] [LN:AF132127] [AC:AF132127] [PN:glucose-6-phosphate isomerase] [GN:gpi] [OR:Streptococcus mutans] 110 SPX1524 1524 4185 457 1371 1764 1.20E−238 [GI:4928281] [LN:AF132127] [AC:AF132127] [PN:glucose-6-phosphate isomerase] [GN:gpi] [OR:Streptococcus mutans] 110 SPX1525 1525 4186 246 738 246 3.10E−28 “[LN:YDP3_LACLA] [AC:P22347] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [DE:HYPOTHETICAL 18.7 KD PROTEIN 162 IN PEPX 3′REGION (ORF3)] [SP:P22347]” SPX1526 1526 4187 604 1812 1001 2.10E−222 [GI:4104142] [LN:AF033015] [AC:AF033015] [PN:ABC transporter homolog Z] [OR:Listeria monocytogenes] 99 SPX1527 1527 4188 72 216 NO-HIT 6 SPX1528 1528 4189 108 324 105 1.60E−07 [GI:6015958] [LN:SSU18930] [AC:Y18930] [PN:hypothetical protein] [GN:ORF-c22_037] [OR:Sulfolobus solfataricus] 110 SPX1529 1529 4190 196 588 455 7.30E−58 [GI:4104141] [LN:AF033015] [AC:AF033015] [PN:ABC transporter homolog Y] [OR:Listeria monocytogenes] 99 SPX1530 1530 4191 361 1083 422 2.80E−66 [GI:4104140] [LN:AF033015] [AC:AF033015] [PN:ABC transporter homolog X] [OR:Listeria monocytogenes] 99 SPX1531 1531 4192 655 1965 3290 0 [LN:HEXA_STRPN] [AC:P10564] [GN:HEXA] [OR:Streptococcus pneumoniae] [DE:DNA MISMATCH REPAIR PROTEIN HEXA] [SP:P10564] 117 SPX1532 1532 4193 182 546 859 6.40E−114 [LN:HEXA_STRPN] [AC:P10564] [GN:HEXA] [OR:Streptococcus pneumoniae] [DE:DNA MISMATCH REPAIR PROTEIN HEXA] [SP:P10564] 117 SPX1533 1533 4194 149 447 740 7.50E−99 [LN:ARGR_STRPN] [AC:Q54870] [GN:ARGR] [OR:Streptococcus pneumoniae] [DE:PROBABLE ARGININE REPRESSOR] [SP:Q54870] 112 SPX1534 1534 4195 564 1692 365 3.20E−102 “[LN:SYRC_YEAST] [AC:Q05506] [GN:YDR341C:D9651.10] [OR:Saccharomyces cerevisiae] [SR:,Baker's yeast] 154 [EC:6.1.1.19] [DE:-TRNA LIGASE) (ARGRS)] [SP:Q05506]” SPX1535 1535 4196 150 450 398 6.20E−51 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX1536 1536 4197 68 204 NO-HIT 6 SPX1537 1537 4198 95 285 102 6.20E−17 “[LN:S74709] [AC:S74709] [PN:hypothetical protein sll1188] [OR:Synechocystis sp.] [SR:PCC 6803, , PCC 6803] [SR:PCC 6803, ]” 124 SPX1538 1538 4199 236 708 1209 4.90E−164 [GI:5830529] [LN:SPAJ6394] [AC:AJ006394] [PN:response regulator] [GN:phoP] [OR:Streptococcus pneumoniae] 104 SPX1539 1539 4200 444 1332 2196 4.10E−300 [GI:5830530] [LN:SPAJ6394] [AC:AJ006394] [PN:histidine kinase] [GN:phoR] [OR:Streptococcus pneumoniae] 102 SPX1540 1540 4201 292 876 1435 1.70E−188 [GI:4530447] [LN:AF118229] [AC:AF118229] [PN:phosphate binding protein PstS] [GN:pstS] [OR:Streptococcus pneumoniae] 116 SPX1541 1541 4202 272 816 1333 2.80E−185 [GI:4530448] [LN:AF118229] [AC:AF118229] [PN:transmembrane protein PstC] [GN:pstC] [OR:Streptococcus pneumoniae] 112 SPX1542 1542 4203 272 816 1312 1.10E−182 [GI:4530449] [LN:AF118229] [AC:AF118229] [PN:transmembrane protein PstA] [GN:PstA] [OR:Streptococcus pneumoniae] 112 SPX1543 1543 4204 251 753 1284 2.00E−174 [GI:4530450] [LN:AF118229] [AC:AF118229] [PN:ATP-binding cassette protein PstB] [GN:pstB] [OR:Streptococcus pneumoniae] 119 SPX1544 1544 4205 217 651 1067 8.20E−144 [GI:4530451] [LN:AF118229] [AC:AF118229] [PN:PhoU] [GN:phoU] [OR:Streptococcus pneumoniae] 90 SPX1545 1545 4206 142 426 131 2.90E−10 [GI:5822769] [LN:AB024553] [AC:AB024553] [OR:Bacillus halodurans] [SR:Bacillus halodurans (strain:C-125) DNA] 109 SPX1546 1546 4207 73 219 NO-HIT 6 SPX1547 1547 4208 153 459 NO-HIT 6 SPX1548 1548 4209 339 1017 921 6.40E−122 [LN:GPDA_BACSU] [AC:P46919] [GN:GPSA:GLYC] [OR:Bacillus subtilis] [EC:1.1.1.94] [DE:DEPENDENT DIHYDROXYACETONE- 144 PHOSPHATE REDUCTASE)] [SP:P46919] SPX1549 1549 4210 300 900 1481 1.60E−199 [GI:3550619] [LN:SPAJ4869] [AC:AJ004869] [PN:UTP-glucose-1-phosphate uridylyltransferase] [GN:galU] [FN:synthesis of UDP-glucose] 159 [OR:Streptococcus pneumoniae] SPX1550 1550 4211 225 675 NO-HIT 6 SPX1551 1551 4212 227 681 520 1.90E−70 [LN:SUB400707] [AC:AJ400707] [PN:hypothetical protein] [OR:Streptococcus uberis] 80 SPX1552 1552 4213 182 546 236 1.30E−55 [GI:3192049] [LN:AB001562] [AC:AB001562] [OR:Streptococcus mutans] [SR:Streptococcus mutans (strain:Xc) DNA] 108 SPX1553 1553 4214 377 1131 622 4.50E−119 [LN:G69866] [AC:G69866] [PN:hippurate hydrolase homolog ykuR] [GN:ykuR] [CL:hippurate hydrolase] [OR:Bacillus subtilis] 119 SPX1554 1554 4215 233 699 578 1.10E−86 “[LN:H72245] [AC:H72245] [PN:2,3,4,5-tetrahydropyridine-2-carboxylate N-succinyltransferase-related protein] [GN:TM1519] 146 [OR:Thermotoga maritima]” SPX1555 1555 4216 153 459 75 5.50E−08 [GI:6103625] [LN:AF172095] [AC:AF172095] [PN:unknown] [OR:Picea rubens] 71 SPX1556 1556 4217 72 216 NO-HIT 6 SPX1557 1557 4218 278 834 214 2.60E−30 [LN:YDED_BACSU] [AC:P96661] [GN:YDED] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 35.3 KD PROTEIN IN CSPC-NAP INTERGENIC 136 REGION] [SP:P96661] SPX1558 1558 4219 821 2463 4147 0 [GI:6165962] [LN:AF101781] [AC:AF101781] [PN:penicillin-binding protein 1b] [GN:pbp1b] [OR:Streptococcus pneumoniae] 116 SPX1559 1559 4220 419 1257 697 1.90E−174 [LN:SYY1_BACSU] [AC:P22326] [GN:TYRS] [OR:Bacillus subtilis] [EC:6.1.1.1] [DE:(TYRRS 1)] [SP:P22326] 100 SPX1560 1560 4221 691 2073 218 1.60E−63 “[LN:COPA_ENTHR] [AC:P32113:Q47841] [GN:COPA] [OR:Enterococcus hirae] [EC:3.6.1.36] [DE:COPPER/POTASSIUM-TRANSPORTING 148 ATPASE A,] [SP:P32113:Q47841]” SPX1561 1561 4222 65 195 NO-HIT 6 SPX1562 1562 4223 88 264 109 2.90E−08 [LN:RRMA_ECOLI] [AC:P36999] [GN:RRMA] [OR:Escherichia coli] [EC:2.1.1.51] [DE:METHYLTRANSFERASE)] [SP:P36999] 109 SPX1563 1563 4224 197 591 192 1.90E−25 [LN:YXJB_BACSU] [AC:P42313] [GN:YXJB:N15I] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 31.5 KD PROTEIN IN KATB 3′REGION] [SP:P42313] 128 SPX1564 1564 4225 57 171 NO-HIT 6 SPX1565 1565 4226 191 573 NO-HIT 6 SPX1566 1566 4227 753 2259 473 5.80E−165 “[LN:PHSG_BACSU] [AC:P39123] [GN:GLGP] [OR:Bacillus subtilis] [EC:2.4.1.1] [DE:GLYCOGEN PHOSPHORYLASE,] [SP:P39123]” 116 SPX1567 1567 4228 506 1518 2687 0 [LN:MALQ_STRPN] [AC:P29851] [GN:MALM] [OR:Streptococcus pneumoniae] [EC:2.4.1.25] [DE:(DISPROPORTIONATING ENZYME) 137 (D-ENZYME)] [SP:P29851] SPX1568 1568 4229 424 1272 2167 3.30E−288 [LN:MALX_STRPN] [AC:P29850] [GN:MALX] [OR:Streptococcus pneumoniae] [DE:MALTOSE/MALTODEXTRIN-BINDING PROTEIN 131 PRECURSOR] [SP:P29850] SPX1569 1569 4230 431 1293 2176 0 [LN:MALC_STRPN] [AC:Q04698] [GN:MALC] [OR:Streptococcus pneumoniae] [DE:MALTODEXTRIN TRANSPORT SYSTEM PERMEASE 136 PROTEIN MALC] [SP:Q04698] SPX1570 1570 4231 281 843 1265 2.40E−177 [LN:MALD_STRPN] [AC:Q04699] [GN:MALD] [OR:Streptococcus pneumoniae] [DE:MALTODEXTRIN TRANSPORT SYSTEM PERMEASE 136 PROTEIN MALD] [SP:Q04699] SPX1571 1571 4232 267 801 540 1.70E−145 [LN:MALA_STRPN] [AC:Q08510] [GN:MALA] [OR:Streptococcus pneumoniae] [DE:MALA PROTEIN] [SP:Q08510] 97 SPX1572 1572 4233 329 987 1668 7.30E−227 [GI:2656094] [LN:STRMALR] [AC:L21856] [PN:repressor protein] [GN:malR] [FN:maltose operon transcriptional repressor] 146 [OR:Streptococcus pneumoniae] SPX1573 1573 4234 114 342 NO-HIT 6 SPX1574 1574 4235 127 381 378 8.30E−48 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX1575 1575 4236 314 942 463 6.90E−73 [GI:1620924] [LN:BS168NPRB] [AC:Z79580] [OR:Bacillus subtilis] 62 SPX1576 1576 4237 588 1764 701 1.30E−229 [LN:SYD_BACSU] [AC:O32038] [GN:ASPS] [OR:Bacillus subtilis] [EC:6.1.1.12] [DE:(ASPRS)] [SP:O32038] 98 SPX1577 1577 4238 144 432 NO-HIT 6 SPX1578 1578 4239 64 192 NO-HIT 6 SPX1579 1579 4240 77 231 NO-HIT 6 SPX1580 1580 4241 214 642 120 9.80E−14 [GI:1402529] [LN:D78257] [AC:D78257] [PN:ORF8] [GN:orf8] [OR:Enterococcus faecalis] [SR:Enterococcus faecalis plasmid:pYI17 DNA] 128 SPX1581 1581 4242 247 741 NO-HIT 6 SPX1582 1582 4243 67 201 NO-HIT 6 SPX1583 1583 4244 155 465 78 0.00011 [LN:T07291] [AC:T07291] [PN:hypothetical protein 42c] [OR:chloroplast Chlorella vulgaris] 89 SPX1584 1584 4245 62 186 NO-HIT 6 SPX1585 1585 4246 64 192 NO-HIT 6 SPX1586 1586 4247 63 189 200 7.00E−24 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX1587 1587 4248 430 1290 1740 7.50E−236 [LN:SYH_STREQ] [AC:P30053] [GN:HISS] [OR:Streptococcus equisimilis] [EC:6.1.1.21] [DE:(HISRS)] [SP:P30053] 106 SPX1588 1588 4249 307 921 NO-HIT 6 SPX1589 1589 4250 416 1248 334 2.10E−57 [GI:3582221] [LN:AE001272] [AC:AE001272] [PN:conserved hypothetical protein] [GN:ORF00049] [OR:Lactococcus lactis] 114 SPX1590 1590 4251 133 399 NO-HIT 6 SPX1591 1591 4252 284 852 301 1.70E−34 [LN:RGG_STRGC] [AC:P49330] [GN:RGG] [OR:Streptococcus gordonii challis] [DE:RGG PROTEIN] [SP:P49330] 100 SPX1592 1592 4253 114 342 227 6.60E−27 [GI:2258088] [LN:AB000631] [AC:AB000631] [OR:Streptococcus mutans] [SR:Streptococcus mutans DNA] 96 SPX1593 1593 4254 568 1704 994 1.30E−207 “[LN:S76895] [AC:S76895] [PN:hypothetical protein] [CL:dihydroxy-acid dehydratase] [OR:Synechocystis sp.] [SR:PCC 6803, , PCC 6803] 148 [SR:PCC 6803, ]” SPX1594 1594 4255 311 933 272 2.40E−45 “[LN:TKTC_METJA] [AC:Q58092] [GN:MJ0679] [OR:Methanococcus jannaschii] [EC:2.2.1.1] [DE:PUTATIVE 149 TRANSKETOLASE C-TERMINAL SECTION, (TK)] [SP:Q58092]” SPX1595 1595 4256 286 858 347 7.70E−66 “[LN:TKTN_METJA] [AC:Q58094] [GN:MJ0681] [OR:Methanococcus jannaschii] [EC:2.2.1.1] [DE:PUTATIVE 149 TRANSKETOLASE N-TERMINAL SECTION, (TK)] [SP:Q58094]” SPX1596 1596 4257 449 1347 535 9.90E−132 [LN:T37066] [AC:T37066] [PN:probable integral membrane protein] [GN:SCJ21.17c] [OR:Streptomyces coelicolor] 107 SPX1597 1597 4258 95 285 NO-HIT 6 SPX1598 1598 4259 677 2031 197 8.80E−31 “[GI:4512373] [LN:AB011837] [AC:AB011837] [GN:yjdC] [OR:Bacillus halodurans] [SR:Bacillus halodurans (strain:C-125) DNA, 144 clone_lib:lambda no.9]” SPX1599 1599 4260 336 1008 133 1.30E−18 [GI:6689167] [LN:SCE20] [AC:AL136058] [PN:putative membrane protein] [GN:SCE20.08c] [OR:Streptomyces coelicolor A3(2)] 118 SPX1600 1600 4261 67 201 NO-HIT 6 SPX1601 1601 4262 61 183 240 3.00E−28 “[LN:RL32_LACLC] [AC:O34101] [GN:RPMF] [OR:Lactococcus lactis] [SR:,subspcremoris:Streptococcus cremoris] [DE:50S RIBOSOMAL 149 PROTEIN L32] [SP:O34101]” SPX1602 1602 4263 642 1926 1320 0 [GI:1914872] [LN:SPZ82001] [AC:Z82001] [PN:PCPA] [GN:pcpA] [OR:Streptococcus pneumoniae] 88 SPX1603 1603 4264 76 228 NO-HIT 6 SPX1604 1604 4265 192 576 429 4.10E−54 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX1605 1605 4266 126 378 303 4.10E−37 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX1606 1606 4267 109 327 495 7.70E−65 [GI:1914871] [LN:SPZ82001] [AC:Z82001] [PN:unknown] [OR:Streptococcus pneumoniae] 81 SPX1607 1607 4268 627 1881 95 0.00073 [LN:T27355] [AC:T27355] [PN:hypothetical protein Y70D2A.2] [GN:Y70D2A.2] [OR:Caenorhabditis elegans] 100 SPX1608 1608 4269 290 870 108 2.70E−22 “[LN:F70203] [AC:F70203] [PN:xylose operon regulatory protein (xylR-2) homolog] [CL:glucose kinase:glucose kinase homology] [OR:Borrelia 181 burgdorferi] [SR:, Lyme disease spirochete]” SPX1609 1609 4270 887 2661 345 6.30E−65 [LN:YBGG_ECOLI] [AC:P54746:P75753] [GN:YBGG] [OR:Escherichia coli] [DE:HYPOTHETICAL 100.0 KD PROTEIN IN HRSA-CYDA 151 INTERGENIC REGION] [SP:P54746:P75753] SPX1610 1610 4271 435 1305 409 6.20E−106 [LN:T37125] [AC:T37125] [PN:hypothetical protein SCJ4.42c] [GN:SCJ4.42c] [OR:Streptomyces coelicolor] 101 SPX1611 1611 4272 695 2085 408 9.50E−105 [GI:5759293] [LN:AF175722] [AC:AF175722] [PN:immunoreactive 89kD antigen PG87] [OR:Porphyromonas gingivalis] 108 SPX1612 1612 4273 560 1680 249 2.20E−63 “[GI:4096756] [LN:SSU39394] [AC:U39394] [PN:alpha-1,3/4-fucosidase precursor] [FN:alpha-fucosidase specific for alpha-1,3 and] [OR:Streptomyces 170 sp.] [SR:Streptomyces sp]” SPX1613 1613 4274 410 1230 942 1.30E−244 [LN:SAGP_STRPY] [AC:P16962] [GN:SAGP] [OR:Streptococcus pyogenes] [DE:STREPTOCOCCAL ACID GLYCOPROTEIN] [SP:P16962] 114 SPX1614 1614 4275 339 1017 897 3.80E−184 [GI:2764612] [LN:LSAJ1330] [AC:AJ001330] [PN:ornithine transcarbamoylase] [GN:arcB] [OR:Lactobacillus sakei] 108 SPX1615 1615 4276 316 948 465 3.40E−129 [GI:2894540] [LN:EFAJ3331] [AC:AJ223331] [PN:carbamate kinase] [GN:arcC] [FN:synthesis of ATP from carbamylphosphate] 143 [OR:Enterococcus faecium] SPX1616 1616 4277 504 1512 426 4.50E−106 [GI:2697115] [LN:AF008219] [AC:AF008219] [PN:unknown] [OR:Borrelia afzelii] 75 SPX1617 1617 4278 444 1332 277 8.20E−67 [LN:S43914] [AC:S43914] [PN:hypothetical protein 1] [CL:peptidase V] [OR:Bacillus stearothermophilus] 101 SPX1618 1618 4279 64 192 NO-HIT 6 SPX1619 1619 4280 79 237 NO-HIT 6 SPX1620 1620 4281 89 267 NO-HIT 6 SPX1621 1621 4282 51 153 NO-HIT 6 SPX1622 1622 4283 72 216 176 4.20E−20 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX1623 1623 4284 55 165 NO-HIT 6 SPX1624 1624 4285 300 900 560 2.70E−78 [GI:6714460] [LN:ATAC008261] [AC:AC008261] [GN:T4P13.3] [OR:Arabidopsis thaliana] [SR:thale cress] 98 SPX1625 1625 4286 64 192 NO-HIT 6 SPX1626 1626 4287 384 1152 840 1.50E−119 “[LN:ADH2_ECOLI] [AC:P37686] [GN:YIAY] [OR:Escherichia coli] [EC:1.1.1.1] [DE:PROBABLE ALCOHOL DEHYDROGENASE,] [SP:P37686]” 123 SPX1627 1627 4288 589 1767 874 7.80E−287 [GI:6015981] [LN:AF137263] [AC:AF137263] [PN:L-fucose isomerase] [GN:fucI] [OR:Bacteroides thetaiotaomicron] 108 SPX1628 1628 4289 243 729 201 8.40E−20 “[LN:B70645] [AC:B70645] [PN:L-fuculose-phosphate aldolase,] [GN:fucA] [CL:L-ribulose-phosphate 4-epimerase] [OR:Mycobacterium tuberculosis] 155 [EC:4.1.2.17]” SPX1629 1629 4290 1029 3087 NO-HIT 6 SPX1630 1630 4291 738 2214 1709 3.00E−243 [GI:4567098] [LN:AF130985] [AC:AF130985] [PN:alpha-galactosidase AgaN] [GN:agaN] [OR:Bacillus stearothermophilus] 113 SPX1631 1631 4292 624 1872 112 5.60E−07 [LN:T36462] [AC:T36462] [PN:hypothetical protein SCF85.02] [GN:SCF85.02] [OR:Streptomyces coelicolor] 101 SPX1632 1632 4293 440 1320 174 1.10E−50 [LN:T36467] [AC:T36467] [PN:probable glycosyl hydrolase] [GN:SCF85.07] [CL:alpha-L-fucosidase] [OR:Streptomyces coelicolor] 123 SPX1633 1633 4294 62 186 NO-HIT 6 SPX1634 1634 4295 295 885 372 3.60E−50 [LN:YURM_BACSU] [AC:O32154] [GN:YURM] [OR:Bacillus subtilis] [DE:HYPOTHETICAL ABC TRANSPORTER PERMEASE PROTEIN YURM] 128 [SP:O32154] SPX1635 1635 4296 310 930 163 7.70E−27 “[LN:E72357] [AC:E72357] [PN:sugar ABC transporter, permease protein] [GN:TM0596] [CL:inner membrane protein malF] [OR:Thermotoga maritima]” 140 SPX1636 1636 4297 431 1293 84 5.60E−07 [GI:1524333] [LN:SCMALREFG] [AC:Y07706] [PN:putative maltose-binding pootein] [GN:malE] [OR:Streptomyces coelicolor] 116 SPX1637 1637 4298 468 1404 210 2.00E−81 “[LN:E70014] [AC:E70014] [PN:rhamnulokinase, yulC] [GN:yulC] [CL:rhamnulokinase] [OR:Bacillus subtilis] [EC:2.7.1.5]” 117 SPX1638 1638 4299 59 177 NO-HIT 6 SPX1639 1639 4300 258 774 123 7.20E−21 [LN:SRLR_ECOLI] [AC:P15082:P77030] [GN:SRLR:GUTR] [OR:Escherichia coli] [DE:GLUCITOL OPERON REPRESSOR] [SP:P15082:P77030] 121 SPX1640 1640 4301 73 219 NO-HIT 6 SPX1641 1641 4302 69 207 NO-HIT 6 SPX1642 1642 4303 502 1506 2158 8.80E−289 [LN:T46756] [AC:T46756] [PN:Zn-binding lipoprotein adcA [imported]] [GN:adcA] [OR:Streptococcus pneumoniae] 107 SPX1643 1643 4304 269 807 1261 4.10E−177 [LN:T46755] [AC:T46755] [PN:membrane protein adcB [imported]] [GN:adcB] [OR:Streptococcus pneumoniae] 101 SPX1644 1644 4305 235 705 1247 1.40E−168 [LN:T46754] [AC:T46754] [PN:AdcC protein [imported]] [GN:adcC] [OR:Streptococcus pneumoniae] 92 SPX1645 1645 4306 64 192 89 1.20E−06 [LN:G72536] [AC:G72536] [PN:hypothetical protein APE1580] [GN:APE1580] [OR:Aeropyrum pernix] 92 SPX1646 1646 4307 167 501 728 1.10E−95 [LN:T46753] [AC:T46753] [PN:repressor protein adcR [imported]] [GN:adcR] [OR:Streptococcus pneumoniae] 102 SPX1647 1647 4308 428 1284 612 1.10E−162 [GI:3403204] [LN:AF050517] [AC:AF050517:S78492] [PN:unknown] [GN:dlt4] [OR:Streptococcus mutans] 96 SPX1648 1648 4309 80 240 360 8.20E−46 [GI:2981430] [LN:AF049357] [AC:AF049357:S78492] [PN:Glg3] [GN:glg3] [OR:Streptococcus mutans] 93 SPX1649 1649 4310 415 1245 1236 2.30E−227 [GI:2952530] [LN:AF051356] [AC:AF051356] [PN:integral membrane protein] [GN:dltB] [OR:Streptococcus mutans] 107 SPX1650 1650 4311 517 1551 2154 1.90E−292 [LN:DLTA_STRMU] [AC:Q53526:O68576] [GN:DLTA] [OR:Streptococcus mutans] [EC:6.3.2.-] [DE:ALANYL CARRIER PROTEIN LIGASE) 144 (DCL)] [SP:Q53526:O68576] SPX1651 1651 4312 66 198 NO-HIT 6 SPX1652 1652 4313 174 522 215 3.50E−24 [LN:H69812] [AC:H69812] [PN:conserved hypothetical protein yfmI] [GN:yfmI] [OR:Bacillus subtilis] 97 SPX1653 1653 4314 237 711 97 2.60E−14 [LN:H69812] [AC:H69812] [PN:conserved hypothetical protein yfmI] [GN:yfmI] [OR:Bacillus subtilis] 97 SPX1654 1654 4315 62 186 NO-HIT 6 SPX1655 1655 4316 63 189 NO-HIT 6 SPX1656 1656 4317 331 993 1712 2.40E−235 [GI:2804734] [LN:AF030367] [AC:AF030367] [PN:maturase-related protein] [OR:Streptococcus pneumoniae] 100 SPX1657 1657 4318 94 282 470 6.40E−60 [GI:2804734] [LN:AF030367] [AC:AF030367] [PN:maturase-related protein] [OR:Streptococcus pneumoniae] 100 SPX1658 1658 4319 82 246 NO-HIT 6 SPX1659 1659 4320 66 198 NO-HIT 6 SPX1660 1660 4321 196 588 NO-HIT 6 SPX1661 1661 4322 68 204 344 4.40E−42 [GI:1217989] [LN:SPU12567] [AC:U12567] [PN:ORF3] [OR:Streptococcus pneumoniae] 78 SPX1662 1662 4323 253 759 968 2.20E−159 [LN:GLPF_STRPN] [AC:P52281] [GN:GLPF] [OR:Streptococcus pneumoniae] [DE:GLYCEROL UPTAKE FACILITATOR PROTEIN] [SP:P52281] 120 SPX1663 1663 4324 609 1827 3058 0 [GI:3551774] [LN:SPU94770] [AC:U94770] [PN:alpha-glycerophosphate oxidase] [GN:glpO] [FN:oxidizes alpha-glycerophosphate to] 154 [OR:Streptococcus pneumoniae] SPX1664 1664 4325 100 300 302 1.90E−38 “[LN:S67936] [AC:S67936] [PN:glycerol-3-phosphate dehydrogenase homolog GlpD] [GN:glpD] [OR:Streptococcus pneumoniae] [SR:strain P13, , 166 strain P13] [SR:strain P13, ]” SPX1665 1665 4326 503 1509 1251 2.90E−274 “[LN:GLPK_ENTFA] [AC:O34154] [GN:GLPK] [OR:Enterococcus faecalis] [SR:,Streptococcus faecalis] [EC:2.7.1.30] [DE:(GLYCEROKINASE) 147 (GK)] [SP:O34154]” SPX1666 1666 4327 476 1428 NO-HIT 6 SPX1667 1667 4328 66 198 NO-HIT 6 SPX1668 1668 4329 291 873 1063 2.60E−140 [GI:4033717] [LN:SPU49397] [AC:U49397] [PN:unknown] [OR:Streptococcus pyogenes] 79 SPX1669 1669 4330 327 981 1303 4.70E−175 [GI:4033718] [LN:SPU49397] [AC:U49397] [PN:unknown] [OR:Streptococcus pyogenes] 79 SPX1670 1670 4331 63 189 NO-HIT 6 SPX1671 1671 4332 222 666 235 4.10E−25 [GI:558538] [LN:SUHSAPI] [AC:D38490] [PN:sperm-activating peptide I precursor] [OR:Hemicentrotus pulcherrimus] [SR:Hemicentrotus pulcherrimus 179 female ovary accessory cell (library] SPX1672 1672 4333 451 1353 500 6.50E−65 [GI:4838563] [LN:AF145055] [AC:AF145055] [PN:surface protein C PspC] [OR:Streptococcus pneumoniae] 98 SPX1673 1673 4334 183 549 213 1.70E−21 [GI:7293488] [LN:AE003509] [AC:AE003509:AE002593] [GN:CG15040] [OR:Drosophila melanogaster] [SR:fruit fly] 106 SPX1674 1674 4335 176 528 112 1.00E−08 [GI:406446] [LN:MGU02192] [AC:U02192] [OR:Mycoplasma genitalium] 64 SPX1675 1675 4336 182 546 107 1.20E−15 [GI:3849798] [LN:U91581] [AC:U91581:U04057] [PN:putative transposase] [GN:tpase] [OR:Lactococcus lactis subsp. lactis] 118 SPX1676 1676 4337 251 753 175 7.10E−43 [GI:6746427] [LN:AF179847] [AC:AF179847] [PN:putative transposase] [OR:Lactococcus lactis] 90 SPX1677 1677 4338 65 195 NO-HIT 6 SPX1678 1678 4339 55 165 183 1.50E−19 [GI:2576331] [LN:SPSPSA2] [AC:AJ002054] [PN:SpsA protein] [FN:IgA binding protein] [OR:Streptococcus pneumoniae] 112 SPX1679 1679 4340 419 1257 2039 1.30E−284 [GI:2804700] [LN:AF030361] [AC:AF030361] [PN:transposase] [OR:Streptococcus pneumoniae] 87 SPX1680 1680 4341 232 696 1296 1.20E−171 [GI:4097980] [LN:SPU72655] [AC:U72655] [PN:surface protein C] [GN:pspC] [OR:Streptococcus pneumoniae] 101 SPX1681 1681 4342 110 330 NO-HIT 6 SPX1682 1682 4343 105 315 98 7.50E−05 [LN:T14867] [AC:T14867] [PN:interaptin] [GN:abpD] [OR:Dictyostelium discoideum] 79 SPX1683 1683 4344 217 651 599 1.00E−117 [GI:6469845] [LN:AF068645] [AC:AF068645] [PN:unknown] [GN:pspC] [OR:Streptococcus pneumoniae] 93 SPX1684 1684 4345 73 219 66 0.001 “[GI:340613] [LN:LEIKPMURF2] [AC:L07545] [GN:MURF2] [OR:Kinetoplast Leishmania tarentolae] [SR:Kinetoplast Leishmania tarentolae 163 (strain UC, organelle Kinetoplas]” SPX1685 1685 4346 105 315 94 1.40E−05 “[LN:YHU3_YEAST] [AC:P38844] [GN:YHR143W] [OR:Saccharomyces cerevisiae] [SR:,Baker's yeast] [DE:PRECURSOR] [SP:P38844]” 119 SPX1686 1686 4347 276 828 697 7.60E−123 [GI:2576333] [LN:SPSPSA47] [AC:AJ002055] [PN:SpsA protein] [FN:IgA binding protein] [OR:Streptococcus pneumoniae] 113 SPX1687 1687 4348 176 528 382 1.80E−50 [LN:F81147] [AC:F81147] [PN:conserved hypothetical protein NMB0883 [imported]] [GN:NMB0883] [OR:Neisseria meningitidis] 119 SPX1688 1688 4349 447 1341 1245 0 [GI:5830533] [LN:SPAJ6395] [AC:AJ006395] [PN:histidine kinase] [GN:hk06] [OR:Streptococcus pneumoniae] 102 SPX1689 1689 4350 218 654 1100 3.60E−150 [GI:5830532] [LN:SPAJ6395] [AC:AJ006395] [PN:response regulator] [GN:rr06] [OR:Streptococcus pneumoniae] 104 SPX1690 1690 4351 75 225 NO-HIT 6 SPX1691 1691 4352 811 2433 1102 3.30E−266 [GI:4103472] [LN:AF023422] [AC:AF023422] [PN:ClpC] [GN:clpC] [OR:Lactococcus lactis] 84 SPX1692 1692 4353 174 522 323 4.90E−44 [LN:LLA249133] [AC:AJ249133] [PN:CtsR protein] [GN:ctsR] [FN:transcriptional regulator] [OR:Lactococcus lactis] 111 SPX1693 1693 4354 243 729 255 1.80E−47 “[LN:B72369] [AC:B72369] [PN:ABC transporter, ATP-binding protein] [GN:TM0483] [CL:unassigned ATP-binding cassette proteins:ATP-binding 180 cassette homology] [OR:Thermotoga maritima]” SPX1694 1694 4355 336 1008 561 9.10E−87 [LN:C72369] [AC:C72369] [PN:hypothetical protein TM0484] [GN:TM0484] [OR:Thermotoga maritima] 93 SPX1695 1695 4356 136 408 NO-HIT 6 SPX1696 1696 4357 250 750 440 1.10E−58 “[LN:D72369] [AC:D72369] [PN:ABC transporter, permease protein, cysTW family] [GN:TM0485] [CL:Synechococcus nitrate transport protein nrtB] 165 [OR:Thermotoga maritima]” SPX1697 1697 4358 97 291 118 4.00E−14 [LN:YVI2_CLOPE] [AC:Q46213] [OR:Clostridium perfringens] [DE:HYPOTHETICAL 10.7 KD PROTEIN IN VIRR 5′REGION (ORF2)] [SP:Q46213] 126 SPX1698 1698 4359 284 852 319 8.30E−35 [LN:S57721] [AC:S57721] [PN:cspB protein] [CL:cpl repeat homology] [OR:Clostridium acetobutylicum] 98 SPX1699 1699 4360 138 414 102 7.10E−06 [GI:1340128] [LN:SA1234] [AC:X97985] [OR:Staphylococcus aureus] 63 SPX1700 1700 4361 89 267 72 3.10E−05 [LN:VEG_BACSU] [AC:P37466] [GN:VEG] [OR:Bacillus subtilis] [DE:VEG PROTEIN] [SP:P37466] 87 SPX1701 1701 4362 451 1353 827 1.60E−171 “[LN:DNAC_BACSU] [AC:P37469] [GN:DNAC] [OR:Bacillus subtilis] [EC:3.6.1.-] [DE:REPLICATIVE DNA HELICASE,] [SP:P37469]” 118 SPX1702 1702 4363 151 453 193 1.20E−44 [LN:RL9_BACST] [AC:P02417] [GN:RPLI] [OR:Bacillus stearothermophilus] [DE:50S RIBOSOMAL PROTEIN L9 (BL17)] [SP:P02417] 118 SPX1703 1703 4364 658 1974 301 6.60E−68 [LN:YYBT_BACSU] [AC:P37484] [GN:YYBT] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 74.3 KD PROTEIN IN RPLI-COTF INTERGENIC 137 REGION] [SP:P37484] SPX1704 1704 4365 183 549 358 5.10E−68 [LN:LLA249134] [AC:AJ249134] [PN:hypothetical protein] [OR:Lactococcus lactis] 78 SPX1705 1705 4366 221 663 143 2.90E−23 [LN:CMF3_BACSU] [AC:P39147] [GN:COMFC:COMF3] [OR:Bacillus subtilis] [DE:COMF OPERON PROTEIN 3] [SP:P39147] 106 SPX1706 1706 4367 433 1299 269 2.00E−31 [LN:CMF1_BACSU] [AC:P39145] [GN:COMFA:COMF1] [OR:Bacillus subtilis] [DE:COMF OPERON PROTEIN 1] [SP:P39145] 106 SPX1707 1707 4368 212 636 475 1.00E−60 [LN:YVYE_BACSU] [AC:P32437:P96500] [GN:YVYE:YVHK] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 24.8 KD PROTEIN IN DEGS-TAGO 156 INTERGENIC REGION] [SP:P32437:P96500] SPX1708 1708 4369 309 927 1289 7.30E−171 [GI:6567187] [LN:AB028865] [AC:AB028865] [PN:O-acetylserine lyase] [GN:cysM] [OR:Streptococcus suis] [SR:Streptococcus 141 suis (strain:SMR) DNA] SPX1709 1709 4370 347 1041 498 1.10E−82 [LN:EFTS_BACSU] [AC:P80700:O31748] [GN:TSF] [OR:Bacillus subtilis] [DE:ELONGATION FACTOR TS (EF-TS)] [SP:P80700:O31748] 119 SPX1710 1710 4371 129 387 NO-HIT 6 SPX1711 1711 4372 288 864 1013 1.60E−135 [LN:RS2_PEDAC] [AC:P49668] [GN:RPSB] [OR:Pediococcus acidilactici] [DE:30S RIBOSOMAL PROTEIN S2] [SP:P49668] 108 SPX1712 1712 4373 75 225 NO-HIT 6 SPX1713 1713 4374 393 1179 459 3.30E−76 [LN:JN0097] [AC:JN0097] [PN:secreted 45K protein precursor] [OR:Lactococcus lactis] 83 SPX1714 1714 4375 80 240 NO-HIT 6 SPX1715 1715 4376 165 495 108 7.90E−08 [LN:MRED_BACSU] [AC:Q01467] [GN:MRED:RODB] [OR:Bacillus subtilis] [DE:ROD SHAPE−DETERMINING PROTEIN MRED] [SP:Q01467] 117 SPX1716 1716 4377 273 819 141 1.60E−17 [LN:MREC_BACSU] [AC:Q01466] [GN:MREC] [OR:Bacillus subtilis] [DE:ROD SHAPE−DETERMINING PROTEIN MREC] [SP:Q01466] 112 SPX1717 1717 4378 265 795 694 1.30E−95 [LN:F69742] [AC:F69742] [PN:hypothetical protein ybaF] [GN:ybaF] [OR:Bacillus subtilis] 87 SPX1718 1718 4379 57 171 NO-HIT 6 SPX1719 1719 4380 280 840 623 4.20E−94 [LN:E69742] [AC:E69742] [PN:ABC transporter (ATP-binding protein) homolog ybaE] [GN:ybaE] [CL:unassigned ATP-binding cassette 188 proteins:ATP-binding cassette homology] [OR:Bacillus subtilis] SPX1720 1720 4381 116 348 127 7.40E−11 [LN:C71234] [AC:C71234] [PN:hypothetical protein PH0133] [GN:PH0133] [OR:Pyrococcus horikoshii] 95 SPX1721 1721 4382 262 786 853 1.50E−116 [GI:3426368] [LN:AF082738] [AC:AF082738] [PN:ABC transporter ATP-binding protein] [GN:stpA] [OR:Streptococcus pyogenes] 119 SPX1722 1722 4383 75 225 106 1.30E−09 [LN:A71007] [AC:A71007] [PN:hypothetical protein PH1351] [GN:PH1351] [OR:Pyrococcus horikoshii] 95 SPX1723 1723 4384 182 546 531 6.40E−72 [GI:3426367] [LN:AF082738] [AC:AF082738] [PN:phosphotidylglycerophosphate synthase] [GN:pgsA] [OR:Streptococcus pyogenes] 121 SPX1724 1724 4385 277 831 100 1.50E−21 [GI:3426366] [LN:AF082738] [AC:AF082738] [PN:unknown] [OR:Streptococcus pyogenes] 81 SPX1725 1725 4386 428 1284 403 1.10E−102 [GI:3426365] [LN:AF082738] [AC:AF082738] [PN:unknown] [OR:Streptococcus pyogenes] 81 SPX1726 1726 4387 417 1251 694 2.70E−103 [GI:3426364] [LN:AF082738] [AC:AF082738] [PN:unknown] [OR:Streptococcus pyogenes] 81 SPX1727 1727 4388 123 369 148 1.20E−26 [LN:JC4754] [AC:JC4754] [PN:hypothetical 13.6k protein] [GN:recF] [OR:Lactococcus lactis] 89 SPX1728 1728 4389 366 1098 1127 1.20E−163 [LN:RECF_STRPY] [AC:P49999] [GN:RECF] [OR:Streptococcus pyogenes] [DE:RECF PROTEIN] [SP:P49999] 95 SPX1729 1729 4390 493 1479 2283 0 [LN:IMDH_STRPY] [AC:P50099] [GN:GUAB] [OR:Streptococcus pyogenes] [EC:1.1.1.205] [DE:DEHYDROGENASE) (IMPDH) (IMPD)] [SP:P50099] 127 SPX1730 1730 4391 49 147 99 1.30E−07 [LN:F71456] [AC:F71456] [PN:hypothetical protein PH0308] [GN:PH0308] [OR:Pyrococcus horikoshii] 95 SPX1731 1731 4392 342 1026 672 2.00E−153 [LN:SYW_CLOLO] [AC:Q46127] [GN:TRPS:TRSA] [OR:Clostridium longisporum] [EC:6.1.1.2] [DE:(TRPRS)] [SP:Q46127] 108 SPX1732 1732 4393 541 1623 1364 9.40E−252 [LN:E69861] [AC:E69861] [PN:ABC transporter (ATP-binding protein) homolog ykpA] [GN:ykpA] [CL:unassigned ATP-binding cassette 188 proteins:ATP-binding cassette homology] [OR:Bacillus subtilis] SPX1733 1733 4394 851 2553 503 1.40E−88 [GI:3043878] [LN:LLU95840] [AC:U95840] [PN:transmembrane protein Tmp5] [OR:Lactococcus lactis] 94 SPX1734 1734 4395 105 315 181 5.50E−19 [LN:YHGE_BACSU] [AC:P32399] [GN:YHGE] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 84.1 KD PROTEIN IN HEMY-GLTT INTERGENIC 144 REGION (ORFB)] [SP:P32399] SPX1735 1735 4396 113 339 138 1.10E−11 [LN:YHGE_BACSU] [AC:P32399] [GN:YHGE] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 84.1 KD PROTEIN IN HEMY-GLTT INTERGENIC 144 REGION (ORFB)] [SP:P32399] SPX1736 1736 4397 256 768 307 2.50E−46 [GI:3043882] [LN:LLU95842] [AC:U95842] [PN:transmembrane protein Tmp7] [OR:Lactococcus lactis] 94 SPX1737 1737 4398 181 543 98 5.30E−09 [GI:6899263] [LN:AE002125] [AC:AE002125:AF222894] [PN:unique hypothetical] [GN:UU290] [OR:Ureaplasma urealyticum] 113 SPX1738 1738 4399 251 753 1294 2.50E−176 [GI:1613769] [LN:SPU33315] [AC:U33315] [PN:response regulator] [GN:comE] [OR:Streptococcus pneumoniae] 102 SPX1739 1739 4400 442 1326 2246 0 [GI:1613768] [LN:SPU33315] [AC:U33315] [PN:histidine protein kinase] [GN:comD] [OR:Streptococcus pneumoniae] 108 SPX1740 1740 4401 160 480 781 4.50E−104 [GI:2109449] [LN:SPDNAARG] [AC:AF000658] [FN:unknown] [OR:Streptococcus pneumoniae] 83 SPX1741 1741 4402 398 1194 1963 8.90E−259 [GI:2109443] [LN:SPDNAARG] [AC:AF000658] [PN:putative serine protease] [GN:sphtra] [OR:Streptococcus pneumoniae] 112 SPX1742 1742 4403 253 759 1225 5.80E−163 [GI:2109444] [LN:SPDNAARG] [AC:AF000658] [PN:SPSpoJ] [GN:spspoJ] [FN:unknown] [OR:Streptococcus pneumoniae] 107 SPX1743 1743 4404 454 1362 2287 0 [LN:DNAA_STRPN] [AC:O08397] [GN:DNAA] [OR:Streptococcus pneumoniae] [DE:CHROMOSOMAL REPLICATION INITIATOR PROTEIN 131 DNAA] [SP:O08397] SPX1744 1744 4405 379 1137 1857 2.90E−250 “[LN:DP3B_STRPN] [AC:O06672] [GN:DNAN] [OR:Streptococcus pneumoniae] [EC:2.7.7.7] [DE:DNA POLYMERASE III, BETA CHAIN,] 131 [SP:O06672]” SPX1745 1745 4406 65 195 339 1.60E−43 [GI:2109447] [LN:SPDNAARG] [AC:AF000658] [FN:unknown] [OR:Streptococcus pneumoniae] 83 SPX1746 1746 4407 375 1125 710 9.10E−176 [LN:YYAF_BACSU] [AC:P37518] [GN:YYAF] [OR:Bacillus subtilis] [DE:REGION] [SP:P37518] 84 SPX1747 1747 4408 190 570 368 3.70E−62 [LN:SP5C_BACSU] [AC:P37470] [GN:SPOVC:PTH] [OR:Bacillus subtilis] [EC:3.1.1.29] [DE:SPORULATION PROTEIN C)] [SP:P37470] 119 SPX1748 1748 4409 1170 3510 2088 0 [GI:3511015] [LN:AF054624] [AC:AF054624] [PN:transcription-repair coupling factor] [GN:mfd] [OR:Lactobacillus sakei] 116 SPX1749 1749 4410 99 297 NO-HIT 6 SPX1750 1750 4411 89 267 275 3.50E−33 [LN:YABO_BACSU] [AC:P37557] [GN:YABO] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 9.7 KD PROTEIN IN MFD-DIVIC INTERGENIC 136 REGION] [SP:P37557] SPX1751 1751 4412 123 369 112 1.50E−08 [GI:4090866] [LN:AF023181] [AC:AF023181] [PN:DivIC homolog] [GN:divL] [OR:Listeria monocytogenes] 97 SPX1752 1752 4413 74 222 NO-HIT 6 SPX1753 1753 4414 446 1338 NO-HIT 6 SPX1754 1754 4415 426 1278 128 6.70E−28 [LN:D72358] [AC:D72358] [PN:conserved hypothetical protein] [GN:TM0579] [CL:hypothetical protein HI0404] [OR:Thermotoga maritima] 129 SPX1755 1755 4416 181 543 374 1.10E−80 “[LN:HPRT_LACLA] [AC:Q02522] [GN:HPT] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:2.4.2.8] [DE:(HGPRTASE)] 142 [SP:Q02522]” SPX1756 1756 4417 653 1959 3277 0 [GI:5030426] [LN:AF061748] [AC:AF061748] [PN:cell division protein FtsH] [GN:ftsH] [OR:Streptococcus pneumoniae] 112 SPX1757 1757 4418 208 624 181 9.80E−25 [LN:A71115] [AC:A71115] [PN:hypothetical protein PH0688] [GN:PH0688] [OR:Pyrococcus horikoshii] 95 SPX1758 1758 4419 36 108 NO-HIT 6 SPX1759 1759 4420 160 480 844 9.40E−114 [GI:5739312] [LN:AF161700] [AC:AF161700] [PN:ComX1] [GN:comX1] [FN:transcriptional regulator of] [OR:Streptococcus pneumoniae] 126 SPX1760 1760 4421 82 246 NO-HIT 6 SPX1761 1761 4422 50 150 82 7.60E−06 [LN:G71244] [AC:G71244] [PN:hypothetical protein PH0217] [GN:PH0217] [OR:Pyrococcus horikoshii] 95 SPX1762 1762 4423 62 186 NO-HIT 6 SPX1763 1763 4424 87 261 136 3.90E−14 [LN:G81516] [AC:G81516] [PN:hypothetical protein CP0988 [imported]] [GN:CP0988] [OR:Chlamydophila pneumoniae:Chlamydia pneumoniae] 130 SPX1764 1764 4425 136 408 NO-HIT 6 SPX1765 1765 4426 52 156 NO-HIT 6 SPX1766 1766 4427 52 156 87 3.30E−06 [LN:D75542] [AC:D75542] [PN:hypothetical protein] [GN:DR0254] [OR:Deinococcus radiodurans] 90 SPX1767 1767 4428 82 246 247 1.10E−29 [LN:F81737] [AC:F81737] [PN:hypothetical protein TC0129 [imported]] [GN:TC0129] [OR:Chlamydia muridarum:Chlamydia trachomatis MoPn] 131 SPX1768 1768 4429 78 234 143 4.90E−15 [LN:F71245] [AC:F71245] [PN:hypothetical protein PHS004] [GN:PHS004] [OR:Pyrococcus horikoshii] 95 SPX1769 1769 4430 69 207 340 7.40E−44 [GI:5019553] [LN:SPN239004] [AC:AJ239004] [PN:putative transposase] [OR:Streptococcus pneumoniae] 97 SPX1770 1770 4431 82 246 256 1.40E−36 [GI:663279] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae 138 (strain RX1) DNA] SPX1771 1771 4432 47 141 119 1.30E−09 [GI:2804700] [LN:AF030361] [AC:AF030361] [PN:transposase] [OR:Streptococcus pneumoniae] 87 SPX1772 1772 4433 91 273 387 3.30E−50 [GI:663278] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae 138 (strain RX1) DNA] SPX1773 1773 4434 81 243 NO-HIT 6 SPX1774 1774 4435 443 1329 1739 2.60E−235 “[LN:A42280] [AC:S65968:A42280:H69683] [PN:adenylosuccinate synthase, purA:IMP--aspartate ligase] [GN:purA] [CL:adenylosuccinate synthase] 175 [OR:Bacillus subtilis] [EC:6.3.4.4]” SPX1775 1775 4436 141 423 365 1.90E−46 [LN:YAAJ_BACSU] [AC:P21335] [GN:YAAJ] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 17.8 KD PROTEIN IN SERS-DNAH INTERGENIC 137 REGION] [SP:P21335] SPX1776 1776 4437 148 444 205 2.80E−38 [GI:2765131] [LN:LLABIKORF] [AC:Y11901] [PN:dUTPase] [OR:Lactococcus lactis] 76 SPX1777 1777 4438 186 558 NO-HIT 6 SPX1778 1778 4439 68 204 NO-HIT 6 SPX1779 1779 4440 455 1365 1167 1.60E−201 [LN:RADA_BACSU] [AC:P37572] [GN:RADA:SMS] [OR:Bacillus subtilis] [DE:DNA REPAIR PROTEIN RADA HOMOLOG (DNA REPAIR 146 PROTEIN SMS HOMOLOG)] [SP:P37572] SPX1780 1780 4441 207 621 NO-HIT 6 SPX1781 1781 4442 166 498 268 2.80E−38 [LN:Y023_MYCTU] [AC:Q10612] [GN:MTCY373.03] [OR:Mycobacterium tuberculosis] [DE:HYPOTHETICAL 18.2 KD PROTEIN 130 CY373.03] [SP:Q10612] SPX1782 1782 4443 264 792 NO-HIT 6 SPX1783 1783 4444 323 969 607 9.40E−148 [GI:532204] [LN:LISTMS] [AC:M92842] [GN:prs] [OR:Listeria monocytogenes] [SR:Listeria monocytogenes (strain L028) DNA] 118 SPX1784 1784 4445 160 480 493 3.90E−65 [GI:663278] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae 138 (strain RX1) DNA] SPX1785 1785 4446 113 339 NO-HIT 6 SPX1786 1786 4447 122 366 NO-HIT 6 SPX1787 1787 4448 131 393 NO-HIT 6 SPX1788 1788 4449 118 354 NO-HIT 6 SPX1789 1789 4450 890 2670 4412 0 “[LN:DPO1_STRPN] [AC:P13252] [GN:POLA] [OR:Streptococcus pneumoniae] [EC:2.7.7.7] [DE:DNA POLYMERASE I, (POL I)] [SP:P13252]” 125 SPX1790 1790 4451 124 372 181 3.30E−32 [LN:B69892] [AC:B69892] [PN:conserved hypothetical protein yneT] [GN:yneT] [CL:hypothetical protein yneT] [OR:Bacillus subtilis] 128 SPX1791 1791 4452 137 411 328 2.80E−41 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX1792 1792 4453 105 315 83 0.00036 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX1793 1793 4454 239 717 398 3.00E−50 [LN:YOR3_BACCE] [AC:O31352] [OR:Bacillus cereus] [DE:HYPOTHETICAL PROTEIN (ORF3) (FRAGMENT)] [SP:O31352] 104 SPX1794 1794 4455 171 513 212 5.40E−30 [LN:YF05_METTH] [AC:O27549] [GN:MTH1505] [OR:Methanobacterium thermoautotrophicum] [DE:HYPOTHETICAL PROTEIN MTH1505] [SP:O27549] 128 SPX1795 1795 4456 126 378 NO-HIT 6 SPX1796 1796 4457 167 501 456 2.50E−57 [LN:RL10_BACSU] [AC:P42923] [GN:RPLJ] [OR:Bacillus subtilis] [DE:(VEGETATIVE PROTEIN 300) (VEG300)] [SP:P42923] 111 SPX1797 1797 4458 123 369 255 1.30E−46 “[LN:RL7_MICLU] [AC:P02395] [GN:RPLL] [OR:Micrococcus luteus] [SR:,Micrococcus lysodeikticus] [DE:50S RIBOSOMAL 150 PROTEIN L7/L12 (MA1/MA2)] [SP:P02395]” SPX1798 1798 4459 115 345 98 1.30E−05 [LN:T40374] [AC:T40374] [PN:hypothetical protein SPBC3D6.14c] [OR:Schizosaccharomyces pombe] 92 SPX1799 1799 4460 196 588 NO-HIT 6 SPX1800 1800 4461 505 1515 214 1.60E−47 [LN:T35180] [AC:T35180] [PN:hypothetical protein SC5A7.31] [GN:SC5A7.31] [CL:Streptomyces coelicolor hypothetical protein SC5A7.31] 160 [OR:Streptomyces coelicolor] SPX1801 1801 4462 198 594 136 6.60E−20 [GI:290801] [LN:FRNVALAB] [AC:L17003] [GN:valA] [OR:Francisella tularensis var. novicida] [SR:Francisella novicida (strain U112) DNA] 133 SPX1802 1802 4463 97 291 NO-HIT 6 SPX1803 1803 4464 247 741 357 1.50E−55 [GI:7288062] [LN:SCD40A] [AC:AL161691] [PN:putative ABC-transporter ATP-binding protein] [GN:SCD40A.12c] 139 [OR:Streptomyces coelicolor A3(2)] SPX1804 1804 4465 60 180 NO-HIT 6 SPX1805 1805 4466 129 387 90 6.90E−06 [LN:F72598] [AC:F72598] [PN:hypothetical protein APE1254] [GN:APE1254] [OR:Aeropyrum pernix] 92 SPX1806 1806 4467 440 1320 NO-HIT 6 SPX1807 1807 4468 60 180 NO-HIT 6 SPX1808 1808 4469 74 222 NO-HIT 6 SPX1809 1809 4470 45 135 109 3.10E−09 “[LN:Y4PE_RHISN] [AC:P55614] [GN:Y4PE,Y4SA] [OR:Rhizobium sp] [SR:,strain NGR234] [DE:HYPOTHETICAL 15.5 KD 138 PROTEIN Y4PE/Y4SA] [SP:P55614]” SPX1810 1810 4471 88 264 301 4.50E−37 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX1811 1811 4472 233 699 331 2.60E−64 “[LN:C70180] [AC:C70180] [PN:conserved hypothetical protein BB0644] [OR:Borrelia burgdorferi] [SR:, Lyme disease spirochete]” 125 SPX1812 1812 4473 308 924 98 4.30E−21 [LN:I40867] [AC:I40867] [PN:hypothetical protein 2] [OR:Clostridium perfringens] 80 SPX1813 1813 4474 543 1629 102 3.10E−21 [LN:B71130] [AC:B71130] [PN:probable oligopeptide binding protein APPA] [GN:PH0807] [CL:dipeptide transport protein] [OR:Pyrococcus horikoshii] 143 SPX1814 1814 4475 317 951 335 2.30E−78 “[LN:D75202] [AC:D75202] [PN:dipeptide abc transporter, dipeptide-binding protein PAB0092] [GN:dppB-1:PAB0092] [CL:transmembrane protein dppB] 166 [OR:Pyrococcus abyssi]” SPX1815 1815 4476 296 888 642 5.70E−87 [LN:APPC_BACSU] [AC:P42063] [GN:APPC] [OR:Bacillus subtilis] [DE:OLIGOPEPTIDE TRANSPORT PERMEASE PROTEIN APPC] [SP:P42063] 122 SPX1816 1816 4477 204 612 NO-HIT 6 SPX1817 1817 4478 661 1983 644 1.60E−146 [LN:YLIA_ECOLI] [AC:P75796] [GN:YLIA] [OR:Escherichia coli] [DE:HYPOTHETICAL ABC TRANSPORTER ATP-BINDING PROTEIN YLIA] 130 [SP:P75796] SPX1818 1818 4479 66 198 NO-HIT 6 SPX1819 1819 4480 470 1410 NO-HIT 6 SPX1820 1820 4481 163 489 450 8.60E−58 [LN:YUTG_BACSU] [AC:O32124] [GN:YUTG] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 18.7 KD PROTEIN IN HOM-MRGA INTERGENIC 136 REGION] [SP:O32124] SPX1821 1821 4482 136 408 190 1.30E−38 “[LN:CDD_BACSU] [AC:P19079] [GN:CDD] [OR:Bacillus subtilis] [EC:3.5.4.5] [DE:CYTIDINE DEAMINASE, (CYTIDINE 142 AMINOHYDROLASE) (CDA)] [SP:P19079]” SPX1822 1822 4483 95 285 NO-HIT 6 SPX1823 1823 4484 274 822 771 1.10E−101 [GI:2385360] [LN:CTSIALIDA] [AC:Y08695] [PN:putative acylneuraminate lyase] [OR:Clostridium tertium] 100 SPX1824 1824 4485 68 204 173 1.10E−18 [LN:S43901] [AC:S43901:S27537] [PN:hypothetical protein A] [OR:Clostridium perfringens] 87 SPX1825 1825 4486 173 519 145 3.80E−20 [GI:2668605] [LN:AF015453] [AC:AF015453] [PN:unknown] [OR:Lactobacillus rhamnosus] 82 SPX1826 1826 4487 214 642 509 7.20E−64 [GI:6318176] [LN:BSP250862] [AC:AJ250862] [PN:MrsT protein] [GN:mrsT] [FN:putative ABC-transporter] [OR:Bacillus sp. HIL-Y85/54728] 131 SPX1827 1827 4488 63 189 NO-HIT 6 SPX1828 1828 4489 449 1347 731 5.00E−191 [GI:3702805] [LN:AF056335] [AC:AF056335] [PN:NADP-specific glutamate dehydrogenase] [GN:gdhA] [OR:Bacillus licheniformis] 121 SPX1829 1829 4490 138 414 99 6.40E−06 [LN:S31840] [AC:S31840] [PN:probable transposase] [OR:Bacillus stearothermophilus] 82 SPX1830 1830 4491 57 171 94 3.30E−07 “[LN:Y4PE_RHISN] [AC:P55614] [GN:Y4PE,Y4SA] [OR:Rhizobium sp] [SR:,strain NGR234] [DE:HYPOTHETICAL 15.5 KD PROTEIN 138 Y4PE/Y4SA] [SP:P55614]” SPX1831 1831 4492 218 654 154 1.00E−20 [GI:722339] [LN:AXU22323] [AC:U22323] [PN:unknown] [OR:Acetobacter xylinus] [SR:Acetobacter xylinum] 100 SPX1832 1832 4493 73 219 NO-HIT 6 SPX1833 1833 4494 95 285 146 8.10E−34 [GI:4193373] [LN:AF072894] [AC:AF072894] [PN:ribosomal protein L31] [GN:rpmE] [OR:Listeria monocytogenes] 105 SPX1834 1834 4495 312 936 397 7.80E−97 [LN:F69999] [AC:F69999] [PN:conserved hypothetical protein ytqI] [GN:ytqI] [CL:Mycoplasma conserved hypothetical protein MG190] 150 [OR:Bacillus subtilis] SPX1835 1835 4496 145 435 271 2.00E−32 [LN:FLAV_BACSU] [AC:O34737] [GN:YKUN] [OR:Bacillus subtilis] [DE:PROBABLE FLAVODOXIN 1] [SP:O34737] 99 SPX1836 1836 4497 89 267 117 2.80E−11 [LN:Y246_METJA] [AC:Q57696] [GN:MJ0246] [OR:Methanococcus jannaschii] [DE:HYPOTHETICAL PROTEIN MJ0246] [SP:Q57696] 114 SPX1837 1837 4498 125 375 169 5.60E−18 [LN:C75108] [AC:C75108] [PN:crcb protein PAB1925] [GN:PAB1925] [CL:hypothetical protein MJ1523] [OR:Pyrococcus abyssi] 118 SPX1838 1838 4499 110 330 93 1.20E−10 [LN:B71026] [AC:B71026] [PN:hypothetical protein PH1502] [GN:PH1502] [CL:hypothetical protein MJ1523] [OR:Pyrococcus horikoshii] 128 SPX1839 1839 4500 116 348 537 4.70E−71 [LN:RL19_STRTR] [AC:O34031] [GN:RPLS] [OR:Streptococcus thermophilus] [DE:50S RIBOSOMAL PROTEIN L19] [SP:O34031] 112 SPX1840 1840 4501 269 807 354 2.70E−85 [LN:YIDA_ECOLI] [AC:P09997:P76737] [GN:YIDA] [OR:Escherichia coli] [DE:HYPOTHETICAL 29.7 KD PROTEIN IN IBPA-GYRB 150 INTERGENIC REGION] [SP:P09997:P76737] SPX1841 1841 4502 448 1344 561 2.90E−126 [LN:YWFO_BACSU] [AC:P39651] [GN:YWFO:IPA-93D] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 51.0 KD PROTEIN IN PTA 3′REGION] 130 [SP:P39651] SPX1842 1842 4503 126 378 NO-HIT 6 SPX1843 1843 4504 111 333 499 3.70E−65 [GI:1850606] [LN:SMU88582] [AC:U88582] [PN:YlxM] [GN:ylxM] [FN:unknown] [OR:Streptococcus mutans] 97 SPX1844 1844 4505 185 555 NO-HIT 6 SPX1845 1845 4506 524 1572 1993 5.90E−290 [LN:SR54_STRMU] [AC:Q54431:P96469] [GN:FFH] [OR:Streptococcus mutans] [DE:SIGNAL RECOGNITION PARTICLE PROTEIN 150 (FIFTY-FOUR HOMOLOG)] [SP:Q54431:P96469] SPX1846 1846 4507 163 489 NO-HIT 6 SPX1847 1847 4508 257 771 500 1.10E−87 [LN:PYRP_BACCL] [AC:P41006] [GN:PYRP] [OR:Bacillus caldolyticus] [DE:URACIL PERMEASE (URACIL TRANSPORTER)] [SP:P41006] 118 SPX1848 1848 4509 147 441 231 5.00E−42 [LN:LLA132624] [AC:AJ132624] [PN:uracil transporter] [GN:pyrP] [OR:Lactococcus lactis] 86 SPX1849 1849 4510 238 714 353 3.70E−81 [LN:GIDB_BACSU] [AC:P25813] [GN:GIDB] [OR:Bacillus subtilis] [DE:GLUCOSE INHIBITED DIVISION PROTEIN B] [SP:P25813] 114 SPX1850 1850 4511 187 561 261 1.60E−57 [GI:1519287] [LN:LMU66186] [AC:U66186] [PN:LemA] [GN:lemA] [OR:Listeria monocytogenes] 86 SPX1851 1851 4512 303 909 757 1.70E−165 [LN:HTPX_STRGC] [AC:O30795] [GN:HTPX] [OR:Streptococcus gordonii challis] [DE:PUTATIVE HEAT SHOCK PROTEIN HTPX] [SP:O30795] 123 SPX1852 1852 4513 520 1560 197 1.40E−47 [LN:YHES_ECOLI] [AC:P45535] [GN:YHES] [OR:Escherichia coli] [DE:HYPOTHETICAL ABC TRANSPORTER ATP-BINDING PROTEIN 130 YHES] [SP:P45535] SPX1853 1853 4514 92 276 NO-HIT 6 SPX1854 1854 4515 122 366 NO-HIT 6 SPX1855 1855 4516 181 543 64 6.40E−07 [LN:C69875] [AC:C69875] [PN:hypothetical protein ylbN] [GN:ylbN] [OR:Bacillus subtilis] 87 SPX1856 1856 4517 62 186 NO-HIT 6 SPX1857 1857 4518 210 630 446 2.10E−57 [LN:END3_BACSU] [AC:P39788] [GN:NTH:JOOB] [OR:Bacillus subtilis] [EC:4.2.99.18] [DE:APYRIMIDINIC SITE) LYASE)] [SP:P39788] 122 SPX1858 1858 4519 174 522 626 4.30E−82 [LN:LLA132624] [AC:AJ132624] [PN:pyrimidine regulatory protein] [GN:pyrR] [FN:Regulates expression of the pyrimidine] [OR:Lactococcus lactis] 141 SPX1859 1859 4520 308 924 942 6.40E−134 [LN:LLA132624] [AC:AJ132624] [PN:aspartate transcarbamoylase] [GN:pyrB] [OR:Lactococcus lactis] 95 SPX1860 1860 4521 360 1080 1492 2.60E−202 [LN:LLA132624] [AC:AJ132624] [PN:carbamoyl phosphate synthetase small subunit] [GN:carA] [OR:Lactococcus lactis] 112 SPX1861 1861 4522 1059 3177 4000 0 [GI:2598551] [LN:LLAJ109] [AC:AJ000109] [PN:carbamoylphosphate synthetase] [GN:carB] [OR:Lactococcus lactis] 108 SPX1862 1862 4523 70 210 NO-HIT 6 SPX1863 1863 4524 281 843 1425 1.90E−195 [GI:5001693] [LN:AF106539] [AC:AF106539] [PN:LicD2] [GN:licD2] [OR:Streptococcus pneumoniae] 92 SPX1864 1864 4525 268 804 1419 6.40E−194 [GI:5001692] [LN:AF106539] [AC:AF106539] [PN:LicD1] [GN:licD1] [OR:Streptococcus pneumoniae] 92 SPX1865 1865 4526 496 1488 2483 0 [GI:5001691] [LN:AF106539] [AC:AF106539] [PN:unknown] [OR:Streptococcus pneumoniae] 83 SPX1866 1866 4527 236 708 96 7.30E−17 [LN:S60902] [AC:S60902:S49238:S44071] [PN:CDP-ribitol pyrophosphorylase] [OR:Haemophilus influenzae] 100 SPX1867 1867 4528 347 1041 66 6.20E−05 [LN:YJJN_ECOLI] [AC:P39400] [GN:YJJN] [OR:Escherichia coli] [DE:INTERGENIC REGION] [SP:P39400] 94 SPX1868 1868 4529 290 870 1361 2.10E−181 [GI:2708632] [LN:AF036951] [AC:AF036951] [PN:choline kinase] [GN:pck] [OR:Streptococcus pneumoniae] 99 SPX1869 1869 4530 293 879 156 1.70E−15 [LN:LICB_HAEIN] [AC:P14182:Q57357:O05075] [GN:LICB:HI1538] [OR:Haemophilus influenzae] [DE:LICB PROTEIN] 130 [SP:P14182:Q57357:O05075] SPX1870 1870 4531 230 690 345 4.10E−54 [LN:D64128] [AC:D64128] [PN:lic-1 protein C] [GN:licC] [OR:Haemophilus influenzae] 82 SPX1871 1871 4532 283 849 458 8.00E−59 [LN:C72399] [AC:C72399] [PN:DNA processing chain A] [GN:TM0250] [OR:Thermotoga maritima] 88 SPX1872 1872 4533 171 513 309 5.10E−41 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX1873 1873 4534 152 456 107 1.30E−07 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX1874 1874 4535 69 207 NO-HIT 6 SPX1875 1875 4536 348 1044 179 2.10E−23 [LN:Y678_METJA] [AC:Q58091] [GN:MJ0678] [OR:Methanococcus jannaschii] [DE:HYPOTHETICAL PROTEIN MJ0678] [SP:Q58091] 114 SPX1876 1876 4537 702 2106 1065 0 [LN:TOP1_BACSU] [AC:P39814] [GN:TOPA:TOPI] [OR:Bacillus subtilis] [EC:5.99.1.2] [DE:(UNTWISTING ENZYME) (SWIVELASE)] 128 [SP:P39814] SPX1877 1877 4538 120 360 208 4.20E−25 [LN:YBAN_ECOLI] [AC:P45808:P77478] [GN:YBAN] [OR:Escherichia coli] [DE:HYPOTHETICAL 14.8 KD PROTEIN IN PRIC-APT 149 INTERGENIC REGION] [SP:P45808:P77478] SPX1878 1878 4539 211 633 181 2.30E−34 [GI:4680703] [LN:AF132966] [AC:AF132966] [PN:CGI-32 protein] [OR:Homo sapiens] [SR:human] 89 SPX1879 1879 4540 219 657 142 3.40E−22 [LN:YYAQ_BACSU] [AC:P37507] [GN:YYAQ] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 13.9 KD PROTEIN IN COTF-TETB 137 INTERGENIC REGION] [SP:P37507] SPX1880 1880 4541 211 633 596 1.30E−93 [GI:2565151] [LN:LLU92974] [AC:U92974:M90760:M90761] [PN:LeuA] [GN:leuA] [OR:Lactococcus lactis] 96 SPX1881 1881 4542 70 210 NO-HIT 6 SPX1882 1882 4543 145 435 308 6.00E−39 “[LN:LEU1_LACLA] [AC:Q02141] [GN:LEUA] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:4.1.3.12] [DE:SYNTHASE) 166 (ALPHA-IPM SYNTHETASE)] [SP:Q02141]” SPX1883 1883 4544 346 1038 608 4.50E−153 “[LN:LEU3_LACLA] [AC:Q02143] [GN:LEUB] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:1.1.1.85] 151 [DE:(IMDH) (3-IPM-DH)] [SP:Q02143]” SPX1884 1884 4545 90 270 129 8.30E−13 [LN:G69983] [AC:G69983] [PN:hypothetical protein ysdA] [GN:ysdA] [OR:Bacillus subtilis] 87 SPX1885 1885 4546 120 360 373 9.40E−47 “[LN:LEUD_LACLA] [AC:Q02144] [GN:LEUD] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [EC:4.2.1.33] 183 [DE:(ISOPROPYLMALATE ISOMERASE) (ALPHA-IPM ISOMERASE)] [SP:Q02144]” SPX1886 1886 4547 79 237 NO-HIT 6 SPX1887 1887 4548 89 267 NO-HIT 6 SPX1888 1888 4549 645 1935 138 1.60E−33 “[LN:MCRB_ECOLI] [AC:P15005] [GN:MCRB:RGLB] [OR:Escherichia coli] [EC:3.1.21.-] [DE:5-METHYLCYTOSINE-SPECIFIC 145 RESTRICTION ENZYME B,] [SP:P15005]” SPX1889 1889 4550 448 1344 96 4.40E−09 [LN:D81431] [AC:D81431] [PN:hypothetical protein Cj0140 [imported]] [GN:Cj0140] [OR:Campylobacter jejuni] 105 SPX1890 1890 4551 329 987 913 1.40E−171 “[LN:C70015] [AC:C70015] [PN:probable GMP reductase, yumD:guanosine monophosphate reductase] [GN:yumD] [CL:GMP reductase:IMP 237 dehydrogenase amino-terminal homology:IMP dehydrogenase catalytic homology] [OR:Bacillus subtilis] [EC:1.6.6.8]” SPX1891 1891 4552 78 234 NO-HIT 6 SPX1892 1892 4553 67 201 NO-HIT 6 SPX1893 1893 4554 233 699 538 1.70E−69 “[LN:B69693] [AC:B69693:JC4821] [PN:ribonuclease III,:RNase D:RNase O] [GN:rncS:srb] [CL:ribonuclease III:double-stranded RNA-binding 188 repeat homology] [OR:Bacillus subtilis] [EC:3.1.26.3]” SPX1894 1894 4555 737 2211 1258 7.10E−169 [LN:G69708] [AC:G69708:JC4819:PC4029] [PN:chromosome segregation SMC protein:minichromosome stabilizing protein SMC] [GN:smc] 189 [CL:conserved hypothetical P115 protein] [OR:Bacillus subtilis] SPX1895 1895 4556 217 651 139 2.70E−09 [GI:2246532] [LN:U93872] [AC:U93872] [OR:Kaposi's sarcoma-associated herpesvirus] [SR:Kaposi's sarcoma-associated herpesvirus - 148 Human herpesvirus 8] SPX1896 1896 4557 102 306 95 0.00014 [LN:P115_MYCHR] [AC:P41508] [OR:Mycoplasma hyorhinis] [DE:P115 PROTEIN] [SP:P41508] 83 SPX1897 1897 4558 196 588 428 2.90E−69 [LN:G69708] [AC:G69708:JC4819:PC4029] [PN:chromosome segregation SMC protein:minichromosome stabilizing protein SMC] [GN:smc] 189 [CL:conserved hypothetical P115 protein] [OR:Bacillus subtilis] SPX1898 1898 4559 265 795 206 4.40E−31 “[GI:4062428] [LN:D90722] [AC:D90722:AB001340] [PN:Hypothetical 30.2 kd protein in idh-deoR] [OR:Escherichia coli] [SR:Escherichia 178 coli(strain:K12) DNA, clone:Kohara clone #209]” SPX1899 1899 4560 273 819 220 3.10E−42 [LN:YIDA_ECOLI] [AC:P09997:P76737] [GN:YIDA] [OR:Escherichia coli] [DE:HYPOTHETICAL 29.7 KD PROTEIN IN IBPA-GYRB 150 INTERGENIC REGION] [SP:P09997:P76737] SPX1900 1900 4561 430 1290 675 1.30E−113 [GI:2633967] [LN:BSUB0009] [AC:Z99112:AL009126] [PN:signal recognition particle (docking protein)] [GN:ftsY] 184 [FN:involved in secretion of extracellular proteins] [OR:Bacillus subtilis] SPX1901 1901 4562 419 1257 2039 1.30E−284 [GI:2804700] [LN:AF030361] [AC:AF030361] [PN:transposase] [OR:Streptococcus pneumoniae] 87 SPX1902 1902 4563 85 255 350 2.40E−45 [GI:663279] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae (strain RX1) DNA] 138 SPX1903 1903 4564 109 327 288 1.40E−35 [GI:2804700] [LN:AF030361] [AC:AF030361] [PN:transposase] [OR:Streptococcus pneumoniae] 87 SPX1904 1904 4565 173 519 858 5.70E−116 [GI:663278] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae (strain RX1) DNA] 138 SPX1905 1905 4566 496 1488 779 6.50E−166 [LN:G6PD_BACSU] [AC:P54547] [GN:ZWF] [OR:Bacillus subtilis] [EC:1.1.1.49] [DE:PROTEIN 11) (VEG11)] [SP:P54547] 110 SPX1906 1906 4567 247 741 772 4.80E−102 [LN:H69334] [AC:H69334] [PN:glutamine transport protein glnQ] [GN:glnQ] [CL:inner membrane protein malK:ATP-binding cassette homology] 162 [OR:Archaeoglobus fulgidus] SPX1907 1907 4568 493 1479 508 2.50E−80 [GI:6560693] [LN:AF141644] [AC:AF141644] [PN:putative integral membrane protein] [FN:putative inner membrane component of a] 148 [OR:Lactococcus lactis] SPX1908 1908 4569 237 711 91 0.00087 “[LN:S76167] [AC:S76167] [PN:hypothetical protein] [OR:Synechocystis sp.] [SR:PCC 6803, , PCC 6803] [SR:PCC 6803, ]” 116 SPX1909 1909 4570 90 270 80 4.20E−05 [LN:T34651] [AC:T34651] [PN:probable transmembrane protein] [GN:SC1A9.02] [OR:Streptomyces coelicolor] 102 SPX1910 1910 4571 663 1989 3350 0 [LN:UVRB_STRPN] [AC:Q54986] [GN:UVRB:UVS402] [OR:Streptococcus pneumoniae] [DE:EXCINUCLEASE ABC SUBUNIT B] [SP:Q54986] 118 SPX1911 1911 4572 188 564 110 3.20E−15 [LN:G75474] [AC:G75474] [PN:probable acetyltransferase] [GN:DR0796] [OR:Deinococcus radiodurans] 96 SPX1912 1912 4573 130 390 65 1.50E−06 [LN:T39482] [AC:T39482] [PN:N-acetyltransferase] [GN:SPBC15D4.06] [CL:Escherichia coli ribosomal-protein-alanine N-acetyltransferase rimI] 169 [OR:Schizosaccharomyces pombe] SPX1913 1913 4574 156 468 110 3.50E−09 [LN:G70031] [AC:G70031] [PN:mutator MutT protein homolog yvcI] [GN:yvcI] [CL:mutT domain homology] [OR:Bacillus subtilis] 121 SPX1914 1914 4575 172 516 206 7.90E−37 “[LN:F72234] [AC:F72234] [PN:transcription regulator, biotin repressor family] [GN:TM1602] [OR:Thermotoga maritima]” 116 SPX1915 1915 4576 194 582 NO-HIT 6 SPX1916 1916 4577 167 501 81 4.70E−09 [GI:806536] [LN:BAMALAMYA] [AC:Z22520] [PN:membrane protein] [OR:Bacillus acidopullulyticus] 92 SPX1917 1917 4578 184 552 465 2.50E−59 [LN:DFP_STRMU] [AC:Q54433] [GN:DFP] [OR:Streptococcus mutans] [DE:DNA/PANTOTHENATE METABOLISM FLAVOPROTEIN HOMOLOG 138 (FRAGMENT)] [SP:Q54433] SPX1918 1918 4579 253 759 120 2.90E−19 [LN:D69029] [AC:D69029] [PN:pantothenate metabolism flavoprotein dfp homolog MTH1216:probable aspartate 1-decarboxylase activase] 230 [GN:MTH1216] [CL:pantothenate metabolism flavoprotein dfp] [OR:Methanobacterium thermoautotrophicum] SPX1919 1919 4580 181 543 NO-HIT 6 SPX1920 1920 4581 557 1671 2475 0 [LN:FTHS_STRMU] [AC:Q59925:Q59926] [GN:FHS] [OR:Streptococcus mutans] [EC:6.3.4.3] [DE:SYNTHETASE) (FHS) (FTHFS)] 132 [SP:Q59925:Q59926] SPX1921 1921 4582 80 240 145 9.20E−16 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX1922 1922 4583 392 1176 989 4.20E−132 [GI:6782414] [LN:SPN271596] [AC:AJ271596] [PN:A/G specific adenine glycosylase] [GN:mutY] [FN:antimutator prevents C to A transversions] 166 [OR:Streptococcus pneumoniae] SPX1923 1923 4584 235 705 1194 9.00E−161 [GI:5830523] [LN:SPAJ6392] [AC:AJ006392] [PN:response regulator] [GN:rr02] [OR:Streptococcus pneumoniae] 104 SPX1924 1924 4585 452 1356 2249 0 [GI:5830524] [LN:SPAJ6392] [AC:AJ006392] [PN:histidine kinase] [GN:hk02] [OR:Streptococcus pneumoniae] 102 SPX1925 1925 4586 270 810 1379 5.30E−185 [GI:6689278] [LN:SPN012049] [AC:AJ012049] [PN:VicX protein] [GN:vicX] [FN:unknown] [OR:Streptococcus pneumoniae] 112 SPX1926 1926 4587 81 243 NO-HIT 6 SPX1927 1927 4588 88 264 93 1.90E−06 [LN:D70886] [AC:D70886] [PN:hypothetical protein Rv2866] [GN:Rv2866] [OR:Mycobacterium tuberculosis] 100 SPX1928 1928 4589 258 774 162 3.00E−20 [LN:C72692] [AC:C72692] [PN:probable potassium channel APE0955] [GN:APE0955] [OR:Aeropyrum pernix] 98 SPX1929 1929 4590 170 510 NO-HIT 6 SPX1930 1930 4591 333 999 1652 9.40E−223 [GI:2275101] [LN:SPR6LDH] [AC:AJ000336] [PN:L-lactate dehydrogenase] [GN:ldh] [FN:conversion of pyruvate to lactate] 146 [OR:Streptococcus pneumoniae] SPX1931 1931 4592 316 948 1617 3.30E−219 “[LN:GYRA_STRPN] [AC:P72524:Q54716:P72536] [GN:GYRA] [OR:Streptococcus pneumoniae] [EC:5.99.1.3] [DE:DNA GYRASE SUBUNIT A,] 150 [SP:P72524:Q54716:P72536]” SPX1932 1932 4593 119 357 214 7.70E−24 “[LN:GYRA_STRPN] [AC:P72524:Q54716:P72536] [GN:GYRA] [OR:Streptococcus pneumoniae] [EC:5.99.1.3] [DE:DNA GYRASE SUBUNIT A,] 150 [SP:P72524:Q54716:P72536]” SPX1933 1933 4594 507 1521 2300 0 [GI:4138535] [LN:SPN5815] [AC:AJ005815] [PN:DNA gyrase subunit A] [GN:gyrA] [OR:Streptococcus pneumoniae] 105 SPX1934 1934 4595 248 744 299 5.50E−36 [GI:488339] [LN:SYNGIP3124] [AC:M77279] [PN:alpha-amylase] [OR:unidentified cloning vector] [SR:Cloning vector (sub_species 153 Cloning vector pGIP3124) DNA] SPX1935 1935 4596 266 798 184 6.20E−26 [GI:4433636] [LN:AF029224] [AC:AF029224:AF029225] [PN:NirC] [GN:nirC] [FN:putative nitrite transporter] [OR:Staphylococcus carnosus] 132 SPX1936 1936 4597 372 1116 426 6.30E−115 “[LN:T44655] [AC:T44655] [PN:O-acetylhomoserine (thiol)-lyase, [imported]:O-acetylhomoserine sulfhydrylase] [CL:O-succinylhomoserine 186 (thiol)-lyase] [OR:Leptospira meyeri] [EC:4.2.99.10]” SPX1937 1937 4598 425 1275 101 4.30E−18 [GI:6899348] [LN:AE002133] [AC:AE002133:AF222894] [PN:conserved hypothetical] [GN:UU367] [OR:Ureaplasma urealyticum] 116 SPX1938 1938 4599 293 879 661 5.10E−86 [LN:TRUB_BACSU] [AC:P32732] [GN:TRUB] [OR:Bacillus subtilis] [EC:4.2.1.70] [DE:HYDROLYASE)] [SP:P32732] 103 SPX1939 1939 4600 101 303 NO-HIT 6 SPX1940 1940 4601 239 717 707 3.50E−93 [LN:G69728] [AC:G69728] [PN:uridine kinase udk] [GN:udk] [CL:uridine kinase] [OR:Bacillus subtilis] 99 SPX1941 1941 4602 447 1341 633 1.60E−115 [LN:EX7L_BACSU] [AC:P54521] [GN:YQIB] [OR:Bacillus subtilis] [EC:3.1.11.6] [DE:VII LARGE SUBUNIT)] [SP:P54521] 110 SPX1942 1942 4603 71 213 113 3.50E−10 [LN:EX7S_ECOLI] [AC:P22938] [GN:XSEB] [OR:Escherichia coli] [EC:3.1.11.6] [DE:SMALL SUBUNIT)] [SP:P22938] 105 SPX1943 1943 4604 292 876 535 1.30E−78 “[LN:ISPA_MICLU] [AC:O66126] [GN:FPS] [OR:Micrococcus luteus] [SR:,Micrococcus lysodeikticus] [EC:2.5.1.10] [DE:(FPP SYNTHASE)] 140 [SP:O66126]” SPX1944 1944 4605 246 738 353 1.20E−79 [LN:YQXC_BACSU] [AC:P19672] [GN:YQXC:YQIF] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 29.7 KD PROTEIN IN FOLD-AHRC 142 INTERGENIC REGION] [SP:P19672] SPX1945 1945 4606 144 432 182 4.10E−26 [GI:4127534] [LN:BSAJ10954] [AC:AJ010954] [PN:arginine repressor] [GN:argR] [FN:ADN binding protein] [OR:Bacillus stearothermophilus] 133 SPX1946 1946 4607 298 894 317 4.20E−76 [LN:RECN_BACSU] [AC:P17894:P19671] [GN:RECN] [OR:Bacillus subtilis] [DE:DNA REPAIR PROTEIN RECN (RECOMBINATION 141 PROTEIN N)] [SP:P17894:P19671] SPX1947 1947 4608 261 783 395 3.20E−68 [LN:RECN_BACSU] [AC:P17894:P19671] [GN:RECN] [OR:Bacillus subtilis] [DE:DNA REPAIR PROTEIN RECN (RECOMBINATION 141 PROTEIN N)] [SP:P17894:P19671] SPX1948 1948 4609 243 729 97 4.90E−15 [GI:2352096] [LN:U97022] [AC:U97022] [OR:Fervidobacterium islandicum] 69 SPX1949 1949 4610 345 1035 1284 9.40E−173 [LN:LEPA_BACSU] [AC:P37949] [GN:LEPA] [OR:Bacillus subtilis] [DE:GTP-BINDING PROTEIN LEPA] [SP:P37949] 102 SPX1950 1950 4611 304 912 1158 1.80E−156 [LN:LEPA_BACSU] [AC:P37949] [GN:LEPA] [OR:Bacillus subtilis] [DE:GTP-BINDING PROTEIN LEPA] [SP:P37949] 102 SPX1951 1951 4612 111 333 95 7.80E−05 “[LN:T04991] [AC:T04991] [PN:hypothetical protein T16L1.230] [OR:Arabidopsis thaliana] [SR:, mouse-ear cress]” 110 SPX1952 1952 4613 112 336 294 3.40E−35 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX1953 1953 4614 96 288 NO-HIT 6 SPX1954 1954 4615 230 690 70 3.10E−05 [LN:G75468] [AC:G75468] [PN:hypothetical protein] [GN:DR0857] [OR:Deinococcus radiodurans] 90 SPX1955 1955 4616 60 180 NO-HIT 6 SPX1956 1956 4617 82 246 NO-HIT 6 SPX1957 1957 4618 70 210 NO-HIT 6 SPX1958 1958 4619 68 204 138 3.20E−14 “[LN:LAFX_LACJO] [AC:Q48509] [GN:LAFX] [OR:Lactobacillus johnsonii] [DE:BACTERIOCIN LACTACIN F, SUBUNIT LAFX 132 PRECURSOR] [SP:Q48509]” SPX1959 1959 4620 85 255 114 8.90E−21 [GI:5441255] [LN:AB029612] [AC:AB029612] [PN:gassericin T1] [GN:gatA] [OR:Lactobacillus gasseri] [SR:Lactobacillus gasseri 144 (strain:SBT2055) DNA] SPX1960 1960 4621 56 168 79 0.00078 [GI:6751696] [LN:ATAC018908] [AC:AC018908] [GN:T7P1.21] [OR:Arabidopsis thaliana] [SR:thale cress] 98 SPX1961 1961 4622 182 546 379 2.90E−48 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX1962 1962 4623 133 399 364 8.90E−50 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX1963 1963 4624 55 165 NO-HIT 6 SPX1964 1964 4625 68 204 NO-HIT 6 SPX1965 1965 4626 69 207 NO-HIT 6 SPX1966 1966 4627 68 204 55 0.00018 [GI:6457574] [LN:AF200347] [AC:AF200347] [PN:lactocin 705 beta-subunit precursor] [OR:Lactobacillus casei] 106 SPX1967 1967 4628 73 219 NO-HIT 6 SPX1968 1968 4629 718 2154 2269 0 [LN:COMA_STRPN] [AC:Q03727] [GN:COMA] [OR:Streptococcus pneumoniae] [DE:TRANSPORT ATP-BINDING PROTEIN COMA] [SP:Q03727] 119 SPX1969 1969 4630 83 249 80 0.00032 [LN:G72510] [AC:G72510] [PN:hypothetical protein APE2061] [GN:APE2061] [OR:Aeropyrum pernix] 92 SPX1970 1970 4631 454 1362 697 7.40E−90 [GI:1698422] [LN:SGU40139] [AC:U40139] [PN:ComB] [GN:comB] [OR:Streptococcus gordonii] [SR:Streptococcus gordonii strain=Challis] 129 SPX1971 1971 4632 67 201 NO-HIT 6 SPX1972 1972 4633 110 330 NO-HIT 6 SPX1973 1973 4634 447 1341 2062 1.10E−288 [GI:5830551] [LN:SPAJ6401] [AC:AJ006401] [PN:histidine kinase] [GN:hk13] [OR:Streptococcus pneumoniae] 102 SPX1974 1974 4635 215 645 972 3.30E−133 [GI:5830550] [LN:SPAJ6401] [AC:AJ006401] [PN:response regulator] [GN:rr13] [OR:Streptococcus pneumoniae] 104 SPX1975 1975 4636 61 183 239 4.40E−28 [GI:5830550] [LN:SPAJ6401] [AC:AJ006401] [PN:response regulator] [GN:rr13] [OR:Streptococcus pneumoniae] 104 SPX1976 1976 4637 113 339 69 0.000063 [GI:1495671] [LN:LPATOVGNS] [AC:X94434] [PN:response regulator PlnC] [GN:plnC] [OR:Lactobacillus plantarum] 107 SPX1977 1977 4638 110 330 NO-HIT 6 SPX1978 1978 4639 69 207 NO-HIT 6 SPX1979 1979 4640 324 972 150 4.10E−24 [LN:ECSB_BACSU] [AC:P55340] [GN:ECSB:PRST] [OR:Bacillus subtilis] [DE:PROTEIN ECSB] [SP:P55340] 95 SPX1980 1980 4641 74 222 NO-HIT 6 SPX1981 1981 4642 115 345 333 4.00E−42 [LN:ECSA_BACSU] [AC:P55339] [GN:ECSA:PRST] [OR:Bacillus subtilis] [DE:ABC-TYPE TRANSPORTER ATP-BINDING PROTEIN ECSA] 128 [SP:P55339] SPX1982 1982 4643 126 378 391 2.60E−49 [LN:ECSA_BACSU] [AC:P55339] [GN:ECSA:PRST] [OR:Bacillus subtilis] [DE:ABC-TYPE TRANSPORTER ATP-BINDING PROTEIN ECSA] 128 [SP:P55339] SPX1983 1983 4644 137 411 334 8.80E−42 [LN:HIT_BACSU] [AC:O07513] [GN:HIT] [OR:Bacillus subtilis] [DE:HIT PROTEIN] [SP:O07513] 87 SPX1984 1984 4645 96 288 NO-HIT 6 SPX1985 1985 4646 85 255 NO-HIT 6 SPX1986 1986 4647 379 1137 1885 4.90E−254 [LN:DNAJ_STRPN] [AC:P95830] [GN:DNAJ] [OR:Streptococcus pneumoniae] [DE:DNAJ PROTEIN (FRAGMENT)] [SP:P95830] 108 SPX1987 1987 4648 47 141 125 7.20E−10 [GI:5305335] [LN:AF071081] [AC:AF071081] [PN:proline-rich mucin homolog] [OR:Mycobacterium tuberculosis] 104 SPX1988 1988 4649 119 357 NO-HIT 6 SPX1989 1989 4650 86 258 NO-HIT 6 SPX1990 1990 4651 608 1824 3008 0 [LN:DNAK_STRPN] [AC:P95829:O66035] [GN:DNAK] [OR:Streptococcus pneumoniae] [DE:DNAK PROTEIN (HEAT SHOCK PROTEIN 70) 143 (HSP70)] [SP:P95829:O66035] SPX1991 1991 4652 120 360 NO-HIT 6 SPX1992 1992 4653 218 654 NO-HIT 6 SPX1993 1993 4654 183 549 346 3.60E−74 “[LN:GRPE_LACLA] [AC:P42369] [GN:GRPE] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [DE:GRPE PROTEIN] 132 [SP:P42369]” SPX1994 1994 4655 356 1068 1712 6.90E−235 [GI:4566769] [LN:AF117740] [AC:AF117740] [PN:heat shock transcription repressor HrcA] [GN:hrcA] [OR:Streptococcus pneumoniae] 125 SPX1995 1995 4656 170 510 NO-HIT 6 SPX1996 1996 4657 778 2334 570 9.20E−238 [LN:I41291] [AC:I41291] [PN:EcoA type I restriction-modification enzyme R subunit] [OR:Escherichia coli] 104 SPX1997 1997 4658 488 1464 846 1.80E−144 [LN:I41293] [AC:I41293] [PN:EcoE type I restriction modification enzyme M subunit] [CL:site-specific methyltransferase (adenine-specific) EcoK] 165 [OR:Escherichia coli] SPX1998 1998 4659 517 1551 323 1.60E−37 [GI:6899439] [LN:AE002141] [AC:AE002141:AF222894] [PN:type I restriction enzyme S protein (fragment)] [GN:hsdS-5] [OR:Ureaplasma urealyticum] 141 SPX1999 1999 4660 430 1290 328 1.40E−38 [GI:6899439] [LN:AE002141] [AC:AE002141:AF222894] [PN:type I restriction enzyme S protein (fragment)] [GN:hsdS-5] [OR:Ureaplasma urealyticum] 141 SPX2000 2000 4661 74 222 NO-HIT 6 SPX2001 2001 4662 449 1347 1265 6.40E−246 [GI:1815634] [LN:SAU61271] [AC:U61271] [PN:glutamine synthetase type 1] [GN:glnA] [OR:Streptococcus agalactiae] 111 SPX2002 2002 4663 119 357 244 7.30E−29 [LN:GLNR_BACCE] [AC:P19083] [GN:GLNR] [OR:Bacillus cereus] [DE:REGULATORY PROTEIN GLNR] [SP:P19083] 99 SPX2003 2003 4664 176 528 100 1.00E−06 [LN:H69815] [AC:H69815] [PN:hypothetical protein ygaE] [GN:ygaE] [OR:Bacillus subtilis] 87 SPX2004 2004 4665 126 378 137 1.10E−11 [LN:S72776] [AC:S72776] [PN:B1496_F1_41 protein] [OR:Mycobacterium leprae] 74 SPX2005 2005 4666 399 1197 622 6.20E−166 [GI:4490614] [LN:SAU133520] [AC:AJ133520] [PN:phosphoglycerate kinase] [GN:pgk] [OR:Staphylococcus aureus] 106 SPX2006 2006 4667 1647 4941 207 3.10E−63 [GI:4204919] [LN:APU59168] [AC:U59168] [PN:endo-beta-N-acetylglucosaminidase] [OR:Arthrobacter protophormiae] 109 SPX2007 2007 4668 171 513 NO-HIT 6 SPX2008 2008 4669 544 1632 249 3.20E−57 “[LN:H71283] [AC:H71283] [PN:conserved hypothetical integral membrane protein TP0771] [GN:TP0771] [OR:Treponema pallidum subsp. 165 pallidum] [SR:, syphilis spirochete]” SPX2009 2009 4670 536 1608 2303 0 [LN:LAJ10153] [AC:AJ010153] [PN:CTP synthetase] [GN:pyrG] [OR:Lactococcus lactis subsp. cremoris] 97 SPX2010 2010 4671 44 132 137 6.60E−15 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX2011 2011 4672 196 588 169 1.20E−25 “[LN:RPOE_BACSU] [AC:P12464] [GN:RPOE] [OR:Bacillus subtilis] [EC:2.7.7.6] [DE:DNA-DIRECTED RNA POLYMERASE DELTA 135 SUBUNIT,] [SP:P12464]” SPX2012 2012 4673 150 450 NO-HIT 6 SPX2013 2013 4674 130 390 NO-HIT 6 SPX2014 2014 4675 217 651 179 5.00E−19 [LN:S32217] [AC:S32217] [PN:hypothetical protein 2] [OR:Bacillus megaterium] 76 SPX2015 2015 4676 188 564 258 3.20E−32 [LN:YPAA_BACSU] [AC:P50726] [GN:YPAA] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 20.5 KD PROTEIN IN SERA-FER INTERGENIC 136 REGION] [SP:P50726] SPX2016 2016 4677 73 219 NO-HIT 6 SPX2017 2017 4678 156 468 243 6.60E−44 [GI:1381681] [LN:BSU58864] [AC:U58864] [PN:CspR] [GN:cspR] [OR:Bacillus subtilis] [SR:Bacillus subtilis strain=JH642] 117 SPX2018 2018 4679 277 831 83 4.70E−12 [LN:Y181_MYCPN] [AC:Q50292] [OR:Mycoplasma pneumoniae] [DE:HYPOTHETICAL PROTEIN MG181 HOMOLOG (GT9_ORF434)] [SP:Q50292] 119 SPX2019 2019 4680 416 1248 343 1.40E−50 [LN:G64435] [AC:G64435] [PN:cobalt transport ATP-binding protein O homolog] [CL:unassigned ATP-binding cassette proteins:ATP-binding cassette 181 homology] [OR:Methanococcus jannaschii] SPX2020 2020 4681 128 384 230 1.10E−25 [LN:G71192] [AC:G71192] [PN:probable cobalt transport ATP-binding protein] [GN:PH1815] [CL:unassigned ATP-binding cassette proteins:ATP- 189 binding cassette homology] [OR:Pyrococcus horikoshii] SPX2021 2021 4682 71 213 NO-HIT 6 SPX2022 2022 4683 86 258 NO-HIT 6 SPX2023 2023 4684 183 549 494 1.60E−73 [GI:6165407] [LN:LLA012388] [AC:AJ012388] [PN:hypothetical protein] [OR:Lactococcus lactis] 91 SPX2024 2024 4685 292 876 546 2.00E−98 [LN:E64608] [AC:E64608] [PN:conserved hypothetical protein HP0709] [OR:Helicobacter pylori] 91 SPX2025 2025 4686 450 1350 258 1.20E−60 [LN:F69354] [AC:F69354] [PN:TRK potassium uptake system protein (trkA-2) homolog] [CL:Methanococcus jannaschii TRK system 177 potassium uptake protein A] [OR:Archaeoglobus fulgidus] SPX2026 2026 4687 479 1437 232 7.20E−73 [LN:G69354] [AC:G69354] [PN:TRK potassium uptake system protein (trkH) homolog] [CL:potassium uptake protein trkG] [OR:Archaeoglobus fulgidus] 142 SPX2027 2027 4688 560 1680 777 1.20E−171 [LN:PTLB_STRMU] [AC:P50976] [GN:LACE] [OR:Streptococcus mutans] [EC:2.7.1.69] [DE:(EC 2.7.1.69) (EII-LAC)] [SP:P50976] 118 SPX2028 2028 4689 471 1413 643 5.80E−164 “[GI:153755] [LN:STRPBGSL] [AC:M19454] [OR:Lactococcus lactis subsp. cremoris] [SR:S.lactis (strain Z268) DNA, clone X25]” 122 SPX2029 2029 4690 65 195 NO-HIT 6 SPX2030 2030 4691 115 345 298 8.20E−37 [LN:PTLA_LACCA] [AC:P11502] [GN:LACF] [OR:Lactobacillus casei] [EC:2.7.1.69] [DE:(EC 2.7.1.69) (EIII-LAC)] [SP:P11502] 118 SPX2031 2031 4692 647 1941 NO-HIT 6 SPX2032 2032 4693 441 1323 395 1.00E−89 “[LN:PTCC_BACST] [AC:Q45400] [GN:CELB] [OR:Bacillus stearothermophilus] [DE:PERMEASE IIC COMPONENT) (PHOSPHOTRANSFERASE 157 ENZYME II, C COMPONENT)] [SP:Q45400]” SPX2033 2033 4694 408 1224 147 2.50E−21 [LN:XYLR_BACSU] [AC:P16557] [GN:XYLR] [OR:Bacillus subtilis] [DE:XYLOSE REPRESSOR] [SP:P16557] 94 SPX2034 2034 4695 73 219 NO-HIT 6 SPX2035 2035 4696 58 174 NO-HIT 6 SPX2036 2036 4697 62 186 NO-HIT 6 SPX2037 2037 4698 95 285 167 2.40E−18 [GI:2707293] [LN:AF036720] [AC:AF036720] [PN:unknown] [OR:Lactococcus lactis] 77 SPX2038 2038 4699 173 519 879 6.50E−119 [GI:663278] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus 138 pneumoniae (strain RX1) DNA] SPX2039 2039 4700 256 768 1235 1.10E−172 [GI:663279] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus 138 pneumoniae (strain RX1) DNA] SPX2040 2040 4701 421 1263 948 4.80E−188 [GI:2687821] [LN:STIS1193] [AC:Y13713] [PN:transposase] [OR:Streptococcus thermophilus] 87 SPX2041 2041 4702 86 258 149 1.10E−14 [GI:2198546] [LN:SPCPS14E] [AC:X85787] [GN:tasA] [OR:Streptococcus pneumoniae] 78 SPX2042 2042 4703 775 2325 3774 0 [GI:3168596] [LN:AB014686] [AC:AB014686] [PN:pyruvate formate-lyase] [GN:pfl] [OR:Streptococcus bovis] [SR:Streptococcus 145 bovis (strain:JB-1) DNA] SPX2043 2043 4704 92 276 133 7.70E−20 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX2044 2044 4705 78 234 NO-HIT 6 SPX2045 2045 4706 357 1071 491 2.70E−83 [GI:7380303] [LN:NMA5Z2491] [AC:AL162756:AL157959] [PN:impB/mucB/samB family protein] [GN:NMA1661] [OR:Neisseria meningitidis] 126 SPX2046 2046 4707 63 189 NO-HIT 6 SPX2047 2047 4708 282 846 289 6.60E−52 [GI:5739401] [LN:AF169967] [AC:AF169967] [PN:BacA] [GN:bacA] [OR:Flavobacterium johnsoniae] 91 SPX2048 2048 4709 217 651 139 3.00E−12 [LN:YIS1_STRCO] [AC:P19780] [GN:SC3C8.10] [OR:Streptomyces coelicolor] [DE:INSERTION ELEMENT IS110 HYPOTHETICAL 43.6 140 KD PROTEIN] [SP:P19780] SPX2049 2049 4710 62 186 NO-HIT 6 SPX2050 2050 4711 631 1893 95 3.20E−08 [LN:H64496] [AC:H64496] [PN:hypothetical protein MJ1577] [OR:Methanococcus jannaschii] 86 SPX2051 2051 4712 522 1566 331 9.10E−53 “[LN:A72357] [AC:A72357] [PN:amino acid ABC transporter, permease protein] [GN:TM0592] [CL:histidine permease protein M] 146 [OR:Thermotoga maritima]” SPX2052 2052 4713 247 741 388 9.60E−89 [LN:F81363] [AC:F81363] [PN:probable glutamine transport ATP-binding protein Cj0902 [imported]] [GN:glnQ:Cj0902] [OR:Campylobacter jejuni] 138 SPX2053 2053 4714 72 216 NO-HIT 6 SPX2054 2054 4715 77 231 NO-HIT 6 SPX2055 2055 4716 66 198 254 1.20E−29 [GI:2804700] [LN:AF030361] [AC:AF030361] [PN:transposase] [OR:Streptococcus pneumoniae] 87 SPX2056 2056 4717 128 384 511 2.70E−66 [GI:5739312] [LN:AF161700] [AC:AF161700] [PN:ComX1] [GN:comX1] [FN:transcriptional regulator of] [OR:Streptococcus pneumoniae] 126 SPX2057 2057 4718 184 552 442 1.30E−63 [LN:NUSG_BACSU] [AC:Q06795] [GN:NUSG] [OR:Bacillus subtilis] [DE:TRANSCRIPTION ANTITERMINATION PROTEIN NUSG] [SP:Q06795] 120 SPX2058 2058 4719 59 177 NO-HIT 6 SPX2059 2059 4720 732 2196 3714 0 [GI:6165960] [LN:AF101780] [AC:AF101780] [PN:penicillin-binding protein 2a] [GN:pbp2a] [OR:Streptococcus pneumoniae] 116 SPX2060 2060 4721 292 876 229 4.10E−34 [LN:YHCT_BACSU] [AC:P54604] [GN:YHCT] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 33.7 KD PROTEIN IN CSPB-GLPP INTERGENIC 137 REGION] [SP:P54604] SPX2061 2061 4722 360 1080 1061 2.30E−215 “[LN:A42963] [AC:A42963:B42963:JH0750] [PN:glyceraldehyde-3-phosphate dehydrogenase,:plasmin receptor] [CL:glyceraldehyde-3-phosphate 186 dehydrogenase] [OR:Streptococcus sp.] [EC:1.2.1.12]” SPX2062 2062 4723 92 276 NO-HIT 6 SPX2063 2063 4724 317 951 124 1.80E−15 [LN:Y797_METJA] [AC:Q58207] [GN:MJ0797] [OR:Methanococcus jannaschii] [DE:HYPOTHETICAL PROTEIN MJ0797] [SP:Q58207] 114 SPX2064 2064 4725 113 339 552 2.20E−73 [GI:5019553] [LN:SPN239004] [AC:AJ239004] [PN:putative transposase] [OR:Streptococcus pneumoniae] 97 SPX2065 2065 4726 87 261 NO-HIT 6 SPX2066 2066 4727 116 348 577 5.80E−76 [GI:4200438] [LN:AF026471] [AC:AF026471] [PN:putative transposase] [OR:Streptococcus pneumoniae] 96 SPX2067 2067 4728 300 900 482 2.20E−71 [LN:B70375] [AC:B70375] [PN:quinolinate phosphoribosyl transferase] [GN:nadC] [CL:nicotinate-nucleotide pyrophosphorylase (carboxylating)] 160 [OR:Aquifex aeolicus] SPX2068 2068 4729 437 1311 448 2.70E−105 [LN:C81402] [AC:C81402] [PN:probable integral membrane protein Cj0555 [imported]] [GN:Cj0555] [OR:Campylobacter jejuni] 119 SPX2069 2069 4730 62 186 NO-HIT 6 SPX2070 2070 4731 65 195 111 7.10E−09 “[LN:H81018] [AC:H81018] [PN:iron(III) ABC transporter, ATP-binding protein NMB1993 [imported]] [GN:NMB1993] [OR:Neisseria meningitidis]” 137 SPX2071 2071 4732 243 729 352 3.20E−72 “[GI:4512387] [LN:AB011838] [AC:AB011838] [GN:ydhQ] [OR:Bacillus halodurans] [SR:Bacillus halodurans (strain:C-125) DNA, 143 clone_lib:lambda no.]” SPX2072 2072 4733 470 1410 808 8.30E−181 [LN:D69785] [AC:D69785] [PN:beta-glucosidase homolog ydhP] [GN:ydhP] [CL:Agrobacterium beta-glucosidase] [OR:Bacillus subtilis] 127 SPX2073 2073 4734 432 1296 330 7.00E−64 “[LN:PTCC_BACSU] [AC:P46317] [GN:CELB:LICC] [OR:Bacillus subtilis] [DE:PERMEASE IIC COMPONENT) (PHOSPHOTRANSFERASE 152 ENZYME II, C COMPONENT)] [SP:P46317]” SPX2074 2074 4735 129 387 NO-HIT 6 SPX2075 2075 4736 103 309 191 2.70E−30 [LN:PTCB_BACST] [AC:Q45399] [GN:CELA] [OR:Bacillus stearothermophilus] [EC:2.7.1.69] [DE:(EC 2.7.1.69)] [SP:Q45399] 115 SPX2076 2076 4737 103 309 210 6.00E−24 [LN:PTCA_BACSU] [AC:P46319] [GN:CELC:LICA] [OR:Bacillus subtilis] [EC:2.7.1.69] [DE:(EC 2.7.1.69) (EIII-CEL)] [SP:P46319] 121 SPX2077 2077 4738 75 225 NO-HIT 6 SPX2078 2078 4739 891 2673 2272 0 “[LN:ADH2_ENTHI] [AC:Q24803:Q27649] [GN:ADH2] [OR:Entamoeba histolytica] [EC:1.1.1.1:1.2.1.10] [DE:(EC 1.1.1.1) (ADH); 176 ALCETALDEHYDE DEHYDROGENASE, (ACDH)]] [SP:Q24803:Q27649]” SPX2079 2079 4740 137 411 168 4.10E−18 [GI:6010051] [LN:ECA270205] [AC:AJ270205] [PN:putative phosphatidylinositol-4-phosphate] [OR:Entodinium caudatum] 113 SPX2080 2080 4741 143 429 91 7.10E−26 “““[LN:E69808] [AC:E69808] [PN:protein-tyrosine phosphatase homolog yfkJ] [GN:yfkJ] [CL:protein-tyrosine-phosphatase, low molecular weight] 161 [OR:Bacillus subtilis]” SPX2081 2081 4742 100 300 177 9.30E−20 [GI:1402532] [LN:D78257] [AC:D78257] [PN:ORF11] [GN:orf11] [OR:Enterococcus faecalis] [SR:Enterococcus faecalis plasmid:pYI17 DNA] 130 SPX2082 2082 4743 659 1977 1671 0 “[LN:TKT_STRPN] [AC:P22976] [GN:RECP] [OR:Streptococcus pneumoniae] [EC:2.2.1.1] [DE:PROBABLE TRANSKETOLASE, (TK)] [SP:P22976]” 127 SPX2083 2083 4744 81 243 171 1.00E−17 “[LN:TKT_STRPN] [AC:P22976] [GN:RECP] [OR:Streptococcus pneumoniae] [EC:2.2.1.1] [DE:PROBABLE TRANSKETOLASE, (TK)] [SP:P22976]” 127 SPX2084 2084 4745 102 306 277 1.50E−33 “[LN:TKT_STRPN] [AC:P22976] [GN:RECP] [OR:Streptococcus pneumoniae] [EC:2.2.1.1] [DE:PROBABLE TRANSKETOLASE, (TK)] [SP:P22976]” 127 SPX2085 2085 4746 245 735 546 8.30E−96 [LN:YJFR_ECOLI] [AC:P39300] [GN:YJFR] [OR:Escherichia coli] [DE:HYPOTHETICAL 40.1 KD PROTEIN IN AIDB-SGAT INTERGENIC 136 REGION] [SP:P39300] SPX2086 2086 4747 136 408 430 3.30E−54 [LN:YJFR_ECOLI] [AC:P39300] [GN:YJFR] [OR:Escherichia coli] [DE:HYPOTHETICAL 40.1 KD PROTEIN IN AIDB-SGAT INTERGENIC 136 REGION] [SP:P39300] SPX2087 2087 4748 558 1674 178 6.30E−20 “[GI:4512373] [LN:AB011837] [AC:AB011837] [GN:yjdC] [OR:Bacillus halodurans] [SR:Bacillus halodurans (strain:C-125) DNA, clone_lib:lambda no.9]” 144 SPX2088 2088 4749 235 705 489 3.20E−93 [GI:5616307] [LN:AF160811] [AC:AF160811] [PN:L-ribulose 5-phosphate 4-epimerase] [GN:araD] [OR:Bacillus stearothermophilus] 123 SPX2089 2089 4750 288 864 777 3.20E−106 “[LN:SGBU_HAEIN] [AC:P44990] [GN:SGBU:HI1026] [OR:Haemophilus influenzae] [EC:5.-.-.-] [DE:PUTATIVE HEXULOSE-6-PHOSPHATE 153 ISOMERASE, (HUMPI)] [SP:P44990]” SPX2090 2090 4751 222 666 349 1.00E−70 [LN:SGAH_ECOLI] [AC:P39304] [GN:SGAH] [OR:Escherichia coli] [EC:4.1.2.-] [DE:3-HEXULOSE 6-PHOSPHATE FORMALDEHYDE LYASE)] 132 [SP:P39304] SPX2091 2091 4752 162 486 266 1.10E−45 [LN:PTXA_ECOLI] [AC:P39303] [GN:SGAA] [OR:Escherichia coli] [EC:2.7.1.69] [DE:(EC 2.7.1.69)] [SP:P39303] 104 SPX2092 2092 4753 94 282 111 6.80E−22 [LN:PTXB_ECOLI] [AC:P39302] [GN:SGAB] [OR:Escherichia coli] [EC:2.7.1.69] [DE:(EC 2.7.1.69)] [SP:P39302] 104 SPX2093 2093 4754 509 1527 275 5.90E−99 [LN:SGAT_ECOLI] [AC:P39301] [GN:SGAT] [OR:Escherichia coli] [DE:PUTATIVE TRANSPORT PROTEIN SGAT] [SP:P39301] 108 SPX2094 2094 4755 208 624 210 1.10E−38 “[GI:6681651] [LN:AB016077] [AC:AB016077] [PN:sakacin A production response regulator] [GN:sapR] [OR:Streptococcus mutans] 183 [SR:Streptococcus mutans (strain:MT8148) DNA, clone:pYT570]” SPX2095 2095 4756 329 987 145 1.90E−24 [LN:JAG_BACSU] [AC:Q01620] [GN:JAG] [OR:Bacillus subtilis] [DE:JAG PROTEIN (SPOIIIJ ASSOCIATED PROTEIN)] [SP:Q01620] 116 SPX2096 2096 4757 277 831 357 1.00E−51 [LN:SP3J_BACSU] [AC:Q01625] [GN:SPOIIIJ] [OR:Bacillus subtilis] [DE:STAGE III SPORULATION PROTEIN J PRECURSOR] [SP:Q01625] 122 SPX2097 2097 4758 124 372 173 3.10E−31 “[GI:5672645] [LN:AB013492] [AC:AB013492] [GN:rnpA] [OR:Bacillus halodurans] [SR:Bacillus halodurans (strain:C-125) DNA, clone:ALBAC001]” 137 SPX2098 2098 4759 397 1191 822 1.30E−149 “[LN:ACKA_BACSU] [AC:P37877] [GN:ACKA] [OR:Bacillus subtilis] [EC:2.7.2.1] [DE:ACETATE KINASE, (ACETOKINASE)] [SP:P37877]” 122 SPX2099 2099 4760 318 954 297 4.70E−44 [LN:YTXK_BACSU] [AC:P37876] [GN:YTXK] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 37.4 KD PROTEIN IN ACKA-SSPA INTERGENIC 137 REGION] [SP:P37876] SPX2100 2100 4761 196 588 132 2.90E−10 [LN:H70323] [AC:H70323] [PN:hypothetical protein aq_262] [GN:aq_262] [OR:Aquifex aeolicus] 90 SPX2101 2101 4762 138 414 NO-HIT 6 SPX2102 2102 4763 169 507 157 1.60E−30 [GI:3287181] [LN:LLC3107] [AC:Y15043] [GN:orf150] [OR:Lactococcus lactis subsp. cremoris] 89 SPX2103 2103 4764 101 303 123 9.50E−12 [GI:3287182] [LN:LLC3107] [AC:Y15043] [PN:hypothetical protein] [GN:orf128] [OR:Lactococcus lactis subsp. cremoris] 115 SPX2104 2104 4765 135 405 626 3.00E−81 [GI:3211751] [LN:AF052207] [AC:AF052207] [PN:competence protein] [GN:cglD] [OR:Streptococcus pneumoniae] 104 SPX2105 2105 4766 109 327 512 5.80E−66 [GI:3211750] [LN:AF052207] [AC:AF052207] [PN:competence protein] [GN:cglC] [OR:Streptococcus pneumoniae] 104 SPX2106 2106 4767 348 1044 1440 3.30E−199 [GI:3211749] [LN:AF052207] [AC:AF052207] [PN:competence protein] [GN:cglB] [OR:Streptococcus pneumoniae] 104 SPX2107 2107 4768 314 942 1592 4.30E−217 [GI:3211748] [LN:AF052207] [AC:AF052207] [PN:competence protein] [GN:cglA] [OR:Streptococcus pneumoniae] 104 SPX2108 2108 4769 124 372 468 9.20E−61 [GI:2058543] [LN:SGU81957] [AC:U81957] [PN:putative DNA binding protein] [OR:Streptococcus gordonii] 100 SPX2109 2109 4770 353 1059 639 1.60E−125 [LN:T36961] [AC:T36961] [PN:probable zinc-containing dehydrogenase] [GN:SCJ1.28c] [CL:alcohol dehydrogenase:long-chain alcohol 179 dehydrogenase homology] [OR:Streptomyces coelicolor] SPX2110 2110 4771 142 426 NO-HIT 6 SPX2111 2111 4772 384 1152 819 3.90E−108 [GI:6683552] [LN:AB024532] [AC:AB024532] [GN:SA8A11-1] [OR:Enterococcus seriolicida] [SR:Enterococcus seriolicida DNA] 118 SPX2112 2112 4773 606 1818 173 2.40E−27 [LN:C69975] [AC:C69975] [PN:acyltransferase homolog yrhL] [GN:yrhL] [OR:Bacillus subtilis] 90 SPX2113 2113 4774 381 1143 1469 3.70E−200 [LN:TGT_BACSU] [AC:O32053] [GN:TGT] [OR:Bacillus subtilis] [EC:2.4.2.29] [DE:TRANSGLYCOSYLASE) (GUANINE INSERTION ENZYME)] 134 [SP:O32053] SPX2114 2114 4775 286 858 90 9.00E−05 [LN:S32215] [AC:S32215] [PN:hypothetical protein 1] [OR:Bacillus megaterium] 76 SPX2115 2115 4776 215 645 769 1.20E−104 [LN:PCP_STRPY] [AC:Q01328] [GN:PCP] [OR:Streptococcus pyogenes] [EC:3.4.19.3] [DE:PEPTIDASE) (PYROGLUTAMYL-PEPTIDASE I) 149 (PGP-I) (PYRASE)] [SP:Q01328] SPX2116 2116 4777 90 270 NO-HIT 6 SPX2117 2117 4778 120 360 221 1.90E−43 “[LN:YTRP_LACLA] [AC:Q02009] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [DE:HYPOTHETICAL 13.3 KD PROTEIN 155 IN TRPE 5′REGION] [SP:Q02009]” SPX2118 2118 4779 142 426 163 3.50E−17 [LN:D69783] [AC:D69783] [PN:transcription regulator MarR family homolog ydgJ] [GN:ydgJ] [CL:regulatory protein mprA] [OR:Bacillus subtilis] 139 SPX2119 2119 4780 69 207 107 2.10E−10 [GI:1914870] [LN:SPZ82001] [AC:Z82001] [PN:unknown] [OR:Streptococcus pneumoniae] 81 SPX2120 2120 4781 371 1113 382 8.00E−79 [GI:517204] [LN:SPU09352] [AC:U09352] [OR:Streptococcus pyogenes] 65 SPX2121 2121 4782 207 621 153 7.60E−14 [LN:A57362] [AC:A57362] [PN:gyrb protein] [GN:gyrb] [OR:Streptococcus pneumoniae] 81 SPX2122 2122 4783 427 1281 216 1.10E−45 [LN:H72331] [AC:H72331] [PN:conserved hypothetical protein] [GN:TM0815] [CL:conserved hypothetical protein HI1612] [OR:Thermotoga maritima] 139 SPX2123 2123 4784 495 1485 412 4.80E−66 [LN:B64532] [AC:B64532] [PN:threonine synthase] [CL:threonine synthase] [OR:Helicobacter pylori] 96 SPX2124 2124 4785 426 1278 70 0.00014 “[LN:T05142] [AC:T05142:S60128:S45018] [PN:gamma-glutamylcysteine synthetase:protein F7H19.290] [OR:Arabidopsis thaliana] [SR:, mouse-ear 158 cress] [EC:6.3.2.2]” SPX2125 2125 4786 59 177 100 1.30E−08 [LN:C64671] [AC:C64671] [PN:hypothetical protein HP1211] [OR:Helicobacter pylori] 81 SPX2126 2126 4787 61 183 81 9.30E−05 [LN:E72688] [AC:E72688] [PN:hypothetical protein APE0925] [GN:APE0925] [CL:Aeropyrum pernix hypothetical protein APE0925] 143 [OR:Aeropyrum pernix] SPX2127 2127 4788 78 234 143 4.90E−15 [LN:F71245] [AC:F71245] [PN:hypothetical protein PHS004] [GN:PHS004] [OR:Pyrococcus horikoshii] 95 SPX2128 2128 4789 82 246 247 1.10E−29 [LN:F81737] [AC:F81737] [PN:hypothetical protein TC0129 [imported]] [GN:TC0129] [OR:Chlamydia muridarum:Chlamydia trachomatis MoPn] 131 SPX2129 2129 4790 52 156 80 3.00E−05 [LN:D75542] [AC:D75542] [PN:hypothetical protein] [GN:DR0254] [OR:Deinococcus radiodurans] 90 SPX2130 2130 4791 105 315 NO-HIT 6 SPX2131 2131 4792 146 438 486 1.80E−62 [GI:517210] [LN:SPU11799] [AC:U11799] [OR:Streptococcus pyogenes] 65 SPX2132 2132 4793 354 1062 824 6.40E−132 [GI:1915907] [LN:LLPEPPGEN] [AC:Y08842] [PN:aminopeptidase P] [GN:pepP] [OR:Lactococcus lactis] 95 SPX2133 2133 4794 944 2832 2029 0 [LN:UVRA_BACSU] [AC:O34863] [GN:UVRA] [OR:Bacillus subtilis] [DE:EXCINUCLEASE ABC SUBUNIT A] [SP:O34863] 104 SPX2134 2134 4795 315 945 236 1.50E−26 [LN:A75272] [AC:A75272] [PN:probable transport protein] [GN:DR2463] [CL:magnesium and cobalt transport protein] [OR:Deinococcus radiodurans] 140 SPX2135 2135 4796 68 204 NO-HIT 6 SPX2136 2136 4797 213 639 NO-HIT 6 SPX2137 2137 4798 51 153 123 1.60E−12 [GI:1914870] [LN:SPZ82001] [AC:Z82001] [PN:unknown] [OR:Streptococcus pneumoniae] 81 SPX2138 2138 4799 344 1032 86 1.10E−19 [LN:E75325] [AC:E75325] [PN:probable mccF protein] [GN:DR2000] [OR:Deinococcus radiodurans] 91 SPX2139 2139 4800 226 678 66 3.80E−08 [GI:6470197] [LN:AF188935] [AC:AF188935] [PN:pXO2-46] [OR:Bacillus anthracis] 77 SPX2140 2140 4801 188 564 465 3.30E−63 [LN:3MGA_HAEIN] [AC:P44321] [GN:TAG:HI0654] [OR:Haemophilus influenzae] [EC:3.2.2.20] [DE:GLYCOSIDASE) (TAG)] [SP:P44321] 121 SPX2141 2141 4802 186 558 NO-HIT 6 SPX2142 2142 4803 198 594 235 1.00E−38 [LN:RUVA_BACSU] [AC:O05392] [GN:RUVA] [OR:Bacillus subtilis] [DE:PROBABLE HOLLIDAY JUNCTION DNA HELICASE RUVA] 122 [SP:O05392] SPX2143 2143 4804 70 210 NO-HIT 6 SPX2144 2144 4805 367 1101 888 6.00E−128 “[LN:RIBD_ACTPL] [AC:P50853] [GN:RIBD:RIBG] [OR:Actinobacillus pleuropneumoniae] [SR:,Haemophilus pleuropneumoniae] [EC:3.5.4.-] 177 [DE:RIBOFLAVIN-SPECIFIC DEAMINASE,] [SP:P50853]” SPX2145 2145 4806 212 636 601 1.70E−81 “[LN:RISA_ACTPL] [AC:P50854] [GN:RIBE:RIBB] [OR:Actinobacillus pleuropneumoniae] [SR:,Haemophilus pleuropneumoniae] [EC:2.5.1.9] 179 [DE:RIBOFLAVIN SYNTHASE ALPHA CHAIN,] [SP:P50854]” SPX2146 2146 4807 412 1236 1266 1.80E−170 “[LN:GCH2_ACTPL] [AC:P50855] [GN:RIBA] [OR:Actinobacillus pleuropneumoniae] [SR:,Haemophilus pleuropneumoniae] [EC:3.5.4.25] 153 [DE:SYNTHASE)]] [SP:P50855]” SPX2147 2147 4808 156 468 546 1.30E−70 “[LN:RISB_ACTPL] [AC:P50856] [GN:RIBH] [OR:Actinobacillus pleuropneumoniae] [SR:,Haemophilus pleuropneumoniae] [EC:2.5.1.9] 194 [DE:(LUMAZINE SYNTHASE) (RIBOFLAVIN SYNTHASE BETA CHAIN)] [SP:P50856]” SPX2148 2148 4809 650 1950 3286 0 [LN:HEXB_STRPN] [AC:P14160] [GN:HEXB] [OR:Streptococcus pneumoniae] [DE:DNA MISMATCH REPAIR PROTEIN HEXB] [SP:P14160] 117 SPX2149 2149 4810 84 252 NO-HIT 6 SPX2150 2150 4811 97 291 NO-HIT 6 SPX2151 2151 4812 61 183 122 1.10E−12 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX2152 2152 4813 174 522 231 9.30E−27 “[GI:1196936] [LN:STRHEXB] [AC:M29686] [PN:unknown protein] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae 144 (clone: pSP(8,41).) DNA]” SPX2153 2153 4814 153 459 NO-HIT 6 SPX2154 2154 4815 126 378 333 1.60E−40 [GI:517210] [LN:SPU11799] [AC:U11799] [OR:Streptococcus pyogenes] 65 SPX2155 2155 4816 211 633 762 7.90E−101 [GI:517210] [LN:SPU11799] [AC:U11799] [OR:Streptococcus pyogenes] 65 SPX2156 2156 4817 201 603 499 7.70E−65 [LN:C81084] [AC:C81084] [PN:hypothetical protein NMB1426 [imported]] [GN:NMB1426] [OR:Neisseria meningitidis] 109 SPX2157 2157 4818 64 192 NO-HIT 6 SPX2158 2158 4819 218 654 461 2.50E−67 [LN:C81084] [AC:C81084] [PN:hypothetical protein NMB1426 [imported]] [GN:NMB1426] [OR:Neisseria meningitidis] 109 SPX2159 2159 4820 201 603 353 3.50E−53 [GI:6782392] [LN:SDY18363] [AC:Y18363] [PN:ribonucleotide reductase-like (Nrd-like)] [GN:nrd] [OR:Streptococcus dysgalactiae] 125 SPX2160 2160 4821 194 582 NO-HIT 6 SPX2161 2161 4822 429 1287 2176 6.20E−298 [GI:5830536] [LN:SPAJ6396] [AC:AJ006396] [PN:response regulator] [GN:rr07] [OR:Streptococcus pneumoniae] 104 SPX2162 2162 4823 568 1704 1183 7.00E−160 [GI:5830535] [LN:SPAJ6396] [AC:AJ006396] [PN:histidine kinase] [GN:hk07] [OR:Streptococcus pneumoniae] 102 SPX2163 2163 4824 205 615 NO-HIT 6 SPX2164 2164 4825 190 570 NO-HIT 6 SPX2165 2165 4826 231 693 395 1.90E−87 [GI:6165406] [LN:LLA012388] [AC:AJ012388] [PN:hypothetical protein] [OR:Lactococcus lactis] 91 SPX2166 2166 4827 354 1062 616 4.50E−130 [GI:6165405] [LN:LLA012388] [AC:AJ012388] [PN:hypothetical protein] [OR:Lactococcus lactis] 91 SPX2167 2167 4828 73 219 94 8.50E−07 [LN:G72536] [AC:G72536] [PN:hypothetical protein APE1580] [GN:APE1580] [OR:Aeropyrum pernix] 92 SPX2168 2168 4829 458 1374 219 7.10E−53 [LN:E75327] [AC:E75327] [PN:ArgE/DapE/Acy1 family protein] [GN:DR2017] [OR:Deinococcus radiodurans] 99 SPX2169 2169 4830 285 855 319 1.50E−63 [GI:6165404] [LN:LLA012388] [AC:AJ012388] [PN:hypothetical protein] [OR:Lactococcus lactis] 91 SPX2170 2170 4831 66 198 NO-HIT 6 SPX2171 2171 4832 184 552 109 1.10E−12 [LN:YXEM_BACSU] [AC:P54952] [GN:YXEM:LP9E] [OR:Bacillus subtilis] [DE:INTERGENIC REGION PRECURSOR] [SP:P54952] 110 SPX2172 2172 4833 62 186 NO-HIT 6 SPX2173 2173 4834 225 675 129 5.60E−10 [LN:G75494] [AC:G75494] [PN:AzlC family protein] [GN:DR0633] [CL:hypothetical protein b2682] [OR:Deinococcus radiodurans] 121 SPX2174 2174 4835 137 411 328 2.80E−41 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX2175 2175 4836 80 240 NO-HIT 6 SPX2176 2176 4837 75 225 NO-HIT 6 SPX2177 2177 4838 410 1230 80 2.70E−10 [GI:3582221] [LN:AE001272] [AC:AE001272] [PN:conserved hypothetical protein] [GN:ORF00049] [OR:Lactococcus lactis] 114 SPX2178 2178 4839 222 666 71 1.80E−05 [LN:E69787] [AC:E69787] [PN:hypothetical protein ydiL] [GN:ydiL] [OR:Bacillus subtilis] 87 SPX2179 2179 4840 66 198 NO-HIT 6 SPX2180 2180 4841 296 888 587 4.20E−77 [GI:4102023] [LN:AF007761] [AC:AF007761] [PN:MutR] [GN:mutR] [FN:positive transcriptional regulator of mutA] [OR:Streptococcus mutans] 134 SPX2181 2181 4842 69 207 NO-HIT 6 SPX2182 2182 4843 206 618 479 1.40E−72 [LN:UDG5_ECOLI] [AC:Q47329] [GN:KFID] [OR:Escherichia coli] [EC:1.1.1.22] [DE:(UDP-GLCDH) (UDPGDH)] [SP:Q47329] 111 SPX2183 2183 4844 252 756 86 3.90E−08 [GI:4689219] [LN:AF115779] [AC:AF115779] [PN:unknown] [GN:mitC] [OR:Streptomyces lavendulae] 92 SPX2184 2184 4845 74 222 NO-HIT 6 SPX2185 2185 4846 115 345 NO-HIT 6 SPX2186 2186 4847 81 243 NO-HIT 6 SPX2187 2187 4848 539 1617 294 1.70E−34 “[LN:D72267] [AC:D72267] [PN:ABC transporter, ATP-binding protein] [GN:TM1328] [CL:unassigned ATP-binding cassette proteins:ATP-binding 180 cassette homology] [OR:Thermotoga maritima]” SPX2188 2188 4849 318 954 137 5.90E−20 [LN:B75096] [AC:B75096] [PN:glycosyl transferase PAB0772] [GN:PAB0772] [CL:Neisseria meningitidis glycosyl transferase A] 144 [OR:Pyrococcus abyssi] SPX2189 2189 4850 175 525 179 6.60E−17 [GI:1276880] [LN:STU40830] [AC:U40830] [PN:EpsG] [GN:epsG] [OR:Streptococcus thermophilus] 90 SPX2190 2190 4851 188 564 NO-HIT 6 SPX2191 2191 4852 107 321 187 3.70E−21 [GI:4200438] [LN:AF026471] [AC:AF026471] [PN:putative transposase] [OR:Streptococcus pneumoniae] 96 SPX2192 2192 4853 88 264 196 2.60E−23 [GI:5019553] [LN:SPN239004] [AC:AJ239004] [PN:putative transposase] [OR:Streptococcus pneumoniae] 97 SPX2193 2193 4854 355 1065 893 8.00E−121 [GI:2804700] [LN:AF030361] [AC:AF030361] [PN:transposase] [OR:Streptococcus pneumoniae] 87 SPX2194 2194 4855 129 387 490 2.90E−65 [GI:663279] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae 138 (strain RX1) DNA] SPX2195 2195 4856 71 213 119 2.60E−10 [GI:2198546] [LN:SPCPS14E] [AC:X85787] [GN:tasA] [OR:Streptococcus pneumoniae] 78 SPX2196 2196 4857 337 1011 913 6.50E−132 [LN:YDIE_BACSU] [AC:O05518] [GN:YDIE] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 36.8 KD PROTEIN IN PHOB-GROES 138 INTERGENIC REGION] [SP:O05518] SPX2197 2197 4858 146 438 92 1.00E−09 [LN:E69786] [AC:E69786] [PN:ribosomal-protein-alanine N-acetyltransfer homolog ydiD] [GN:ydiD] [CL:Escherichia coli ribosomal-protein-alanine 190 N-acetyltransferase rimI] [OR:Bacillus subtilis] SPX2198 2198 4859 228 684 303 1.40E−53 [GI:3341437] [LN:EFY17797] [AC:Y17797] [PN:hypothetical protein] [GN:ydiC] [OR:Enterococcus faecalis] 101 SPX2199 2199 4860 62 186 NO-HIT 6 SPX2200 2200 4861 77 231 NO-HIT 6 SPX2201 2201 4862 78 234 78 2.50E−10 [LN:D69871] [AC:D69871] [PN:hypothetical protein ykzG] [GN:ykzG] [OR:Bacillus subtilis] 87 SPX2202 2202 4863 560 1680 1841 6.00E−251 [LN:YKQC_BACSU] [AC:Q45493] [GN:YKQC] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 61.5 KD PROTEIN IN ADEC-PDHA 137 INTERGENIC REGION] [SP:Q45493] SPX2203 2203 4864 121 363 NO-HIT 6 SPX2204 2204 4865 638 1914 1698 2.50E−282 “[LN:GIDA_LACLC] [AC:O32806] [GN:GIDA] [OR:Lactococcus lactis] [SR:,subspcremoris:Streptococcus cremoris] [DE:GLUCOSE INHIBITED 171 DIVISION PROTEIN A (FRAGMENT)] [SP:O32806]” SPX2205 2205 4866 158 474 NO-HIT 6 SPX2206 2206 4867 161 483 73 2.50E−06 [LN:F75354] [AC:F75354] [PN:MutT/nudix family protein] [GN:DR1776] [OR:Deinococcus radiodurans] 95 SPX2207 2207 4868 392 1176 578 1.10E−170 [LN:TRMU_BACSU] [AC:O35020] [GN:TRMU] [OR:Bacillus subtilis] [EC:2.1.1.61] [DE:(EC 2.1.1.61)] [SP:O35020] 105 SPX2208 2208 4869 60 180 NO-HIT 6 SPX2209 2209 4870 66 198 NO-HIT 6 SPX2210 2210 4871 551 1653 1324 7.00E−210 [LN:A41971] [AC:A41971:A60282:A33134] [PN:surface protein pspA precursor:pneumococcal surface protein A] [GN:pspA] [CL:cpl repeat 169 homology] [OR:Streptococcus pneumoniae] SPX2211 2211 4872 79 237 98 1.60E−06 [GI:311109] [LN:YSCISCLRP] [AC:L16900] [PN:intrastrand crosslink recognition protein] [GN:Ixr1] [OR:Saccharomyces cerevisiae] 169 [SR:Saccharomyces cerevisiae (strain ) DNA] SPX2212 2212 4873 64 192 77 0.00063 [LN:B72392] [AC:B72392] [PN:hypothetical protein] [GN:TM0315] [OR:Thermotoga maritima] 86 SPX2213 2213 4874 103 309 87 0.0009 [GI:7292943] [LN:AE003494] [AC:AE003494:AE002593] [GN:CG11075] [OR:Drosophila melanogaster] [SR:fruit fly] 106 SPX2214 2214 4875 106 318 NO-HIT 6 SPX2215 2215 4876 103 309 459 8.20E−56 [GI:6752385] [LN:AF071807] [AC:AF071807] [PN:PspA] [GN:pspA] [OR:Streptococcus pneumoniae] 90 SPX2216 2216 4877 93 279 NO-HIT 6 SPX2217 2217 4878 100 300 NO-HIT 6 SPX2218 2218 4879 71 213 NO-HIT 6 SPX2219 2219 4880 253 759 NO-HIT 6 SPX2220 2220 4881 129 387 NO-HIT 6 SPX2221 2221 4882 301 903 NO-HIT 6 SPX2222 2222 4883 61 183 NO-HIT 6 SPX2223 2223 4884 125 375 NO-HIT 6 SPX2224 2224 4885 62 186 NO-HIT 6 SPX2225 2225 4886 227 681 NO-HIT 6 SPX2226 2226 4887 76 228 NO-HIT 6 SPX2227 2227 4888 319 957 1739 3.00E−234 “[LN:ALYS_BPHB3] [AC:P32762] [GN:HBL] [OR:Streptococcus pneumoniae phage HB-3] [EC:3.5.1.28] [DE:LYTIC AMIDASE, (N- 162 ACETYLMURAMOYL-L-ALANINE AMIDASE)] [SP:P32762]” SPX2228 2228 4889 111 333 NO-HIT 6 SPX2229 2229 4890 139 417 97 1.20E−08 [LN:VG14_BPB03] [AC:Q37895] [GN:14] [OR:Bacteriophage B103] [DE:LYSIS PROTEIN (LATE PROTEIN GP14)] [SP:Q37895] 110 SPX2230 2230 4891 117 351 NO-HIT 6 SPX2231 2231 4892 68 204 NO-HIT 6 SPX2232 2232 4893 2120 6360 154 1.40E−22 [GI:4530154] [LN:AF085222] [AC:AF085222] [PN:putative tail-host specificity protein] [OR:Streptococcus thermophilus bacteriophage DT1] 134 SPX2233 2233 4894 79 237 NO-HIT 6 SPX2234 2234 4895 117 351 NO-HIT 6 SPX2235 2235 4896 1218 3654 236 2.10E−30 [GI:2392838] [LN:AF011378] [AC:AF011378] [PN:unknown] [OR:Bacteriophage sk1] 76 SPX2236 2236 4897 187 561 106 2.00E−07 [GI:5305335] [LN:AF071081] [AC:AF071081] [PN:proline-rich mucin homolog] [OR:Mycobacterium tuberculosis] 104 SPX2237 2237 4898 70 210 NO-HIT 6 SPX2238 2238 4899 73 219 NO-HIT 6 SPX2239 2239 4900 127 381 NO-HIT 6 SPX2240 2240 4901 138 414 NO-HIT 6 SPX2241 2241 4902 123 369 77 0.00049 [LN:T13522] [AC:T13522] [PN:hypothetical protein 33] [CL:Bacillus phage phi-105 hypothetical protein 33] [OR:Bacillus phage phi-105] 132 SPX2242 2242 4903 172 516 71 7.90E−06 [LN:T42287] [AC:T42287] [PN:hypothetical protein] [OR:phage SPP1] 65 SPX2243 2243 4904 61 183 NO-HIT 6 SPX2244 2244 4905 113 339 NO-HIT 6 SPX2245 2245 4906 104 312 NO-HIT 6 SPX2246 2246 4907 63 189 NO-HIT 6 SPX2247 2247 4908 61 183 73 0.0003 [LN:F75258] [AC:F75258] [PN:hypothetical protein] [GN:DR2560] [OR:Deinococcus radiodurans] 90 SPX2248 2248 4909 282 846 226 2.60E−48 [GI:1369939] [LN:BTP9011] [AC:X84706] [PN:major head protein] [GN:mhp] [OR:Bacteriophage B1] 92 SPX2249 2249 4910 195 585 NO-HIT 6 SPX2250 2250 4911 86 258 NO-HIT 6 SPX2251 2251 4912 76 228 NO-HIT 6 SPX2252 2252 4913 468 1404 80 1.20E−06 [LN:T13317] [AC:T13317] [PN:hypothetical protein 28] [OR:Streptococcus phage phi-O1205] 87 SPX2253 2253 4914 490 1470 154 3.40E−39 [LN:T13620] [AC:T13620] [PN:hypothetical protein gp502] [OR:Streptococcus phage phi-Sfi11] 90 SPX2254 2254 4915 433 1299 330 6.80E−48 [LN:TERL_BPSPP] [AC:P54308] [GN:2] [OR:Bacteriophage SPP1] [DE:TERMINASE LARGE SUBUNIT (G2P)] [SP:P54308] 105 SPX2255 2255 4916 160 480 215 2.30E−32 [GI:4680607] [LN:AF125198] [AC:AF125198] [PN:terminase small subunit] [GN:TS1] [OR:bacteriophage phi-FC1] 105 SPX2256 2256 4917 135 405 154 4.60E−16 [GI:4530181] [LN:AF085222] [AC:AF085222] [PN:unknown] [OR:Streptococcus thermophilus bacteriophage DT1] 103 SPX2257 2257 4918 124 372 NO-HIT 6 SPX2258 2258 4919 146 438 115 1.00E−14 [GI:5001708] [LN:AF109874] [AC:AF109874] [PN:unknown] [OR:Bacteriophage Tuc2009] 80 SPX2259 2259 4920 153 459 NO-HIT 6 SPX2260 2260 4921 87 261 109 9.50E−12 [GI:4530179] [LN:AF085222] [AC:AF085222] [PN:unknown] [OR:Streptococcus thermophilus bacteriophage DT1] 103 SPX2261 2261 4922 232 696 203 1.70E−24 [LN:T13308] [AC:T13308] [PN:hypothetical protein 19] [OR:Streptococcus phage phi-O1205] 87 SPX2262 2262 4923 450 1350 358 1.30E−46 [GI:2689558] [LN:U93688] [AC:U93688] [OR:Staphylococcus aureus] 63 SPX2263 2263 4924 274 822 470 7.10E−87 [LN:T13301] [AC:T13301] [PN:hypothetical protein 12] [OR:Streptococcus phage phi-O1205] 87 SPX2264 2264 4925 78 234 NO-HIT 6 SPX2265 2265 4926 66 198 NO-HIT 6 SPX2266 2266 4927 169 507 NO-HIT 6 SPX2267 2267 4928 276 828 NO-HIT 6 SPX2268 2268 4929 106 318 NO-HIT 6 SPX2269 2269 4930 398 1194 NO-HIT 6 SPX2270 2270 4931 163 489 NO-HIT 6 SPX2271 2271 4932 120 360 NO-HIT 6 SPX2272 2272 4933 161 483 256 2.10E−45 [GI:2352435] [LN:AF004379] [AC:AF004379] [OR:Streptococcus thermophilus bacteriophage Sfi21] 92 SPX2273 2273 4934 258 774 NO-HIT 6 SPX2274 2274 4935 77 231 NO-HIT 6 SPX2275 2275 4936 114 342 NO-HIT 6 SPX2276 2276 4937 63 189 NO-HIT 6 SPX2277 2277 4938 87 261 NO-HIT 6 SPX2278 2278 4939 91 273 NO-HIT 6 SPX2279 2279 4940 80 240 NO-HIT 6 SPX2280 2280 4941 64 192 NO-HIT 6 SPX2281 2281 4942 68 204 NO-HIT 6 SPX2282 2282 4943 67 201 NO-HIT 6 SPX2283 2283 4944 72 216 101 3.70E−09 [LN:Y272_METJA] [AC:Q57720] [GN:MJ0272] [OR:Methanococcus jannaschii] [DE:HYPOTHETICAL TRANSCRIPTIONAL REGULATOR 132 MJ0272] [SP:Q57720] SPX2284 2284 4945 68 204 NO-HIT 6 SPX2285 2285 4946 230 690 NO-HIT 6 SPX2286 2286 4947 264 792 112 4.00E−15 [LN:T13264] [AC:T13264] [PN:repressor protein] [OR:Lactococcus lactis phage BK5-T] 82 SPX2287 2287 4948 317 951 102 5.00E−09 [LN:F59095] [AC:F59095] [PN:hypothetical protein pXO1-38] [GN:pXO1-38] [OR:Bacillus anthracis] 94 SPX2288 2288 4949 58 174 NO-HIT 6 SPX2289 2289 4950 376 1128 212 3.50E−43 [GI:2689564] [LN:U93688] [AC:U93688] [PN:integrase] [GN:int] [OR:Staphylococcus aureus] 87 SPX2290 2290 4951 62 186 NO-HIT 6 SPX2291 2291 4952 353 1059 81 0.00071 [LN:AF147045] [AC:AF147045] [PN:cytochrome c oxidase subunit 1] [GN:COI] [OR:Mitochondrion Dolichoderus lutosus] [SR:Dolichoderus lutosus] 138 SPX2292 2292 4953 64 192 NO-HIT 6 SPX2293 2293 4954 71 213 NO-HIT 6 SPX2294 2294 4955 81 243 NO-HIT 6 SPX2295 2295 4956 149 447 NO-HIT 6 SPX2296 2296 4957 60 180 NO-HIT 6 SPX2297 2297 4958 117 351 137 3.30E−14 [GI:4760910] [LN:AF099088] [AC:AF099088] [PN:EntT] [GN:entT] [OR:Enterococcus faecium] 86 SPX2298 2298 4959 288 864 117 4.70E−08 [GI:4102023] [LN:AF007761] [AC:AF007761] [PN:MutR] [GN:mutR] [FN:positive transcriptional regulator of mutA] [OR:Streptococcus mutans] 134 SPX2299 2299 4960 125 375 NO-HIT 6 SPX2300 2300 4961 76 228 NO-HIT 6 SPX2301 2301 4962 127 381 NO-HIT 6 SPX2302 2302 4963 75 225 NO-HIT 6 SPX2303 2303 4964 70 210 NO-HIT 6 SPX2304 2304 4965 68 204 NO-HIT 6 SPX2305 2305 4966 288 864 117 4.70E−08 [GI:4102023] [LN:AF007761] [AC:AF007761] [PN:MutR] [GN:mutR] [FN:positive transcriptional regulator of mutA] [OR:Streptococcus mutans] 134 SPX2306 2306 4967 173 519 840 6.50E−114 [GI:663278] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae (strain RX1) DNA] 138 SPX2307 2307 4968 122 366 NO-HIT 6 SPX2308 2308 4969 96 288 279 1.60E−35 [GI:663279] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae (strain RX1) DNA] 138 SPX2309 2309 4970 256 768 1235 1.10E−172 [GI:663279] [LN:STRCOMAA] [AC:M36180:L15190] [PN:transposase] [OR:Streptococcus pneumoniae] [SR:Streptococcus pneumoniae (strain RX1) DNA] 138 SPX2310 2310 4971 157 471 375 6.90E−56 [LN:ASSY_BACSU] [AC:O34347] [GN:ARGG] [OR:Bacillus subtilis] [EC:6.3.4.5] [DE:LIGASE)] [SP:O34347] 98 SPX2311 2311 4972 266 798 200 6.10E−32 “[LN:B72357] [AC:B72357] [PN:amino acid ABC transporter, periplasmic amino acid-binding protein] [GN:TM0593] [CL:lysine-arginine- 181 ornithine-binding protein] [OR:Thermotoga maritima]” SPX2312 2312 4973 214 642 420 1.80E−51 [LN:F81408] [AC:F81408] [PN:ABC-type transmembrane transport protein Cj0607 [imported]] [GN:Cj0607] [OR:Campylobacter jejuni] 125 SPX2313 2313 4974 59 177 80 1.80E−07 [LN:F72598] [AC:F72598] [PN:hypothetical protein APE1254] [GN:APE1254] [OR:Aeropyrum pernix] 92 SPX2314 2314 4975 439 1317 NO-HIT 6 SPX2315 2315 4976 371 1113 NO-HIT 6 SPX2316 2316 4977 72 216 NO-HIT 6 SPX2317 2317 4978 84 252 NO-HIT 6 SPX2318 2318 4979 288 864 117 4.70E−08 [GI:4102023] [LN:AF007761] [AC:AF007761] [PN:MutR] [GN:mutR] [FN:positive transcriptional regulator of mutA] [OR:Streptococcus mutans] 134 SPX2319 2319 4980 196 588 300 1.00E−34 [GI:1619598] [LN:LGAPFA] [AC:Y08498] [PN:aggregation promoting protein] [GN:apfA] [OR:Lactobacillus gasseri] 108 SPX2320 2320 4981 97 291 NO-HIT 6 SPX2321 2321 4982 224 672 276 8.70E−69 [LN:SDHB_BACSU] [AC:O34635] [GN:YLOW] [OR:Bacillus subtilis] [EC:4.2.1.13] [DE:DEAMINASE) (SDH) (L-SD)] [SP:O34635] 115 SPX2322 2322 4983 291 873 877 9.00E−119 [LN:SDHA_BACSU] [AC:O34607] [GN:YLPA] [OR:Bacillus subtilis] [EC:4.2.1.13] [DE:DEAMINASE) (SDH) (L-SD)] [SP:O34607] 115 SPX2323 2323 4984 178 534 NO-HIT 6 SPX2324 2324 4985 211 633 123 1.50E−15 [GI:7576264] [LN:ECH277403] [AC:AJ277403] [PN:IndB protein] [GN:indB] [OR:Erwinia chrysanthemi] 95 SPX2325 2325 4986 72 216 NO-HIT 6 SPX2326 2326 4987 617 1851 1006 3.00E−136 [GI:6601348] [LN:AF155805] [AC:AF155805] [PN:Cps9E] [GN:cps9E] [OR:Streptococcus suis] 86 SPX2327 2327 4988 84 252 135 6.70E−14 [LN:S28486] [AC:S28486] [PN:hypothetical protein 2] [OR:Vibrio cholerae] 72 SPX2328 2328 4989 392 1176 123 7.20E−25 [LN:T44514] [AC:T44514] [PN:hypothetical protein 6P [imported]] [OR:Plesiomonas shigelloides] 93 SPX2329 2329 4990 102 306 NO-HIT 6 SPX2330 2330 4991 249 747 142 5.40E−29 [LN:YYCB_BACSU] [AC:P37482] [GN:YYCB] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 43.2 KD PROTEIN IN DNAC-RPLI INTERGENIC 137 REGION] [SP:P37482] SPX2331 2331 4992 143 429 143 9.10E−15 [LN:PQ0016] [AC:PQ0016] [PN:hypothetical 9K protein] [OR:Lactobacillus confusus] 80 SPX2332 2332 4993 109 327 102 4.10E−07 [LN:D75250] [AC:D75250] [PN:conserved hypothetical protein] [GN:DR2629] [OR:Deinococcus radiodurans] 100 SPX2333 2333 4994 198 594 NO-HIT 6 SPX2334 2334 4995 304 912 NO-HIT 6 SPX2335 2335 4996 123 369 NO-HIT 6 SPX2336 2336 4997 355 1065 118 3.00E−07 [LN:T18283] [AC:T18283] [PN:hypothetical protein G5] [OR:Dictyostelium discoideum] 82 SPX2337 2337 4998 318 954 NO-HIT 6 SPX2338 2338 4999 329 987 925 1.60E−165 [GI:2565150] [LN:LLU92974] [AC:U92974:M90760:M90761] [PN:unknown] [OR:Lactococcus lactis] 89 SPX2339 2339 5000 69 207 NO-HIT 6 SPX2340 2340 5001 515 1545 NO-HIT 6 SPX2341 2341 5002 134 402 NO-HIT 6 SPX2342 2342 5003 308 924 389 1.50E−61 [GI:1483212] [LN:ATCELD] [AC:Z77855] [PN:sugar-binding transport protein] [OR:Anaerocellum thermophilum] 104 SPX2343 2343 5004 320 960 601 9.60E−95 [GI:1483211] [LN:ATCELD] [AC:Z77855] [PN:sugar-binding transport protein] [OR:Anaerocellum thermophilum] 104 SPX2344 2344 5005 70 210 NO-HIT 6 SPX2345 2345 5006 120 360 NO-HIT 6 SPX2346 2346 5007 116 348 577 5.80E−76 [GI:4200438] [LN:AF026471] [AC:AF026471] [PN:putative transposase] [OR:Streptococcus pneumoniae] 96 SPX2347 2347 5008 177 531 299 3.70E−73 [LN:A37146] [AC:A37146:A44901:S11354:C69699:I39962] [PN:ribosomal protein S4:ribosomal protein BS4 (rpsD)] [GN:rpsD] [CL:Escherichia 182 coli ribosomal protein S4] [OR:Bacillus subtilis] SPX2348 2348 5009 359 1077 1709 2.00E−231 [GI:5830539] [LN:SPAJ6397] [AC:AJ006397] [PN:histidine kinase] [GN:hk08] [OR:Streptococcus pneumoniae] 102 SPX2349 2349 5010 233 699 1196 1.40E−161 [GI:5830538] [LN:SPAJ6397] [AC:AJ006397] [PN:response regulator] [GN:rr08] [OR:Streptococcus pneumoniae] 104 SPX2350 2350 5011 124 372 NO-HIT 6 SPX2351 2351 5012 891 2673 106 0.00022 [GI:7293562] [LN:AE003511] [AC:AE003511:AE002593] [GN:CG7874] [OR:Drosophila melanogaster] [SR:fruit fly] 105 SPX2352 2352 5013 190 570 NO-HIT 6 SPX2353 2353 5014 137 411 NO-HIT 6 SPX2354 2354 5015 179 537 199 2.70E−20 [GI:3550634] [LN:SPAJ6986] [AC:AJ006986] [PN:glycosyl transferase] [GN:cap33fH] [FN:synthesis of capsular polysaccharide] 151 [OR:Streptococcus pneumoniae] SPX2355 2355 5016 222 666 346 1.00E−42 [LN:YKQB_BACSU] [AC:P39760] [GN:YKQB] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 24.3 KD PROTEIN IN KINC-ADEC INTERGENIC 144 REGION (ORF4)] [SP:P39760] SPX2356 2356 5017 460 1380 339 7.90E−94 [LN:G75367] [AC:G75367] [PN:potassium uptake protein KtrB] [GN:DR1668] [OR:Deinococcus radiodurans] 99 SPX2357 2357 5018 62 186 162 1.60E−17 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX2358 2358 5019 255 765 75 8.50E−08 [LN:D72516] [AC:D72516] [PN:probable uridine phosphorylase APE2105] [GN:APE2105] [CL:purine-nucleoside phosphorylase pnp] 143 [OR:Aeropyrum pernix] SPX2359 2359 5020 63 189 91 8.80E−06 “[GI:6332762] [LN:AB033763] [AC:AB033763:AB014419:AB014429:AB014439] [PN:hypothetical protein] [OR:Staphylococcus aureus] 194 [SR:Staphylococcus aureus (strain:NCTC10442) DNA, clone_lib:Lambda das]” SPX2360 2360 5021 99 297 153 6.00E−20 [LN:YQHL_BACSU] [AC:P54510] [GN:YQHL] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 14.6 KD PROTEIN IN GCVT-SPOIIIAA INTERGENIC 141 REGION] [SP:P54510] SPX2361 2361 5022 121 363 NO-HIT 6 SPX2362 2362 5023 98 294 194 1.30E−21 “[GI:6332750] [LN:AB033763] [AC:AB033763:AB014419:AB014429:AB014439] [PN:hypothetical protein] [OR:Staphylococcus aureus] 194 [SR:Staphylococcus aureus (strain:NCTC10442) DNA, clone_lib:Lambda das]” SPX2363 2363 5024 82 246 167 8.40E−17 [LN:A75356] [AC:A75356] [PN:conserved hypothetical protein] [GN:DR1764] [OR:Deinococcus radiodurans] 100 SPX2364 2364 5025 132 396 175 2.80E−26 [LN:T44495] [AC:T44495] [PN:hypothetical protein YFIE [imported]] [OR:Bacillus halodurans] 90 SPX2365 2365 5026 346 1038 219 2.60E−44 [GI:6562808] [LN:SC4A7] [AC:AL133423] [PN:putative aldose 1-epimerase] [GN:SC4A7.35] [OR:Streptomyces coelicolor A3(2)] 119 SPX2366 2366 5027 153 459 NO-HIT 6 SPX2367 2367 5028 389 1167 473 3.90E−95 [LN:AGAS_ECOLI] [AC:P42907] [GN:AGAS] [OR:Escherichia coli] [DE:AGAS PROTEIN] [SP:P42907] 89 SPX2368 2368 5029 83 249 77 6.20E−05 [GI:1914870] [LN:SPZ82001] [AC:Z82001] [PN:unknown] [OR:Streptococcus pneumoniae] 81 SPX2369 2369 5030 135 405 103 3.80E−13 [GI:5669855] [LN:AF130465] [AC:AF130465] [PN:mannose-specific phosphotransferase system] [GN:manL] [OR:Streptococcus salivarius] 128 SPX2370 2370 5031 277 831 144 4.90E−34 “[LN:PTPD_ECOLI] [AC:P42911] [GN:AGAD] [OR:Escherichia coli] [DE:ENZYME II, D COMPONENT)] [SP:P42911]” 102 SPX2371 2371 5032 302 906 128 6.60E−16 [GI:1732200] [LN:VFU65015] [AC:U65015] [PN:PTS permease for mannose subunit IIPMan] [GN:manY] [OR:Vibrio furnissii] 115 SPX2372 2372 5033 159 477 298 2.50E−36 [GI:6690421] [LN:AF129168] [AC:AF129168] [PN:EIIB sorbose-PTS homolog] [GN:sorB] [OR:Lactobacillus casei] 105 SPX2373 2373 5034 509 1527 265 3.30E−90 “[LN:JC5618] [AC:JC5618] [PN:beta-galactosidase,:lactase] [GN:bgaC] [CL:beta-galactosidase bga] [OR:Bacillus circulans] [EC:3.2.1.23]” 134 SPX2374 2374 5035 131 393 358 5.70E−44 “[LN:JC5618] [AC:JC5618] [PN:beta-galactosidase,:lactase] [GN:bgaC] [CL:beta-galactosidase bga] [OR:Bacillus circulans] [EC:3.2.1.23]” 134 SPX2375 2375 5036 239 717 142 7.80E−15 [LN:F69750] [AC:F69750] [PN:transcription regulator GntR family homolog ybgA] [GN:ybgA] [CL:transcription regulator GntR] [OR:Bacillus subtilis] 144 SPX2376 2376 5037 1304 3912 6324 0 “[LN:STRH_STRPN] [AC:P49610] [GN:STRH] [OR:Streptococcus pneumoniae] [EC:3.2.1.52] [DE:BETA-N-ACETYLHEXOSAMINIDASE 139 PRECURSOR,] [SP:P49610]” SPX2377 2377 5038 130 390 NO-HIT 6 SPX2378 2378 5039 433 1299 1678 1.40E−227 [LN:PUR8_BACSU] [AC:P12047] [GN:PURB:PURE] [OR:Bacillus subtilis] [EC:4.3.2.2] [DE:(GLUTAMYL-TRNA SYNTHETASE REGULATORY 140 FACTOR)] [SP:P12047] SPX2379 2379 5040 76 228 NO-HIT 6 SPX2380 2380 5041 384 1152 286 1.70E−65 [GI:5051462] [LN:NME242842] [AC:AJ242842] [PN:putative phosphoribosylaminoimidazole] [GN:purK] [FN:purine nucleotide synthesis] 155 [OR:Neisseria meningitidis] SPX2381 2381 5042 155 465 515 5.30E−66 [GI:3892884] [LN:LLJ000883] [AC:AJ000883] [GN:purE] [OR:Lactococcus lactis] 75 SPX2382 2382 5043 421 1263 589 2.10E−157 [GI:3892883] [LN:LLJ000883] [AC:AJ000883] [GN:purD] [OR:Lactococcus lactis] 75 SPX2383 2383 5044 227 681 NO-HIT 6 SPX2384 2384 5045 523 1569 881 2.30E−213 [LN:PUR9_BACSU] [AC:P12048] [GN:PURH:PURHJ] [OR:Bacillus subtilis] [EC:2.1.2.3:3.5.4.10] [DE:(IMP SYNTHETASE) (ATIC)]] [SP:P12048] 130 SPX2385 2385 5046 170 510 136 9.10E−15 “[LN:VANZ_ENTFC] [AC:Q06242] [GN:VANZ] [OR:Enterococcus faecium] [SR:,Streptococcus faecium] [DE:VANZ PROTEIN] [SP:Q06242]” 123 SPX2386 2386 5047 116 348 NO-HIT 6 SPX2387 2387 5048 182 546 553 2.20E−72 [GI:6446399] [LN:SPU70775] [AC:U70775] [PN:phosphoribosylglycinamide formyltransferase] [OR:Streptococcus pyogenes] 115 SPX2388 2388 5049 341 1023 1084 7.20E−148 [GI:3150047] [LN:AF016634] [AC:AF016634] [PN:phosphoribosylformylglycinamide cyclo-ligase] [GN:pur5] [OR:Lactococcus lactis subsp. cremoris] 140 SPX2389 2389 5050 481 1443 1727 7.50E−248 [GI:4097534] [LN:LLU64311] [AC:U64311] [PN:phosphoribosylpyrophosphate amidotransferase] [GN:purF] [OR:Lactococcus lactis] 122 SPX2390 2390 5051 1243 3729 149 3.00E−49 “[LN:C69492] [AC:C69492] [PN:phosphoribosylformylglycinamidine synthase, component II:formylglycinamide ribotide amidotransferase: 217 phosphoribosylformylglycinamidine synthetase] [OR:Archaeoglobus fulgidus] [EC:6.3.5.3]” SPX2391 2391 5052 45 135 NO-HIT 6 SPX2392 2392 5053 204 612 875 9.90E−117 [LN:PUR7_STRPN] [AC:Q07296] [GN:PURC] [OR:Streptococcus pneumoniae] [EC:6.3.2.6] [DE:(SAICAR SYNTHETASE)] [SP:Q07296] 117 SPX2393 2393 5054 124 372 175 1.90E−17 “[LN:H75412] [AC:H75412] [PN:spermidine/putrescine ABC transporter, periplasmic spermidine/putrescine-binding protein] [GN:DR1305] 160 [OR:Deinococcus radiodurans]” SPX2394 2394 5055 431 1293 2159 2.90E−302 [GI:2804700] [LN:AF030361] [AC:AF030361] [PN:transposase] [OR:Streptococcus pneumoniae] 87 SPX2395 2395 5056 86 258 NO-HIT 6 SPX2396 2396 5057 166 498 300 8.70E−37 [LN:YEBR_ECOLI] [AC:P76270:O07976:O07978] [GN:YEBR] [OR:Escherichia coli] [DE:HYPOTHETICAL 20.3 KD PROTEIN IN PRC-PPHA 163 INTERGENIC REGION] [SP:P76270:O07976:O07978] SPX2397 2397 5058 552 1656 749 7.10E−135 “[LN:S13786] [AC:S13786:S00745:S66049:B69618] [PN:DNA-directed DNA polymerase, III chain dnaX:DNA polymerase III (gamma and tau 245 subunits) dnaX] [GN:dnaX:dnaZX] [CL:DNA-directed DNA polymerase III gamma chain] [OR:Bacillus subtilis] [EC:2.7.7.7]” SPX2398 2398 5059 65 195 NO-HIT 6 SPX2399 2399 5060 257 771 948 1.70E−125 [LN:V296_BACSU] [AC:P80866] [GN:YURI] [OR:Bacillus subtilis] [DE:VEGETATIVE PROTEIN 296 (VEG296)] [SP:P80866] 109 SPX2400 2400 5061 420 1260 583 1.90E−87 [LN:G70019] [AC:G70019] [PN:conserved hypothetical protein yurX] [GN:yurX] [CL:Methanobacterium thermoautotrophicum ABC transporter 161 Ycf24] [OR:Bacillus subtilis] SPX2401 2401 5062 409 1227 622 8.60E−181 [LN:F70019] [AC:F70019] [PN:nifS protein homolog yurW] [GN:yurW] [CL:nifS protein] [OR:Bacillus subtilis] 105 SPX2402 2402 5063 157 471 229 1.90E−43 [LN:E70019] [AC:E70019] [PN:nitrogen fixation protein nifU homolog yurV] [GN:yurV] [CL:Yeast nitrogen fixation protein:nitrogen fixation 177 protein homology] [OR:Bacillus subtilis] SPX2403 2403 5064 470 1410 1721 1.20E−229 [LN:D70019] [AC:D70019] [PN:conserved hypothetical protein yurU] [GN:yurU] [CL:Methanobacterium thermoautotrophicum ABC transporter 161 Ycf24] [OR:Bacillus subtilis] SPX2404 2404 5065 65 195 NO-HIT 6 SPX2405 2405 5066 62 186 112 8.10E−11 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX2406 2406 5067 414 1242 2059 6.00E−276 “[GI:1620468] [LN:SPDACAO] [AC:X99400] [PN:D,D-carboxypeptidase] [GN:dacA] [OR:Streptococcus pneumoniae]” 105 SPX2407 2407 5068 370 1110 1807 5.00E−255 [GI:1620467] [LN:SPDACAO] [AC:X99400] [PN:membrane protein] [OR:Streptococcus pneumoniae] 89 SPX2408 2408 5069 73 219 NO-HIT 6 SPX2409 2409 5070 67 201 NO-HIT 6 SPX2410 2410 5071 247 741 258 7.40E−41 [LN:B69627] [AC:B69627] [PN:transcription repressor of fructose operon fruR] [GN:fruR] [CL:regulatory protein gutR] [OR:Bacillus subtilis] 138 SPX2411 2411 5072 304 912 725 2.80E−94 [LN:A69627] [AC:A69627] [PN:fructose 1-phosphate kinase fruB] [GN:fruB] [CL:6-phosphofructokinase 2] [OR:Bacillus subtilis] 123 SPX2412 2412 5073 76 228 NO-HIT 6 SPX2413 2413 5074 651 1953 371 4.60E−168 “[LN:H69626] [AC:H69626] [PN:PTS fructose-specific enzyme IIBC component fruA] [GN:fruA] [CL:phosphotransferase system enzyme II, fructose- 246 specific:phosphotransferase system mannitol-specific enzyme II factor III homology] [OR:Bacillus subtilis]” SPX2414 2414 5075 738 2214 934 4.10E−198 [LN:SP3E_BACSU] [AC:P21458:P21459] [GN:SPOIIIE] [OR:Bacillus subtilis] [DE:STAGE III SPORULATION PROTEIN E] [SP:P21458:P21459] 126 SPX2415 2415 5076 84 252 82 0.00017 [GI:2257458] [LN:AB000222] [AC:AB000222] [GN:epr] [FN:glycylglycine endopeptidase resistance] [OR:Staphylococcus capitis] 153 [SR:Staphylococcus capitis DNA] SPX2416 2416 5077 95 285 124 7.00E−12 “[LN:A70132] [AC:A70132] [PN:cell division protein homolog] [OR:Borrelia burgdorferi] [SR:, Lyme disease spirochete]” 117 SPX2417 2417 5078 72 216 NO-HIT 6 SPX2418 2418 5079 220 660 102 0.00013 “[LN:T06029] [AC:T06029] [PN:hypothetical protein T28I19.100] [GN:T28I19.100] [OR:Arabidopsis thaliana] [SR:, mouse-ear cress]” 127 SPX2419 2419 5080 401 1203 698 8.70E−120 “[LN:NIFS_LACDE] [AC:P31672] [OR:Lactobacillus delbrueckii] [SR:,subspbulgaricus] [DE:NIFS PROTEIN HOMOLOG (FRAGMENT)] 131 [SP:P31672]” SPX2420 2420 5081 405 1215 982 1.40E−130 [LN:THII_BACSU] [AC:O34595] [GN:THII] [OR:Bacillus subtilis] [DE:PROBABLE THIAMINE BIOSYNTHESIS PROTEIN THII] [SP:O34595] 121 SPX2421 2421 5082 210 630 115 3.40E−15 [LN:G75475] [AC:G75475] [PN:conserved hypothetical protein] [GN:DR0779] [OR:Deinococcus radiodurans] 100 SPX2422 2422 5083 116 348 NO-HIT 6 SPX2423 2423 5084 112 336 NO-HIT 6 SPX2424 2424 5085 144 432 NO-HIT 6 SPX2425 2425 5086 61 183 NO-HIT 6 SPX2426 2426 5087 389 1167 82 2.50E−06 [LN:T35924] [AC:T35924] [PN:hypothetical protein SC9B5.04] [GN:SC9B5.04] [OR:Streptomyces coelicolor] 101 SPX2427 2427 5088 498 1494 137 2.50E−32 [GI:1841495] [LN:SEHSDRMS] [AC:Y11005] [PN:StySKI methylase] [GN:hsdM] [OR:Salmonella enterica] 95 SPX2428 2428 5089 374 1122 109 3.30E−14 [LN:YC18_METJA] [AC:Q58615] [GN:MJ1218] [OR:Methanococcus jannaschii] [DE:HYPOTHETICAL PROTEIN MJ1218] [SP:Q58615] 114 SPX2429 2429 5090 79 237 NO-HIT 6 SPX2430 2430 5091 138 414 NO-HIT 6 SPX2431 2431 5092 276 828 153 1.90E−22 [LN:A75153] [AC:A75153] [PN:integrase/recombinase xerd PAB0255] [GN:xerD-like:PAB0255] [CL:probable site-specific 164 integrase/recombinase XerC] [OR:Pyrococcus abyssi] SPX2432 2432 5093 369 1107 148 4.50E−19 [GI:3057063] [LN:AF013165] [AC:AF013165] [PN:HsdS] [GN:hsds] [OR:Lactococcus lactis] 84 SPX2433 2433 5094 1117 3351 153 6.50E−30 “[LN:T1R_ECOLI] [AC:P08956] [GN:HSDR:HSR] [OR:Escherichia coli] [EC:3.1.21.3] [DE:TYPE I RESTRICTION ENZYME ECOK I R 139 PROTEIN,] [SP:P08956]” SPX2434 2434 5095 157 471 132 1.60E−24 [LN:AHRC_BACSU] [AC:P17893] [GN:AHRC] [OR:Bacillus subtilis] [DE:ARGININE HYDROXIMATE RESISTANCE PROTEIN] [SP:P17893] 117 SPX2435 2435 5096 758 2274 1298 1.20E−249 “[LN:PEPX_LACLC] [AC:P22093] [GN:PEPX] [OR:Lactococcus lactis] [SR:,subspcremoris:Streptococcus cremoris] [EC:3.4.14.11] [DE:PEPTIDASE) 195 (X-PROLYL-DIPEPTIDYL AMINOPEPTIDASE) (X-PDAP)] [SP:P22093]” SPX2436 2436 5097 1034 3102 563 5.40E−170 “[LN:DP3A_BACSU] [AC:O34623] [GN:DNAE] [OR:Bacillus subtilis] [EC:2.7.7.7] [DE:DNA POLYMERASE III, ALPHA CHAIN,] [SP:O34623]” 125 SPX2437 2437 5098 63 189 NO-HIT 6 SPX2438 2438 5099 336 1008 1356 2.50E−182 “[LN:K6PF_LACLA] [AC:Q07636] [GN:PFKA:PFK] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] 157 [EC:2.7.1.11] [DE:(PHOSPHOHEXOKINASE)] [SP:Q07636]” SPX2439 2439 5100 236 708 1007 8.20E−134 [GI:6708108] [LN:AF172173] [AC:AF172173] [PN:pyruvate kinase] [GN:pyk] [FN:conversion of phosphoenolpyruvate to pyruvate] 153 [OR:Streptococcus thermophilus] SPX2440 2440 5101 305 915 1099 9.10E−150 [GI:6708108] [LN:AF172173] [AC:AF172173] [PN:pyruvate kinase] [GN:pyk] [FN:conversion of phosphoenolpyruvate to pyruvate] 153 [OR:Streptococcus thermophilus] SPX2441 2441 5102 74 222 137 1.60E−13 [LN:G71171] [AC:G71171] [PN:hypothetical protein PH0571] [GN:PH0571] [OR:Pyrococcus horikoshii] 95 SPX2442 2442 5103 67 201 73 3.00E−08 [LN:VINT_BPL54] [AC:P20709] [GN:INT] [OR:Bacteriophage L54a] [DE:INTEGRASE] [SP:P20709] 87 SPX2443 2443 5104 101 303 95 3.10E−05 [GI:763050] [LN:BTU21935] [AC:U21935] [PN:repressor protein] [OR:Bacteriophage T270] 84 SPX2444 2444 5105 85 255 89 1.90E−08 [GI:509672] [LN:TU2CIRPRSR] [AC:L26219] [PN:repressor protein] [GN:cI] [OR:Bacteriophage Tuc2009] [SR:Bacteriophage Tuc2009 DNA] 128 SPX2445 2445 5106 291 873 393 1.90E−60 [GI:4580015] [LN:AF049342] [AC:AF049342] [PN:unknown] [OR:Treponema denticola] 78 SPX2446 2446 5107 128 384 364 3.60E−46 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX2447 2447 5108 104 312 NO-HIT 6 SPX2448 2448 5109 239 717 NO-HIT 6 SPX2449 2449 5110 132 396 NO-HIT 6 SPX2450 2450 5111 272 816 184 2.20E−58 [LN:D69759] [AC:D69759] [PN:hypothetical protein ycgQ] [GN:ycgQ] [CL:Bacillus subtilis hypothetical protein ycgQ] [OR:Bacillus subtilis] 136 SPX2451 2451 5112 302 906 369 7.00E−86 [LN:E69759] [AC:E69759] [PN:hypothetical protein ycgR] [GN:ycgR] [OR:Bacillus subtilis] 87 SPX2452 2452 5113 710 2130 644 1.20E−222 [LN:G69773] [AC:G69773] [PN:conserved hypothetical protein ydcI] [GN:ydcI] [CL:hypothetical protein ydcI] [OR:Bacillus subtilis] 128 SPX2453 2453 5114 150 450 256 7.80E−44 [GI:7007441] [LN:AB031213] [AC:AB031213] [PN:YdcK] [GN:ydcK] [OR:Bacillus halodurans] [SR:Bacillus halodurans (strain:C-125) DNA] 129 SPX2454 2454 5115 85 255 90 7.80E−11 [LN:E70043] [AC:E70043] [PN:hypothetical protein yvlC] [GN:yvlC] [OR:Bacillus subtilis] 87 SPX2455 2455 5116 64 192 NO-HIT 6 SPX2456 2456 5117 253 759 486 8.70E−81 [LN:A70001] [AC:A70001] [PN:ABC transporter (ATP-binding protein) homolog ytsC] [GN:ytsC] [CL:unassigned ATP-binding cassette proteins:ATP- 188 binding cassette homology] [OR:Bacillus subtilis] SPX2457 2457 5118 75 225 76 3.20E−05 [LN:G72510] [AC:G72510] [PN:hypothetical protein APE2061] [GN:APE2061] [OR:Aeropyrum pernix] 92 SPX2458 2458 5119 663 1989 249 1.70E−50 [LN:B70001] [AC:B70001] [PN:ABC transporter (permease) homolog ytsD] [GN:ytsD] [OR:Bacillus subtilis] 101 SPX2459 2459 5120 197 591 230 2.10E−25 [LN:SPBC1683] [AC:AL355920] [PN:hypothetical protein] [GN:SPBC1683.10c] [OR:Schizosaccharomyces pombe] [SR:fission yeast] 121 SPX2460 2460 5121 365 1095 1143 8.40E−154 [GI:517210] [LN:SPU11799] [AC:U11799] [OR:Streptococcus pyogenes] 65 SPX2461 2461 5122 61 183 NO-HIT 6 SPX2462 2462 5123 492 1476 585 3.60E−138 “[LN:DCLY_BACSU] [AC:P21885:P26934] [GN:CAD] [OR:Bacillus subtilis] [EC:4.1.1.18] [DE:LYSINE DECARBOXYLASE, (LDC)] 134 [SP:P21885:P26934]” SPX2463 2463 5124 79 237 NO-HIT 6 SPX2464 2464 5125 176 528 83 1.20E−07 “[GI:6009430] [LN:AB024946] [AC:AB024946] [GN:orf54] [OR:Escherichia coli] [SR:Escherichia coli (sub_species:enteropathogenic, strain:B171]” 140 SPX2465 2465 5126 287 861 439 5.40E−79 [LN:SPEE_BACSU] [AC:P70998] [GN:SPEE] [OR:Bacillus subtilis] [EC:2.5.1.16] [DE:(SPDSY)] [SP:P70998] 99 SPX2466 2466 5127 420 1260 1090 2.30E−187 [LN:C81435] [AC:C81435] [PN:hypothetical protein Cj0172c [imported]] [GN:Cj0172c] [OR:Campylobacter jejuni] 107 SPX2467 2467 5128 376 1128 411 7.60E−103 [LN:E75398] [AC:E75398] [PN:carboxynorspermidine decarboxylase] [GN:DR1410] [OR:Deinococcus radiodurans] 104 SPX2468 2468 5129 362 1086 530 3.80E−94 [GI:5712716] [LN:AF153708] [AC:AF153708] [PN:unknown] [OR:Pseudomonas sp. BG33R] 80 SPX2469 2469 5130 292 876 585 1.20E−110 [GI:5262946] [LN:LES19104] [AC:Y19104] [PN:beta-alanine synthase] [OR:Lycopersicon esculentum] [SR:tomato] 106 SPX2470 2470 5131 270 810 209 6.80E−43 [LN:YXEH_BACSU] [AC:P54947] [GN:YXEH:IP1B] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 30.2 KD PROTEIN IN IDH-DEOR 141 INTERGENIC REGION] [SP:P54947] SPX2471 2471 5132 74 222 NO-HIT 6 SPX2472 2472 5133 224 672 90 2.30E−09 [LN:E69787] [AC:E69787] [PN:hypothetical protein ydiL] [GN:ydiL] [OR:Bacillus subtilis] 87 SPX2473 2473 5134 303 909 229 5.80E−46 [LN:T44638] [AC:T44638] [PN:capsular polysaccharide biosynthesis protein cpsY [imported]] [GN:cpsY] [CL:probable transcription regulator lsyR] 172 [OR:Streptococcus agalactiae] SPX2474 2474 5135 154 462 197 1.80E−31 [LN:LSPA_BACSU] [AC:Q45479] [GN:LSPA:LSP] [OR:Bacillus subtilis] [EC:3.4.23.36] [DE:PEPTIDASE) (SIGNAL PEPTIDASE II) (SPASE II)] 140 [SP:Q45479] SPX2475 2475 5136 296 888 888 1.80E−117 [LN:YLYB_BACSU] [AC:Q45480:O31732] [GN:YLYB] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 33.7 KD PROTEIN IN LSP-PYRR 158 INTERGENIC REGION (ORF-X)] [SP:Q45480:O31732] SPX2476 2476 5137 628 1884 461 1.70E−56 [GI:1914872] [LN:SPZ82001] [AC:Z82001] [PN:PCPA] [GN:pcpA] [OR:Streptococcus pneumoniae] 88 SPX2477 2477 5138 377 1131 1387 4.40E−185 [LN:F81125] [AC:F81125] [PN:glutamate 5-kinase NMB1069 [imported]] [GN:NMB1069] [OR:Neisseria meningitidis] 107 SPX2478 2478 5139 421 1263 1530 1.10E−204 [GI:7413448] [LN:AE002457] [AC:AE002457:AE002098] [PN:gamma-glutamyl phosphate reductase] [GN:NMB1068] [OR:Neisseria meningitidis] 130 SPX2479 2479 5140 266 798 396 3.30E−67 “[LN:PROC_ARATH] [AC:P54904] [GN:PROC1] [OR:Arabidopsis thaliana] [SR:,Mouse-ear cress] [EC:1.5.1.2] [DE:PYRROLINE- 176 5-CARBOXYLATE REDUCTASE, (P5CR) (P5C REDUCTASE)] [SP:P54904]” SPX2480 2480 5141 213 639 528 4.30E−68 “[LN:KTHY_BACSU] [AC:P37537] [GN:TMK] [OR:Bacillus subtilis] [EC:2.7.4.9] [DE:THYMIDYLATE KINASE, (DTMP KINASE)] [SP:P37537]” 125 SPX2481 2481 5142 84 252 NO-HIT 6 SPX2482 2482 5143 297 891 244 4.80E−37 “[LN:HOLB_BACSU] [AC:P37540] [GN:HOLB] [OR:Bacillus subtilis] [EC:2.7.7.7] [DE:DNA POLYMERASE III, DELTA′ SUBUNIT,] [SP:P37540]” 128 SPX2483 2483 5144 106 318 103 9.60E−09 [LN:YABA_BACSU] [AC:P37542] [GN:YABA] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 14.1 KD PROTEIN IN XPAC-ABRB 137 INTERGENIC REGION] [SP:P37542] SPX2484 2484 5145 290 870 618 1.60E−84 [LN:YABC_BACSU] [AC:P37544] [GN:YABC] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 33.0 KD PROTEIN IN XPAC-ABRB 137 INTERGENIC REGION] [SP:P37544] SPX2485 2485 5146 182 546 362 2.50E−61 [LN:S62019] [AC:S62019] [PN:hypothetical protein YDR540c:hypothetical protein D3703.8] [GN:YDR540c] [CL:Saccharomyces hypothetical 177 protein YDR540c] [OR:Saccharomyces cerevisiae] SPX2486 2486 5147 168 504 82 2.90E−09 [GI:6690333] [LN:AF117259] [AC:AF117259] [PN:replication protein] [GN:repX] [OR:Staphylococcus aureus] 102 SPX2487 2487 5148 150 450 400 5.20E−51 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX2488 2488 5149 134 402 370 1.00E−54 [LN:S52544] [AC:S52544] [PN:ISL2 protein] [OR:Lactobacillus helveticus] 71 SPX2489 2489 5150 91 273 NO-HIT 6 SPX2490 2490 5151 445 1335 585 1.40E−196 [LN:GID_BACSU] [AC:P39815] [GN:GID] [OR:Bacillus subtilis] [DE:GID PROTEIN] [SP:P39815] 87 SPX2491 2491 5152 246 738 793 2.20E−104 [LN:F69708] [AC:F69708] [PN:uridylate kinase smbA] [GN:smbA] [CL:uridine 5′-monophosphate kinase] [OR:Bacillus subtilis] 120 SPX2492 2492 5153 146 438 NO-HIT 6 SPX2493 2493 5154 186 558 545 2.50E−69 [LN:G69626] [AC:G69626] [PN:ribosome recycling factor frr] [GN:frr] [CL:ribosome releasing factor] [OR:Bacillus subtilis] 121 SPX2494 2494 5155 139 417 NO-HIT 6 SPX2495 2495 5156 285 855 180 3.70E−45 [GI:2145404] [LN:BSY09476] [AC:Y09476] [PN:YitL] [OR:Bacillus subtilis] 71 SPX2496 2496 5157 72 216 134 1.00E−13 [LN:A69931] [AC:A69931] [PN:hypothetical protein yozE] [GN:yozE] [OR:Bacillus subtilis] 87 SPX2497 2497 5158 323 969 956 1.30E−128 [LN:PHOL_BACSU] [AC:P46343] [GN:PHOH] [OR:Bacillus subtilis] [DE:PHOH-LIKE PROTEIN] [SP:P46343] 95 SPX2498 2498 5159 65 195 NO-HIT 6 SPX2499 2499 5160 167 501 87 0.00031 [LN:E75272] [AC:E75272] [PN:hypothetical protein] [GN:DR2441] [OR:Deinococcus radiodurans] 90 SPX2500 2500 5161 92 276 253 1.30E−28 “[LN:DHA_BACSU] [AC:Q08352] [GN:ALD:SPOVN] [OR:Bacillus subtilis] [EC:1.4.1.1] [DE:ALANINE DEHYDROGENASE, (STAGE V 151 SPORULATION PROTEIN N)] [SP:Q08352]” SPX2501 2501 5162 65 195 168 5.10E−17 “[LN:JE0388] [AC:JE0388] [PN:alanine dehydrogenase,] [CL:alanine dehydrogenase:alanine dehydrogenase homology] [OR:Enterobacter aerogenes] 152 [EC:1.4.1.1]” SPX2502 2502 5163 73 219 239 3.30E−27 “[LN:S74638] [AC:S74638] [PN:alanine dehydrogenase:hypothetical protein sll1682:hypothetical protein sll1682] [CL:alanine 233 dehydrogenase:alanine dehydrogenase homology] [OR:Synechocystis sp.] [SR:PCC 6803, , PCC 6803] [SR:PCC 6803, ]” SPX2503 2503 5164 142 426 405 2.90E−56 “[LN:DHA_BACSU] [AC:Q08352] [GN:ALD:SPOVN] [OR:Bacillus subtilis] [EC:1.4.1.1] [DE:ALANINE DEHYDROGENASE, (STAGE V 151 SPORULATION PROTEIN N)] [SP:Q08352]” SPX2504 2504 5165 196 588 147 8.00E−20 [LN:C69895] [AC:C69895] [PN:conserved hypothetical protein yoaA] [GN:yoaA] [CL:Escherichia coli ribosomal-protein-alanine N-acetyltransferase 170 rimJ] [OR:Bacillus subtilis] SPX2505 2505 5166 217 651 1062 6.40E−138 [GI:3211753] [LN:AF052208] [AC:AF052208] [PN:competence protein] [GN:celA] [OR:Streptococcus pneumoniae] 104 SPX2506 2506 5167 459 1377 2213 0 [GI:3211754] [LN:AF052208] [AC:AF052208] [PN:competence protein] [GN:celB] [OR:Streptococcus pneumoniae] 104 SPX2507 2507 5168 306 918 1215 1.90E−162 [GI:3211754] [LN:AF052208] [AC:AF052208] [PN:competence protein] [GN:celB] [OR:Streptococcus pneumoniae] 104 SPX2508 2508 5169 196 588 164 1.60E−26 [LN:YYBJ_BACSU] [AC:P37494] [GN:YYBJ] [OR:Bacillus subtilis] [DE:INTERGENIC REGION] [SP:P37494] 95 SPX2509 2509 5170 392 1176 NO-HIT 6 SPX2510 2510 5171 88 264 NO-HIT 6 SPX2511 2511 5172 196 588 589 4.10E−77 [LN:IF3_LISMO] [AC:O53084] [GN:INFC] [OR:Listeria monocytogenes] [DE:TRANSLATION INITIATION FACTOR IF-3] [SP:O53084] 116 SPX2512 2512 5173 67 201 235 1.10E−28 [LN:R5BS35] [AC:S05347] [PN:ribosomal protein L35] [GN:rpmI] [CL:Escherichia coli ribosomal protein L35] [OR:Bacillus stearothermophilus] 137 SPX2513 2513 5174 120 360 476 9.30E−63 [LN:RL20_BACSU] [AC:P55873] [GN:RPLT] [OR:Bacillus subtilis] [DE:50S RIBOSOMAL PROTEIN L20] [SP:P55873] 103 SPX2514 2514 5175 127 381 130 6.20E−24 [LN:LGUL_HAEIN] [AC:P44638] [GN:GLOA:HI0323] [OR:Haemophilus influenzae] [EC:4.4.1.5] [DE:(S-D-LACTOYLGLUTATHIONE 147 METHYLGLYOXAL LYASE)] [SP:P44638] SPX2515 2515 5176 190 570 354 2.10E−55 [LN:YLXD_BACCL] [AC:P46536] [OR:Bacillus caldolyticus] [DE:HYPOTHETICAL 27.6 KD PROTEIN IN PYRAB-PYRD INTERGENIC REGION 139 (ORF2)] [SP:P46536] SPX2516 2516 5177 94 282 172 7.70E−23 [LN:YLXD_BACCL] [AC:P46536] [OR:Bacillus caldolyticus] [DE:HYPOTHETICAL 27.6 KD PROTEIN IN PYRAB-PYRD INTERGENIC REGION 139 (ORF2)] [SP:P46536] SPX2517 2517 5178 313 939 563 8.20E−147 “[LN:PYDB_LACLC] [AC:P54322] [GN:PYRDB] [OR:Lactococcus lactis] [SR:,subspcremoris:Streptococcus cremoris] [EC:1.3.3.1] 159 [DE:(DHODEHASE B) (DHODB)] [SP:P54322]” SPX2518 2518 5179 722 2166 2390 0 [GI:4218533] [LN:SPN010312] [AC:AJ010312] [PN:endo-beta-N-acetylglucosaminidase] [GN:lytB] [FN:cell wall degradation and cell separation] 167 [OR:Streptococcus pneumoniae] SPX2519 2519 5180 561 1683 2767 0 [GI:6175915] [LN:AF181976] [AC:AF181976] [PN:adherence and virulence protein A] [GN:pavA] [FN:adhesin] [OR:Streptococcus pneumoniae] 132 SPX2520 2520 5181 77 231 NO-HIT 6 SPX2521 2521 5182 166 498 705 5.20E−92 [GI:2749950] [LN:AF000954] [AC:AF000954] [OR:Streptococcus mutans] 66 SPX2522 2522 5183 132 396 507 6.90E−71 [LN:A36933] [AC:A36933] [PN:diacylglycerol kinase homolog] [CL:Bacillus subtilis diacylglycerol kinase dgkA] [OR:Streptococcus mutans] 134 SPX2523 2523 5184 300 900 1502 1.40E−204 [GI:5305399] [LN:AF072811] [AC:AF072811] [PN:GTPase Era] [GN:era] [OR:Streptococcus pneumoniae] 95 SPX2524 2524 5185 275 825 892 1.90E−119 [LN:FPG_STRMU] [AC:P55045] [GN:MUTM:FPG] [OR:Streptococcus mutans] [EC:3.2.2.23] [DE:GLYCOSYLASE)] [SP:P55045] 110 SPX2525 2525 5186 61 183 NO-HIT 6 SPX2526 2526 5187 203 609 167 2.40E−32 “[LN:Y553_SYNY3] [AC:Q55515] [GN:SLR0553] [OR:Synechocystis sp] [SR:,strain PCC 6803] [DE:HYPOTHETICAL 140 22.5 KD PROTEIN SLR0553] [SP:Q55515]” SPX2527 2527 5188 67 201 NO-HIT 6 SPX2528 2528 5189 400 1200 1989 9.60E−280 [GI:3820455] [LN:SPN7367] [AC:AJ007367] [PN:multi-drug resistance efflux pump] [GN:pmrA] [OR:Streptococcus pneumoniae] 118 SPX2529 2529 5190 50 150 177 8.70E−20 “[LN:RL33_LACLA] [AC:P27167] [GN:RPMG] [OR:Lactococcus lactis] [SR:,subsplactis:Streptococcus lactis] [DE:50S RIBOSOMAL PROTEIN 145 L33] [SP:P27167]” SPX2530 2530 5191 78 234 82 8.20E−06 [LN:A70028] [AC:A70028] [PN:hypothetical protein yvaL] [GN:yvaL] [CL:protein-export protein secG] [OR:Bacillus subtilis] 120 SPX2531 2531 5192 785 2355 564 4.00E−180 [LN:G70027] [AC:G70027] [PN:conserved hypothetical protein yvaJ] [GN:yvaJ] [CL:virulence-associated protein vacB homolog] 144 [OR:Bacillus subtilis] SPX2532 2532 5193 156 468 793 1.30E−104 [GI:3211758] [LN:AF052209] [AC:AF052209] [PN:VacB homolog] [OR:Streptococcus pneumoniae] 88 SPX2533 2533 5194 287 861 1499 8.30E−203 [GI:4883699] [LN:AF079807] [AC:AF079807] [PN:tellurite resistance protein TehB] [GN:tehB] [OR:Streptococcus pneumoniae] 119 SPX2534 2534 5195 129 387 326 5.30E−41 [GI:3211758] [LN:AF052209] [AC:AF052209] [PN:VacB homolog] [OR:Streptococcus pneumoniae] 88 SPX2535 2535 5196 74 222 NO-HIT 6 SPX2536 2536 5197 318 954 800 5.10E−182 [GI:3211759] [LN:AF052209] [AC:AF052209] [PN:competence protein] [GN:coiA] [OR:Streptococcus pneumoniae] 104 SPX2537 2537 5198 601 1803 2159 2.10E−292 “[LN:PEPB_STRAG] [AC:Q53778] [GN:PEPB] [OR:Streptococcus agalactiae] [EC:3.4.24.-] [DE:GROUP B OLIGOPEPTIDASE PEPB,] [SP:Q53778]” 129 SPX2538 2538 5199 238 714 680 4.90E−90 [GI:1771204] [LN:LLLVSFPEP] [AC:X99710] [PN:methyltransferase] [OR:Lactococcus lactis] 86 SPX2539 2539 5200 314 942 189 3.10E−32 [LN:PRTM_LACPA] [AC:Q02473] [GN:PRTM] [OR:Lactobacillus paracasei] [DE:PROTEASE MATURATION PROTEIN PRECURSOR] [SP:Q02473] 121 SPX2540 2540 5201 114 342 567 4.00E−74 [GI:1490399] [LN:SPPARCETP] [AC:Z67739] [PN:DNA transposase] [OR:Streptococcus pneumoniae] 90 SPX2541 2541 5202 191 573 422 2.30E−53 [LN:B30868] [AC:B30868] [PN:hypothetical protein 1] [OR:Streptococcus agalactiae] 81 SPX2542 2542 5203 91 273 NO-HIT 6 SPX2543 2543 5204 64 192 NO-HIT 6 SPX2544 2544 5205 207 621 86 4.90E−12 “[LN:T46083] [AC:T46083] [PN:hypothetical protein T20E23.120] [CL:Aquifex aeolicus phosphoglycerate mutase:phosphoglycerate mutase homology] 190 [OR:Arabidopsis thaliana] [SR:, mouse-ear cress]” SPX2545 2545 5206 161 483 210 1.70E−35 “[LN:EBSC_ENTFA] [AC:P36922] [OR:Enterococcus faecalis] [SR:,Streptococcus faecalis] [DE:EBSC PROTEIN] [SP:P36922]” 115 SPX2546 2546 5207 281 843 128 6.60E−17 [LN:B72411] [AC:B72411] [PN:conserved hypothetical protein] [GN:TM0164] [OR:Thermotoga maritima] 96 SPX2547 2547 5208 263 789 102 2.10E−09 [GI:1865711] [LN:BPPLYBA] [AC:Y11477] [PN:endolysin] [GN:plyBa] [FN:cell wall hydrolase] [OR:Bacteriophage Bastille] 116 SPX2548 2548 5209 460 1380 1180 1.90E−156 [LN:S66080] [AC:S66080:I40018:C69629:S05371:S18903] [PN:UDP-N-acetylglucosamine pyrophosphorylase gcaD:cell division protein tms26:tms 237 protein] [GN:gcaD:tms26] [CL:N-acetylglucosamine-1-phosphate uridyltransferase] [OR:Bacillus subtilis] SPX2549 2549 5210 182 546 167 2.40E−45 [LN:YQKG_BACSU] [AC:P54570] [GN:YQKG] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 21.0 KD PROTEIN IN GLNQ-ANSR 137 INTERGENIC REGION] [SP:P54570] SPX2550 2550 5211 105 315 NO-HIT 6 SPX2551 2551 5212 231 693 477 1.60E−61 [LN:PFS_ECOLI] [AC:P24247] [GN:PFS] [OR:Escherichia coli] [EC:3.2.2.16:3.2.2.9] [DE:(EC 3.2.2.9)]] [SP:P24247] 110 SPX2552 2552 5213 164 492 124 1.90E−12 [GI:2769573] [LN:LLCPJW565] [AC:Y12736] [OR:Lactococcus lactis subsp. cremoris] 79 SPX2553 2553 5214 197 591 137 1.00E−08 “[LN:DPO3_BACSU] [AC:P13267] [GN:POLC:DNAF:MUTI] [OR:Bacillus subtilis] [EC:2.7.7.7] [DE:DNA POLYMERASE III, ALPHA 154 CHAIN POLC-TYPE, (POLIII)] [SP:P13267]” SPX2554 2554 5215 257 771 105 1.40E−11 [LN:E69827] [AC:E69827] [PN:glycerophosphodiester phosphodiesterase homolog yhdW] [GN:yhdW] [CL:glycerophosphodiester phosphodiesterase] 159 [OR:Bacillus subtilis] SPX2555 2555 5216 116 348 577 5.80E−76 [GI:4200438] [LN:AF026471] [AC:AF026471] [PN:putative transposase] [OR:Streptococcus pneumoniae] 96 SPX2556 2556 5217 47 141 186 5.40E−22 [GI:5019553] [LN:SPN239004] [AC:AJ239004] [PN:putative transposase] [OR:Streptococcus pneumoniae] 97 SPX2557 2557 5218 67 201 NO-HIT 6 SPX2558 2558 5219 211 633 NO-HIT 6 SPX2559 2559 5220 100 300 84 0.00082 [GI:1707287] [LN:BBU80959] [AC:U80959:L78251] [PN:putative outer membrane protein] [GN:ospFi] [OR:Borrelia burgdorferi] [SR:Lyme disease spirochete] 148 SPX2560 2560 5221 236 708 267 1.40E−53 [LN:YE54_HAEIN] [AC:P44202] [GN:HI1454] [OR:Haemophilus influenzae] [DE:HYPOTHETICAL CYTOCHROME C-TYPE BIOGENESIS PROTEIN 141 HI1454] [SP:P44202] SPX2561 2561 5222 186 558 239 6.40E−28 [LN:YE53_HAEIN] [AC:Q57127:O05062] [GN:HI1453] [OR:Haemophilus influenzae] [DE:HYPOTHETICAL PROTEIN HI1453 PRECURSOR] 136 [SP:Q57127:O05062] SPX2562 2562 5223 464 1392 481 1.60E−122 [LN:D69814] [AC:D69814] [PN:metabolite transporter homolog yfnA] [GN:yfnA] [CL:arginine permease] [OR:Bacillus subtilis] 120 SPX2563 2563 5224 308 924 985 7.10E−129 [LN:T46757] [AC:T46757] [PN:lipoprotein lmb [validated]] [GN:lmb] [OR:Streptococcus agalactiae] 95 SPX2564 2564 5225 839 2517 409 3.50E−104 [LN:T46758] [AC:T46758] [PN:hypothetical protein [imported]] [OR:Streptococcus agalactiae] 90 SPX2565 2565 5226 1040 3120 400 1.50E−93 [LN:T46758] [AC:T46758] [PN:hypothetical protein [imported]] [OR:Streptococcus agalactiae] 90 SPX2566 2566 5227 63 189 NO-HIT 6 SPX2567 2567 5228 63 189 240 1.40E−26 [LN:T46758] [AC:T46758] [PN:hypothetical protein [imported]] [OR:Streptococcus agalactiae] 90 SPX2568 2568 5229 67 201 104 3.80E−14 [LN:T46758] [AC:T46758] [PN:hypothetical protein [imported]] [OR:Streptococcus agalactiae] 90 SPX2569 2569 5230 161 483 152 4.70E−20 [LN:T46758] [AC:T46758] [PN:hypothetical protein [imported]] [OR:Streptococcus agalactiae] 90 SPX2570 2570 5231 80 240 NO-HIT 6 SPX2571 2571 5232 86 258 NO-HIT 6 SPX2572 2572 5233 145 435 107 6.20E−05 [GI:7228476] [LN:AF163151] [AC:AF163151] [PN:dentin sialophosphoprotein precursor] [GN:DSPP] [OR:Homo sapiens] [SR:human] 121 SPX2573 2573 5234 408 1224 961 7.20E−190 “[LN:PEPT_LACLC] [AC:P42020] [GN:PEPT] [OR:Lactococcus lactis] [SR:,subspcremoris:Streptococcus cremoris] [EC:3.4.11.-] [DE:PEPTIDASE 185 T, (AMINOTRIPEPTIDASE) (TRIPEPTIDASE)] [SP:P42020]” SPX2574 2574 5235 365 1095 215 4.70E−41 [LN:HEMZ_BACSU] [AC:P32396] [GN:HEMH:HEMF] [OR:Bacillus subtilis] [EC:4.99.1.1] [DE:SYNTHETASE)] [SP:P32396] 108 SPX2575 2575 5236 126 378 149 2.80E−25 [GI:6136300] [LN:AF065159] [AC:AF065159] [PN:MscL] [GN:mscL] [OR:Bradyrhizobium japonicum] 90 SPX2576 2576 5237 87 261 NO-HIT 6 SPX2577 2577 5238 129 387 180 3.60E−29 “[LN:T44787] [AC:T44787] [PN:glucokinase, [imported]] [CL:glucose kinase:glucose kinase homology] [OR:Bacillus megaterium] [EC:2.7.1.2]” 136 SPX2578 2578 5239 88 264 61 0.0009 [GI:2897104] [LN:AF020798] [AC:AF020798] [PN:putative host cell surface-exposed lipoprotein] [OR:Streptococcus thermophilus bacteriophage TP-J34] 145 SPX2579 2579 5240 273 819 279 1.60E−30 “[GI:4218526] [LN:SPAJ9639] [AC:AJ009639] [PN:1,4-beta-N-acetylmuramidase] [GN:lytC] [FN:lysis of cell wall peptidoglycan] 153 [OR:Streptococcus pneumoniae]” SPX2580 2580 5241 510 1530 289 6.20E−30 “[GI:4218526] [LN:SPAJ9639] [AC:AJ009639] [PN:1,4-beta-N-acetylmuramidase] [GN:lytC] [FN:lysis of cell wall peptidoglycan] 153 [OR:Streptococcus pneumoniae]” SPX2581 2581 5242 574 1722 339 6.40E−76 “[LN:A71951] [AC:A71951] [PN:p-aminobenzoate synthetase] [GN:pabB] [OR:Helicobacter pylori] [SR:strain J99, , strain J99] [SR:strain J99, ]” 140 SPX2582 2582 5243 1964 5892 7027 0 [GI:6911257] [LN:AF221126] [AC:AF221126] [PN:putative zinc metalloprotease] [GN:zmpB] [OR:Streptococcus pneumoniae] 115 SPX2583 2583 5244 78 234 NO-HIT 6 SPX2584 2584 5245 108 324 71 7.10E−06 [GI:501027] [LN:TBU01849] [AC:U01849] [OR:Kinetoplast Trypanosoma brucei] [SR:Trypanosoma brucei] 97 SPX2585 2585 5246 188 564 392 1.60E−49 [LN:YWLG_BACSU] [AC:P39157] [GN:YWLG:IPC-33D] [OR:Bacillus subtilis] [DE:HYPOTHETICAL 19.4 KD PROTEIN IN SPOIIR-GLYC 147 INTERGENIC REGION] [SP:P39157] SPX2586 2586 5247 378 1134 1862 7.80E−253 [GI:6911256] [LN:AF221126] [AC:AF221126] [PN:putative histidine kinase] [GN:zmpS] [OR:Streptococcus pneumoniae] 111 SPX2587 2587 5248 63 189 NO-HIT 6 SPX2588 2588 5249 186 558 898 5.90E−119 [GI:6911256] [LN:AF221126] [AC:AF221126] [PN:putative histidine kinase] [GN:zmpS] [OR:Streptococcus pneumoniae] 111 SPX2589 2589 5250 246 738 1237 2.00E−167 [GI:6911255] [LN:AF221126] [AC:AF221126] [PN:putative response regulator] [GN:zmpR] [OR:Streptococcus pneumoniae] 113 SPX2590 2590 5251 371 1113 1110 1.40E−147 [LN:YE55_HAEIN] [AC:P45213] [GN:HI1455] [OR:Haemophilus influenzae] [DE:HYPOTHETICAL PROTEIN HI1455] [SP:P45213] 112 SPX2591 2591 5252 198 594 335 9.20E−41 [LN:YE53_HAEIN] [AC:Q57127:O05062] [GN:HI1453] [OR:Haemophilus influenzae] [DE:HYPOTHETICAL PROTEIN HI1453 PRECURSOR] 136 [SP:Q57127:O05062] SPX2592 2592 5253 237 711 139 3.50E−49 [LN:YE54_HAEIN] [AC:P44202] [GN:HI1454] [OR:Haemophilus influenzae] [DE:HYPOTHETICAL CYTOCHROME C-TYPE BIOGENESIS 141 PROTEIN HI1454] [SP:P44202] SPX2593 2593 5254 287 861 312 4.30E−47 [GI:3608389] [LN:AF071085] [AC:AF071085] [PN:Orfde2] [OR:Enterococcus faecalis] 79 SPX2594 2594 5255 685 2055 564 1.00E−82 [LN:E70040] [AC:E70040] [PN:conserved hypothetical protein yvgP] [GN:yvgP] [CL:hypothetical protein yvgP] [OR:Bacillus subtilis] 128 SPX2595 2595 5256 64 192 NO-HIT 6 SPX2596 2596 5257 85 255 NO-HIT 6 SPX2597 2597 5258 63 189 NO-HIT 6 SPX2598 2598 5259 188 564 221 1.00E−42 [LN:E69999] [AC:E69999] [PN:hypothetical protein ytqB] [GN:ytqB] [OR:Bacillus subtilis] 87 SPX2599 2599 5260 149 447 329 6.50E−47 [LN:D69999] [AC:D69999] [PN:conserved hypothetical protein ytqA] [GN:ytqA] [CL:Methanococcus jannaschii conserved hypothetical protein MJ0486] 165 [OR:Bacillus subtilis] SPX2600 2600 5261 84 252 209 2.10E−24 [LN:D69999] [AC:D69999] [PN:conserved hypothetical protein ytqA] [GN:ytqA] [CL:Methanococcus jannaschii conserved hypothetical protein MJ0486] 165 [OR:Bacillus subtilis] SPX2601 2601 5262 146 438 210 2.60E−23 [LN:D69999] [AC:D69999] [PN:conserved hypothetical protein ytqA] [GN:ytqA] [CL:Methanococcus jannaschii conserved hypothetical protein MJ0486] 165 [OR:Bacillus subtilis] SPX2602 2602 5263 120 360 NO-HIT 6 SPX2603 2603 5264 82 246 182 1.20E−19 [GI:1022726] [LN:SHU35635] [AC:U35635] [PN:unknown] [OR:Staphylococcus haemolyticus] [SR:Staphylococcus haemolyticus strain=Y176] 129 SPX2604 2604 5265 208 624 156 1.10E−37 “[GI:6332767] [LN:AB033763] [AC:AB033763:AB014419:AB014429:AB014439] [PN:hypothetical protein] [OR:Staphylococcus aureus] 194 [SR:Staphylococcus aureus (strain:NCTC10442) DNA, clone_lib:Lambda das]” SPX2605 2605 5266 2173 6519 309 2.70E−130 [GI:6468240] [LN:SCF81] [AC:AL133171] [PN:putative secreted beta-galactosidase] [GN:SCF81.25c] [OR:Streptomyces coelicolor A3(2)] 129 SPX2606 2606 5267 62 186 NO-HIT 6 SPX2607 2607 5268 64 192 NO-HIT 6 SPX2608 2608 5269 144 432 184 6.10E−21 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX2609 2609 5270 262 786 92 2.70E−11 “[LN:SGCC_ECOLI] [AC:P39365] [GN:SGCC] [OR:Escherichia coli] [DE:PUTATIVE PHOSPHOTRANSFERASE ENZYME II, C 134 COMPONENT SGCC] [SP:P39365]” SPX2610 2610 5271 231 693 231 3.70E−25 “[GI:1736815] [LN:D90848] [AC:D90848:AB001340] [PN:PTS system, Galactitol-specific IIC component] [GN:gatC] [OR:Escherichia coli] 201 [SR:Escherichia coli (strain:K12) DNA, clone_lib:Kohara lambda minise]” SPX2611 2611 5272 102 306 NO-HIT 6 SPX2612 2612 5273 159 477 95 5.10E−13 “[GI:4512375] [LN:AB011837] [AC:AB011837] [PN:phosphotransferase system (PTS)] [GN:fruA] [OR:Bacillus halodurans] [SR:Bacillus halodurans 181 (strain:C-125) DNA, clone_lib:lambda no.9]” SPX2613 2613 5274 2139 6417 10556 0 [GI:5726291] [LN:AF127143] [AC:AF127143] [PN:cell wall-associated serine proteinase precursor] [GN:prtA] [OR:Streptococcus pneumoniae] 134 SPX2614 2614 5275 68 204 136 2.70E−14 [LN:T30285] [AC:T30285] [PN:hypothetical protein] [OR:Streptococcus pneumoniae] 79 SPX2615 2615 5276 66 198 NO-HIT 6 SPX2616 2616 5277 262 786 107 2.30E−18 [GI:7635999] [LN:SCE6] [AC:AL353832] [PN:putative integral membrane transport protein.] [GN:SCE6.32c] [OR:Streptomyces coelicolor A3(2)] 136 SPX2617 2617 5278 287 861 113 2.80E−10 [GI:7636000] [LN:SCE6] [AC:AL353832] [PN:putative integral membrane protein.] [GN:SCE6.33c] [OR:Streptomyces coelicolor A3(2)] 126 SPX2618 2618 5279 318 954 601 1.60E−83 “[LN:G75548] [AC:G75548] [PN:ABC transporter, ATP-binding protein] [GN:DR0205] [CL:unassigned ATP-binding cassette proteins:ATP-binding 184 cassette homology] [OR:Deinococcus radiodurans]” SPX2619 2619 5280 83 249 NO-HIT 6 SPX2620 2620 5281 132 396 NO-HIT 6 SPX2621 2621 5282 158 474 123 3.70E−11 [GI:1914870] [LN:SPZ82001] [AC:Z82001] [PN:unknown] [OR:Streptococcus pneumoniae] 81 SPX2622 2622 5283 230 690 765 9.20E−100 [LN:RL1_BACST] [AC:P04447] [GN:RPLA] [OR:Bacillus stearothermophilus] [DE:50S RIBOSOMAL PROTEIN L1] [SP:P04447] 111 SPX2623 2623 5284 142 426 596 4.50E−77 [LN:S38871] [AC:S38871] [PN:ribosomal protein L11] [GN:rplK] [CL:Escherichia coli ribosomal protein L11] [OR:Staphylococcus carnosus] 133 SPX2624 2624 5285 75 225 NO-HIT 6 SPX2625 2625 5286 239 717 133 3.00E−20 [GI:2529473] [LN:AF006665] [AC:AF006665] [PN:YokZ] [GN:yokZ] [FN:unknown] [OR:Bacillus subtilis] 96 SPX2626 2626 5287 60 180 NO-HIT 6 SPX2627 2627 5288 170 510 103 7.80E−07 [LN:A81062] [AC:A81062] [PN:conserved hypothetical protein NMB1619 [imported]] [GN:NMB1619] [OR:Neisseria meningitidis] 119 SPX2628 2628 5289 72 216 187 1.80E−19 [LN:B71121] [AC:B71121] [PN:hypothetical protein PH0737] [GN:PH0737] [CL:thermophilic aminopeptidase I alpha chain] [OR:Pyrococcus horikoshii] 142 SPX2629 2629 5290 199 597 306 4.10E−72 [LN:C69830] [AC:C69830] [PN:glucanase homolog yhfE] [GN:yhfE] [CL:thermophilic aminopeptidase I alpha chain] [OR:Bacillus subtilis] 131 SPX2630 2630 5291 114 342 145 6.70E−14 [GI:2315995] [LN:SAU87144] [AC:U87144] [PN:branched-chain amino acid carrier protein] [OR:Staphylococcus aureus] 112 SPX2631 2631 5292 447 1341 391 6.60E−90 [LN:BRNQ_BACSU] [AC:P94499:O07082] [GN:BRNQ] [OR:Bacillus subtilis] [DE:CHAIN AMINO ACID UPTAKE CARRIER)] [SP:P94499:O07082] 124 SPX2632 2632 5293 63 189 88 3.10E−06 “[LN:YC61_SYNY3] [AC:P73801] [GN:SLR1261] [OR:Synechocystis sp] [SR:,strain PCC 6803] [DE:HYPOTHETICAL 19.1 KD PROTEIN 140 SLR1261] [SP:P73801]” SPX2633 2633 5294 80 240 100 1.90E−17 [GI:1914870] [LN:SPZ82001] [AC:Z82001] [PN:unknown] [OR:Streptococcus pneumoniae] 81 SPX2634 2634 5295 193 579 548 7.70E−95 [GI:3212185] [LN:U32707] [AC:U32707:L42023] [PN:H. influenzae predicted coding region HI0220.2] [GN:HI0220.2] [OR:Haemophilus influenzae Rd] 140 SPX2635 2635 5296 467 1401 646 4.20E−200 [GI:2160707] [LN:LLU78036] [AC:U78036] [PN:dipeptidase] [OR:Lactococcus lactis] 79 SPX2636 2636 5297 202 606 113 2.60E−17 “[LN:NOX_THETH] [AC:Q60049:Q53306] [GN:NOX] [OR:Thermus aquaticus] [SR:,subspthermophilus] [EC:1.6.99.3] [DE:(NADH:OXYGEN 158 OXIDOREDUCTASE)] [SP:Q60049:Q53306]” SPX2637 2637 5298 80 240 NO-HIT 6 SPX2638 2638 5299 267 801 141 2.90E−22 [GI:2108229] [LN:LFU97348] [AC:U97348] [PN:basic surface protein] [FN:L-cystine transporter] [OR:Lactobacillus fermentum] 121 SPX2639 2639 5300 278 834 106 6.20E−12 [LN:G75297] [AC:G75297] [PN:conserved hypothetical protein] [GN:DR2233] [CL:probable phosphoesterase MJ0912:phosphoesterase core homology] 167 [OR:Deinococcus radiodurans] SPX2640 2640 5301 615 1845 1882 5.00E−256 [LN:UVRC_BACSU] [AC:P14951] [GN:UVRC] [OR:Bacillus subtilis] [DE:EXCINUCLEASE ABC SUBUNIT C] [SP:P14951] 104 SPX2641 2641 5302 241 723 NO-HIT 6 SPX2642 2642 5303 411 1233 95 3.90E−07 [LN:SPN250764] [AC:AJ250764] [PN:MurM protein] [GN:murM] [FN:serine/alanine adding enzyme] [OR:Streptococcus pneumoniae] 120 SPX2643 2643 5304 407 1221 2088 3.50E−283 [LN:SPN277484] [AC:AJ277484] [PN:beta-lactam resistance factor] [GN:fibA] [FN:putative role in peptidoglycan crosslinking] 152 [OR:Streptococcus pneumoniae] SPX2644 2644 5305 260 780 482 7.10E−100 [GI:7453516] [LN:AF157484] [AC:AF157484] [PN:tributyrin esterase] [GN:estA] [OR:Lactococcus lactis subsp. lactis] 113 SPX2645 2645 5306 554 1662 581 1.80E−136 [LN:H69884] [AC:H69884] [PN:conserved hypothetical protein ymfA] [GN:ymfA] [CL:conserved hypothetical protein MG139] [OR:Bacillus subtilis] 139 SPX2646 2646 5307 647 1941 529 3.20E−120 [LN:H69980] [AC:H69980] [PN:single-strand DNA-specific exonuclease homolog yrvE] [GN:yrvE] [OR:Bacillus subtilis] 113 SPX2647 2647 5308 741 2223 529 8.40E−150 [LN:H69980] [AC:H69980] [PN:single-strand DNA-specific exonuclease homolog yrvE] [GN:yrvE] [OR:Bacillus subtilis] 113 SPX2648 2648 5309 253 759 527 8.90E−103 [LN:GLNQ_BACST] [AC:P27675] [GN:GLNQ] [OR:Bacillus stearothermophilus] [DE:GLUTAMINE TRANSPORT ATP-BINDING PROTEIN 132 GLNQ] [SP:P27675] SPX2649 2649 5310 65 195 69 0.00063 [LN:E72756] [AC:E72756] [PN:hypothetical protein APE0042] [GN:APE0042] [OR:Aeropyrum pernix] 92 SPX2650 2650 5311 73 219 92 9.10E−12 [LN:G72510] [AC:G72510] [PN:hypothetical protein APE2061] [GN:APE2061] [OR:Aeropyrum pernix] 92 SPX2651 2651 5312 265 795 422 2.40E−66 [LN:PEB1_CAMJE] [AC:P45678] [GN:PEB1A] [OR:Campylobacter jejuni] [DE:MAJOR CELL-BINDING FACTOR PRECURSOR (CBF1) 131 (PEB1)] [SP:P45678] SPX2652 2652 5313 226 678 400 3.80E−74 [LN:G81365] [AC:G81365] [PN:probable ABC-type amino-acid transporter permease protein Cj0920c [imported]] [GN:Cj0920c] 144 [OR:Campylobacter jejuni] SPX2653 2653 5314 220 660 234 2.00E−50 [LN:F69633] [AC:F69633] [PN:glutamine ABC transporter (membrane protein) glnP] [GN:glnP] [CL:histidine permease protein M] 145 [OR:Bacillus subtilis] SPX2654 2654 5315 401 1203 78 7.00E−08 [GI:1255667] [LN:PSEORF1] [AC:D84146] [PN:reductase] [GN:pahA] [OR:Pseudomonas aeruginosa] [SR:Pseudomonas aeruginosa (strain:PaK1) DNA] 136 SPX2655 2655 5316 294 882 1498 3.00E−201 “[LN:ALF_STRPN] [AC:O65944] [GN:FBA] [OR:Streptococcus pneumoniae] [EC:4.1.2.13] [DE:FRUCTOSE−BISPHOSPHATE ALDOLASE,] 130 [SP:O65944]” SPX2656 2656 5317 443 1329 2174 1.90E−297 [GI:4583524] [LN:AF140356] [AC:AF140356] [PN:VncS] [GN:vncS] [FN:putative histidine kinase/phosphatase] [OR:Streptococcus pneumoniae] 133 SPX2657 2657 5318 219 657 1089 1.00E−146 [GI:4583523] [LN:AF140356] [AC:AF140356] [PN:VncR] [GN:vncR] [FN:putative response regulator] [OR:Streptococcus pneumoniae] 123 SPX2658 2658 5319 460 1380 2273 0 [GI:5712669] [LN:AF140784] [AC:AF140784] [PN:Vexp3] [GN:vex3] [OR:Streptococcus pneumoniae] 91 SPX2659 2659 5320 216 648 1066 2.30E−141 [GI:5712668] [LN:AF140784] [AC:AF140784] [PN:Vexp2] [GN:vex2] [OR:Streptococcus pneumoniae] 91 SPX2660 2660 5321 426 1278 2070 2.40E−280 [GI:5712667] [LN:AF140784] [AC:AF140784] [PN:Vexp1] [GN:vex1] [OR:Streptococcus pneumoniae] 91 SPX2661 2661 5322 85 255 NO-HIT 6 

1. An isolated polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:
 4263. 2. An isolated polypeptide having at least 90% identity to SEQ ID NO: 4263, wherein the polypeptide is a surface protein.
 3. An isolated polypeptide having at least 90% identity to SEQ ID NO: 4263, wherein the polypeptide is a surface protein and elicits an immune response.
 4. The isolated polypeptide of claim 2, wherein the polypeptide has at least 95% identity to SEQ ID NO:
 4263. 5. The isolated polypeptide of claim 2, wherein the polypeptide has at least 98% identity to SEQ ID NO:
 4263. 6. The isolated polypeptide of claim 2, wherein the polypeptide has at least 99% identity to SEQ ID NO:
 4263. 7. The isolated polypeptide of claim 3, wherein the polypeptide has at least 95% identity to SEQ ID NO:
 4263. 8. The isolated polypeptide of claim 3, wherein the polypeptide has at least 98 % identity to SEQ ID NO:
 4263. 9. The isolated polypeptide of claim 3, wherein the polypeptide has at least 99% identity to SEQ ID NO:
 4263. 